TABLE OF CONTENTS

As filed with the Securities and Exchange Commission on March 29, 2022
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 20-F

REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended          
OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report          
For the transition period from        to       
Commission File No.       
IPERIONX LIMITED
(Exact name of Registrant as specified in its charter)
N/A
AUSTRALIA
(Translation of Registrant’s name into English)
(Jurisdiction of incorporation or organization)
129 W Trade Street
Suite 1405
Charlotte, NC 28202
(Address of principal executive offices)
Anastasios Arima
Chief Executive Officer and Managing Director
(704) 578-3217 (telephone)
129 W Trade Street
Suite 1405
Charlotte, NC 28202
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class:
Name of each exchange on which registered or to be registered:
American Depositary Shares each representing     
10 Ordinary Shares, no par value(1)
The Nasdaq Stock Market LLC
(1)
Evidenced by American Depositary Receipts
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2021: 139,488,491 ordinary shares.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes ☐ No ☒
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act of 1934.
Yes ☐ No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☐ No ☒
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months.
Yes ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Emerging growth company
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing.
U.S. GAAP
International Financial Reporting Standards as issued by the International Accounting Standards Board ☒
Other
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.
Item 17 ☐ Item 18
If this is an annual report, indicate by check mark whether the registrant is a shell company.
Yes ☐ No
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.
Yes ☐ No

TABLE OF CONTENTS

TABLE OF CONTENTS
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
i

TABLE OF CONTENTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ii

TABLE OF CONTENTS


INTRODUCTION
IperionX Limited (formerly Hyperion Metals Limited) (“IperionX”) aims to be a leading developer of sustainable critical mineral and critical material supply chains in the United States, a mission we believe is important for the global transition towards a closed-loop, low-carbon, resource efficient green economy.
We aim to achieve this mission through a multi-pronged strategy comprising a variety of technology, integration, and sustainability focused initiatives.
Technologies
IperionX aims to commercialize a series of patented titanium manufacturing technologies (the “Technologies”) that have the potential to reduce the cost and carbon emissions of titanium production relative to what is commercially available today. With these Technologies, which we do not currently own but hold an exclusive option to acquire, we plan to enable the widespread use of titanium and possibly displace metals like steel and aluminum which have lower strength-to-weight ratios, inferior corrosion resistance and likely higher net-carbon emissions.
IperionX holds an exclusive option to acquire Blacksand Technology, LLC (“Blacksand”), which holds the rights to commercialize the Technologies to produce metal products from titanium and/or its alloy. The Technologies were invented by Dr. Zhigang Zak Fang at the University of Utah with support from the Advanced Research Programs Agency – Energy (“ARPA-E”) within the Department of Energy (“DOE”). The partnership between Dr. Fang and ARPA-E focused largely on reducing vehicular weight through the use of titanium in place of steel to reduce energy consumption and emissions in the transportation sector.
The Technologies have successfully produced titanium at a pilot scale level and have shown the potential to be applied to other critical minerals as well.
The Technologies offer IperionX the potential to produce U.S.-sourced, low-carbon titanium metal products at potentially reduced cost and carbon emissions relative to what is commercially available today with higher strength-to-weight ratios and superior corrosion resistance. Such titanium is potentially substitutable for stainless steel and aluminum in a wide variety of applications.
The Technologies can utilize not only raw titanium minerals, but also titanium metal scrap as feedstock, potentially allowing for a 100% closed-loop, circular titanium process, once commercialized. These Technologies may also be applied to other metals including zirconium and other rare earth elements. The Company has secured a prospective source of feedstock for these metals via its wholly owned Titan critical minerals project (the “Titan Project”) in Tennessee.
Integration
We aim to vertically integrate these Technologies with sustainable, resource-efficient material feedstocks, to develop a U.S. based titanium and critical mineral supply chain.
We believe that one key competitive advantage of the Technologies is their ability to take titanium scrap as feedstock, which potentially facilitates the development of a 100% closed-loop, recyclable titanium metal supply chain.
Vertical integration and supply chain transparency are key components to IperionX’s strategy, and we aim to achieve this through the development of IperionX’s 100% interest in the Titan Project in Tennessee, U.S. The Titan Project represents a potential secure source of high-quality mineral feedstock for the Technologies, to supplement scrap titanium metal feedstocks.
The Titan Project forms part of a large-scale critical mineralization trend in the physiographical area of the United States known as the Mississippi embayment that contains significant potential for critical materials including titanium, zirconium, and rare earth elements. We believe that vertical integration with U.S.-based resource operations would be a major competitive advantage for IperionX, providing a potential source of critical mineral feedstock.
1

TABLE OF CONTENTS

Using any potential future mineral feedstock from the Titan Project, if developed, is likely to be a strategic advantage for IperionX, but the commercial success of the Technologies is not reliant upon commercial success at the Titan Project.
Sustainability
We believe the global transition towards the green economy could drive significant increased demand for sustainable critical minerals and advanced metals.
In particular, we believe high demand could arise for those minerals and metals needed for the drive to achieve decarbonization via electrification, especially those that enable advanced technologies including titanium and rare earth elements. We believe that these raw materials have historically been produced without a focus on environmental sustainability, resource scarcity, or social equity. Through the Technologies, the development of a 100% closed-loop, recyclable, sustainable titanium metal supply chain could be made possible for the first time.
IperionX’s efforts to develop the Titan Project (and any future critical mineral operations) would focus on environmental sustainability and improving the well-being of the surrounding communities, setting the standard for future development of similar critical mineral projects.
IperionX’s strategy, if successful, could allow for the substitution of titanium metal in structural applications providing for closed-loop recyclability, longer product lifetimes and increased product reusability. Together with the integration of the Titan Project, IperionX’s strategy aims to re-shore a fully integrated mineral-to-metal U.S. titanium supply chain in accordance with sustainable best practices.
The result would be the creation of a domestic U.S. circular, closed-loop titanium metal supply chain that would have a focus on environmental sustainability and social equity whilst also providing sustainable, low-carbon valuable critical minerals including rare earth elements.
Why Titanium?
Titanium is a strong, lightweight metal with ideal properties for broad applications in defense, aerospace, space exploration, transportation and electric vehicles, unmanned vehicles, and many other advanced manufacturing applications.
We believe the global transition towards the green economy could drive significant increased demand for critical materials. This is especially true of those needed to decarbonize and electrify the global economy and enable advanced technologies, like titanium and rare earth elements. These raw materials have historically been produced without a heavy focus on environmental sustainability, resource scarcity, or social equity.
We believe titanium has the potential to be a key green economy enabling critical material via its substitution for stainless steel and aluminum. In our opinion, the use of stainless steel or aluminum as structural metals, whether it be for the structural components in an electric vehicle battery pack, case components in consumer electronic devices, or the mounting structures in solar arrays, will increase with the transition to a green economy. We believe the existing production of these metals results in significant global carbon emissions which must be addressed to transition to net-zero economy.
We believe titanium is a superior metal to stainless steel and aluminum in many applications due to its combined superior properties including high strength-to-weight ratio and excellent corrosion resistance. In our opinion, only titanium’s historically high production cost has held it back from being widely used in place of stainless steel and aluminum.
Titanium metal manufacturing capacity in the U.S. from titanium minerals is almost non-existent. As of 2021, the current U.S. titanium metal demand from the aerospace, medical, space and defense sectors is heavily reliant on international supply chains. We believe these supply chains are not only environmentally and socially unsustainable but could also be a threat to U.S. national security given the reliance on imported titanium feedstocks for use within the U.S. defense sector.
The Technologies have the potential to create a cost-competitive production of low-carbon titanium via scrap-to-metal and mineral-to-metal manufacturing processes within the United States that has a focus on recyclability, environmental sustainability and social equity with the ultimate aim of allowing for the proliferation of titanium use across industries.
2

TABLE OF CONTENTS

History of the Company
IperionX was originally incorporated in Western Australia as Tao Commodities Limited on May 5, 2017 and changed its name to Hyperion Metals Limited on April 14, 2021, following our acquisition of the Titan Project on December 1, 2020, and most recently changed to its current name, IperionX Limited, on February 9, 2022. We are subject to the provisions of the Australian Corporations Act.
Our head office is located at 129 West Trade Street, Suite 1405, Charlotte, North Carolina 28202, United States. Our registered office is located at Level 9, 28 The Esplanade, Perth WA 6000, Australia, and our telephone number there is +61 (8) 9322-6322.
Our ordinary shares have been listed on the Australian Securities Exchange since 2018, previously under the symbols “TAO” and “HYM” and currently under the symbol “IPX.”
We are filing this registration statement on Form 20-F in anticipation of the listing of the American Depositary Shares, or ADSs, each representing 10 of our ordinary shares, on the Nasdaq Capital Market, or Nasdaq, under the symbol “IPX”. The Bank of New York Mellon, acting as depositary, will register and deliver the ADSs.
We also maintain a website at www.iperionx.com. The information contained on our website or available through our website is not incorporated by reference into and should not be considered a part of this registration statement on Form 20-F, and the reference to our website in this registration statement on Form 20-F is an inactive textual reference only.
3

TABLE OF CONTENTS

ABOUT THIS REGISTRATION STATEMENT
Unless otherwise indicated or the context implies otherwise, any reference in this registration statement on Form 20-F to:
“IperionX” refers to IperionX Limited, an Australian corporation;
“the Company,” “we,” “us,” or “our” refer to IperionX and its consolidated subsidiaries, through which it conducts its business, unless otherwise indicated;
“shares” or “ordinary shares” refers to ordinary shares of IperionX;
“ADS” refers to the American depositary shares; and
“ASX” refers to the Australian Securities Exchange.
Unless otherwise indicated, all references to “A$” are to Australian dollars, and all references to “US$” are to United States dollars. Our financial statements are presented in U.S. dollars which is the Company’s presentation currency. This registration statement on Form 20-F contains references to U.S. dollars where the underlying transaction or event was denominated in U.S. dollars. This registration statement on Form 20-F contains forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements.”
4

TABLE OF CONTENTS

CAUTIONARY NOTE TO UNITED STATES INVESTORS
We are subject to the reporting requirements of the applicable U.S. and Australian securities laws, and as a result we will report any mineral reserves and mineral resources as required by both of these standards. As an Australian listed public company, we will be required to report any estimates of mineral resources and ore reserves in terms of “Measured, Indicated and Inferred” Mineral Resources and “Proved and Probable” Ore Reserves in compliance with the JORC 2012, Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves (the “JORC Code”). The JORC Code was prepared by the Joint Ore Reserves Committee of The Australasian Institute of Mining and Metallurgy, Australian Institute of Geoscientists and Minerals Council of Australia. These defined terms contained within the JORC Code differ in some respects from the definitions under the U.S. Securities Act of 1933, as amended (the “Securities Act”), including in Regulation S-K, Subpart 1300 (“Subpart 1300”).
Information about mineral reserves and resources, if any, contained in our filings with the SEC also will be presented in compliance with Subpart 1300. While guidelines for reporting mineral resources, including subcategories of measured, indicated and inferred resources, are largely similar between JORC Code and Subpart 1300 standards, information contained in our future SEC filings that describes mineral deposits may not be directly comparable to similar information made public by other U.S. companies under the SEC’s old reporting standard, Industry Guide 7, or to similar information published by other ASX-listed companies. Investors are cautioned that any public disclosure we make in Australia as to mineral reserves or resources in accordance with ASX Listing Rules will not form a part of our SEC filings except to the extent stated therein.
INDUSTRY AND MARKET DATA
This registration statement includes information with respect to market and industry conditions and market share from third-party sources or that is based upon estimates using such sources when available. We believe that such information and estimates are reasonable and reliable. We also believe the information extracted from publications of third-party sources has been accurately reproduced. However, we have not independently verified any of the data from third party sources. Similarly, our internal research is based upon the understanding of industry conditions, and such information has not been verified by any independent sources.
5

TABLE OF CONTENTS

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain information included or incorporated by reference in this registration statement on Form 20-F may be deemed to be “forward-looking statements” within the meaning of applicable securities laws. Such forward-looking statements concern our anticipated results and progress of our operations in future periods, planned exploration and, if warranted, development of our properties, plans related to our business and other matters that may occur in the future. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. All statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate”, “believe”, “expect”, “estimate”, “may”, “will”, “could”, “leading”, “intend”, “contemplate”, “shall” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Forward-looking statements in this registration statement on Form 20-F include, but are not limited to, statements with respect to: risks related to the effects of health epidemics, including the COVID-19 pandemic; risks related to our limited operating history in the titanium metal manufacturing industry; risks related to our ability to commercialize our titanium metal technologies; risks related to our ability to produce titanium metal powders and products to customers’ exact specification; risks related to our ability to identify and contract long-term offtake customers for our titanium metal products; risks related to our limited operating history in the minerals extraction industry, risks related to our status as an exploration stage company; risks related to our ability to identify mineralization and achieve commercial minerals extraction; risks related to minerals extraction, exploration and extraction site construction, if warranted, on our properties; risks related to our ability to achieve and maintain profitability and to develop positive cash flow from any minerals extraction activities; risks related to investment risk and operational costs associated with our exploration activities; risks related to our ability to access capital and the financial markets; risks related to compliance with government regulations; risks related to our ability to acquire necessary minerals extraction licenses, permits or access rights; risks related to environmental liabilities and reclamation costs; risks related to volatility in minerals and metals prices or demand for minerals and metals; risks related to stock price and trading volume volatility; risks relating to the development of an active trading market for the ADSs; risks related to ADS holders not having certain shareholder rights; risks related to ADS holders not receiving certain distributions; risks related to our status as a foreign private issuer and emerging growth company; and risks related to the other matters described in the section titled “Risk Factors” beginning on page 9.
All forward-looking statements reflect our beliefs and assumptions based on information available at the time the assumption was made. These forward-looking statements are not based on historical facts but rather on management’s expectations regarding future activities, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. By its nature, forward-looking information involves numerous assumptions, inherent risks and uncertainties, both general and specific, known and unknown, that contribute to the possibility that the predictions, forecasts, projections or other forward-looking statements will not occur. Although we have attempted to identify important factors that could cause actual results to differ materially from those described in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the securities laws of the United States and Australia, we disclaim any obligation to subsequently revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. We qualify all the forward-looking statements contained in this registration statement on Form 20-F by the foregoing cautionary statements.
PRESENTATION OF FINANCIAL INFORMATION
Our fiscal year ends on June 30. We designate our fiscal year by the year in which that fiscal year ends; for example, fiscal 2021 refers to our fiscal period ended June 30, 2021. All dates in this registration statement refer to calendar years, except where a fiscal year or quarter is indicated.
6

TABLE OF CONTENTS

On December 1, 2020, IperionX (formerly Hyperion Metals Limited and Tao Commodities Limited) acquired 100% of Hyperion Metals (Australia) Pty Ltd (“HMAPL”). The transaction was accounted for as a reverse acquisition with HMAPL as the accounting acquirer. Therefore, our consolidated financial statements have been prepared as a continuation of the consolidated financial statements of HMAPL. As HMAPL was only incorporated during fiscal 2021 on July 20, 2020, there is no comparative period information presented in our June 30, 2021 financial statements. From the date of the reverse acquisition of Tao Commodities Limited (renamed Hyperion Metals Limited from April 14, 2021 and IperionX Limited from February 9, 2022) (“TAO”), its financial results have been included in our consolidated financial results as of and for the period ended June 30, 2021. The financial results of TAO are not reflected in our consolidated financial results for any period prior to the acquisition date. However, we have included in this registration statement the unaudited pro forma combined statement of profit or loss which reflects the pro forma impact of the reverse acquisition of TAO for the period ended June 30, 2021, reflecting the financial results of TAO as if we had acquired it on July 1, 2020. See “Unaudited Pro Forma Combined Statement of Profit or Loss” for more information. The unaudited pro forma combined statement of profit or loss of IperionX presented in this registration statement has been derived from the application of pro forma adjustments to the historical consolidated financial statements of HMAPL and TAO included elsewhere in this registration statement. See “Unaudited Pro Forma Combined Statement of Profit or Loss” for a complete description of the adjustments and assumptions underlying the unaudited pro forma combined statement of profit or loss included in this registration statement.
Unless otherwise indicated, the consolidated financial statements and related notes included in this registration statement are presented in U.S. dollars and have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) which differ in certain significant respects from generally accepted accounting principles in the United States, or U.S. GAAP. As a result, our financial statements may not be comparable to the financial statements of U.S. companies. Because the U.S. Securities and Exchange Commission (“SEC”) has adopted rules to accept financial statements prepared in accordance with IFRS as issued by the IASB without reconciliation to U.S. GAAP from foreign private issuers such as us, we will not be providing a description of the principal differences between U.S. GAAP and IFRS.
Our financial statements are presented in U.S. dollars which is the Company’s presentation currency. This registration statement contains translations of some Australian dollar amounts into U.S. dollars. Except as otherwise stated in this registration statement, all translations from Australian dollars to U.S. dollars are based on the rates published by the Reserve Bank of Australia. No representation is made that the Australian dollar amounts referred to in this registration statement could have been or could be converted into U.S. dollars at such rate.
7

TABLE OF CONTENTS

PART I.
ITEM 1.
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
A. Directors and Senior Management
The following table lists the current members of our board of directors and our executive officers. The address for our directors and officers is c/o Level 9, 28 The Esplanade, Perth WA 6000, Australia.
Name
Position
Anastasios (Taso) Arima
Chief Executive Officer and Managing Director
Todd W. Hannigan
Executive Chairman
Lorraine M. Martin
Independent Non-Executive Director
Vaughn W. Taylor
Independent Non-Executive Director
Melissa G. Waller
Independent Non-Executive Director
Beverly M. Wyse
Independent Non-Executive Director
Dominic P. Allen
Vice President and Chief Commercial Officer
Lamont Leatherman
Vice President and Chief Geologist
Toby Symonds
Vice President and Chief Strategy Officer
Jeanne McMullin
Vice President and Chief Legal Officer
Gregory D. Swan
Vice President and Company Secretary (principal financial officer)
For further details, see “Directors, Senior Management and Employees.”
B. Advisers
Our principal Australian legal advisers are Thomson Geer, located at Level 27, Exchange Tower, 2 The Esplanade, Perth WA 6000, Australia. Our principal U.S. legal advisors are Gibson, Dunn & Crutcher LLP, located at 200 Park Avenue, New York, New York 10166.
C. Auditors
PricewaterhouseCoopers served as our principal independent registered public accounting firm for fiscal 2021. The address of PricewaterhouseCoopers is Brookfield Place, Level 15, 125 St Georges Terrace, Perth WA 6000, Australia.
ITEM 2.
OFFER STATISTICS AND EXPECTED TIMETABLE
Not applicable.
ITEM 3.
KEY INFORMATION
A. [Reserved]
B. Capitalization and Indebtedness
The following table sets forth IperionX’s cash and cash equivalents and capitalization as of December 31, 2021. You should read this information together with IperionX’s financial statements and the related notes and with “Item 5. Operating and Financial Review and Prospects” appearing elsewhere in this registration statement on Form 20-F.
 
As of December 31, 2021
(US$)
Cash and cash equivalents
US$14,256,359
Non-current debt
Equity
 
Contributed equity
29,669,773
Reserves
9,175,176
Accumulated losses
(23,792,992)
Total equity
US$15,051,957
Total capitalization
US$15,051,957
C. Reasons for the Offer and Use of Proceeds
Not applicable.
8

TABLE OF CONTENTS

D. Risk Factors
You should carefully consider the risks described below, together with all of the other information in this registration statement on Form 20-F. If any of the following risks occur, our business, financial condition and results of operations could be seriously harmed, and you could lose all or part of your investment. Further, if we fail to meet the expectations of the public market in any given period, the market price of the ADSs could decline. We operate in a competitive environment that involves significant risks and uncertainties, some of which are outside of our control. If any of these risks actually occurs, our business and financial condition could suffer and the price of the ADSs could decline.
Risks Related to Our Business
Our continued growth depends on our ability to commercialize our titanium metal production capacity.
Sustained growth of our company relies on successfully commercializing our titanium metal production capacity. Examples of things that could jeopardize that production progress include: an adverse event of some kind at our production facility in Salt Lake City, where we currently process our titanium; a delay in procuring necessary equipment for processing our titanium; and/or difficulty hiring and training qualified employees. If we are unsuccessful in reaching and maintaining expected production rates, including by failing to reach anticipated throughput, recoveries, uptimes, yields, or any combination thereof, within expected time frames or at all, we may not be able to build a sustainable or profitable metals technology business as currently expected or at all.
Our access to the Technologies depends on our ability to comply with the terms of third-party agreements.
We do not currently own the Technologies. We currently have access to the Technologies through a master services agreement (the “MSA”) with Blacksand pursuant to which we and Blacksand will investigate the scale up and commercialization of Blacksand's HAMR and GSD patented technologies for the processing of titanium ore or feedstock and the production of titanium metal or alloy products under two statements of work. Separately, we and Blacksand entered into in an option agreement October 2021 (the “Blacksand Option Agreement”) whereby Blacksand granted us an exclusive option to purchase 100% of the ownership interests of Blacksand. If we fail to comply with the terms of these agreements, are unable to pay the exercise price of the Blacksand Option Agreement or otherwise decide not to exercise the option pursuant to the Blacksand Option Agreement, we may lose access to the Technologies, which would adversely affect our business, prospects, financial condition and operating results. For more information on our agreements with Blacksand, see “Item 4. Information on the Company—B. Business Overview—Additional Business Information—Potential Acquisition of Blacksand.”
Failure to commercially scale our closed-loop titanium production processes may result in material adverse impacts to, or failure to achieve, our growth projections.
The Technologies have shown the potential to be capable of closed-loop titanium production, taking recycled titanium scrap metal as feedstock, at the pilot-scale level, but we have not yet reproduced this process at commercial-scale. Failure to do so may result in material adverse impacts to, or failure to achieve, our growth projections.
Unanticipated costs or delays associated with our ongoing titanium metal commercialization may materially and adversely affect our financial condition or results of operations.
The commercialization of the Technologies will require the commitment of substantial resources and capital expenditures. Our future expenditures may increase as consultants, personnel and equipment associated with our efforts are added. The success of the commercialization of the Technologies and the amounts and timing of expenditures to commercialize the Technologies will depend in part on the following: our ability to timely procure equipment or repair existing equipment, certain of which may involve long lead-times; maintaining, and procuring, as required, applicable federal, state and local permits; the results of consultants’ analysis and recommendations; negotiating contracts for equipment, earthwork, construction, equipment installation, labor and completing infrastructure and construction work; effects of planned and unplanned shut-downs and delays in our production; effects of stoppages or delays on construction projects; disputes with contractors or other third parties; negotiating sales and offtake contracts for our planned production; the execution of any joint venture agreements or similar arrangements with strategic partners; the impact of COVID-19 or similar pandemics on our business, our strategic partners’ or suppliers’ businesses, logistics or the global economy; and other factors, many
9

TABLE OF CONTENTS

of which are beyond our control. Most of these activities require significant lead times and must be advanced concurrently. Unanticipated costs or delays associated with the commercialization of the Technologies could materially and adversely affect our financial condition or results of operations and could require us to seek additional capital.
We may encounter substantial delays in the engineering and design, manufacturing, regulatory approval, and commercial launch of our titanium metal products, which could prevent us from commercializing the Technologies on a timely basis, if at all.
Any delay in the development and manufacturing scale-up of our titanium metal products would adversely affect our business because it will delay our ability to generate revenue and adversely affect the development of customer relationships. Additionally, we may encounter delays in obtaining the necessary regulatory approvals or launching our titanium metal products on the market, including delays in entering into agreements for the supply of component parts and manufacturing tools and supplies. Delays in the launching of our product would materially and adversely affect our business, prospects, financial condition and operating results.
We rely and will rely on independent contractors, consultants and other third parties to provide key development and operational services, and any disruption of their services, or an increase in cost of these services, would adversely affect our financial condition and results of operations.
We depend and will depend on subcontractors, consultants and other third parties to provide supply chain functions, including sourcing certain subcomponents and assemblies, and in process development activities. Our operations and operating results may be adversely affected if we experience problems with our subcontractors, consultants or other third parties. These problems may include delays in software or hardware development timelines; prolonged inability to obtain components with competitive performance and cost attributes; inability to achieve adequate yields or timely delivery; inability to meet customer timelines or demands; disruption or defects in assembly, test or shipping services; or delays in stabilizing manufacturing processes or increasing production volumes. If third-party providers were to reduce or discontinue services for us or their operations are disrupted, our financial condition and results of operations could be adversely affected.
We expect to incur significant research and development costs, which could materially reduce our profitability.
We intend to continue to incur costs and devote significant resources to the research and development of the Technologies and other metal processing technologies, which could significantly reduce our profitability. Our research and development efforts may not result in successful or commercially viable products. We also may elect to discontinue our research and development at any time, which may adversely affect our business prospects.
If our titanium metal products fail to perform as expected in our customers’ desired applications, our ability to develop, market and sell our products could be adversely affected.
Even if we are able to commence commercial production of titanium metal products, our products may contain defects in design and manufacture that may cause them to not perform as expected or that may require repairs, recalls, and design changes. Our products are inherently complex and incorporate technology and components that have not been used for other applications and that may contain defects and errors, particularly when first introduced. We have a limited frame of reference from which to evaluate the long-term performance of our planned products. We cannot assure you that we will be able to detect and fix any defects in our products prior to sale. If our products fail to perform as expected, we may lose customers or customers may delay or terminate orders, each of which could adversely affect our business, prospects and results of operations.
An inability to perfect the mineral extraction processes at our upstream Titan Project, or to perfect subsequent titanium metal production processes at our downstream titanium processing facility, may materially and adversely affect our financial condition or results of operations.
An inability to perfect the mineral extraction processes at our upstream Titan Project, or an inability to perfect subsequent titanium metal production processes at our downstream titanium processing facility, may materially and adversely affect our financial condition or results of operations. In addition, any delay or failure in developing processes to meet changing customer needs or specifications may materially and adversely affect our financial condition or results of operations.
10

TABLE OF CONTENTS

We may be unable to adequately control the costs associated with building our planned titanium metal production capacity.
We require significant capital to develop and grow our business, and we expect to incur significant expenses, including those relating to research and development, raw material procurement, leases, sales and distribution, as we build our titanium metal production capacity. Our ability to become profitable will depend on our ability to successfully market our titanium metal products while controlling our costs. If we are unable to cost effectively design, manufacture, market, sell and distribute our titanium metal products, our margins, profitability and prospects would be materially and adversely affected.
Titanium mineral extraction and processing and the production of titanium products involves complex machinery and operational risks.
The extraction and processing of titanium minerals and the production of titanium metal products requires complex machinery, some of which has not yet been operated in large-scale manufacturing. As a result, there is a significant degree of uncertainty and risk and that the Technologies and related machinery will not operate as expected or will be more costly to operate than expected. In addition, operational problems with the machinery could result in the personal injury to or death of workers, the loss of production equipment, damage to manufacturing facilities, monetary losses, delays and unanticipated fluctuations in production. In addition, operational problems may result in environmental damage, administrative fines, increased insurance costs and potential legal liabilities. All of these operational problems could materially and adversely affect our business, results of operations, cash flows, financial condition or prospects.
If we fail to accurately predict our manufacturing requirements and timelines, we could incur additional costs or experience delays.
We have not yet begun to commercialize our products. As a result, it is difficult to predict our future revenues and expenses or trends in such revenues or expenses. We have limited historical information to assess demand for our ability to extract and process titanium and to develop, manufacture and deliver titanium metal products.
We may be adversely affected by fluctuations in demand for, and prices of, titanium metal and products.
We expect to generate revenue from the sale of titanium metal and titanium products. As a result, our profitability could be adversely affected by changes in demand for, and the market price of, titanium metal and products.
The success of our business will depend on the growth of existing and emerging uses for titanium.
The success of our business will depend on the growth of existing and emerging uses for titanium. Our business strategy principally relies on commercializing the Technologies to produce titanium metal powders for high-growth markets, including the defense, space, aerospace and electric vehicle industries. Our long-term success depends on the continued growth of these markets and successfully commercializing titanium metal products in such markets. Our estimates of market opportunity and market growth, whether derived from third-party sources or developed internally, are subject to significant uncertainty and are based on assumptions and estimates that may prove to be inaccurate. If these markets do not grow as we expect or if the demand for our intended products decreases, then our business, prospects, financial condition and operating results could be adversely affected.
If we are unable to protect our intellectual property rights, our business and competitive position could be adversely affected.
We expect to rely heavily on our intellectual property portfolio. We may not be able to prevent unauthorized use of such intellectual property, which could harm our business and competitive position. We will rely upon a combination of patent, copyright, trademark and trade secret laws in the United States and other jurisdictions, as well as license agreements and other contractual protections, to establish, maintain and enforce rights in the Technologies. Despite our efforts to protect our proprietary rights, third parties may attempt to copy or otherwise obtain and use our intellectual property. Monitoring unauthorized use of our intellectual property is difficult and costly, and the steps we have taken or will take to prevent misappropriation may not be sufficient. Any enforcement efforts we undertake, including litigation, could be time-consuming and expensive and could divert management’s attention, which could harm our business, results of operations and financial condition. In addition, existing intellectual property laws and contractual remedies may afford less protection than needed to safeguard our intellectual property portfolio.
11

TABLE OF CONTENTS

Patent, copyright, trademark and trade secret laws vary significantly throughout the world. A number of foreign countries do not protect intellectual property rights to the same extent as do the laws of the United States. Therefore, our intellectual property rights may not be as strong or as easily enforced outside of the United States and efforts to protect against the unauthorized use of our intellectual property rights, technology and other proprietary rights may be more expensive and difficult outside of the United States. Failure to adequately protect our intellectual property rights could result in our competitors using our intellectual property to offer products, potentially resulting in the loss of some of our competitive advantage and a decrease in its revenue which would adversely affect our business, prospects, financial condition and operating results.
We may need to defend ourselves against intellectual property infringement claims, which may be time-consuming and could result in substantial costs to us.
Third parties may hold or obtain patents, trademarks or other proprietary rights that would prevent, limit or interfere with our ability to manufacture, develop or sell our products, which could make it more difficult for us to operate our business and generate revenue. From time to time, we may receive inquiries from holders of patents or trademarks inquiring whether we are infringing their proprietary rights and/or seeking court declarations that they do not infringe upon our intellectual property rights. Companies holding patents or other intellectual property rights relating to titanium metal products may bring suits alleging infringement of such rights or otherwise asserting their rights and seeking licenses. In addition, if we are determined to have infringed upon a third party’s intellectual property rights, we may be required to do one or more of the following: cease selling, incorporating or using products that incorporate the challenged intellectual property; pay substantial damages; obtain a license from the holder of the infringed intellectual property right, which license may not be available on reasonable terms or at all; or redesign our titanium metal products. In the event of a successful claim of infringement against us and our failure or inability to obtain a license to the infringed technology, our business, prospects, operating results and financial condition could be materially adversely affected. In addition, any litigation or claims, whether or not valid, could result in substantial costs and diversion of resources and management’s attention.
We may not be able to obtain additional intellectual property rights or the legal protection afforded by any existing intellectual property rights we hold may not adequately protect us.
Our ability to obtain additional intellectual property rights is uncertain and the legal protection afforded by our existing intellectual property rights may not adequately protect us. In addition, the specific content required of patents and patent applications that are necessary to support and interpret patent claims is highly uncertain due to the complex nature of the relevant legal, scientific and factual issues. Changes in either intellectual property laws or interpretations of intellectual property laws in the United States or elsewhere may narrow or diminish the value of our intellectual property rights. For example, even if patents are issued regarding our products and processes, our competitors may challenge the validity of those patents or competitors may devise ways of making products without infringing our patents.
Changes in the U.S. political environment and federal policies, including changes in research grant funding policy or the potential critical materials designation of titanium metal may adversely affect our financial condition and results of operations.
Our sales may be adversely affected by the current and future political environment in the United States and the policies of the U.S. federal government, including changes in research grant funding policy or the potential critical materials designation of titanium metal, which may adversely affect our financial condition and results of operations.
Our operations may be further disrupted, and our financial results may be adversely affected by the novel coronavirus pandemic.
If a significant portion of our workforce or the consultants we have engaged to perform certain studies regarding our proposed operations becomes unable to work or travel to our operations due to illness or state or federal government restrictions in response to the COVID-19 pandemic, we may be forced to reduce or suspend our exploration, development or manufacturing activities, any of which could materially and adversely affect our business and results of operations.
There is no guarantee that our properties will result in the commercial extraction of mineral deposits.
In our upstream operations, we are engaged in the business of exploring and developing mineral properties with the intention of locating economic deposits of titanium metal. We cannot assure you that, to the extent economic deposits of minerals are located, such minerals can be commercially extracted. The exploration and development
12

TABLE OF CONTENTS

of mineral deposits involves a high degree of financial risk over a significant period of time which a combination of careful evaluation, experience and knowledge of management may not eliminate. While discovery of additional ore-bearing deposits may result in substantial rewards, few properties which are explored are ultimately developed into producing extraction sites. Major expenses may be required to establish reserves by drilling and to construct extraction and processing facilities. Exploration project items, such as any future estimates of reserves, metal recoveries or cash operating costs will to a large extent be based upon the interpretation of geologic data, obtained from a limited number of drill holes and other sampling techniques, and future feasibility studies. Actual operating costs and economic returns of any and all exploration projects may materially differ from the costs and returns estimated, and accordingly our financial condition, results of operations, and cash flows may be adversely affected.
Because the probability of an individual prospect ever having reserves is not known, our properties may not contain any reserves, and any funds spent on exploration and evaluation may be lost.
We currently have no reserves, and we cannot assure you about the existence of economically extractable mineralization at this time, nor about the quantity or grade of any mineralization we may have found. Because the probability of an individual prospect ever having reserves is uncertain, our properties may not contain any reserves and any funds spent on evaluation and exploration may be lost. Even if we confirm reserves on our properties, any quantity or grade of reserves we indicate must be considered as estimates only until such reserves are actually extracted. We do not know with certainty that economically recoverable metals exist on our properties.
We face risks related to minerals extraction, exploration and site construction.
It is impossible to ensure that the current and future exploration programs or feasibility studies on our existing properties will establish reserves. Whether it will be economically feasible to extract metals depends on a number of factors, including, but not limited to: the particular attributes of the deposit, such as size, grade and proximity to infrastructure; sales prices; minerals extraction, processing and transportation costs; the willingness of lenders and investors to provide project financing; labor costs and possible labor strikes; and governmental regulations, including, without limitation, regulations relating to prices, taxes, royalties, land tenure, land use, importing and exporting materials, foreign exchange, environmental protection, employment, worker safety, transportation, and reclamation and closure obligations. The exact effect of these factors cannot be accurately predicted, but the combination of these factors may result in us receiving an inadequate return on invested capital. In addition, we are subject to the risks normally encountered in the minerals extraction industry, such as: the discovery of unusual or unexpected geological formations; accidental fires, floods, earthquakes or other natural disasters; unplanned power outages and water shortages; controlling water and other similar extraction hazards; operating labor disruptions and labor disputes; the ability to obtain suitable or adequate machinery, equipment, or labor; our liability for pollution or other hazards; and other known and unknown risks involved in the conduct of exploration and operation of minerals extraction sites. The nature of these risks is such that liabilities could exceed any applicable insurance policy limits or could be excluded from coverage. There are also risks against which we cannot insure or against which we may elect not to insure. The potential costs which could be associated with any liabilities not covered by insurance, or in excess of insurance coverage, or compliance with applicable laws and regulations may cause substantial delays and require significant capital outlays, adversely affecting our results of operations and financial viability.
We depend on our ability to successfully access the capital and financial markets. Any inability to access the capital or financial markets may limit our ability to fund our ongoing operations, execute our business plan or pursue investments that we may rely on for future growth.
Until we achieve commercial production of titanium metals or titanium products, we will continue to incur operating and investing net cash outflows associated with, among other things, exploration and development activities and maintaining and acquiring exploration properties. As a result, we rely on access to capital markets as a source of funding for our capital and operating requirements. We will require substantial additional capital to fund ongoing operations, explore and define metal reserves and resources, conduct feasibility studies and construct extraction and manufacturing operations. We cannot assure you that such additional funding will be available to us on satisfactory terms, or at all. If we are unable to obtain additional financing, as needed and at competitive rates, our ability to implement our business plan and strategy will be adversely affected. We cannot assure you that we will be able to secure any additional funding or be able to secure funding which will provide us with sufficient funds to meet our objectives, which may adversely affect our business and financial position. Certain market disruptions may increase our cost of borrowing or affect our ability to access one or more
13

TABLE OF CONTENTS

financial markets. Such market disruptions could result from: adverse economic conditions; adverse general capital market conditions; poor performance and health of the minerals and metals industry or minerals extraction in general; bankruptcy or financial distress of other metals companies; significant decrease in the demand for metals; or adverse regulatory actions that affect our exploration and construction plans.
We depend on key management employees.
The responsibility of overseeing the day-to-day operations and the strategic management of our business depends substantially on our senior management and our key personnel. Loss of such personnel may have an adverse effect on our performance. The success of our operations will depend upon numerous factors, many of which are beyond our control, including our ability to attract and retain key employees and hire qualified management, technical, engineering and sales personnel. We currently depend upon a relatively small number of key persons to seek out and form strategic alliances and find and retain additional employees. Certain areas in which we operate are highly competitive regions and competition for qualified personnel is intense. We may be unable to hire suitable field personnel for our technical team or there may be periods of time where a particular position remains vacant while a suitable replacement is identified and appointed. We may not be successful in attracting and retaining the personnel required to grow and operate our business profitably.
Our growth will require new personnel, which we will be required to recruit, hire, train and retain.
Our ability to achieve our objectives depends on the ability of our directors, officers and management to implement current plans and respond to any unforeseen circumstances that require changes to those plans. The execution of our exploration and development plans will place demands on us and our management. Our ability to recruit and assimilate new personnel will be critical to our performance. We will be required to recruit additional personnel and to train, motivate and manage employees, which may adversely affect our plans.
Our success will depend in part on developing and maintaining relationships with local communities and other stakeholders.
Our success will depend in part on developing and maintaining productive relationships with the communities surrounding our operations and other stakeholders in our operating locations. Notwithstanding our ongoing efforts, local communities and stakeholders can become dissatisfied with our activities, which may result in legal or administrative proceedings or campaigns against us, which could materially adversely affect our financial condition, results of operations and cash flows.
Our business could be materially adversely affected if our reputation is harmed.
Our reputation is important to the success of our business, including our ability to develop our minerals extraction operations, obtain required permits and license the Technologies. If our reputation is damaged, as a result of our actions or by events outside of our control, our business and results of operations could be adversely affected. If we fail to address, or appear to fail to address, successfully and promptly, the underlying causes of any reputational harm, we may be unsuccessful in repairing any damage to our reputation and our future business prospects would likely be materially adversely affected.
Our mineral properties may be subject to defects in title.
The ownership and validity or title of unpatented minerals extraction claims and concessions are often uncertain and may be contested. We also may not have, or may not be able to obtain, all necessary surface rights to develop a property. Although we have taken reasonable measures to ensure proper title to our properties, there is no guarantee that title to any of our properties will not be challenged or impugned. Title insurance is generally not available for mineral properties and our ability to ensure that we have obtained a secure claim to individual mineral properties or extraction concessions may be severely constrained. Our mineral properties may be subject to prior unregistered agreements, transfers or claims, and title may be affected by, among other things, undetected defects. We may incur significant costs related to defending the title to our properties. A successful claim contesting our title to a property may cause us to compensate other persons or perhaps reduce our interest in the affected property or lose our rights to explore and, if warranted, develop that property. This could result in us not being compensated for our prior expenditures relating to the property.
Our directors and officers may be in a position of conflict of interest.
Some of our directors and officers currently also serve as directors and officers of other companies involved in natural resource exploration, development and production, and any of our directors may in the future serve in such positions. In particular, Todd Hannigan and Lamont Leatherman currently serve as director and chief
14

TABLE OF CONTENTS

geologist, respectively, of Piedmont Lithium Inc., and Gregory Swan serves as director and secretary of certain subsidiaries of Piedmont Lithium Inc. There exists the possibility that they may in the future be in a position of conflict of interest. Any decision made by such persons involving us will be made in accordance with their duties and obligations to deal fairly and in good faith with us and such other companies. In addition, any such directors will declare, and refrain from voting on, any matter in which such directors may have a material interest.
Lawsuits may be filed against us and an adverse ruling in any such lawsuit may adversely affect our business, financial condition or liquidity or the market price of the ADSs.
The products we intend to supply may be used in potentially hazardous or critical applications that could result in death, personal injury, property damage, loss of production, punitive damages and consequential damages. Actual or claimed defects in the products we supply could result in our being named as a defendant in lawsuits asserting potentially large claims. The outcome of outstanding, pending or future proceedings cannot be predicted with certainty and may be determined adversely to us and as a result, could have a material adverse effect on our assets, liabilities, business, financial condition or results of operations. Even if we prevail in any such legal proceeding, the proceedings could be costly and time-consuming and may divert the attention of management and key personnel from our business operations, which could adversely affect our financial condition.
Risks Related to Regulatory and Industry Matters
We will be subject to significant governmental regulations, including the U.S. Federal Mine Safety and Health Act.
Minerals extraction activities in the United States are subject to extensive federal, state, local and foreign laws and regulations governing environmental protection, natural resources, prospecting, development, production, post-closure reclamation, taxes, labor standards and occupational health and safety laws and regulations, including mine safety, toxic substances and other matters. The costs associated with compliance with such laws and regulations are substantial. In addition, changes in such laws and regulations, or more restrictive interpretations of current laws and regulations by governmental authorities, could result in unanticipated capital expenditures, expenses or restrictions on or suspensions of our operations and delays in the development of our properties.
We will be required to obtain governmental permits in order to conduct development and minerals extraction operations, a process which is often costly and time-consuming.
We are required to obtain and renew governmental permits for our exploration activities and, prior to developing or extracting any mineralization that we discover, we will be required to obtain new governmental permits. Obtaining and renewing governmental permits is a complex and time-consuming process. The timeliness and success of permitting efforts are contingent upon many variables not within our control, including the interpretation of permit approval requirements administered by the applicable permitting authority. We may not be able to obtain or renew permits that are necessary to our planned operations or the cost and time required to obtain or renew such permits may exceed our expectations, which in turn could materially adversely affect our future revenues and profitability. In addition, private parties, such as environmental activists, frequently attempt to intervene in the permitting process and to persuade regulators to deny necessary permits or seek to overturn permits that have been issued. These third-party actions can materially increase the costs and cause delays in the permitting process and could cause us to not proceed with the development or operation of a property.
Compliance with environmental regulations and litigation based on environmental regulations could require significant expenditures.
Environmental regulations mandate, among other things, the maintenance of air and water quality standards, land development and land reclamation, and set forth limitations on the generation, transportation, storage and disposal of solid and hazardous waste. In connection with our current exploration activities or in connection with our prior extraction operations, we may incur environmental costs that could have a material adverse effect on financial condition and results of operations. Any failure to remedy an environmental problem could require us to suspend operations or enter into interim compliance measures pending completion of the required remedy. Moreover, governmental authorities and private parties may bring lawsuits based upon damage to property and injury to persons resulting from the environmental, health and safety impacts of prior and current operations, including operations conducted by other extraction companies many years ago at sites located on properties that we currently own or formerly owned. We cannot assure you that any such law, regulation, enforcement or private claim would not have a material adverse effect on our financial condition, results of operations or cash flows. If
15

TABLE OF CONTENTS

we violate or fail to comply with applicable environmental laws and regulations, we could be subject to penalties, restrictions on operations or other sanctions. Such liability could materially adversely affect our reputation, business, results of operations and financial condition.
Mineral and metal prices are subject to unpredictable fluctuations.
We expect our future revenues, if any, to be derived in part from the extraction and sale of critical minerals including titanium, rare earth elements, silica sand and zircon. The price of such minerals and metals may fluctuate widely and is affected by numerous factors beyond our control, including international, economic and political trends, expectations of inflation, currency exchange fluctuations, interest rates, global or regional consumptive patterns, speculative activities, increased production due to new extraction developments and improved extraction and production methods and technological changes in the markets for the end products. The effect of these factors on metals prices, and therefore the economic viability of any of our exploration properties, cannot accurately be predicted. Additionally, new production of critical minerals including titanium, rare earth elements, silica sand and zircon from current or new competitors in the critical minerals markets could adversely affect prices. In recent years, new and existing competitors have increased the supply of certain critical minerals including titanium, rare earth elements, silica sand and zircon, which has affected its price. Further production increases could negatively affect prices. We cannot make accurate projections regarding the capacities of possible new entrants into the market and the dates on which they could become operational.
Risks Related to Our ADSs
An active trading market for the ADSs may not develop and the trading price for our ADSs may fluctuate significantly.
Currently, there is no public market in the United States for the ADSs. However, in connection with the filing of this registration statement on Form 20-F, we intend to apply for a listing of the ADSs on Nasdaq. If an active public market in the United States for the ADSs does not develop the market price and liquidity of the ADSs may be adversely affected. While we intend to apply for a listing of the ADSs on Nasdaq, a liquid public market in the United States for the ADSs may not develop or be sustained should the ADSs be approved for listing on Nasdaq, which means you may experience a decrease in the value of the ADSs regardless of our operating performance. In the past, following periods of volatility in the market price of a company’s securities, shareholders often instituted securities class action litigation against that company. If we were involved in a class action suit, it could divert the attention of senior management and, if adversely determined, could have a material adverse effect on our results of operations and financial condition.
The market price and trading volume of the ADSs may be volatile and may be affected by economic conditions beyond our control.
The market price of the ADSs may be highly volatile and subject to wide fluctuations. In addition, the trading volume of the ADSs may fluctuate and cause significant price variations to occur. If the market price of the ADSs declines significantly, you may be unable to resell your ADSs at or above the purchase price, if at all. We cannot assure you that the market price of the ADSs will not fluctuate or significantly decline in the future. Some specific factors that could negatively affect the price of the ADSs or result in fluctuations in their price and trading volume include: actual or expected fluctuations in our prospects or operating results; changes in the demand for, or market price of, metals prices; additions to or departures of our key personnel; fluctuations of exchange rates between the U.S. dollar and the Australian dollar; changes or proposed changes in laws and regulations; changes in trading volume of ADSs on Nasdaq and of our ordinary shares on the ASX; sales or perceived potential sales of the ADSs or ordinary shares by us, our directors, senior management or our shareholders in the future; announcement or expectation of additional financing efforts; and conditions in the U.S. or Australian financial markets or changes in general economic conditions.
Our ADS holders are not shareholders and do not have shareholder rights.
The Bank of New York Mellon, as depositary, issues and delivers ADSs. Our ADS holders will not be treated as shareholders and will not have shareholders rights. The depositary will be the holder of our ordinary shares underlying our ADSs. Holders of our ADSs will have ADS holder rights. A deposit agreement among us, the depositary, our ADS holders, and the beneficial owners of ADSs, sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs. We and the depositary may amend or terminate the deposit agreement without the ADS holders’ consent in a manner that
16

TABLE OF CONTENTS

could prejudice ADS holders. For a description of ADS holder rights, see “Item 12. Description of Securities Other Than Equity Securities—D. American Depositary Shares.” Our shareholders have shareholder rights. Australian law and our Constitution govern shareholder rights. For a description of the rights of our ordinary shares, see “Item 10. Additional Information—A. Share Capital.”
Our ADS holders do not have the same voting rights as our shareholders. Shareholders are entitled to receive our notices of general meetings and to attend and vote at our general meetings of shareholders. At a general meeting, every shareholder present (in person or by proxy, attorney or representative) and entitled to vote has one vote on a show of hands. Every shareholder present (in person or by proxy, attorney or representative) and entitled to vote has one vote per fully paid ordinary share on a poll. This is subject to any other rights or restrictions which may be attached to any shares. Our ADS holders may instruct the depositary to vote the ordinary shares underlying their ADSs, but only if we ask the depositary to ask for their instructions. If we do not ask the depositary to ask for the instructions, our ADS holders are not entitled to receive our notices of general meeting. Our ADS holders will not be entitled to attend and vote at a general meeting unless they surrender their ADSs and withdraw the ordinary shares. However, our ADS holders may not have sufficient advance notice about the meeting to surrender their ADSs and withdraw the shares. If we ask for our ADS holders’ instructions, the depositary will notify our ADS holders of the upcoming vote and arrange to deliver our voting materials and form of notice to them. The depositary will try, as far as practical, subject to Australian law and the provisions of the deposit agreement, to vote the shares as our ADS holders instruct. The depositary will not vote or attempt to exercise the right to vote other than in accordance with the instructions of the ADS holders. We cannot assure our ADS holders that they will receive the voting materials in time to ensure that they can instruct the depositary to vote their shares. In addition, there may be other circumstances in which our ADS holders may not be able to exercise voting rights.
Our ADS holders do not have the same rights to receive dividends or other distributions as our shareholders. Subject to any special rights or restrictions attached to any shares, the directors may determine that a dividend will be payable on our ordinary shares and fix the amount, the time for payment and the method for payment (although we have never declared or paid any cash dividends on our ordinary shares and we do not anticipate paying any cash dividends in the foreseeable future). Dividends may be paid on our ordinary shares of one class but not another and at different rates for different classes. Dividends and other distributions payable to our shareholders with respect to our ordinary shares generally will be payable directly to them. Any dividends or distributions payable with respect to ordinary shares will be paid to the depositary, which has agreed to pay to our ADS holders the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, after deducting its fees and expenses and subject to the provisions of the deposit agreement. Before the depositary makes a distribution to you on behalf of your ADSs, any withholding taxes that must be paid will be deducted. Additionally, if the exchange rate fluctuates during a time when the ADS depositary cannot convert the foreign currency, you may lose some or all of the value of the distribution. Our ADS holders will receive these distributions in proportion to the number of ordinary shares their ADSs represent. In addition, there may be certain circumstances in which the depositary may not pay to our ADS holders amounts distributed by us as a dividend or distribution.
There are circumstances where it may be unlawful or impractical to make distributions to the holders of our ADSs.
The deposit agreement with the depositary allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. If a distribution is payable by us in Australian dollars, the depositary will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, our ADS holders may lose some of the value of the distribution. The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. This means that our ADS holders may not receive the distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to them.
Holders of the ADSs may have difficulty in effecting service of process in the United States or enforcing judgments obtained in the United States.
We are a public company incorporated under the laws of Australia. Therefore, the rights of holders of our ordinary shares are governed by Australian law and our Constitution. These rights differ from the typical rights of shareholders in U.S. corporations. The rights of holders of ADSs are affected by Australian law and our Constitution but are governed by U.S. law. Circumstances that under U.S. law may entitle a shareholder in a U.S. company to claim damages may also give rise to a cause of action under Australian law entitling a
17

TABLE OF CONTENTS

shareholder in an Australian company to claim damages. However, this will not always be the case. Holders of the ADSs may have difficulties enforcing, in actions brought in courts in jurisdictions located outside the United States, liabilities under U.S. securities laws. In particular, if such a holder sought to bring proceedings in Australia based on U.S. securities laws, the Australian court might consider whether: it did not have jurisdiction; it was not an appropriate forum for such proceedings; applying Australian conflict of laws rule, U.S. law (including U.S. securities laws) did not apply to the relationship between holders of our ordinary shares or ADSs and us or our directors and officers; or the U.S. securities laws were of a public or penal nature and should not be enforced by the Australian court.
Certain of our directors and executive officers are residents of countries other than the United States. Furthermore, a portion of our and their assets are located outside the United States. As a result, it may not be possible for a holder of our ordinary shares or ADSs to: effect service of process within the United States upon certain directors and executive officers or on us; enforce in U.S. courts judgments obtained against any of our directors and executive officers or us in the U.S. courts in any action, including actions under the civil liability provisions of U.S. securities laws; enforce in U.S. courts judgments obtained against any of our directors and senior management or us in courts of jurisdictions outside the United States in any action, including actions under the civil liability provisions of U.S. securities laws; or bring an action in an Australian court to enforce liabilities against any of our directors and executive officers or us based upon U.S. securities laws. Holders of our ordinary shares and ADSs may also have difficulties enforcing in courts outside the U.S. judgments obtained in the U.S. courts against any of our directors and executive officers or us, including actions under the civil liability provisions of the U.S. securities laws.
ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s) in any such action.
The deposit agreement governing the ADSs provides that, to the fullest extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. The waiver of jury trial provision applies to all holders of our ADSs, including purchasers who acquire the ADSs on the open market. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. In addition, New York courts will not enforce a jury trial waiver provision in order to bar a viable setoff or counterclaim sounding in fraud or one which is based upon a creditor’s negligence in failing to liquidate collateral upon a guarantor’s demand, or in the case of an intentional tort claim (as opposed to a contract dispute), none of which we believe are applicable in the case of the deposit agreement or the ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before entering into the deposit agreement.
If you or any other owner or holder of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, you or such other owner or holder may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us and/or the depositary. If a lawsuit is brought against us and/or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s) in any such action. Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any owner or holder of ADSs or by us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules and regulations promulgated thereunder. By agreeing to the jury trial waiver provision in the deposit agreement, investors will
18

TABLE OF CONTENTS

not be deemed to have waived our compliance with or the depositary’s compliance with the federal securities laws and the rules and regulations promulgated thereunder.
The dual listing of our ordinary shares and the ADSs may adversely affect the liquidity and value of the ADSs.
Our ordinary shares are listed on the ASX and our ADSs are expected to be listed on Nasdaq. We cannot predict the effect of this dual listing on the value of our ordinary shares and ADSs. However, the dual listing of our ordinary shares and ADSs may dilute the liquidity of these securities in one or both markets and may adversely affect the development of an active trading market for the ADSs in the United States. The price of the ADSs could also be adversely affected by trading in our ordinary shares on the ASX.
Certain of outstanding securities may dilute the value of our ordinary shares.
As of December 31, 2021, we had 139,488,491 ordinary shares outstanding. We also have 39,600,000 ordinary shares reserved for issuance upon conversion of performance shares upon the satisfaction of the performance conditions. To the extent that the conditions to the vesting of such securities are satisfied, the value of our ordinary shares may be diluted.
Currency fluctuations may adversely affect the price of the ADSs relative to the price of our ordinary shares.
The price of our ordinary shares is quoted in Australian dollars, and the price of the ADSs is quoted in U.S. dollars. Movements in the Australian dollar/U.S. dollar exchange rate may adversely affect the U.S. dollar price of the ADSs and the U.S. dollar equivalent of the price of our ordinary shares. If the Australian dollar weakens against the U.S. dollar, the U.S. dollar price of the ADSs could decline, even if the price of our ordinary shares in Australian dollars increases or remains unchanged. If we pay dividends, we will likely calculate and pay any cash dividends in Australian dollars and, as a result, exchange rate movements will affect the U.S. dollar amount of any dividends holders of the ADSs will receive from the depositary.
As a foreign private issuer, we are permitted and expect to follow certain home country corporate governance practices in lieu of certain Nasdaq requirements applicable to domestic issuers.
As a foreign private issuer listed on Nasdaq, we are permitted to follow certain home country corporate governance practices in lieu of certain Nasdaq practices. Following our home country corporate governance practices, as opposed to the requirements that would otherwise apply to a U.S. company listed on Nasdaq, may provide less protection than is afforded to investors under the Nasdaq rules applicable to domestic issuers.
In particular, we follow home country law instead of Nasdaq practice regarding:
Nasdaq’s requirement that our independent directors meet regularly in executive sessions. The ASX Listing Rules and the Corporations Act do not require the independent directors of an Australian company to have such executive sessions and, accordingly, we have claimed this exemption.
Nasdaq’s requirement that an issuer provide for a quorum as specified in its bylaws for any meeting of the holders of ordinary shares, which quorum may not be less than 33 1/3% of the outstanding shares of an issuer’s voting ordinary shares. In compliance with Australian law, our Constitution provides that two shareholders present shall constitute a quorum for a general meeting.
Nasdaq’s requirement that issuers obtain shareholder approval prior to the issuance of securities in connection with certain acquisitions, changes of control or private placements of securities, or the establishment or amendment of certain stock option, purchase or other compensation plans. Applicable Australian law and rules differ from Nasdaq requirements, with the ASX Listing Rules providing generally for prior shareholder approval in numerous circumstances, including (i) issuance of equity securities exceeding 15% (or an additional 10% capacity to issue equity securities for the proceeding 12-month period if shareholder approval by special resolution is sought at the Company’s annual general meeting) of our issued share capital in any 12-month period (but, in determining the available issue limit, securities issued under an exception to the rule or with shareholder approval are not counted), (ii) issuance of equity securities to related parties (as defined in the ASX Listing Rules) and (iii) directors or their associates acquiring securities under an employee incentive plan.
As a foreign private issuer, we are permitted to file less information with the SEC than a domestic issuer.
As a foreign private issuer, we are exempt from certain rules under the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”), that impose requirements for proxy solicitations under Section 14 of the
19

TABLE OF CONTENTS

Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as a domestic issuer, nor are we generally required to comply with the SEC’s Regulation FD, which restricts the selective disclosure of material non-public information. Under Australian law, we prepare financial statements on an annual and semi-annual basis, we are not required to prepare or file quarterly financial information other than quarterly updates. Our quarterly updates have consisted of a brief review of operations for the quarter together with a statement of cash expenditure during the quarter and the cash and cash equivalents balance as at the end of the quarter.
We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act’s domestic reporting regime and cause us to incur additional legal, accounting and other expenses.
We are required to determine our status as a foreign private issuer on an annual basis at the end of our second fiscal quarter. In order to maintain our current status as a foreign private issuer, either (1) a majority of our ordinary shares must be either directly or indirectly owned of record by non-residents of the United States or (2) (a) a majority of our executive officers or directors must not be U.S. citizens or residents, (b) more than 50 percent of our assets cannot be located in the United States and (c) our business must be administered principally outside the United States. If we lost this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices and to comply with United States generally accepted accounting principles, as opposed to IFRS. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs.
We are an emerging growth company, and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies may make the ADSs less attractive to investors and, as a result, adversely affect the price of the ADSs and result in a less active trading market for the ADSs.
We are an emerging growth company as defined in the U.S. Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. For example, we have elected to rely on an exemption from the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) relating to internal control over financial reporting, and we will not provide such an attestation from our auditors. We may avail ourselves of these disclosure exemptions until we are no longer an emerging growth company. We cannot predict whether investors will find the ADSs less attractive because of our reliance on some or all of these exemptions. If investors find the ADSs less attractive, it may adversely affect the price of the ADSs and there may be a less active trading market for the ADSs. We will cease to be an emerging growth company upon the earliest of: the last day of the fiscal year during which we have total annual gross revenues of US$1,070,000,000 (as such amount is indexed for inflation every five years by the SEC) or more; the last day of our fiscal year following the fifth anniversary of the completion of our first sale of common equity securities pursuant to an effective registration statement under the Securities Act; the date on which we have, during the previous three-year period, issued more than US$1,070,000,000 in non-convertible debt; or the date on which we are deemed to be a “large accelerated filer,” as defined in Rule 12b-2 of the Exchange Act, which would occur if the market value of our ordinary shares and ADSs that are held by non-affiliates exceeds US$700,000,000 as of the last day of our most recently completed second fiscal quarter.
We will incur significant costs as a result of operating as a company whose ADSs are publicly traded in the United States, and our management is required to devote substantial time to compliance initiatives.
As a company whose ADSs will be publicly traded in the United States, we will incur significant legal, accounting, insurance and other expenses that we did not previously incur. In addition, the Sarbanes-Oxley Act, Dodd-Frank Wall Street Reform and Consumer Protection Act and related rules implemented by the SEC, have imposed various requirements on public companies including requiring establishment and maintenance of effective disclosure and internal controls. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives, and we may need to add additional personnel and build our internal compliance infrastructure. Moreover, these rules and regulations increase our legal and financial
20

TABLE OF CONTENTS

compliance costs and make some activities more time consuming and costly. These laws and regulations could also make it more difficult and expensive for us to attract and retain qualified persons to serve on our board of directors, our board committees or as our senior management. Furthermore, if we are unable to satisfy our obligations as a public company in the United States, we could be subject to delisting of the ADSs, fines, sanctions and other regulatory action and potentially civil litigation.
We do not anticipate paying dividends in the foreseeable future.
We have not declared any dividends during the last three fiscal years and do not anticipate that we will do so in the foreseeable future. We currently intend to retain future earnings, if any, to finance the development of our business. Dividends, if any, on our outstanding ordinary shares will be declared by and subject to the discretion of the Board on the basis of our earnings, financial requirements and other relevant factors, and subject to Australian law. As a result, a return on your investment will only occur if our ADS price appreciates. We cannot assure you that the ADSs will appreciate in value or even maintain the price at which you purchase the ADSs.
If U.S. securities or industry analysts do not publish research reports about our business, or if they issue an adverse opinion about our business, the market price and trading volume of our ordinary shares or ADSs could decline.
The trading market for our ordinary shares and ADSs will be influenced by the research and reports that U.S. securities or industry analysts publish about us or our business. Securities and industry analysts may discontinue research on us, to the extent such coverage currently exists, or in other cases, may never publish research on us. If no or too few U.S. securities or industry analysts commence coverage of our Company, the trading price for the ADSs would likely be negatively affected. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade the ADSs or publish inaccurate or unfavorable research about our business, the market price of the ADSs would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for the ADSs could decrease, which might cause our price and trading volume to decline. In addition, research and reports that Australian securities or industry analysts publish about us, our business or our ordinary shares may impact the market price of the ADSs.
You may be subject to limitations on transfers of your ADSs.
Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason.
We and the depositary are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, and we may terminate the deposit agreement, without the prior consent of the ADS holders.
We and the depositary are entitled to amend the deposit agreement and to change the rights of the ADS holders under the terms of such agreement, without the prior consent of the ADS holders. In the event that the terms of an amendment are materially prejudicial to ADS holders’ substantial rights, ADS holders will only receive 30 days’ advance notice of the amendment, and no prior consent of the ADS holders is required under the deposit agreement. Furthermore, we may decide to terminate the ADS facility at any time for any reason, or the depositary agent may on its own initiative terminate the deposit agreement. If the ADS facility will terminate, ADS holders will receive at least 90 days’ prior notice, but no prior consent is required from them. Under the circumstances that we decide to make an amendment to the deposit agreement that is materially prejudicial to the substantial rights of the ADS holders or terminate the deposit agreement, the ADS holders may choose to sell their ADSs or surrender their ADSs and become direct holders of the underlying ordinary shares, but will have no right to any compensation whatsoever.
ADS holders have limited recourse if we or the depositary fail to meet our respective obligations under the deposit agreement.
The deposit agreement expressly limits our obligations and liability and those of the depositary. We and the depositary are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith, and the depositary will not be a fiduciary or have any fiduciary duty to holders of ADSs;
21

TABLE OF CONTENTS

are not liable if we are or it is prevented or delayed by law or by events or circumstances beyond our or its ability to prevent or counteract with reasonable care or effort from performing our or its obligations under the deposit agreement; are not liable if we or it exercises discretion permitted under the deposit agreement; are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement; have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person; and are not liable for the acts or omissions of any securities depository, clearing agency or settlement system.
Our Constitution and Australian laws and regulations applicable to us may adversely affect our ability to take actions that could be beneficial to our shareholders.
As an Australian company we are subject to different corporate requirements than a corporation organized under the laws of the United States. Our Constitution, as well as the Australian Corporations Act, set forth various rights and obligations that are unique to us as an Australian company. These requirements may operate differently than those of many U.S. companies.
If we fail to maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.
We are subject to the reporting obligations under the U.S. securities laws. The SEC, as required under Section 404 of the Sarbanes-Oxley Act, has adopted rules requiring a public company to include a report of management on the effectiveness of such company’s internal control over financial reporting in its annual report on Form 20-F. In addition, once we cease to be an “emerging growth company,” as such term is defined in the JOBS Act, an independent registered public accounting firm for a public company must issue an attestation report on the effectiveness of our internal control over financial reporting. If in the future we are unable to conclude that we have effective internal controls over financial reporting or our independent auditors are unwilling or unable to provide us with an unqualified report on the effectiveness of our internal controls over financial reporting as required by the Sarbanes-Oxley Act, investors may lose confidence in our operating results, the price of the ADSs could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of the Sarbanes-Oxley Act, we may not be able to remain listed on Nasdaq.
We believe that we were a passive foreign investment company (“PFIC”) for U.S. federal income tax purposes for the taxable year ended June 30, 2021, and we expect to be a PFIC for the taxable year ending June 30, 2022, which could have adverse tax consequences for our investors.
The rules governing PFICs can have adverse consequences for U.S. investors for U.S. federal income tax purposes. Under the Internal Revenue Code of 1986, as amended (the “Code”), we will be a PFIC for any taxable year in which, after the application of certain “look-through” rules with respect to our subsidiaries, either (i) 75% or more of our gross income consists of “passive income,” or (ii) 50% or more of the average quarterly value of our assets consist of assets that produce, or are held for the production of, “passive income.” Passive income generally includes interest, dividends, rents, certain non-active royalties and capital gains. We believe that we were a PFIC for the taxable year ended June 30, 2021 because we did not have active business income in that taxable year, and we expect to be a PFIC for the current taxable year ending June 30, 2022 because we do not expect to begin active business operations in the current taxable year. If we are characterized as a PFIC for any taxable year during which a U.S. Holder (as defined in “Item 10. Additional Information—E. Taxation—Material U.S. Federal Income Tax Considerations”) holds ADSs or ordinary shares, we generally would continue to be treated as a PFIC with respect to that U.S. Holder for all succeeding years during which the U.S. Holder holds ADSs or ordinary shares, even if we ceased to meet the threshold requirements for PFIC status. Such a U.S. Holder may suffer adverse tax consequences, including ineligibility for any preferential tax rates on capital gains or on actual or deemed dividends, interest charges on certain taxes treated as deferred and additional reporting requirements under U.S. federal income tax laws and regulations. A U.S. Holder may, in certain circumstances, make a timely qualified electing fund (“QEF”) election or a mark to market election to avoid or minimize the adverse tax consequences described above. We do not, however, expect to provide the information regarding our income that would be necessary in order for a U.S. Holder to make a QEF election. Potential investors should consult their own tax advisors regarding all aspects of the application of the PFIC rules to our ADSs and ordinary shares.
22

TABLE OF CONTENTS

Our internal controls over financial reporting do not currently meet all of the standards contemplated by Section 404 of the Sarbanes-Oxley Act, and failure to achieve and maintain effective internal control over financial reporting in accordance with Section 404 could have a material adverse effect on our business and the price of our ordinary shares.
We are not currently required to comply with the rules of the SEC implementing Section 404 of the Sarbanes-Oxley Act, and therefore we and our independent registered public accounting firm were not required to, and did not, make a formal assessment of the effectiveness of our internal control over financial reporting for that purpose. Upon becoming a public company, we will be required to comply with the SEC’s rules implementing Sections 302 and 404 of the Sarbanes-Oxley Act, which will require management to certify financial and other information in our SEC reports and provide an annual management report on the effectiveness of control over financial reporting. We will not be required to make our first annual assessment of our internal control over financial reporting pursuant to Section 404 until the year following our first annual report required to be filed with the SEC. As an emerging growth company, our independent registered public accounting firm will generally not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 until we are no longer an emerging growth company (but in no case earlier than the year following our first annual report required to be filed with the SEC).
Our management has not completed an assessment of the effectiveness of our internal control over financial reporting, and our independent registered public accounting firms have not conducted an audit of our internal control over financial reporting. In connection with the preparation of our financial statements as of and for the years ended June 30, 2021, we identified certain control deficiencies in the design and implementation of our internal control over financial reporting that constituted material weaknesses. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. Our evaluation was based on the Committee of Sponsoring Organizations of the Treadway Commission Internal Control—Integrated Framework (2013).
The material weaknesses identified by management relate to the following:
We have not sufficiently designed, implemented and documented internal controls at the entity level and across the key business and financial processes to allow us to achieve complete, accurate and timely financial reporting.
We have not designed and implemented controls to maintain appropriate segregation of duties in our manual and IT based business processes.
As of the date of this registration statement these remain material weaknesses. We cannot assure you that we have identified all of our existing material weaknesses. Material weaknesses may still exist when we report on the effectiveness of our internal control over financial reporting as required under Section 404 of the Sarbanes-Oxley Act. In addition, prior acquisitions, such as the HMAPL acquisition, and future acquisitions may present challenges in implementing appropriate internal controls. Any future material weaknesses in internal control over financial reporting could result in material misstatements in our financial statements.
The presence of material weaknesses could result in financial statement errors which, in turn, could lead to errors in our financial reports or delays in our financial reporting, which could require us to restate our financial statements or result in our auditors issuing a qualified audit report. Moreover, any future disclosures of additional material weaknesses, or errors as a result of those weaknesses, could result in a negative reaction in the financial markets if there is a loss of confidence in the reliability of our financial reporting.
We have implemented a number of measures intended to remediate these material weaknesses, including: (i) establishing effective monitoring and oversight controls for non-recurring and complex transactions to ensure the accuracy and completeness of our company’s consolidated financial statements and related disclosures, (ii) implementing formal processes and controls to identify, monitor and mitigate segregation of duties conflicts, and (iii) improving our IT systems and monitoring of the IT function. We may incur substantial costs related to remediation of material weaknesses and to developing, implementing and testing changes to our internal controls.
We cannot assure you that the measures that we have taken, and that will be taken, to remediate these material weaknesses will, in fact, remedy the material weaknesses or will be sufficient to prevent future material weaknesses from occurring.
23

TABLE OF CONTENTS

Remediating material weaknesses will absorb management time and will require us to incur additional expenses, which could have a negative effect on the trading price of our shares. In order to establish and maintain effective disclosure controls and procedures and internal controls over financial reporting, we will need to expend significant resources and provide significant management oversight. Developing, implementing and testing changes to our internal controls may require specific compliance training of our directors and employees, entail substantial costs in order to modify our existing accounting systems, take a significant period of time to complete and divert management’s attention from other business concerns. These changes may not, however, be effective in establishing and maintaining adequate internal controls.
It is possible that, had we and our independent registered public accounting firm performed a formal assessment of the effectiveness of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional material weaknesses may have been identified.
If we fail to remediate our material weaknesses or fail to establish and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results, meet our reporting obligations or prevent fraud.
Any of the foregoing could harm our business. If either we are unable to conclude that we have effective internal controls over financial reporting or our independent registered public accounting firm is unable to provide us with an unqualified report on the effectiveness of our internal controls over financial reporting as required by Section 404(b) of the Sarbanes-Oxley Act, this may cause investors to lose confidence in our reported financial information, cause the price of our ordinary shares to decline or result in litigation or regulatory enforcement actions. In addition, if we are unable to meet the requirements of Section 404 of the Sarbanes-Oxley Act, we may not be able to remain listed on the Nasdaq.
ITEM 4.
INFORMATION ON THE COMPANY
A. History and Development of the Company
Our head office is located at 129 West Trade Street, Suite 1405, Charlotte, North Carolina 28202, United States. Our registered office is located at 28 The Esplanade, Level 9, Perth WA 6000, Australia. The telephone number of our registered office is +(61) 8-9322-6322.
IperionX was originally incorporated in Western Australia as Tao Commodities Limited on May 5, 2017 and changed its name to Hyperion Metals Limited on April 14, 2021, following our acquisition of the Titan Project on December 1, 2020, and most recently changed to its current name, IperionX Limited, on February 9, 2022. We are subject to the provisions of the Australian Corporations Act.
We also maintain a web site at www.iperionx.com. The information contained on our website or available through our website is not incorporated by reference into and should not be considered a part of this registration statement on Form 20-F, and the reference to our website in this registration statement on Form 20-F is an inactive textual reference only.
B. Business Overview
Our Mission
Our mission is to be a leading developer of U.S.-based sustainable critical mineral and critical material supply chains, to facilitate the global transition towards a closed-loop, low-carbon, resource efficient and socially inclusive green economy.
IperionX holds an exclusive option to acquire titanium processing technologies with the potential to enable the development of a mineral-to-metal, low-carbon, cost-competitive, high-quality titanium supply chain, and is rapidly working to expand its titanium metal production. These technologies have demonstrated to be effective means of producing titanium at the pilot scale and have shown the potential to be applied to other critical minerals as well.
IperionX’s immediate focus is on the commercialization of these Technologies to re-shore the titanium metal and other critical mineral supply chains in North America. To facilitate the commercialization of these Technologies, the Company has secured a potentially large source of titanium and other critical minerals, including rare earth elements, in Tennessee.
24

TABLE OF CONTENTS

We aim to achieve this mission through a multi-pronged strategy focused on technology, integration, and sustainability.
Technologies
Blacksand invented the Technologies at the University of Utah in partnership with the U.S. Department of Energy’s Advanced Research Projects Agency – Energy (ARPA-E) and industry leaders Boeing and Arconic. By combining the Technologies with wide scale industrial advanced manufacturing capabilities such as Additive Manufacturing (AM)/3D printing, MIM and other methods, there is a compelling market opportunity with the potential to produce low-carbon spherical titanium powders at a fraction of current costs.
We believe Titanium to be a superior metal to stainless steel and aluminum for a wide range of high-performance applications in the aerospace, medical, space and defense sectors. No metal has the same combined superior properties of light weight, strength and corrosive resistance as titanium. Only titanium’s historically high cost has held it back from being used in larger consumer markets.
The Technologies offers IperionX the potential to produce US-sourced, closed-loop, low-carbon titanium that costs less and can reduce the carbon emissions of an advanced economy through replacing inferior metals. The potential exists to apply the Technologies to produce other metals as well.
Blacksand is a materials innovation company founded in 2013 by Dr. Z. Zak Fang, Professor of Materials Science and Engineering of the University of Utah. Blacksand has developed proprietary and patented technologies to produce low-cost, low carbon spherical and non-spherical titanium and its alloys, stainless-steel powders, and refractory metal alloy powders. Core competencies of Blacksand include expertise on metallic materials manufacturing processes, especially metal powders synthesis, characterization, processing, sintering, and mechanical properties. Blacksand expertise covers titanium, refractory metals, hard materials, and other specialty alloys.
The patented technology is a potential low-cost, low-carbon titanium powder production process that utilizes hydrogen to destabilize Ti-O, making it possible to turn the reduction of TiO2 with magnesium from thermodynamically impossible to thermodynamically favored. This allows TiO2 to be reduced and deoxygenated directly by magnesium to form TiH2, with low oxygen levels that can meet the needs of the industry. TiH2 can be further processed to titanium metal through standard industry methods. The patented Hydrogen Assisted Magnesiothermic Reduction (“HAMR”) process reduces the energy intensity and resulting carbon emissions and cost of producing titanium metals.
The Granulation-Sintering-Deoxygenation (“GSD”) process applies the HAMR technology to a simple process that has the potential to produce spherical titanium powders which can then be used in 3D printing and additive manufacturing. GSD significantly improves the yield of metal powders compared to traditional gas and plasma atomization techniques and produces a spherical powder with low oxygen, controllable particle size and excellent flowability.
The Hydrogen Sintering and Phase Transformation (“HSPT”) process is a patented technology that makes it possible to achieve a wrought-like microstructure in Ti-6Al-4V alloy parts without thermo-mechanical working. We believe the ability to leave out thermo-mechanical processing opens the door for potential production of Ti-6Al-4V parts at a fraction of the cost without compromising performance.
Importantly, with these Technologies the source material can be recycled titanium scrap material. The manufacturing of titanium components and structures can generate a large amount of titanium machining chips. This ‘scrap’ loss can account for a substantial portion of the weight of complex traditionally milled parts. This scrap titanium can be sorted, cleaned, and prepared for processing as a source material for the GSD process. This recycling pathway can reduce costs and significantly improve the sustainability of titanium metal manufacturing.
Integration
Integration of these Technologies with sustainable, resource efficient material feedstocks could be accomplished (in part) by the development of a U.S.-based titanium mineral supply chain through the potential future development of IperionX’s 100% interest in the Titan Project in Tennessee, United States.
In addition to any future potential IperionX’s supply from the Titan Project, the Technologies can accept scrap metal feedstocks. The Technologies have demonstrated the effectiveness of using both mineral and scrap
25

TABLE OF CONTENTS

feedstock at the pilot scale and the Company is working to secure additional scrap feedstocks and to potentially develop the Titan Project to secure long-term vertically integrated supply of feedstock for the Technologies.
The Titan Project covers over 11,000 acres in Tennessee, United States, and is considered prospective for critical minerals including titanium, rare earth elements, zircon, and silica sand. The Titan Project is located in West Tennessee, a region the Company believes has access to world class infrastructure, with nearby access to excellent roads, rail, river, power and skilled labor.
The Titan Project forms part of a large-scale critical mineralization trend in the physiographical area of the United States known as the Mississippi embayment that contains significant potential for critical materials including titanium, zirconium and rare earth elements.
We believe that vertical integration with U.S.-based resource operations would be a major competitive advantage for IperionX, providing a potential source of critical mineral feedstock.
Sustainability
We believe the global transition towards the green economy could drive significant increased demand for critical minerals and advanced metals. In particular, we believe high demand could arise for those minerals and metals needed for the drive to achieve decarbonization via electrification, especially those that enable advanced technologies including titanium and rare earth elements. We believe these raw materials have historically been produced without a focus on environmental sustainability, resource scarcity, or social equity.
Through the Technologies, utilization of titanium scrap could result in the development of a closed-loop, recyclable titanium metal supply chain. In addition, IperionX’s aim for the development of the Titan Project (and any future critical mineral operations) would focus on environmental sustainability and improving the well-being of the surrounding communities, setting the standard for future development of similar critical mineral projects.
Why Titanium?
Titanium is a strong, lightweight metal with ideal properties for broad applications in defense, aerospace, space exploration, transportation and electric vehicles, unmanned vehicles, and many other advanced manufacturing applications.
We believe titanium has the potential to be a key critical material via its substitution for stainless steel and aluminum. In our opinion, the use of stainless steel or aluminum as structural metals, whether it be for the structural components in an electric vehicle battery pack, light weighting components to reduce fuel emissions in the transport sector, or the mounting structures in solar arrays, will increase with the transition to a green economy. We believe the existing production of these metals results in carbon emissions which must be addressed to transition to a net-zero economy.
We believe titanium to be a superior metal to stainless steel and aluminum due to its combined superior properties including high strength-to-weight ratio and excellent corrosion resistance. In our opinion, only titanium’s historically high production cost has held it back from being widely used in place of stainless steel and aluminum.
Titanium metal manufacturing capacity in the United States from titanium minerals is almost non-existent. As of 2021, the current U.S. titanium metal demand from the aerospace, medical, space and defense sectors are heavily reliant on international supply chains. We believe these supply chains are not only environmentally and socially unsustainable but are also a threat to U.S. national security given the reliance on imported titanium feedstocks for use within the U.S. defense sector.
The Technologies have the potential to create a cost-competitive production of low-carbon titanium via scrap-to-metal and mineral-to-metal manufacturing processes within the U.S. The Company’s strategy would allow for the substitution of titanium metal in numerous applications ranging from aerospace and defense to electric vehicles and transportation. Widespread use of the Company’s titanium would enable a domestic, closed-loop supply chain, longer product lifetimes and increased product re-usability.
The United States is one of the largest global consumers of titanium metal for aerospace and defense applications and has become highly reliant on titanium feedstock imports to service these industries. IperionX aims to address this import dependence by developing a domestic supply chain in accordance with manufacturing and extraction industry best practices.
26

TABLE OF CONTENTS

Domestic U.S. Titanium Market
Primary titanium metal is called titanium sponge and is produced from converting titanium minerals via the energy intensive and expensive Kroll process. Titanium products are produced by melting titanium sponge into semi-finished goods (ingot, billet) which are then used to create final products (wire, plate, bar, sheet).
In the report publicly delivered in July 2021 by the U.S. Department of Commerce Bureau of Industry and Security, The Effect of Imports of Titanium Sponge on The National Security, Congress noted that it has recognized that titanium sponge is critical to national security by including titanium as a strategic material in the Specialty Metals Clause, with all titanium used in national defense systems directed to be melted or produced in the United States or a qualifying country.
Titanium was further recognized as essential to U.S. security by the Department of the Interior. In 2018, the Department of the Interior found that the absence of a titanium sponge supply would have significant consequences for the U.S. economy and national security and added titanium to its List of Critical Minerals.
While the United States was the first nation ever to commercialize titanium sponge production in the 1950s, by 2020 the United States did not have a single large-scale titanium sponge plant.
The United States now has minimal commercial titanium sponge production capacity, a critical material for many U.S. defense systems, including fighter jets, bombers, attack aircraft, transports and helicopters, with newer aircraft using increased amounts of titanium, shown in the table below.
Titanium Content in Select U.S. Military Airframes
Airframe
Introduction into Service
% of Titanium Content
CH-47 Chinook
1962
8
F-15 Eagle
1976
10
F-16 Fighting Falcon
1978
7
F/A-18 Hornet
1984
12
F-22 Raptor
2005
39
V-22 Osprey
2007
31
F-35 Lightning II
2015
20
Military airframes entering service after 2000 have an average 30 percent titanium content; airframes entering service prior to 2000 had an average of just 9 percent.
Source: Arconic Engineered Structures, “World Titanium Trends in Defense”, Presentation at the Titanium USA conference, September 24, 2019
Titanium is frequently deployed in applications which require high strength and low weight, such as the A-10 Thunderbolt II attack aircraft, where a titanium cockpit tub has proved vital to the safe return of pilots despite heavy damage from enemy ground fire.
Titanium is also extensively used in naval applications due to its excellent anti-corrosion characteristics, as well as army ground vehicles due to its very high strength and light weight.
Currently only Japan, Russia, and Kazakhstan have titanium sponge plants certified to produce aerospace rotating-quality sponge that can be used for aerospace engine parts and other sensitive aerospace applications. In 2018, Russian and Chinese titanium sponge producers controlled 61% of the world’s titanium sponge production, an increase on their combined 55% share in 2008 and 37% share in 1998. In 2020, Russia and China’s control of global titanium sponge production had increased to approximately 70%.
Absent domestic titanium sponge production capacity, the United States is completely dependent on imports of titanium sponge and scrap and lacks the surge capacity required to support defense and critical infrastructure needs in an extended national emergency. IperionX’s potentially closed-loop titanium has the potential to supply additional markets and industries outside of defense. Titanium’s historical high-cost and high-carbon profile have precluded its use in a variety of other industries including consumer electronics and medical technology – IperionX’s potential low-cost, low carbon titanium supply opens up an array of these potential new applications.
27

TABLE OF CONTENTS

Given the lack of domestic production capacity, and that the United States no longer maintains titanium sponge in the National Defense Stockpile, U.S. producers of titanium-containing products including fighter jets, bombers, attack aircraft, transports and helicopters are dependent on non-U.S. sources of titanium. We believe that this dependence presents the possibility that in a national emergency, U.S. titanium producers would be denied access to imports of titanium sponge and scrap.
In addition to bringing titanium production back to the United States, we believe IperionX’s potential low-cost, low carbon titanium supply opens up an array of potential new applications including in consumer electronics and medical technology.
Why IperionX
IperionX, upon exercising its exclusive rights to acquire or lease the Technologies, is a company which has the potential to combine both groundbreaking proprietary metal processing technologies with upstream mineral supply, positioning the Company to re-shore the critical material supply chains to the United States in the future which is needed to facilitate the transition towards an electrified, sustainable, and socially inclusive net-zero carbon economy.
Our Strategies
We aim to re-shore U.S. critical mineral supply at reduced carbon intensity through the continued development and growth of the closed-loop advanced metal Technologies and the development of our critical mineral properties.
Our objective is to create long-term shareholder value through the development, scale up and commercialization of the Technologies, and the potential development of additional critical metal and material products to support a future-facing, renewable and sustainable economy in the United States.
Additionally, we aim to create long-term, productive jobs for the communities in which we operate, and invest into our communities and ensure that they remain beneficiaries and participants in our continued growth as a company.
To achieve our stated mission and objectives, we currently have the following business strategies and prospects over the medium to long term:
Continue to research, investigate, scale-up and commercialize the Technologies to produce titanium metal powders for the stakeholders within defense, space, aerospace, electric vehicles and additive manufacturing.
Complete techno-economic evaluations, including providing titanium samples produced using the Technologies for potential customers, to outline material physical and economic metrics of the development of the Technologies as well as securing long term offtake contracts.
Continue to investigate potential alternative applications of the Technologies to develop additional value-added metal closed-loop production capabilities, including zircon and synthetic rutile, and the potential production of rare earth elements.
Continue to progress Environmental, Sustainability and Corporate Governance (“ESG”) assessments and integration studies to outline material physical and economic ESG metrics as well as major development milestones and timelines.
Continue discussions with potential customers and strategic partners for future production and sale of titanium metal products and critical minerals, including, but not limited to rare earth elements.
Continue to expand IperionX’s land position in the United States, explore for additional critical minerals and secure relevant permit and zoning approvals.
To date, we have only commenced pilot scale production of titanium metal but have not commenced commercial production of any titanium metal, titanium minerals or other minerals, nor have we identified any ore reserves in accordance with the JORC Code.
28

TABLE OF CONTENTS

Our Competitive Strengths
We believe that we are well-positioned to successfully execute our business strategies because of the following competitive strengths:
Patented titanium metal production technologies. We have an exclusive option to acquire Blacksand which holds the exclusive commercial licensing rights for the patented Technologies to produce low carbon titanium metal and spherical powders developed by Blacksand at the University of Utah with support from ARPA-E.
Market opportunity that capitalizes on a shift to low carbon metal production. The social and macroeconomic shift to the low carbon production of metals and a circular economy provides a significant opportunity for IperionX to apply the Technologies and position us to take advantage of a compelling high growth market.
Ability to recycle existing titanium metal feedstock and titanium metal products in a closed-loop process. The Technologies have demonstrated, at pilot-scale, to be capable of producing fully recycled titanium metal powders using titanium scrap as feedstock in a closed-loop process, technology that potentially offers lower cost, low carbon titanium metal and powders.
Differentiated and integrated U.S. domestic supply chain. We believe that our integrated business model in the U.S. will allow us to achieve our objective to provide a domestic end-to-end supply chain of low-cost and low carbon titanium metal for strategic and high value applications including light-weighting for electric vehicles and battery packs as well as broad defense and light-weighting applications for commercial and military applications.
Sales of critical minerals. The Titan Project contains titanium minerals that can supply the titanium pigment and metals markets as well as the Technologies. It also contains significant volumes of other highly valuable critical minerals which may be sold as co-products, including zircon and rare earth elements.
Strategically located close to existing processing facilities. The Titan Project is strategically located in the southeastern U.S., close to significant manufacturing capacity, including the Chemours facility in New Johnsonville TN, one of the world’s largest producers of titanium dioxide.
Significant existing infrastructure available. The Titan Project’s location enjoys low-cost access to road, rail and water logistics connecting it to world class manufacturing industries. The Titan Project is also well situated to take advantage of a highly skilled labor force and low-cost renewable baseload grid power.
First mover in restarting exploration of critical minerals in the West Tennessee area. As a first mover in restarting exploration of critical minerals in West Tennessee, IperionX aims to develop a strategic, U.S. domestic source of high-quality, low-cost and low carbon titanium metal products and other critical minerals, including rare earths and silica sand. The Titan Project is located in an area which saw significant historic exploration from the 1950’s to the 1990’s by companies including DuPont, Kerr-McGee Corp., BHP Group, RGC Ltd and Altair International Corp.
Experienced management team. Our senior management team has significant experience in acquiring, developing, and financing minerals extraction projects in the United States. They have previously held senior business development, financial, and operational positions at both large, publicly traded extraction companies as well as successful private extraction operations.
Customers and Partnerships
IperionX is engaged in a wide range of commercial discussions that are advancing with potential customers, collaborators, and strategic partners interested in titanium metal and products produced with the Technologies.
Because IperionX is an early-stage company, we do not currently have established marketing or distribution channels or sales contracts. However, we have non-binding memoranda of understanding related to the development of sales channels for our products with the following companies:
IperionX has a non-binding Memorandum of Understanding (“MOU”) to potentially establish a partnership with Energy Fuels that aims to build an integrated, all-American rare earths supply chain.
29

TABLE OF CONTENTS

The MOU will evaluate the potential supply of rare earth minerals from the Titan Project to Energy Fuels for value added processing at Energy Fuels’ White Mesa Mill. Rare earths are highly valued as critical materials for magnet production essential for wind turbines, electric vehicles, consumer electronics and military applications.
IperionX has a non-binding MOU with Chemours to investigate a potential supply agreement between IperionX and Chemours for up to 50,000 metric tons of ilmenite, 10,000 metric tons of rutile, and 10,000 metric tons of staurolite. Chemours operates one of the largest titanium dioxide plants at its New Johnsonville plant which is located approximately 20 miles from IperionX’s Titan Project in Tennessee.
IperionX has a non-binding MOU with EOS to accelerate the deployment of the Technologies for the potential production of low-cost, low carbon titanium metal powders. IperionX and EOS have agreed to negotiate in good faith to enter into definitive agreements to give effect to a partnership that allows IperionX and EOS to work together to advance deployment of spherical and non-spherical titanium metal powders for use in the additive manufacturing industry.
IperionX has a non-binding MOU with Mario Pilato BLAT S.A. for the potential supply of zircon products. The MOU contemplates a supply agreement for an initial five-year term on an agreed market-based pricing methodology for the annual supply of up to 20,000 tonnes of zircon products from IperionX’s Titan Project in Tennessee.
Competition
IperionX competes with other metals technology, metal, natural resource, and exploration companies in what is a fragmented industry. For now, IperionX represents a small portion in this sector. Many of our competitors have been in business longer than we have and have established more strategic partnerships and relationships and have greater financial accessibility than we have.
While we compete with other companies in the metals and natural resource space, we believe that there are readily available purchasers of critical materials, including titanium metal, titanium minerals and rare earth minerals, if they are able to be produced by our business operations. The price of metals and minerals can be affected by a number of factors beyond our control, including:
Fluctuations in the market prices for critical materials, titanium metal, titanium minerals and rare earth minerals;
Fluctuating supplies of critical materials, titanium metal, titanium minerals and rare earth minerals;
Fluctuating demand for critical materials, titanium metal, titanium minerals and rare earth minerals; and
Metals and extraction activities of others.
Capital Expenditures
Our capital expenditures for fiscal 2021 amounted to US$571,568 which represents the purchase of exploration and evaluation properties and the purchase of property, plant, and equipment.
We expense all other exploration and evaluation expenditures when incurred (other than expenditures incurred in the acquisition of the rights to explore, including option payments to landowners).
If we complete a definitive Feasibility Study for the Titan Project and ultimately make a decision to develop the Titan Project, this will require substantial additional funds, which would require future debt or equity financings. Similar rare earth projects that are planned to be constructed in Australia by other companies have estimated capital expenditures of between US$200 to US$300 million.
EXPLORATION AND DEVELOPMENT PLANS
We are required by ASX Listing Rules to report ore reserves and mineral resources in Australia in compliance with the Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves (the JORC Code 2012 Edition) prepared by the Joint Ore Reserves Committee of The Australasian Institute of Mining and Metallurgy, Australian Institute of Geoscientists and Minerals Council of Australia (JORC). In contrast, the SEC generally requires disclosure of extraction reserves in accordance with Regulation S-K, Subpart 1300. We are an exploration stage minerals extraction company, and we have no reserves as defined under Subpart 1300 standards. See “Cautionary Note to United States Investors.”
30

TABLE OF CONTENTS

We have completed multiple exploration drilling programs at the Titan Project, comprising more than 10,000 total meters drilled. Over the next twelve months we have plans to complete further drilling to expand and increase confidence in Titan Project deposit, and complete technical studies, including a scoping study and pre-feasibility study as well as hydrology and geotechnical studies. We may elect to undertake further drilling, metallurgical testwork, and technical studies to assess the economic potential of the Titan Project and define a critical minerals reserve base. Following the completion of all technical studies and all necessary permitting activities, IperionX may undertake minerals extraction and processing activities.
Subject to market conditions and the ability to define an economically viable critical minerals deposit, our separate business plan for the Titan Project is to become a strategic, U.S. domestic source of high-quality and sustainable titanium and other critical mineral feedstocks, including rare earths, to the United States. The titanium minerals could form an important sustainable feedstock for the Technologies and assist in the scale up of the Technologies to meet potential future market demand. We believe that vertical integration with U.S.-based resource operations is a major competitive advantage for IperionX, providing a potential source of critical mineral feedstock.
We plan to effect our business plan for the Titan Project by:
completing our exploration drilling program on initial land position and continuing to secure additional land leases to undertake additional exploration;
undertaking necessary technical studies to assess the economic potential of the Titan Project and defining a critical minerals reserve base;
completing required permitting and zoning activities;
undertaking discussions with potential customers for future sale of titanium and other critical minerals, including rare earths;
completing required financing activities;
completing construction of the Titan Project’s minerals extraction and processing facilities; and
commencing minerals extraction and processing activities to supply the United States demand for clean, low-cost domestic sources of titanium and other critical minerals, including rare earths.
ADDITIONAL BUSINESS INFORMATION
Potential Acquisition of Blacksand
IperionX and Blacksand entered into Blacksand Option Agreement in October 2021 whereby Blacksand granted IperionX an exclusive Option to purchase 100% of the ownership interests of Blacksand. The option period terminates upon the earliest to occur of (i) the closing of the purchase of Blacksand, (ii) termination of the existing Blacksand Research Agreement, (iii) December 31, 2022, or (iv) the termination of the Blacksand Option Agreement.
Separately, IperionX and Blacksand also have the MSA in place pursuant to which IperionX and Blacksand will investigate the scale up and commercialization of Blacksand’s HAMR and GSD patented technologies for the processing of titanium ore or feedstock and the production of titanium metal or alloy products under two statements of work. Under the first statement of work (“SOW 1”), Blacksand provides research and development services to investigate the scale up and commercialization of the HAMR technology for a cost of US$480,000. The term of SOW 1 ends on on the earlier of (i) termination of the MSA or (ii) the completion of the research and development program. Under the second statement of work (“SOW 2”), Blacksand provides research and development services to investigate the scale up and commercialization of the GSD technology for a cost of US$1,200,000. The term of SOW 2 ends on on the earliest of (i) termination of the MSA, (ii) the completion of the research and development program or (iii) June 1, 2023.
While the Blacksand Option Agreement (detailed above) gives IperionX exclusive rights to develop Blacksand’s patented technologies, including the HAMR and GSD patented technologies and related products, the MSA separately grants IperionX with options to enter into license agreements with Blacksand with respect to the same technologies. If IperionX exercises the option to license the HAMR technology, it will pay total license fees to Blacksand of US$1.9 million over a two-year period. From the third anniversary of the option exercise, IperionX will pay Blacksand the greater of the minimum annual license payment (between US$150,000 and US$250,000) and a royalty of 3% of the net value of licensed product sold. If IperionX exercises the option to license the
31

TABLE OF CONTENTS

GSD technology, it will pay total license fees to Blacksand of US$3 million over a two-year period. From the third anniversary of the option exercise, IperionX will pay Blacksand the greater of the minimum annual license payment (between US$250,000 and US$500,000) and a royalty of 5% of the net value of licensed product sold.
Blacksand holds the exclusive commercial licensing rights for more than forty global patents through a license agreement with the University of Utah (“UoU License Agreement”) including the global patents for the patented HAMR and GSD technologies that can produce low-cost and low carbon titanium metal. The License Agreement grants Blacksand a royalty bearing exclusive license to commercialize the intellectual property that Blacksand developed in conjunction with the University of Utah. The UoU License Agreement automatically continues unless one of the parties terminates. IperionX will be able to apply this patent and technology platform across a wider range of advanced metal alloys and powders for markets including space, aerospace, electric vehicles and 3D printing and additive manufacturing.
If IperionX chooses to exercise its option under the Blacksand Option Agreement, IperionX will: (i) pay US$12,000,000 to Blacksand and its members, of which the Company can elect to pay an amount (between 22.5% to 30%) in shares of the Company (based on a share price equal to 75% of the 10-day VWAP of IperionX shares on ASX immediately preceding the closing date, subject to a floor of A$0.85 and a ceiling of A$3.00), subject to IperionX obtaining shareholder approval; (ii) commit to invest US$1,000,000 over a 3 year period towards the establishment of an endowed chair professorship at the University of Utah, which shall be used to support research and development related to Blacksand and IperionX, and other related technologies in the field of titanium, critical metals, and minerals; and (iii) pay the Blacksand members a royalty equal to 0.5% of cumulative net sales that relate to Blacksand assets or properties above US$300,000,000.
If IperionX chooses not to exercise its option under the Blacksand Option Agreement, the existing MSA and statements of work will continue which provide IperionX with options to enter into license agreements with Blacksand over a suite of patents, including the HAMR and GSD patented technologies and related products, to be applied to certain applications.
Acquisition of the Titan Project
Following its acquisition of HMAPL in December 2020 (the “Acquisition”), IperionX holds a 100% interest in the Titan Project, covering over 11,000 acres of critical minerals properties in Tennessee, United States, considered prospective for critical minerals including titanium, rare earth elements zircon, and silica sand. The Titan Project is located in West Tennessee and we believe the Titan Project has access to world class infrastructure, with nearby access to excellent roads, rail, river, power and skilled labor. Mineral sands projects operational costs are heavily influenced by electricity and labor costs.
Since securing the initial Titan Project land position in late-2020, IperionX has successfully focused on proving the Titan Project’s potential. We have completed multiple drilling programs at the Titan Project, confirming consistent grade and thickness of critical minerals mineralization over approximately 2 miles of strike. Assays from all holes of the first two drilling programs and the first batch of the third program have returned thick zones of high-grade total heavy minerals near surface.
GOVERNMENTAL REGULATIONS
U.S. Securities Regulations
Emerging Growth Company Status
We are an “emerging growth company” under the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and will continue to qualify as an “emerging growth company” until the earliest to occur of:
the last day of the fiscal year during which we have total annual gross revenues of US$1,070,000,000 (as such amount is indexed for inflation every five years by the SEC) or more;
the last day of our fiscal year following the fifth anniversary of the completion of our first sale of common equity securities pursuant to an effective registration statement under the Securities Act;
the date on which we have, during the previous three-year period, issued more than US$1,070,000,000 in non-convertible debt; or
32

TABLE OF CONTENTS

the date on which we are deemed to be a “large accelerated filer”, as defined in Rule 12b-2 of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our ordinary shares and ADSs that are held by non-affiliates exceeds US$700,000,000 as of the last day of our most recently completed second fiscal quarter.
An emerging growth company may take advantage of specified exemptions from various requirements that are otherwise applicable to public companies in the United States. Generally, a company that registers any class of its securities under Section 12 of the Exchange Act is required to include in the second and all subsequent annual reports filed by it under the Exchange Act, a management report on internal control over financial reporting and, subject to an exemption available to companies that meet the definition of a “smaller reporting company” in Rule 12b-2 under the Exchange Act, an auditor attestation report on management’s assessment of the company’s internal control over financial reporting. However, for so long as we continue to qualify as an emerging growth company, we will be exempt from the requirement to include an auditor attestation report in our annual reports filed under the Exchange Act, even if we do not qualify as a “smaller reporting company.” In addition, Section 103(a)(3) of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, has been amended by the JOBS Act, to provide that, among other things, auditors of an emerging growth company are exempt from any rules of the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor’s report in which the auditor would be required to provide additional information about the audit and the financial statements of the company.
Pursuant to Section 107(b) of the JOBS Act, an emerging growth company may elect to utilize an extended transition period for complying with new or revised accounting standards for public companies until such standards apply to private companies. We have elected not to utilize this extended transition period. This election is irrevocable.
For information on the risks that accompany our status as an emerging growth company, see “Item 3 Key Information—D. Risk Factors—Risks Related to Our ADSs—We are an emerging growth company, and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies may make the ADSs less attractive to investors and, as a result, adversely affect the price of the ADSs and result in a less active trading market for the ADSs.”
In the event that we cease to qualify as an emerging growth company, we will still be exempt from certain rules under the Exchange Act as a foreign private issuer, as described immediately below.
Foreign Private Issuer Status
We are also considered a “foreign private issuer” pursuant to Rule 405 under the Securities Act. As a foreign private issuer, we are exempt from certain rules under the Exchange Act that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section 14 of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions of Section 16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our ordinary shares or ADSs. Moreover, we are not required to file periodic reports and financial statements with the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. In addition, we are not required to comply with Regulation FD (Fair Disclosure), which restricts the selective disclosure of material information.
Nasdaq also allows us a foreign private issuer to elect to follow certain home country laws instead of Nasdaq practices applicable to U.S. companies. In particular, we follow home country law instead of Nasdaq practice regarding:
Nasdaq’s requirement that our independent directors meet regularly in executive sessions. The ASX Listing Rules and the Corporations Act do not require the independent directors of an Australian company to have such executive sessions and, accordingly, we have claimed this exemption.
Nasdaq’s requirement that an issuer provide for a quorum as specified in its bylaws for any meeting of the holders of ordinary shares, which quorum may not be less than 33 1/3% of the outstanding shares of an issuer’s voting ordinary shares. In compliance with Australian law, our Constitution provides that two shareholders present shall constitute a quorum for a general meeting.
Nasdaq’s requirement that issuers obtain shareholder approval prior to the issuance of securities in connection with certain acquisitions, changes of control or private placements of securities, or the
33

TABLE OF CONTENTS

establishment or amendment of certain stock option, purchase or other compensation plans. Applicable Australian law and rules differ from Nasdaq requirements, with the ASX Listing Rules providing generally for prior shareholder approval in numerous circumstances, including (i) issuance of equity securities exceeding 15% (or an additional 10% capacity to issue equity securities for the proceeding 12-month period if shareholder approval by special resolution is sought at the Company’s annual general meeting) of our issued share capital in any 12-month period (but, in determining the available issue limit, securities issued under an exception to the rule or with shareholder approval are not counted), (ii) issuance of equity securities to related parties (as defined in the ASX Listing Rules) and (iii) directors or their associates acquiring securities under an employee incentive plan.
For as long as we are a “foreign private issuer” we intend to file our annual financial statements on Form 20-F and furnish our semi-annual financial statements and quarterly updates on Form 6-K to the SEC for so long as we are subject to the reporting requirements of Section 13(g) or 15(d) of the Exchange Act. However, the information we file or furnish is not the same as the information that is required in annual and quarterly reports on Form 10-K or Form 10-Q for U.S. domestic issuers. Accordingly, there may be less information publicly available concerning us than there is for a company that files as a domestic issuer.
We may take advantage of these exemptions until such time as we are no longer a foreign private issuer. We are required to determine our status as a foreign private issuer on an annual basis at the end of our second fiscal quarter. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (1) the majority of our executive officers or directors are U.S. citizens or residents; (2) more than 50% of our assets are located in the United States; or (3) our business is administered principally in the United States. Since more than 50% of our assets are located in the United States, we will lose our status as a foreign private issuer if more than 50% of our outstanding voting securities are held by U.S. residents as of the last day of our second fiscal quarter in any year.
For information on the risks that accompany our status as a foreign private issuer, see “Item 3 Key Information—D. Risk Factors—Risks Related to Our ADSs—As a foreign private issuer, we are permitted to file less information with the SEC than a domestic issuer and “Item 3 Key Information—D. Risk Factors—Risks Related to Our ADSs—We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act’s domestic reporting regime and cause us to incur additional legal, accounting and other expenses.”
U.S. Environmental, Health and Safety Laws
IperionX’s business operations, including the Technologies and the Titan Project, will be required to comply with applicable environmental protection laws and regulations and licensing and permitting requirements. The material environmental, health and safety laws and regulations that we must comply with include, among others, the following United States federal laws and regulations:
National Environmental Protection Act (“NEPA”), which requires careful evaluation of the environmental impacts of extraction operations that require federal approvals;
Clean Air Act (“CAA”) and its amendments, which governs air emissions;
Clean Water Act (“CWA”), which governs discharges to and excavations within the waters of the United States;
Safe Drinking Water Act (“SDWA”), which governs the underground injection and disposal of wastewater;
Resource Conservation and Recovery Act (“RCRA”), which governs the management of solid waste;
Comprehensive Environmental Response, Compensation, and Liability Act (“CERCLA”), which imposes liability where hazardous substances have been released into the environment (commonly known as Superfund); and
Federal Mine Safety and Health Act, which established the primary safety and health standards regarding working conditions of employees engaged in extraction, related operations, and preparation and milling of the minerals extracted, as well as the Occupation Safety and Health Act, which regulates the protection of the health and safety of workers to the extent such protection is not already addressed by the Federal Mine Safety and Health Act.
34

TABLE OF CONTENTS

Our operations may also be subject to state environmental law and regulations, including but not limited to laws and regulations related to the reclamation of mined lands, which may require reclamation permits to be acquired prior to the commencement of minerals extraction operations and may require substantial financial guarantees to cover the cost of future reclamation activities.
Solid and Hazardous Waste
RCRA, and comparable state statutes, affect our operations by imposing regulations on the generation, transportation, treatment, storage, disposal and cleanup of hazardous wastes and on the disposal of non-hazardous wastes. Under the auspices of the United States Environmental Protection Agency (“EPA”), the individual states administer some or all of the provisions of RCRA, sometimes in conjunction with their own, more stringent requirements.
In addition, the federal Superfund law can impose joint and several liability without regard to fault or legality of conduct on classes of persons who are statutorily responsible for the release of a hazardous substance into the environment. These persons can include the current and former owners, lessees or operators of a site where a release occurs, and anyone who disposes or arranges for the disposal of a hazardous substance. Under CERCLA, such persons may be subject to strict, joint and several liability for the entire cost of cleaning up hazardous substances that have been released into the environment and for other costs, including response costs, alternative water supplies, damage to natural resources and for the costs of certain health studies. Moreover, it is not uncommon for neighboring landowners, workers and other third parties to file claims for personal injury and property damage allegedly caused by hazardous substances released into the indoor or outdoor environment. Each state also has environmental cleanup laws analogous to CERCLA. Hazardous wastes may have been previously handled, disposed of, or released on or under properties currently or formerly owned or leased by us or on or under other locations to which we sent waste for disposal. These properties and any materials disposed or released on them may subject us to liability under CERCLA, RCRA and analogous state laws. Under such laws, we could be required to remove or remediate disposed wastes or property contamination, to contribute to remediation costs, or to perform remedial activities to prevent future environmental harm.
Air Emissions
The federal CAA and comparable state laws restrict the emission of air pollutants from numerous sources through the issuance of permits and the imposition of other requirements. Major sources of air pollutants are subject to more stringent, federally imposed permitting requirements. Air pollution regulations may require us to obtain pre-approval for the construction or modification of certain projects or facilities expected to produce or significantly increase air emissions, obtain air permits and comply with stringent permit requirements or utilize specific equipment or technologies to control emissions of certain pollutants. The need to obtain permits has the potential to delay our operations, and we may be required to incur capital expenditures for air pollution control equipment or other air emissions related obligations. Administrative enforcement actions for failure to comply strictly with air pollution regulations or permits are generally resolved by payment of monetary fines and correction of any identified deficiencies. Alternatively, regulatory agencies could require us to forego construction, modification or operation of certain air emission sources.
Climate Change
Numerous regulatory initiatives have been enacted, and are likely to continue to be developed, at the international, national, regional and state levels of government to monitor and limit existing emissions of greenhouse gases (“GHGs”) as well as to restrict or eliminate such future emissions. At the federal level, in December 2009, the EPA determined that emissions of carbon dioxide, methane and other GHGs endanger public health and the environment because emissions of such gases are, according to the EPA, contributing to warming of the Earth’s atmosphere and other climatic changes. Based on these findings, the EPA began adopting and implementing regulations to restrict emissions of GHGs under existing provisions of the CAA.
President Biden and the Democratic Party, which now controls the U.S. Congress, have identified climate change as a priority, and it is expected that new executive orders, regulatory action and/or legislation targeting greenhouse gas emissions, or prohibiting or restricting oil and gas development activities in certain areas, will be proposed and/or promulgated during the Biden Administration.
Congress has from time to time considered adopting legislation to reduce emissions of GHGs, and a number of state and regional efforts have emerged that are aimed at tracking and/or reducing GHG emissions by means of
35

TABLE OF CONTENTS

cap-and-trade programs. Cap and trade programs typically require major sources of GHG emissions to acquire and surrender emission allowances in return for emitting those GHGs. Further, the United States has rejoined the Paris Agreement and has committed to reduce U.S. GHG emissions by up to 52% by 2030. The adoption of legislation or regulatory programs or other government action to reduce emissions of GHGs could require us to incur increased operating costs.
Clean Water Act
The CWA imposes restrictions and strict controls regarding the discharge of wastes, including mineral processing wastes, into waters of the United States, a term broadly defined to include, among other things, certain wetlands. Permits must be obtained to discharge pollutants into federal waters. The CWA provides for civil, criminal and administrative penalties for unauthorized discharges, both routine and accidental, of pollutants. It imposes substantial potential liability for the costs of removal or remediation associated with discharges of oil or hazardous substances. State laws governing discharges to water also provide varying civil, criminal and administrative penalties, and impose liabilities in the case of a discharge of petroleum or its derivatives, or other hazardous substances, into state waters. In addition, the EPA has promulgated regulations that require permits to discharge storm water runoff, including discharges associated with construction activities. In the event of an unauthorized discharge of wastes, we may be liable for penalties and costs.
Pursuant to these laws and regulations, we may also be required to develop and implement spill prevention, control and countermeasure plans, also referred to as “SPCC plans,” in connection with on-site storage of significant quantities of oil. Some states also maintain groundwater protection programs that require permits for discharges or operations that may impact groundwater conditions. The CWA also prohibits the discharge of fill materials to regulated waters including wetlands without a permit from the USACE.
In May 2015, the EPA issued a final rule that attempted to clarify the federal jurisdictional reach over waters of the United States, but the agency repealed this rule in September 2019 and replaced it with the Navigable Water Protection Rule in April 2020, which narrowed federal jurisdictional reach relative to the 2015 rule. The repeal and replacement of the 2015 rule is currently subject to litigation and the scope of the jurisdictional reach of the Clean Water Act may therefore remain uncertain for several years, with a patchwork of legal guidelines applicable to various states potentially developing. We could face increased costs and delays with respect to obtaining permits for dredge and fill activities in wetland areas to the extent they are required.
Underground Injection Control Permits
The federal SDWA creates a nationwide regulatory program protecting groundwater. This act is administered by the EPA. However, to avoid the burden of dual federal and state (or Indian tribal) regulation, the SDWA allows for the Underground Injection Control (“UIC”) permits issued by states (and Indian tribes determined eligible for treatment as states) to satisfy the UIC permit required under the SDWA under two conditions. First, the state’s program must have been granted primacy. Second, the EPA must have granted, upon request by the state, an aquifer exemption. The EPA may delay or decline to process the state’s application if the EPA questions the state’s jurisdiction over the mine site. Permits must be obtained before developing and using deep injection wells for the disposal or storage of produced fluids, and well casing integrity monitoring must be conducted periodically to ensure the well casing is not leaking produced fluids to groundwater. Contamination of groundwater by natural gas and oil drilling, production and related operations may result in fines, penalties, remediation costs and natural resource damages, among other sanctions and liabilities under the SDWA and other federal and state laws. In addition, third-party claims may be filed by landowners and other parties claiming damages for groundwater contamination, alternative water supplies, property impacts and bodily injury.
NEPA
NEPA requires federal agencies to evaluate major agency actions having the potential to significantly impact the environment. The NEPA process involves public input through comments which can alter the nature of a proposed project either by limiting the scope of the project or requiring resource-specific mitigation. NEPA decisions can be appealed through the court system by process participants. This process may result in delaying the permitting and development of projects or increase the costs of permitting and developing some facilities.
Endangered Species Act
The federal Endangered Species Act (“ESA”) restricts activities that may affect endangered and threatened species or their habitats. Some of our operations may be located in areas that are designated as habitats for endangered or threatened species. A critical habitat designation could result in further material restrictions to
36

TABLE OF CONTENTS

federal and private land use and could delay or prohibit land access or development. The United States Fish and Wildlife Service continues its effort to make listing decisions and critical habitat designations where necessary. The ESA has not previously had a significant impact on our operations. However, the designation of previously unprotected species as being endangered or threatened could cause us to incur additional costs or become subject to operating restrictions in areas where the species are known to exist.
Environmental, Social and Governance
During fiscal 2021, IperionX engaged Presidio Graduate School’s expert consulting division, PGS Consults to commence an Environmental, Sustainability and Corporate Governance (“ESG”) assessment and subsequent integration study. PGS Consults is housed in Presidio Graduate School, the country’s first and only independent graduate school focused entirely on sustainability and social justice, with corporate clients including HP Inc., Flex Ltd., Granite Construction, Thermo Fisher Scientific and Domaine Chandon.
PGS Consults will undertake a materiality assessment, a life cycle assessment and create a playbook for ESG leadership. The review and assessment will identify priority ESG focus areas, highlight key ESG recommendations, and deliver an actionable life cycle assessment. PGS Consults will conduct the study in accordance with Global Reporting Initiative, UN Sustainable Development Goals, and Task Force on Climate-Related Financial Disclosures standards. The ESG integration study will outline material physical and economic ESG metrics as well as major development milestones and timelines. IperionX expects the ESG assessment and integration study to be completed in the first half of 2022.
Extraction Permits and Approvals
We currently have permits authorizing the exploration drilling activities with respect to the Titan Project. We are required to obtain governmental permits for some of our exploration activities and may be required to renew the permits we already have. Prior to developing or extracting any mineralization that we discover, we will be required to obtain new governmental permits authorizing, among other things, any site development activities and site operating activities. Obtaining and renewing governmental permits is a complex and time-consuming process and involves numerous jurisdictions. public hearings and possibly costly undertakings. The timeliness and success of permitting efforts are contingent upon many variables not within our control, including the interpretation of permit approval requirements administered by the applicable permitting authority. We may not be able to obtain or renew permits that are necessary to our planned operations or the cost and time required to obtain or renew such permits may exceed our expectations. Any unexpected delays or costs associated with the permitting process could delay the exploration, development or operation of our properties.
See “Item 3 Key Information—D. Risk Factors—Risks Related to Regulatory and Industry Matters—We will be required to obtain governmental permits in order to conduct development and minerals extraction operations, a process which is often costly and time-consuming.”
Our exploration operations are subject to extensive laws and regulations, which are overseen and enforced by multiple U.S. federal, state and local authorities. These laws govern exploration, development, production, exports, various taxes, labor standards, occupational health and safety, waste disposal, protection and remediation of the environment, protection of endangered and protected species and other matters. Mineral exploration operations are also subject to U.S. federal and state laws and regulations that seek to maintain health and safety standards by regulating the design and use of drilling methods and equipment. Various permits from government bodies are required for drilling operations to be conducted, and we cannot assure you such permits will be received. Environmental laws and regulations may also, among other things:
Require notice to stakeholders of proposed and ongoing operations.
Require the installation of pollution control equipment.
Restrict the types, quantities and concentration of various substances that can be released into the environment in connection with minerals extraction or drilling activities.
Limit or prohibit extraction or drilling activities on lands located within wetlands, areas inhabited by endangered species and other protected areas, or otherwise restrict or prohibit activities that could impact the environment, including water resources.
Impose substantial liabilities for pollution resulting from current or former operations on or for any preexisting environmental impacts at the Titan Project site.
37

TABLE OF CONTENTS

Require preparation of an Environmental Assessment or an Environmental Impact Statement.
As of the date hereof, other than with respect to the acquisition of the Titan Project and related permitting activities, we have not been required to spend material amounts on compliance with environmental regulations. However, compliance with these laws and regulations may impose substantial costs on us, subject us to significant potential liabilities, and have an adverse effect upon our capital expenditures, results of operations or competitive position. Violations and liabilities with respect to these laws and regulations could result in significant administrative, civil, or criminal penalties, remedial clean-ups, natural resource damages, permit modifications or revocations, operational interruptions or shutdowns and other liabilities. The costs of remedying such conditions may be significant, and remediation obligations could adversely affect our business, results of operations and financial condition. Additionally, Congress and federal and state agencies frequently revise environmental laws and regulations, and any changes in these regulations or the interpretations thereof could require us to expend significant resources to comply with new laws or regulations or changes to current requirements and could have a material adverse effect on our business operations.
C. Organizational Structure
The following reflects our organizational structure. All our subsidiaries are wholly-owned.

D. Property, Plant and Equipment
IperionX holds a 100% interest in the Titan Project, covering over 11,000 acres of critical minerals properties in Tennessee, United States, considered prospective for critical minerals including titanium, rare earth elements, silica sand and zircon.
The Titan Project is located in west Tennessee and we believe the Titan Project has access to world class infrastructure, with nearby access to excellent roads, rail, river, power and skilled labor. We believe mineral sands projects operational costs are heavily influenced by electricity and labor costs.
At December 31, 2021, the Titan Project comprised of approximately 11,071 acres of surface and associated mineral rights in Tennessee within 84 separate property tracts, of which approximately 137 acres are owned outright, approximately 1,357 acres are subject to exclusive option to purchase agreements, and approximately 9,577 acres are subject to exclusive option to lease agreements. Other than the option agreements described above, there currently are no material liens or encumbrances on the property comprising the Titan Project. However, in order to develop the project, we will need to obtain permits and approvals as described under “Item 4. Information on the Company—B. Business Overview—Governmental Regulations—Extraction Permits and Approvals.”
Our option to lease agreements, upon exercise, allow us to lease the surface property and associated mineral rights from the local landowners, and generally have expiry dates between mid-2026 to late-2027. During the option period, our option to lease agreements provide for annual option payments and bonus payments during periods when we conduct drilling. Our annual option payments generally range between $25.00 to $75.00 per acre and our drilling bonuses generally average approximately $1.00 per drill foot. Our obligation to make annual option payments and drilling bonus payments cease if we exercise our option to lease. Upon exercise, in the case of an option to lease, we will pay an annual minimum royalty, generally $75 per acre, and a mining royalty, generally 5% of net revenues from products sold.
38

TABLE OF CONTENTS

Our option to purchase agreements, upon exercise, allow us to purchase outright the surface property and associated mineral rights from the local landowners, and generally have expiry dates between mid-2022 to late-2023. During the option period, our option to purchase agreements provide for annual option payments and bonus payments during periods when we conduct drilling. Our annual option payments generally range between $25.00 to $50.00 per acre and our drilling bonuses generally average approximately $1.00 per drill foot. Our obligation to make annual option payments and drilling bonus payments cease if we exercise our option to purchase. Upon exercise, in the case of a purchase, we will pay cash consideration approximating the fair market value of the property, excluding the value of any minerals, plus a premium.
At June 30, 2021, the book carrying value of the Titan Project was US$504,750. See note 6 to our audited consolidated financial statements for the period ended June 30, 2021 for further details.
The Titan Project is located in an area which saw significant historic exploration from the 1950’s to the 1990’s by companies including DuPont, Kerr-McGee Corp., BHP Group, RGC Ltd and Altair International Corp. The Titan Project is also strategically located in the southeast of the United States, close to significant manufacturing capacity, including the Chemours facility in New Johnsonville, one of the world’s largest producers of titanium dioxide.
Since securing the initial Project land position in late-2020, we have focused on proving the Titan Project’s potential. We have conducted multiple drilling programs at the Titan Project, comprising more than 10,000 total meters drilled during the fiscal years ended June 30, 2021 and 2022.
We may elect to undertake further drilling, metallurgical testwork, and technical studies to assess the economic potential of the Titan Project and define a critical minerals reserve base. Following the completion of all technical studies and all necessary permitting activities, we may undertake minerals extraction and processing activities.
Subject to market conditions and the ability to define an economically viable critical minerals deposit, our separate business plan for the Titan Project is to become a strategic, U.S. domestic source of high-quality, sustainable, low-cost and low-carbon titanium and other critical mineral feedstocks, including rare earths, to the United States.
39

TABLE OF CONTENTS

We plan to effect our business plan as described in “Item 4. Information on the Company—A. History and Development of the Company—Exploration and Development Plans.”

ITEM 4A.
UNRESOLVED STAFF COMMENTS
Not applicable.
40

TABLE OF CONTENTS

ITEM 5.
OPERATING AND FINANCIAL REVIEW AND PROSPECTS
The following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in this registration statement on Form 20-F. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this registration statement on Form 20-F, particularly those in the section of this registration statement on Form 20-F entitled “Risk Factors.” The consolidated general purpose financial statements of the consolidated group have been prepared in accordance with IFRS as issued by the IASB.
The IASB sets out accounting policies that it has concluded would result in a financial report containing relevant and reliable information about transactions, events and conditions. Material accounting policies adopted in the preparation of this financial report are presented below and have been consistently applied unless otherwise stated.
Our financial statements for fiscal 2021 are presented in U.S. dollars and have been prepared in accordance with IFRS.
Business Strategy
IperionX’s mission is to be the leading developer of low-carbon, sustainable, critical materials supply chains for advanced American industries including space, aerospace, electric vehicles, and 3D printing. We plan to effect our business plan as described in “Item 4. Information on the Company—A. History and Development of the Company—Exploration and Development Plans.”
A. Operating Results
Financial Overview of IperionX
The following discussion relates to our consolidated results of operations, financial condition and capital resources. You should read this discussion in conjunction with our consolidated financial statements and the notes thereto incorporated by reference in this registration statement.
Six Months Ended December 31, 2021 Compared to Period Ended December 31, 2020
Continuing operations
Six Months Ended
December 31, 2021
US$
Six Months Ended
December 31, 2020
(restated)
US$
Exploration and evaluation expenses
(3,431,522)
(285,215)
Corporate and administrative expenses
(998,378)
(185,031)
Business development expenses
(1,501,724)
(71,946)
Share-based payment expense
(4,764,135)
(841,896)
Finance income
157,435
118
Finance costs
(23,831)
Cost of listing on reverse acquisition
(5,141,126)
Exploration and evaluation expenses
Exploration and evaluation expenses encompasses expenditures incurred by the Company in connection with the exploration for and evaluation of mineral resources before the technical feasibility and commercial viability of extracting a mineral resource are demonstrable (other than costs associated with acquiring our exploration properties, which are capitalized), including drilling and sampling costs, technical and engineering studies, permitting costs and overhead costs associated with maintaining our exploration headquarters.
Exploration and evaluation expenses increased by US$3,146,307, to US$3,431,522, from the period ended December 31, 2020 to the period ended December 31, 2021 principally due to increased exploration and appraisal activities, including drilling, on the Titan Project, which was only acquired by the Group on December 1, 2020.
41

TABLE OF CONTENTS

Corporate and administrative expenses
Corporate and administrative expenses encompass overhead costs, such as maintaining our corporate headquarters, public company costs, audit and other fees for professional services and legal compliance.
Corporate and administrative expenses increased by US$813,347, to US$998,378, from the period ended December 31, 2020 to the period ended December 31, 2021 principally due to increased hiring and overheads to support our increased exploration and appraisal activities on the Titan Project, which was only acquired by the Group on December 1, 2020.
Business development expenses
Business development expenses encompass investor relations expenses, including costs for press releases, maintenance of the Company’s website and other investor marketing and information initiatives, and other fees for corporate advisory services.
Business development expenses increased by US$1,429,778, to US$1,501,724, from the period ended December 31, 2020 to the period ended December 31, 2021 principally due to increased consultancy costs to support our increased investor marketing and information initiatives.
Share-based payment expense
Share-based payment expense encompasses expenses incurred by the Company in connection with Restricted Stock Units, Unlisted Options and Performance Rights granted by the Company to officers, employees, consultants and other key advisors as part of remuneration and incentive arrangements.
Share-based payment expenses from such remuneration arrangements increased by US$3,922,239, to US$4,764,135, from the period ended December 31, 2020 to the period ended December 31, 2021 principally due to increased hiring to support our increased exploration and appraisal activities on the Titan Project, which was only acquired by the Group on December 1, 2020.
Finance income
Finance income encompasses interest income and foreign exchange gains.
Finance income increased by US$157,317, to US$157,435, from the period ended December 31, 2020 to the period ended December 31, 2021 principally due to the result of increasing average cash and cash equivalent balances over this period.
Finance costs
Finance costs encompass interest expenses and foreign exchange losses.
Finance costs increased by US$23,831 in the period ended December 31, 2021 compared to nil in the period ended December 31, 2020 principally due to new leases for premises and vehicles entered into by the Group since the end of the period ended December 31, 2020.
Cost of listing on reverse acquisition
In addition, the Company determined that the deemed consideration in respect of the reverse acquisition of the Company by HMAPL represents a share-based payment in accordance with IFRS 2. The Company determined the fair value of the deemed consideration to be US$7,055,446, of which US$1,914,320 of this was allocated to the fair value of the net assets acquired and US$5,141,126 was recognized as a share-based expense in the statement of profit and loss for the period ended December 31, 2020, representing the cost of the listing.
Year Ended June 30, 2021
Exploration and evaluation expenses
Exploration and evaluation expenses were US$2,568,386 for the period ended June 30, 2021.
Corporate and administrative expenses
Corporate and administrative expenses were US$852,944 for the period ended June 30, 2021.
42

TABLE OF CONTENTS

Business development expenses
Business development expenses were US$581,200 for the period ended June 30, 2021.
Share-based payment expense
Share-based payment expense arising from the Company’s remuneration arrangements were US$4,084,764 for the period ended June 30, 2021.
Finance income
Finance income was US$5,075 for the period ended June 30, 2021.
Finance costs
Finance costs were US$7,492 for the period ended June 30, 2021.
Cost of listing on reverse acquisition
In addition, the Company determined that the deemed consideration in respect of the reverse acquisition of the Company by HMAPL represents a share-based payment in accordance with IFRS 2. The Company determined the fair value of the deemed consideration to be US$7,055,446, of which US$1,914,320 of this was allocated to the fair value of the net assets acquired and US$5,141,126 was recognized as a share-based expense in the statement of profit and loss for the period ended June 30, 2021, representing the cost of the listing.
43

TABLE OF CONTENTS

Unaudited Pro Forma Combined Statement of Profit or Loss
The following unaudited pro forma combined statement of profit or loss and related notes presents the combination of the financial information of TAO and HMAPL, adjusted to give effect to the “Reverse Asset Acquisition,” as defined below, and has been prepared for informational purposes only.
The unaudited pro forma combined financial information does not necessarily reflect what the combined company’s financial results of operations would have been had the Reverse Asset Acquisition occurred on July 1, 2020. The unaudited pro forma combined statement of profit or loss also may not be useful in predicting the future financial condition and results of operations of the combined company. The results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors, including those described under the captions “Risk Factors” and “Forward-Looking Statements” and elsewhere in this registration statement.
This information should be read together with the accompanying notes to the unaudited pro forma combined statement of profit or loss, HMAPL’s and TAO’s audited financial statements and related notes, IperionX’s audited financial statements and related notes, the section titled “Item 5. Operating and Financial Review and Prospects” and other financial information included elsewhere in this Form 20-F.
The unaudited pro forma combined statement of profit or loss was prepared in accordance with Article 11 of SEC Regulation S-X as amended by the final rule, Release No. 33-10786 “Amendments to Financial Disclosures about Acquired and Disposed Businesses” as adopted by the SEC on May 21, 2020. Release No. 33-10786 replaces the existing pro forma adjustment criteria with simplified requirements to depict the accounting for the transaction (the “Acquisition Adjustments”) and present the reasonably estimable synergies and other transaction effects that have occurred or are reasonably expected to occur (“Management’s Adjustments”). Management has elected not to present Management’s Adjustments and no Acquisition Adjustments were identified.
Unaudited Pro Forma Combined
Statement of Profit or Loss
HMAPL
(accounting
acquirer)
For the period
from July 20,
2020 to
June 30, 2021
(historical)
US$
TAO
(accounting
acquiree)
For the period
from July 1 to
December 1, 2020
(historical)
US$
Acquisition
Adjustments
US$
Pro Forma
Combined
US$
Continuing operations
 
 
 
 
Exploration and evaluation expenses
(2,568,386)
(43,620)
(2,612,006)
Corporate and administrative expenses
(852,944)
(262,889)
(1,115,833)
Business development expenses
(581,200)
(581,200)
Share based payment expenses
(4,084,764)
(62,716)
(4,147,480)
Finance income
5,075
2,775
7,850
Finance costs
(7,492)
(7,492)
Cost of listing on reverse acquisition
(5,141,126)
(5,141,126)
Impairment expenses
(332,881)
(332,881)
Other expenses
(47,917)
(47,917)
Loss before income tax
(13,230,837)
(747,248)
(13,978,085)
Income tax expense
Loss for the year
(13,230,837)
(747,248)
(13,978,085)
 
 
 
 
 
Loss per share:
 
 
 
 
Weighted average number of ordinary shares – basic and diluted
60,336,252
31,737,316
60,336,252
Loss per ordinary share – basic and diluted
US$0.22
US$0.02
US$0.23
44

TABLE OF CONTENTS

The unaudited pro forma combined statement of profit or loss has been prepared using the assumptions below:
Note 1—Description of the Reverse Asset Acquisition
On December 1, 2020, IperionX Limited (formerly Hyperion Metals Limited and Tao Commodities Limited) (the “Company”) completed its acquisition of Hyperion Metals (Australia) Pty Ltd (“HMAPL”) after issuing 26,500,000 ordinary shares, 5,000,000 unlisted options, 8,000,000 performance options and 36,000,000 performance shares in the Company to the vendors, following shareholder approval received at the Company’s general meeting held on November 30, 2020 (the “Reverse Asset Acquisition”).
As a result of the Reverse Asset Acquisition, the former shareholders of HMAPL effectively obtained control of the combined entity. Accordingly, using the reverse acquisition principles of the business combination accounting standard, while the Company is the legal acquirer of HMAPL, for accounting purposes HMAPL is deemed to be the acquirer of the Company.
Therefore, the consolidated financial statements of the Company for the period ended June 30, 2021 have been prepared as a continuation of the consolidated financial statements of HMAPL. The deemed acquirer, HMAPL, has accounted for the acquisition of the Company from December 1, 2020. As HMAPL was only incorporated during the financial period on July 20, 2020, there is no comparative period information for HMAPL.
In addition, at the date of the Reverse Asset Acquisition, it was determined that the Company was not a business as defined under IFRS 3 Business Combinations (which differs to the definition of a business under Article 11 of SEC Regulation S-X as amended by the final rule, Release No. 33-10786). Accordingly, for accounting purposes, the Reverse Asset Acquisition has been treated as a share-based payment transaction.
Note 2—Basis of Presentation
The unaudited pro forma combined statement of profit or loss has been prepared to illustrate the effect of the Reverse Asset Acquisition and has been prepared for informational purposes only.
The unaudited pro forma combined statement of profit or loss of profit or loss for the period ended June 30, 2021 is based on the historical financial statements of TAO and HMAPL. The Acquisition Adjustments consist of those necessary to account for the Reverse Asset Acquisition.
The unaudited pro forma adjustments are based on information currently available, and assumptions and estimates underlying the unaudited pro forma adjustments are described in the accompanying notes. Actual results may differ materially from the assumptions used to present the accompanying unaudited pro forma combined statement of profit or loss.
The Company and HMAPL did not have any historical relationship prior to the Reverse Asset Acquisition. Accordingly, no pro forma adjustments were required to eliminate activities between the companies.
The unaudited pro forma combined statements of profit or loss for the period ended June 30, 2021, presents pro forma effect to the Reverse Asset Acquisition as if it had been completed on July 1, 2020, the beginning of the earliest period presented.
The unaudited pro forma combined statement of profit or loss has been prepared in accordance with Article 11 of SEC Regulation S-X as amended by the final rule, Release No. 33-10786 to reflect the Reverse Asset Acquisition.
The presentation currency for TAO is Australian dollars. The adjusted historical financial statements of profit and loss have been translated into U.S. dollars using the average exchange rate during the period from July 1, 2020 to December 1, 2020, which was 1 AUD = 0.7171 USD.
The unaudited pro forma combined statement of profit or loss for the period ended June 30, 2021 has been prepared using, and should be read in conjunction with, the following:
the audited financial statements of HMAPL for the period from July 20, 2020 to June 30, 2021 and related notes, included elsewhere in this Form 20-F, which have been prepared as a continuation of the financial statements of HMAPL, due to the fact that, for accounting purposes, HMAPL is deemed to be the acquirer of the Company; and
45

TABLE OF CONTENTS

the audited financial statements of TAO for the period from July 1, 2020 to December 1, 2020 and related notes, included elsewhere in this Form 20-F, which have been prepared on a standalone basis for the period prior to consummation of the Reverse Asset Acquisition on December 1, 2020.
The unaudited pro forma combined statement of profit or loss does not give effect to any anticipated synergies, operating efficiencies, tax savings or cost savings that may be associated with the Reverse Asset Acquisition.
As a SEC registered company, we will be implementing additional procedures and processes for the purpose of addressing the standards and requirements applicable to SEC registered companies. We expect to incur additional annual expenses related to these steps and, among other things, additional directors’ and officers’ liability insurance, director fees, reporting requirements of the SEC, transfer agent fees, hiring additional accounting, legal and administrative personnel, increased auditing, tax and legal fees, stock exchange listing fees and similar expenses. We have not included any pro forma adjustments relating to these costs.
The pro forma adjustments reflecting the consummation of the Reverse Asset Acquisition are based on certain currently available information and certain assumptions and methodologies that the Company believes are reasonable under the circumstances. The unaudited pro forma adjustments, which are described in the accompanying notes, may be revised as additional information becomes available and is evaluated. Therefore, it is likely that the actual adjustments will differ from the pro forma adjustments and it is possible the difference may be material. The Company believes that its assumptions and methodologies provide a reasonable basis for presenting all of the significant effects of the business combination based on information available to management at the time and that the pro forma adjustments give appropriate effect to those assumptions and are properly applied in the unaudited pro forma combined statement of profit or loss.
The unaudited pro forma combined statement of profit or loss is not necessarily indicative of what the actual results of operations would have been had the Reverse Asset Acquisition taken place on the date indicated, nor are they indicative of the future consolidated results of operations or financial position of the combined company. They should be read in conjunction with the historical financial statements and notes thereto of TAO and HMAPL.
Note 3—Accounting Policies
Based on a review of the two entities’ accounting policies, management did not identify any differences that would have a material impact on the unaudited pro forma combined financial information. As a result, the unaudited pro forma combined statement of profit or loss does not assume any differences in accounting policies.
B. Liquidity and Capital Resources
The liquidity and capital resources discussion that follows contains certain estimates as of the date of this registration statement of our estimated future sources and uses of liquidity (including estimated future capital resources and capital expenditures) and future financial and operating results. These estimates reflect numerous assumptions made by us with respect to general business, economic, regulatory, market and financial conditions, industry conditions and other future events, and matters specific to our businesses, all of which are difficult or impossible to predict and many of which are beyond our control. Please carefully read the risks discussed in “Risk Factors” contained in this registration statement which describe significant risks and uncertainties that may affect us and our financial conditions.
Sources and Uses of Liquidity
We have not yet commenced commercial production at any of our properties and expect to continue to incur losses during the exploration, evaluation, and development of the Titan Project. Our operations have been financed by proceeds from issuances of ordinary shares.
At June 30, 2021, we had cash reserves of US$1.7 million and net assets of US$1.8 million. In addition, subsequent to the end of the 2021 fiscal year, IperionX completed a placement of 20 million shares at an issue price of A$1.20 per share to institutional, sophisticated and professional investors to raise gross proceeds of A$24.0 million (US$17.6 million) (the “Placement”). Our primary use of cash currently comprises exploration and evaluation expenditures relating to the Titan Project and for ongoing operating expenses. Based on our current financial position, we expect to have sufficient cash flow to operate for the next 12 months, complete a Scoping Study for the Titan Project in 2022, and to maintain adequate liquidity to satisfy working capital requirements.
46

TABLE OF CONTENTS

Until we have completed a definitive Feasibility Study for the Titan Project, we are not able to say if or when we will decide to develop the Titan Project. If we complete a definitive Feasibility Study for the Titan Project and ultimately make a decision to develop the Titan Project, this will require substantial additional funds, which would require future debt or equity financings. Similar rare earth projects that are planned to be constructed in Australia by other companies have estimated capital expenditures of between US$200 to US$300 million.
We may decide to pursue additional financing activities to facilitate development activities at the Titan Project and to fund working capital and our corporate operations. We expect that such financing will result in additional sales or issuances of our ordinary shares or ADSs, but we also may engage in debt financing.
If we decide to raise capital by issuing equity securities, the issuance of additional ordinary shares or ADSs would result in dilution to our existing shareholders. We cannot assure you that we will be successful in completing any financings or that any such equity or debt financing will be available to us if and when required or on satisfactory terms.
Funding Requirements and Capital Expenditures
Our capital expenditures for fiscal 2021 amounted to US$571,568 which represents the purchase of exploration and evaluation properties and the purchase of property, plant and equipment.
We expense all other exploration and evaluation expenditures when incurred (other than expenditures incurred in the acquisition of the rights to explore, including option payments to landowners).
If we complete a definitive Feasibility Study for the Titan Project and ultimately make a decision to develop the Titan Project, this will require substantial additional funds, which would require future debt or equity financings. Similar rare earth projects that are planned to be constructed in Australia by other companies have estimated capital expenditures of between US$200 to US$300 million.
Potential acquisition of Blacksand
IperionX has secured an exclusive option to acquire 100% of the ownership interests in Blacksand, valid until December 31, 2022. Blacksand holds the rights to produce low carbon titanium metal and spherical powders using the patented Technologies. Upon exercise of the option under the Blacksand Option Agreement, IperionX will: (i) pay US$12,000,000 to Blacksand and its members, of which IperionX can elect to pay an amount (between 22.5% to 30%) in shares of IperionX (based on a share price equal to 75% of the 10-day VWAP of IperionX shares on ASX immediately preceding the closing date, subject to a floor of A$0.85 and a ceiling of A$3.00), subject to IperionX obtaining shareholder approval; (ii) commit to invest US$1,000,000 over a 3 year period towards the establishment of an endowed chair professorship at the University of Utah, which shall be used to support research and development related to Blacksand and IperionX and other related technologies in the field of titanium, critical metals, and minerals; and (iii) pay the Blacksand members a royalty equal to 0.5% of cumulative net sales that relate to Blacksand assets or properties above US$300,000,000. If we choose to exercise our option under the Blacksand Option Agreement this will require additional funds, which would require future debt or equity financings.
Cash Flows
The following table summarizes our sources and uses of cash for the six months ended December 31, 2021 and the year ended June 30, 2021:
 
Six Months Ended
December 31,
Year Ended
June 30,
 
2021
2021
Net cash provided by (used in):
 
 
Operating activities
$(5,900,944)
$(3,558,025)
Investing activities
(744,865)
(571,568)
Financing activities
19,295,299
5,829,916
Net increase (decrease) in cash and cash equivalents
$12,649,490
US$1,700,323
47

TABLE OF CONTENTS

Operating Activities
For the six months ended December 31, 2021 net cash used in operating activities was US$5,900,944. For the year ended June 30, 2021, net cash used in operating activities was US$3,558,025, which represents payments to suppliers and employees and interest paid and received.
Investing Activities
For the six months ended December 31, 2021, net cash used in investing activities was US$744,865. For the year ended June 30, 2021, net cash used in investing activities was US$571,568, which represents the purchase of exploration and evaluation properties, and the purchase of property, plant and equipment .
Financing Activities
For the six months ended December 31, 2021, net cash provided by financing activities was US$19,295,299. For the year ended June 30, 2021, net cash provided by financing activities was US$5,829,916, which represents proceeds and costs from the issuance of Ordinary Shares, payment of the principal portion of lease liabilities and a net cash inflow from the Acquisition.
Climate Change
Numerous regulatory initiatives have been enacted, and are likely to continue to be developed, at the international, national, regional and state levels of government to monitor and limit existing emissions of GHGs as well as to restrict or eliminate such future emissions. See “Item 4. Information on the Company—B. Business Overview—Governmental Regulations—Climate Change” for additional information. We do not currently anticipate that the adoption of legislation or regulatory programs or other government action to reduce emissions of GHGs will materially and adversely affect our business or results of operations. However, we cannot assure you as to the effect of future legislation or rules, any of which could require us to incur increased operating costs.
Off-balance sheet arrangements
During the six months ended December 31, 2021 and fiscal 2021, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.
C. Research and Development, Patents and Licenses
IperionX’s research and development (“R&D”) policies are focused on optimizing its R&D resources relating to human talent, infrastructure, and working with select partners including leading academic institutions to bring specific, high-level skills to its core R&D projects. These projects include the rapid commercialization of proprietary technologies to produce low-cost, low-carbon titanium products and powders, as well as recycled scrap. The core technologies behind IperionX’s products were discovered by researchers at the University of Utah. IperionX acquired and holds the exclusive rights to commercialize these technologies. The potential end-market applications for IperionX’s products are broad, as its titanium can be produced in powder form or milled product (bar, rod, sheet). Ultimately, IperionX aims to displace steel and aluminum to reduce carbon and GHG emissions in the transportation and other sectors.
D. Trend Information
Not applicable, as the Company is in the exploration stage and therefore has no material trends in production, sales or inventory.
E. Critical Accounting Policies and Estimates
The preparation of our consolidated financial statements requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the
48

TABLE OF CONTENTS

estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. See note 1 to our audited consolidated financial statements for the period ended June 30, 2021, incorporated by reference in this registration statement, for a description of our other significant accounting policies.
In particular, information about significant areas of estimation uncertainty and critical judgements in applying accounting policies that have the most significant effect on the amount recognized in the financial statements are described below.
Recognition of tax losses
The income tax expense for a particular period is the tax payable on the current period’s taxable income based on the national income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses.
Deferred tax assets and liabilities are recognized for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates which are enacted or substantively enacted for each jurisdiction. The relevant tax rates are applied to the cumulative amounts of deductible and taxable temporary differences to measure the deferred tax asset or liability. An exception is made for certain temporary differences arising from the initial recognition of an asset or a liability. No deferred tax asset or liability is recognized in relation to these temporary differences if they arose on goodwill or in a transaction, other than a business combination, that at the time of the transaction did not affect either accounting profit or taxable profit or loss.
Deferred tax liabilities and assets are not recognized for temporary differences between the carrying amount and tax bases of investments in controlled entities where the Company is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.
Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses.
The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.
Unrecognized deferred income tax assets are reassessed at each balance date and are recognized to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.
Current and deferred tax balances attributable to amounts recognized directly in equity are also recognized directly in equity.
Deferred tax assets and deferred tax liabilities are offset only if a legally enforceable right exists to set off current tax assets against tax liabilities and the deferred tax liabilities relate to the same taxable entity and the same taxation authority.
Impairment of exploration and evaluation assets
The ultimate recoupment of costs carried forward for exploration and evaluation is dependent on the successful development and commercial exploitation or sale of the respective areas of interest. See note 6 to our audited consolidated financial statements for the period ended June 30, 2021, incorporated by reference in this registration statement.
Determination of the accounting acquirer in reverse acquisition and fair value of the consideration paid
As a result of the Acquisition, the former shareholders of HMAPL effectively obtained control of the combined entity. Accordingly, using the reverse acquisition principles of the business combination accounting standard, while the Company is the legal acquirer of HMAPL, for accounting purposes HMAPL is deemed to be the acquirer of the Company.
Therefore, the consolidated financial statements of IperionX have been prepared as a continuation of the consolidated financial statements of HMAPL. The deemed acquirer, HMAPL, has accounted for the acquisition
49

TABLE OF CONTENTS

of the Company from December 1, 2020. As HMAPL was incorporated on July 20, 2020, and therefore there is no comparative period information available for HMAPL.
In addition, at the date of the transaction, it was determined that the Company was not a business. Accordingly, for accounting purposes, the Acquisition has been treated as a share-based payment transaction.
Share-based payments
The fair value of Unlisted Options granted is estimated as at the date of grant using the Black Scholes option valuation model taking into account the terms and conditions upon which the Unlisted Options were granted. The fair value of Performance Rights granted that have market-based vesting conditions is estimated as at the date of grant using trinomial lattice valuation model taking into account the market-based vesting criteria upon which the Performance Rights were granted. The fair value of Performance Rights granted that do not have market-based vesting conditions is estimated as at the date of grant on the underlying share price (being the five-day volume weighted average share price prior to issuance). For additional information, see note 17 to our audited consolidated financial statements for the period ended June 30, 2021, incorporated by reference in this registration statement.
50

TABLE OF CONTENTS

ITEM 6.
DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
A. Directors and Senior Management
The following discussion sets forth information regarding our directors and executive officers as of the date of this registration statement on Form 20-F. In accordance with the ASX Listing Rules, a Director (other than the Managing Director) must not hold office, without re-election, past the third annual general meeting following the Director’s appointment or three years, whichever is longer. The following table lists the names of our directors and executive officers. The business address for each director and member of senior management is c/o Level 9, 28 The Esplanade, Perth WA 6000, Australia.
Name
Age
Position
Anastasios (Taso) Arima
37
Chief Executive Officer and Managing Director
Todd W. Hannigan
49
Executive Chairman
Lorraine M. Martin
59
Independent Non-Executive Director
Vaughn W. Taylor
37
Independent Non-Executive Director
Melissa G. Waller
51
Independent Non-Executive Director
Beverly M. Wyse
59
Independent Non-Executive Director
Dominic P. Allen
38
Vice President and Chief Commercial Officer
Lamont Leatherman
56
Vice President and Chief Geologist
Toby Symonds
53
Vice President and Chief Strategy Officer
Jeanne McMullin
55
Vice President and Chief Legal Officer
Gregory D. Swan
40
Vice President and Company Secretary (principal financial officer)
Anastasios (Taso) Arima (37 years of age) – Chief Executive Officer and Managing Director
Anastasios (Taso) Arima has extensive experience in the development of energy and resource projects in North America, establishing outstanding management teams and high-quality projects, and has raised over A$500 million in equity funding over his career. Mr. Arima has been based in the United States since 2014. He was a founder and director of Piedmont Lithium Limited (NASDAQ/ASX: PLL), which has rapidly grown into a A$1 billion company and was instrumental in identifying and securing Piedmont’s lithium project. Mr. Arima is also the founder of Hyperion Metals (Australia) Pty Ltd, which the Company acquired during the period and holds the Company’s Titan Project, a potentially large-scale titanium and zircon minerals sands project in west Tennessee. Mr. Arima attended the University of Western Australia where he earned a Bachelor of Commerce whilst studying for a Bachelor of Engineering. Mr. Arima was appointed as Director of Hyperion Metals (Australia) Pty Ltd on July 20, 2021, as Executive Director of the Company on December 1, 2020, and as Managing Director and Chief Executive Officer on March 1, 2021. During the three-year period to the end of the financial period, Mr. Arima held a directorship in Piedmont Lithium Limited (October 2016 – June 2021).
Todd Hannigan (49 years of age) – Executive Chairman
Todd Hannigan has over 25 years of global experience in natural resources as company founder, chief executive officer, private capital investor and non-executive director. In these lead roles Mr. Hannigan has helped build multiple billion-dollar companies in the private and public markets. He is a large shareholder and non-executive director of Piedmont Lithium Limited (NASDAQ/ASX: PLL). Mr. Hannigan has worked internationally in the extraction and resources sector for Aston Resources, Xstrata Coal, Hanson PLC, BHP Billiton and MIM. Mr. Hannigan was the Chief Executive Officer of Aston Resources from 2010 to 2011. During this time, the company significantly progressed the Maules Creek project, including upgrades to the project’s resources and reserves, completion of all technical and design work for the definitive Feasibility Study, negotiation of two major project stake sales and joint venture agreements, securing port and rail access and progression of planning approvals to final stages. Mr. Hannigan holds a Bachelor of Engineering (Mining) from The University of Queensland and an MBA from INSEAD. Mr. Hannigan was appointed as Non-Executive Chairman of the Company on February 1, 2021, and as Executive Chairman on May 24, 2021. During the three-year period to the end of the financial period, Mr. Hannigan held directorships in Piedmont Lithium Limited (March 2021 – present), Paringa Resources Limited (May 2014 – present), and Prairie Mining Limited (September 2014 – February 2021).
51

TABLE OF CONTENTS

Lorraine M. Martin (59 years of age) – Independent Non-Executive Director
Lorraine M. Martin is President and Chief Executive Officer of the National Safety Council, a non-profit with a century-long legacy of eliminating preventable deaths and injuries from the workplace. Ms. Martin has 35 years of experience in aerospace, including leading and developing complex global aircraft programs as a senior executive at Lockheed Martin. Ms. Martin was Executive Vice President and Deputy of Rotary and Mission Systems where she led a team of 34,000 global employees in the U.S., Canada, Mexico, Taiwan, Japan, United Kingdom, Germany, Poland, the Netherlands, New Zealand and Australia with operations in more than 75 worldwide facilities. In this role, she spearheaded the successful operational and cultural integration of Sikorsky, a global leader in helicopters. Ms. Martin led Lockheed Martin’s largest defense program, the F-35 Lightning II Program, where she was Executive Vice President & General Manager with full P&L responsibility for a program with over $8 billion in annual revenue and 9,000 employees. Before this, she was Vice President of the C-130 & C-5 Programs where she led 3,000 employees for a $2 billion aircraft mobility portfolio. Ms. Martin has a Master of Science in computer science from Boston University and a BA in computational mathematics from DePauw University. Ms. Martin was appointed as Non-Executive Director of the Company on September 13, 2021. During the three-year period to the end of the financial period, Ms. Martin held a directorship in Kennametal Inc. (NYSE: KMT) (July 2018 – present). Kennametal is a global materials science firm with a market capitalization of approximately US$3 billion that serves customers across aerospace, energy, engineering and transportation.
Vaughn Taylor (37 years of age) – Independent Non-Executive Director
Vaughn Taylor was previously Executive Director and Chief Investment Officer of AMB Capital Partners (“AMB”), the global investment platform of the Western Australian based Bennett Family, whose wealth is tied to the Australian Iron Ore industry. Mr. Taylor was with AMB since the formation of the investment platform over 10 years ago, and was responsible for executing on the investment strategy, expanding the investment platform and portfolio into offshore markets, overseeing the operations and portfolio on a day-to-day basis and sourcing new investment opportunities. Mr. Taylor is a board member of multiple leading organizations both in Australia and internationally, including Cornerstone Health, 4Cyte Pathology, Arrow Capital Partners, Invictus Capital Partners and GB Energy. Mr. Taylor holds a Bachelor of Business (Accounting) and a Master of Business (Real Estate) from RMIT University and gained further accreditation at the Robert H. Smith School of Business at the University of Maryland (USA). Mr. Taylor also holds a Graduate Diploma in Applied Finance and Investment from FINSIA and is a member of FINSIA and the Australian Institute of Company Directors. Mr. Taylor was appointed as Non-Executive Director of the Company on March 3, 2021. During the three-year period to the end of the financial period, Mr. Taylor has not held a directorship in any other listed companies.
Melissa G. Waller (51 years of age) – Independent Non-Executive Director
Melissa G. Waller has over 30 years’ experience as a senior finance executive and is President for the AIF Institute, providing essential education, research and resources to investors and investment firms globally with over $50 trillion assets under management. Ms. Waller is the former Deputy Treasurer and Chief of Staff for the North Carolina Department of State Treasury, where she successfully oversaw Department strategic planning, operations, and public-policy implementation, along with a staff of more than 400 employees, including the North Carolina Retirement Systems, the pension fund for the state and the tenth largest public pension fund in the United States, with assets in excess of $90 billion. Ms. Waller has served as Chair of the Department’s Corporate Governance Committee, as well as on the Council of Institutional Investors Board of Directors and the Governor’s Board of Innovation for the North Carolina University System. She currently serves as Executive Program Director for the National Institute of Public Finance, as well as Director of Public and Private Partnerships for the Kenan Institute. Ms. Waller has a bachelor’s degree in journalism and mass communications from the University of North Carolina. Ms. Waller was appointed as Non-Executive Director of the Company on September 13, 2021. During the three-year period to the end of the financial period, Ms. Waller has not held a directorship in any other listed companies.
Beverly M. Wyse (59 years of age) – Independent Non-Executive Director
Beverly M. Wyse has over 30 years of senior leadership in the aerospace industry with Boeing, the world’s largest aerospace company. Ms. Wyse was the President of Shared Services, a +7,000-person, multi-billion dollar operating group that provides internal services across Boeing’s global enterprises in more than 65 countries.
52

TABLE OF CONTENTS

Previously, Ms. Wyse was the Vice President & General Manager of Boeing South Carolina, a major engineering design, manufacturing, assembly, and delivery site for Boeing that included the 787 Dreamliner Aft-body and Mid-body operations, 787 final assembly, delivery and test operations. Ms. Wyse was Vice President and General Manager of the 737 Program, from 2010 to 2015, successfully leading the design, development, certification, production and delivery for Boeing’s largest commercial program. Before this, Ms. Wyse was the Vice President & General Manager of the 767 Program. Ms. Wyse has a bachelor’s degree in Mechanical Engineering and a Master’s in Business Administration, from the University of Washington in Seattle. Ms. Wyse was appointed as Non-Executive Director of the Company on September 13, 2021. During the three-year period to the end of the financial period, Ms. Wyse held a directorship in Héroux-Devtek Inc. (TSX: HRX) (February 2019 – present). Héroux-Devtek is an international company specializing in the design, development, manufacture, integration, testing and repair, and overhaul of landing gear, actuation systems and components for the aerospace market.
Dominic Allen (38 years of age) – Vice President and Chief Commercial Officer
Dominic Allen is a Chartered Accountant with over 10 years commercial experience, including senior roles with Rio Tinto Limited and Oyu Tolgoi LLC. Mr. Allen previously worked for Ernst & Young Transaction Advisory Services, completing multiple resource and industrial transactions both in Australia and internationally.
Lamont Leatherman (56 years of age) – Vice President and Chief Geologist
Lamont Leatherman is an exploration geologist with over 25 years of experience. Mr. Leatherman is the former project geologist for BHP Minerals and Noranda. He has extensive experience in numerous styles of mineralization including lithium bearing pegmatite systems. Mr. Leatherman was a founder of and currently Chief Geologist of Nasdaq-listed Piedmont Lithium Inc., responsible for the leasing and delineation of Piedmont Lithium’s North Carolina lithium project.
Toby Symonds (53 years of age) – Vice President and Chief Strategy Officer
Toby Symonds has over 30 years of experience in finance and asset management. This includes advisory board roles across private equity and real estate investment firms and executive leadership positions within global hedge fund firms and investment banking firms based in London, New York and San Francisco. Mr. Symonds has core competencies in capital markets, corporate strategy, product development, business development, management information systems and project and team management. Mr. Symonds graduated from North Carolina State University with a B.A. degree in Political Science.
Jeanne McMullin (55 years of age) – Vice President and Chief Legal Officer
Jeanne McMullin is a corporate attorney and business executive with over 25 years’ experience advising early and growth stage companies on legal, commercial, operational, and regulatory matters. Ms. McMullin has held senior legal and operational roles at Twist Capital, a technology investment firm in Los Angeles and at Colchester Global Investors, a global bond manager in London. Ms. McMullin has a JD from the University of Pennsylvania Law School and a BA with honors from Brown University. She is a member of the New York bar.
Gregory Swan (40 years of age) – Vice President and Company Secretary
Gregory Swan is a Chartered Accountant with over 15 years’ experience in the formation and development of publicly listed natural resources companies. He currently serves as Chief Financial Officer and/or Company Secretary for several listed companies that operate in the resources sector. He commenced his career at a large international Chartered Accounting firm and has since been involved with a number of extraction exploration and development companies, including Piedmont Lithium Inc. (NASDAQ:PLL, ASX:PLL), Mantra Resources Limited (ASX:MRU) and Papillon Resources Limited (ASX:PIR). Mr. Swan holds a Bachelor of Commerce from the University of Western Australia and is a Member of the Chartered Accountants Australia and New Zealand, a Fellow of the Governance Institute of Australia, and a Fellow of the Financial Services Institute of Australasia. Mr. Swan was appointed as Director of Hyperion Metals (Australia) Pty Ltd on July 20, 2020 and as Company Secretary of the Company on December 16, 2020.
Family Relationships
There are no family relationships between any members of our executive management and our directors.
53

TABLE OF CONTENTS

Arrangements for Election of Directors and Members of Management
There are no contracts or other arrangements pursuant to which directors have been or must be selected.
B. Compensation
Overview
Our remuneration policy for our key management personnel (“KMP”) has been developed by the Board taking into account the size of the Company, the size of the management team for the Company, the nature and stage of development of the Company’s current operations, and market conditions and comparable salary levels for companies of a similar size and operating in similar sectors.
In addition to considering the above general factors, the Board has also placed emphasis on the following specific issues in determining the remuneration policy for KMP: (a) the Company is currently focused on undertaking exploration, appraisal and development activities at the Titan Project; (b) risks associated with small cap resource companies whilst exploring and developing projects; and (c) other than profit which may be generated from asset sales, the Company does not expect to be undertaking profitable operations until sometime after the commencement of commercial production on any of its projects.
The objective of our remuneration structure reward framework is to ensure that reward for performance is competitive and appropriate for the results delivered. The remuneration framework provides a mix of fixed and variable remuneration, which incorporates a blend of short and long-term incentives. There is a deliberate emphasis on lower fixed base and higher variable results-based remuneration to ensure that management focus is aligned with that of shareholders. This has been achieved by ensuring that a significant proportion of executive’s remuneration is ‘at risk’. Long-term incentives are based on Company milestones linked to value drivers of the Titan Project.
Executive Remuneration
The Company’s remuneration policy is to provide a fixed remuneration component and a performance-based component (short term incentive and long-term incentive). The Board believes that this remuneration policy is appropriate given the considerations discussed in the section above and is appropriate in aligning executives’ objectives with shareholder and business objectives.
Fixed Remuneration
Fixed remuneration consists of base salaries, as well as employer 401(k) contributions or contributions to superannuation funds and other non-cash benefits. Non-cash benefits may include provision of motor vehicles, rental allowance, health care benefits, health insurance, and life insurance.
Fixed remuneration is reviewed annually by the Board. The process consists of a review of Company and individual performance, relevant comparative remuneration externally and internally and, where appropriate, external advice on policies and practices.
Performance Based Remuneration – Short Term Incentive
Some executive KMP are entitled to an annual cash bonus upon achieving various key performance indicators (“KPI’s”), as set by the Board. Having regard to the current size, nature and opportunities of the Company, the Board has determined that these KPI’s will include measures such as successful completion of the acquisition of new projects, exploration activities (e.g. completion of exploration programs within budgeted timeframes and costs), development activities (e.g. completion of scoping and/or feasibility studies), corporate activities (e.g. recruitment of key personnel) and business development activities (e.g. project acquisitions and capital raisings). Prior to the end of each financial year, the Board assesses performance against these criteria.
During fiscal 2021, no bonuses were paid to executive KMP.
54

TABLE OF CONTENTS

Performance Based Remuneration – Long Term Incentive
The Company has a long-term incentive plan (“LTIP”) comprising the “IperionX Limited Employee Equity Incentive Plan” (the “Plan”) to reward executive KMP and other key employees and contractors for long-term performance. The Plan provides for the issuance of unlisted options (“Unlisted Options”) and unlisted performance rights (“Performance Rights”) to eligible employees and contractors as part of their remuneration and incentive arrangements in order to attract and retain their services and to provide an incentive linked to the performance of the Company.
To achieve our corporate objectives, we need to attract, incentivize, and retain our executive KMP and other key employees and contractors. The Board believes that grants made to eligible participants under the Plan will provide a useful tool to underpin our employment and engagement strategy, and enables us to:
recruit, incentivize and retain KMP and other key employees and contractors needed to achieve our business objectives;
link the reward of key staff with the achievement of strategic goals and the long-term performance of the Company;
align the financial interest of participants of the Plan with those of shareholders; and
provide incentives to participants of the Plan to focus on superior performance that creates shareholder value.
Performance Rights
The Plan provides for the issuance of Performance Rights to eligible participants which, upon satisfaction of the relevant performance conditions attached to the Performance Rights, will result in the issue of an Ordinary Share for each Performance Right. Performance Rights are issued for no consideration and no amount is payable upon conversion thereof.
Performance Rights granted under the Plan to eligible participants will be linked to the achievement by the Company of certain performance conditions as determined by the Board from time to time. These performance conditions must be satisfied in order for the Performance Rights to vest. Upon Performance Rights vesting, Ordinary Shares are automatically issued for no consideration. If a performance condition of a Performance Right is not achieved by the expiry date, then the Performance Right will lapse.
During fiscal 2021, 13,450,000 Performance Rights were granted to executive KMP and 2,000,000 Performance Rights held by executive KMP vested and converted into Ordinary Shares. No Performance Rights held by executive KMP lapsed during fiscal 2021.
Unlisted Options
The Plan provides for the issuance of Unlisted Options to eligible participants. The Board’s policy is to grant Unlisted Options to KMP with exercise prices at or above market share price (at the time of agreement). As such, the Unlisted Options granted to KMP are generally only of benefit if the KMP performs to the level whereby the value of the Group increases sufficiently to warrant exercising the Unlisted Options granted.
Other than service-based vesting conditions (if any) and the exercise price required to exercise the Unlisted Options, there are no additional performance criteria on the Unlisted Options granted to KMP, as given the speculative nature of the Company’s activities and the small management team responsible for its running, it is considered that the performance of the KMP and the performance and value of the Company are closely related. The Company prohibits executive KMP from entering into arrangements to limit their exposure to Unlisted Options granted as part of their remuneration package.
During fiscal 2021, 8,125,000 Unlisted Options were granted to executive KMP and no Unlisted Options were exercised by executive KMP. No Unlisted Options held by executive KMP lapsed during fiscal 2021.
55

TABLE OF CONTENTS

Non-Executive Director Remuneration
The Board’s policy is to remunerate Non-Executive Directors at market rates for comparable companies for time, commitment and responsibilities. Given the current size, nature and risks of the Company, Unlisted Options have been used to attract and retain Non-Executive Directors, where deemed appropriate. The Board determines payments to the Non-Executive Directors and reviews their remuneration annually, based on market practice, duties and accountability. Independent external advice is sought when required.
The maximum aggregate amount of fees that can be paid to Non-Executive Directors is subject to approval by shareholders at a general meeting. Director’s fees paid to Non-Executive Directors accrue on a daily basis. Fees for Non-Executive Directors are not linked to the performance of the economic entity. However, to align directors’ interests with shareholder interests, the directors are encouraged to hold shares in the Company and Non-Executive Directors may in limited circumstances receive grants of restricted stock options, unlisted options or performance rights in order to secure their services. The Company prohibits Non-Executive Directors from entering into arrangements to limit their exposure to options granted as part of their remuneration package.
Fees for Non-Executive Directors are presently set at US$30,000 per annum. These fees cover main board activities only. Non-Executive Directors may receive additional remuneration for other services provided to the Company, including but not limited to, membership of committees.
Relationship between Remuneration of KMP and Shareholder Wealth
During the Company’s exploration and development phases of its business, the Board anticipates that the Company will retain earnings (if any) and other cash resources for the exploration and development of its resource projects. Accordingly, we do not currently have a policy with respect to the payment of dividends and returns of capital. Therefore, there was no relationship between the Board’s policy for determining, or in relation to, the nature and amount of remuneration of KMP and dividends paid and returns of capital by the Company during the current and previous four financial years.
The Board did not determine, and in relation to, the nature and amount of remuneration of the KMP by reference to changes in the price at which shares in the Group traded between the beginning and end of the current and the previous four financial years. Discretionary annual cash bonuses are based upon achieving various non-financial KPI’s that are not based on share price or earnings, such as the successful acquisition of new projects, exploration activities (e.g. completion of exploration programs within budgeted timeframes and costs), development activities (e.g. completion of scoping and/or feasibility studies), corporate activities (e.g. recruitment of key personnel) and business development activities (e.g. project acquisitions and capital raisings). However, as noted above, certain KMP are granted Performance Rights and/or Unlisted Options which generally will be of greater value to KMP if the value of the Ordinary Shares increases (subject to vesting conditions being met).
Relationship between Remuneration of KMP and Earnings
As discussed above, the Company is currently undertaking exploration and development activities, and does not expect to be undertaking profitable operations (other than by way of material asset sales, none of which is currently planned) until sometime after the successful commercialization, production and sales of commodities from one or more of its projects. Accordingly, the Board does not consider earnings during the current and previous four financial years when determining, and in relation to, the nature and amount of remuneration of KMP.
Details of Remuneration
Details of the nature and amount of each element of the emoluments of each KMP of the Company for the period ended June 30, 2021 are as follows. Note that emoluments of each KMP of the Company prior to completion of the reverse acquisition on December 1, 2020 have been excluded from the below amounts, on the basis that the consolidated financial statements of the Company for the period ended June 30, 2021 have been prepared as a continuation of the consolidated financial statements of HMAPL. Further, due to the fact that HMAPL was only incorporated during fiscal 2021, there is no comparative period information.
56

TABLE OF CONTENTS

2021
Short-term benefits
Post-
employment
benefits
US$
Termination
benefits
US$
Share-based
payments US$
Total
US$
Performance
related
%
Salary &
fees
US$
Other
US$
Current KMP
 
 
 
 
 
 
 
Todd Hannigan(1)
18,670
1,774
981,359
1,001,803
98%
Anastasios Arima(2)
87,514
1,543
1,052,363
1,141,420
92%
Vaughn Taylor(3)
8,962
73,167
82,129
89%
Dominic Allen(4)
45,704
496,205
541,909
92%
Lamont Leatherman(5)
45,000
74,483
119,483
62%
Gregory Swan(6)
391,309
391,309
100%
Former KMP
 
 
 
 
 
 
 
Patric Glovac(7)
48,168
1,490
335,930
385,588
87%
Mark Connelly(8)
8,908
846
216,756
226,510
96%
Frank Knezovic(9)
4,481
426
59,587
64,494
92%
Alastair Smith(10)
7,839
7,839
 
275,246
6,079
3,681,159
3,962,484
 
(1)
Mr. Hannigan was appointed effective February 1, 2021.
(2)
Mr. Arima was appointed as Executive Director of the Company effective December 1, 2020 and as CEO and Managing Director of the Company effective from March 1, 2021. Mr. Arima was appointed as Director of HMAPL on July 20, 2020.
(3)
Mr. Taylor was appointed effective March 3, 2021.
(4)
Mr. Allen was appointed Corporate Development Officer of the Company effective December 1, 2020. Mr. Allen was appointed as Director of HMAPL on July 20, 2020.
(5)
Mr. Leatherman was appointed effective December 1, 2020. Mr. Leatherman was appointed as a consultant of HMAPL on July 20, 2020.
(6)
Mr. Swan was appointed Company Secretary of the Company effective December 16, 2020. Mr. Swan provides services as the Company Secretary through a services agreement with Apollo Group Pty Ltd (“Apollo”). During the period, Apollo was paid or is payable A$105,000 for the provision of serviced office facilities and administrative, accounting and company secretarial services to the Group. Mr. Swan was appointed as Director of HMAPL on July 20, 2020.
(7)
Mr. Glovac resigned effective March 1, 2021. US$33,905 received by Mr. Glovac prior to completion of the reverse acquisition on December 1, 2020 has been excluded.
(8)
Mr. Connelly resigned effective February 18, 2021. US$20,444 received by Mr. Connelly prior to completion of the reverse acquisition on December 1, 2020 has been excluded.
(9)
Mr. Knezovic resigned effective December 29, 2020. US$12,266 received by Mr. Knezovic prior to completion of the reverse acquisition on December 1, 2020 has been excluded.
(10)
Mr. Smith appointed effective January 11, 2021 and resigned effective April 23, 2021.
Loans with Key Management Personnel
No loans were provided to or received from KMP during fiscal 2021.
Employment Agreements with Executive Officers and Directors
Mr. Hannigan, Executive Chairman, has a director appointment letter with the Company. Mr. Hannigan receives a fixed remuneration component of A$60,000 (US$44,808) per annum.
Mr. Arima, Chief Executive Officer and Managing Director, has an employment agreement with the Company which may be terminated upon six months’ advance written notice, unless mutually agreed upon with the Company. Mr. Arima receives a fixed remuneration component of US$180,000 per annum and a discretionary annual bonus of up to US$100,000 to be paid upon the successful completion of KPIs as determined by the Board.
All Non-Executive Directors have a letter of appointment confirming the terms and conditions of their appointment as director of the Company.
57

TABLE OF CONTENTS

C. Board Practices
The Board is responsible for and has the authority to determine all matters relating to the strategic direction, policies, practices, establishing goals for management and the operation of the Company. The functions and responsibilities reserved for the Board and those delegated to the Managing Director and executive management are set out in our Board Charter.
Nasdaq listing standards require that a majority of the Board be independent. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the Board, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. The Board has determined that Mses. Martin, Waller and Wyse and Mr. Taylor are “independent directors” as defined in the Nasdaq listing standards and applicable SEC rules.
In addition to being set out in the Board Charter, the roles and responsibilities of our directors are also formalized in the letter of appointment which each director receives and commits to on their appointment. The letters of appointment specify the term of appointment, time commitment envisaged, expectations in relations to committee work or any other special duties attaching to the position, reporting lines, remuneration arrangements, disclosure obligations in relation to personal interests, confidentiality obligations, insurance and indemnity entitlements and details of the Company’s key governance policies. Each KMP enters into a service contract which sets out the material terms of employment, including a description of position and duties, reporting lines, remuneration arrangement and termination rights and entitlement.
The Constitution of the Company requires the Company, to the extent permitted by law, to indemnify any person who is or has been a director or officer of the Company for any liability caused by such a director or officer and any legal costs incurred by a director or officer in defending an action for any liability caused by such a director or officer. During or since the end of fiscal 2021, no amounts have been paid by the Company in relation to the above indemnities. During fiscal 2021, an insurance premium of US$44,271 was paid by the Company to insure against a liability incurred by a person who is or has been a director or officer of the Company.
Board Committees
The Board has three standing committees, being an audit committee, a remuneration and nomination committee, and an environmental, social and governance committee.
Audit Committee
The Board has established an audit committee. Assignments to, and chairs of, audit committee will be selected by the Board. The audit committee operates under a charter approved by the Board and reports on its activities to the Board. The audit committee monitors the integrity of our financial statements, the independence and qualifications of our independent auditors, the performance of our accounting staff and independent auditors, our compliance with legal and regulatory requirements and the effectiveness of our internal controls. The audit committee is responsible for selecting, retaining (subject to shareholder approval), evaluating, setting the remuneration of, and, if appropriate, recommending the termination of our independent auditors. The audit committee is established in accordance with Section 10A(m) of the Exchange Act. Under the Nasdaq listing standards and applicable SEC rules, we are required to have at least three members of the audit committee, all of whom must be independent. The audit committee currently consists of Mr. Vaughn Taylor (chairperson), Ms. Lorraine Martin, and Ms. Beverly Wyse, all of whom are considered independent under the listing standards of the Nasdaq Capital Market for audit committee members and the heightened independence requirement for audit committee members required by Rule 10A-3 under the Exchange Act. Mr. Vaughn Taylor is also an audit committee financial expert.
Remuneration and Nomination Committee
The Board has established a separate remuneration and nomination committee. The remuneration and nomination committee operates under a charter approved by the Board and reports on its activities to the board. The remuneration and nomination committee charter sets out the processes the Board employs for setting the level and composition of compensation for directors and senior executives and ensuring that such compensation is appropriate and not excessive. Under the Nasdaq listing standards and applicable SEC rules, we are required to
58

TABLE OF CONTENTS

have at least two members of the Compensation Committee, all of whom must be independent. The remuneration and nomination committee currently consists of Mr. Vaughn Taylor (chairperson), Ms. Beverly Wyse and Ms. Melissa Waller, all of whom are considered independent under the Nasdaq listing standards and applicable SEC rules.
Environmental, Social and Governance Committee
The Board has established a separate ESG committee. The ESG committee operates under a charter approved by the Board and reports on its activities to the board. The ESG committee charter sets out the processes the Board employs to oversee the Company’s ESG strategy and initiatives, including the Company’s reporting on its commitment to sustainability, social responsibility and other related matters. The ESG committee currently consists of Ms. Melissa Waller (chairperson), Ms. Beverly Wyse, Ms. Lorraine Martin, and Mr. Anastasios Arima.
Code of Conduct
The Company has adopted a Code of Conduct which provides a framework for decisions and actions in relation to ethical conduct in employment. It aims to encourage the appropriate standards of conduct and behavior of the directors, officers, employees and contractors of the Company. The document sets out the principles covering appropriate conduct in a variety of contexts and outlines the minimum standard of behavior expected from employees, including to:
act honestly, in good faith and in the best interests of the Company as a whole;
exercise their duty to use due care and diligence in fulfilling the functions of their position;
recognize that their primary responsibility is to the Company’s shareholders as a whole;
not take advantage of their position for personal gain, or the gain of their associates; and
preserve the confidentiality of sensitive information of the Company.
The directors and executives also have a fiduciary relationship with shareholders of the Company, making it unlawful to improperly use their position to gain advantage for themselves. At all times, directors and officers must act in the best interest of the Company and eliminate or abstain from participating in any discussion or decision-making process in relation to matters which they have a conflict of interest, not engage in insider trading and comply with all applicable anti-bribery laws.
D. Employees
As of June 30, 2021, we had 20 employees and 24 employee contractors based in 3 different countries, as shown in the chart below.
 
United States
Australia
Canada
Employees
19
1
Employee Contractors
19
2
3
The workforce is non-unionized.
59

TABLE OF CONTENTS

E. Share Ownership
The following table lists as of December 31, 2021, the number of our shares beneficially owned by each of our directors, our chief executive officer and other members of our senior management as a group. Beneficial ownership is calculated based on 139,488,491 ordinary shares outstanding as of December 31, 2021.
Shareholder
Ordinary Shares
Beneficially Owned(1)
Number
Percent
Officers and Directors
 
 
Anastasios (Taso) Arima
4,937,500
3.5%
Todd W. Hannigan
11,169,086
7.9%
Lorraine M. Martin
*
Vaughn W. Taylor
376,829
*
Melissa G. Waller
*
Beverly M. Wyse
*
Dominic P. Allen
3,352,500
2.4%
Lamont Leatherman
3,302,500
2.3%
Toby Symonds
*
Jeanne McMullin
*
Gregory D. Swan
2,250,000
1.6%
Officers and directors as a group (10 persons)
25,388,415
18.0%
*
Represents beneficial ownership of less than 1% of the outstanding ordinary shares of IperionX.
(1)
Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power of that security, including options and performance rights that are currently exercisable or exercisable within 60 days of December 31, 2021.
60

TABLE OF CONTENTS

ITEM 7.
MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
A. Major Shareholders
The following table and accompanying footnotes set forth, as of December 31, 2021, information regarding beneficial ownership of our ordinary shares by each person known by us to be the beneficial owner of more than 5% of our ordinary shares. In preparing the disclosure below, we have relied to the extent we believe appropriate on substantial shareholder notices provided to us by our substantial shareholders and released to ASX.
Beneficial ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power of that security, including options and performance rights that are currently exercisable or exercisable within 60 days of December 31, 2021. Ordinary shares subject to options and performance rights currently exercisable or exercisable within 60 days of December 31, 2021 are deemed to be outstanding for computing the percentage ownership of the person holding these options and/or performance rights and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage of any other person.
Our calculation of the percentage of beneficial ownership is based on 139,488,491 ordinary shares issued and outstanding as at December 31, 2021. A large number of our ordinary shares are held by nominee companies so we cannot be certain of the identity of those beneficial owners.
Unless otherwise indicated, to our knowledge each shareholder possesses sole voting and investment power over the ordinary shares listed subject to community property laws, where applicable. None of our shareholders has different voting rights from other shareholders.
Shareholder
Ordinary Shares
Beneficially Owned
Number
Percent
FMR LLC (1 St. Martin’s Le Grand, London, EC1A 4AS, United Kingdom)
13,499,999
9.7%
DITM Holdings Pty Ltd (15 Lennox Street, Mosman, NSW, 2088, Australia)(1)
11,169,086
7.9%
(1)
DITM Holdings Pty Limited is an Australian corporation controlled by Mr. Todd Hannigan.
To our knowledge, there have not been any significant changes in the ownership of our Ordinary Shares by major shareholders over the past three years, except as follows (which is based upon substantial shareholder notices filed with the ASX):
FMR LLC became a substantial shareholder on August 31, 2021, when it acquired 13,499,999 ordinary shares, or 9.7% of the total voting power, pursuant to a private placement by the Company;
DITM Holdings Pty Ltd became a substantial shareholder on December 1, 2020, when it reported that it held 4,618,357 ordinary shares, or 5.3% of the total voting power, as of that date. On January 27, 2021, DITM Holdings Pty Ltd had a change in substantial holding (due to additional purchases) and reported it held 7,951,691 ordinary shares, or 8.1% of the total voting power, as of that date. DITM Holdings Pty Ltd is an entity associated with Mr. Todd Hannigan, Director of the Company;
Arredo Pty Ltd became a substantial shareholder on December 1, 2020, when it reported that it held 5,475,000 ordinary shares, or 6.3% of the total voting power, as of that date. Arredo Pty Ltd ceased to be a substantial holder on August 31, 2021 (due to dilution);
Syracuse Capital Pty Ltd became a substantial shareholder on June 18, 2019, when it reported that it held 2,107,784 ordinary shares, or 6.8% of the total voting power, as of that date. On October 29, 2019, Syracuse Capital Pty Ltd had a change in substantial holding (due to additional purchases) and reported it held 2,364,854 ordinary shares, or 7.5% of the total voting power, as of that date. On April 20, 2020, Syracuse Capital Pty Ltd had a change in substantial holding (due to additional purchases) and reported it held 2,919,778 ordinary shares, or 9.3% of the total voting power, as of that date. On September 24, 2020, Syracuse Capital Pty Ltd had a change in substantial holding (due to additional purchases) and reported it held 3,464,944 ordinary shares, or 11.0% of the total voting power, as of that date. Syracuse Capital Pty Ltd ceased to be a substantial holder on February 1, 2021 (due to dilution);
61

TABLE OF CONTENTS

IPConcept (Luxembourg) S.A. became a substantial shareholder on October 21, 2020, when it reported that it held 1,700,000 ordinary shares, as of that date. IPConcept (Luxembourg) S.A. ceased to be a substantial holder on December 7, 2021 (due to dilution);
Mounts Bay Investments Pty Ltd became a substantial shareholder on April 16, 2018, when it reported that it held 1,874,444 ordinary shares, or 6.1% of the total voting power, as of that date. On August 3, 2018, Mounts Bay Investments Pty Ltd had a change in substantial holding (due to additional purchases) and reported it held 1,909,444 ordinary shares, or 6.2% of the total voting power, as of that date. On September 24, 2020, Mounts Bay Investments Pty Ltd had a change in substantial holding (due to additional purchases) and reported it held 2,269,444 ordinary shares, or 7.2% of the total voting power, as of that date. Mounts Bay Investments Pty Ltd ceased to be a substantial holder on December 2, 2020 (due to dilution); and
Mr. Patric Glovac became a substantial shareholder on November 3, 2020, when he reported that he held 1,859,445 ordinary shares, or 5.7% of the total voting power, as of that date. Mr. Patric Glovac ceased to be a substantial holder on December 2, 2020 (due to dilution).
Record Holders
Based on information known to us, as of December 31, 2021, we had 17 shareholders of record in the United States. These shareholders held an aggregate of 9,339,500 of our outstanding Ordinary Shares, or approximately 6.7% of our outstanding Ordinary Shares. A number of our Ordinary Shares are held by nominee companies so we cannot be certain of the identity of those beneficial owners.
We are not controlled by another corporation, by any foreign government or by any natural or legal persons except as set forth herein, and there are no arrangements known to us which would result in a change in control of us at a subsequent date.
B. Related Party Transactions
Other than as disclosed below, since July 20, 2020, other than employment and remuneration matters described in “Item 6. Directors, Senior Management and Employees—Compensation” we did not enter into any transactions or loans with any: (i) enterprises that directly or indirectly, through one or more intermediaries, control, are controlled by or are under common control with us; (ii) associates; (iii) individuals owning, directly or indirectly, an interest in our voting power that gives them significant influence over us, and close members of any such individual’s family; (iv) key management personnel and close members of such individuals’ families; or (v) enterprises in which a substantial shareholder interest in our voting power is owned, directly or indirectly, by any person described in (iii) or (iv) or over which such person is able to exercise significant influence.
Focus Capital Partners, LLC (“Focus Capital”), a company of which Mr. Smith is a partner, was paid: (a) US$67,792 for the provision of services in relation to business development activities during fiscal 2021, which has been recognized as an expense through profit or loss; and (b) US$25,493 in share placement fees during fiscal 2021, which has been recognized as a share issue costs in equity.
C. Interests of Experts and Counsel
Not Applicable.
62

TABLE OF CONTENTS

ITEM 8.
FINANCIAL INFORMATION.
A. Consolidated Statements and Other Financial Information.
See “Item 18. Financial Statements.”
Legal Proceedings
We are not a party to any material legal proceedings.
Dividends
We have not declared any dividends during fiscal 2021, 2020 or 2019 and do not anticipate that we will do so in the foreseeable future. We currently intend to retain future earnings, if any, to finance the development of our business. Dividends, if any, on our outstanding ordinary shares will be declared by and subject to the discretion of our Board of Directors on the basis of our earnings, financial requirements and other relevant factors, and subject to Australian law.
Any dividend we declare will be paid to the holders of ADSs, subject to the terms of the deposit agreement, to the same extent as holders of our ordinary shares, to the extent permitted by applicable law and regulations, less the fees and expenses payable under the deposit agreement. Any dividend we declare will be distributed by the depositary bank to the holders of the ADSs, subject to the terms of the deposit agreement. See “Item 12. Description of Securities Other Than Equity Securities—D. American Depositary Shares.”
B. Significant Changes
No significant change, other than as otherwise described in this registration statement on Form 20-F, has occurred in our operations since the date of our consolidated financial statements included in this registration statement on Form 20-F.
ITEM 9.
THE OFFER AND LISTING
A. Offer and Listing Details
The principal trading market for our ordinary shares is the ASX in Australia. Our ordinary shares trade under the symbol “IPX”.
On February 15, 2022, the closing price of our ordinary shares as traded on the ASX was A$0.91 per ordinary share. We intend to apply to have the ADSs listed on Nasdaq under the symbol “IPX”.
For a description of the rights of the ADSs, see “Item 12. Description of Securities Other Than Equity Securities—D. American Depositary Shares.”
B. Plan of Distribution
Not applicable.
C. Markets
Our ordinary shares are publicly traded on the ASX under the symbol “IPX”. We are filing this registration statement on Form 20-F in anticipation of the listing of the American Depositary Shares, or ADSs, each representing 10 of our ordinary shares, on Nasdaq under the symbol “IPX”. The Bank of New York Mellon, acting as depositary, will register and deliver the ADSs.
D. Selling Shareholders
Not applicable.
E. Dilution
Not applicable.
F. Expenses of the Issue
Not applicable.
63

TABLE OF CONTENTS

ITEM 10.
ADDITIONAL INFORMATION
A. Share Capital
Overview
The following description of our ordinary shares is only a summary. We encourage you to read our Constitution, which is included as an exhibit to this registration statement.
We are a public company limited by shares registered under the Corporations Act by the Australian Securities and Investments Commission (“ASIC”). Our corporate affairs are principally governed by our Constitution, the Corporations Act and the ASX Listing Rules. Our ordinary shares trade on the ASX.
The Australian law applicable to our Constitution is not significantly different than a U.S. company’s charter documents except we do not have a limit on our authorized share capital and the concept of par value is not recognized under Australian law.
Subject to restrictions on the issue of securities in our Constitution, the Corporations Act and the ASX Listing Rules and any other applicable law, we may at any time issue shares and grant options or warrants on any terms, with the rights and restrictions and for the consideration that the Board determine.
The rights and restrictions attaching to ordinary shares are derived through a combination of our Constitution, the common law applicable to Australia, the ASX Listing Rules, the Corporations Act and other applicable law. A general summary of some of the rights and restrictions attaching to our ordinary shares are summarized below. Each ordinary shareholder is entitled to receive notice of, and to be present, vote and speak at, general meetings.
As of December 31, 2021, we had 139,488,491 ordinary shares outstanding. In addition, as of December 31, 2021, we had potential ordinary shares for future issuance as follows: (i) 24,624,000 potential ordinary shares for issuance pursuant to options to purchase ordinary shares at a weighted average exercise price of A$0.26 per share, (ii) 600,000 potential ordinary shares for issuance upon conversion of restricted stock units upon the satisfaction of the relevant vesting condition, (iii) 39,600,000 potential ordinary shares for issuance upon conversion of performance shares upon the satisfaction of the performance conditions and (iv) 25,315,000 potential ordinary shares for issuance upon conversion of performance rights upon the satisfaction of the relevant performance condition.
Share Options, Restricted Stock Units, Performance Shares and Performance Rights
As at December 31, 2021, the following Unlisted Options, Restricted Stock Units, Performance Shares and Performance Rights have been issued over unissued ordinary shares of the Company:
5,224,000 Unlisted Options exercisable at A$0.25 each on or before December 31, 2023;
3,650,000 Unlisted Options exercisable at A$0.20 each on or before December 31, 2023;
5,000,000 Unlisted Options exercisable at A$0.20 each on or before December 1, 2025;
4,000,000 Class A Performance Unlisted Options exercisable at A$0.20 each on or before December 1, 2025;
4,000,000 Class B Performance Unlisted Options exercisable at A$0.20 each on or before December 1, 2025;
1,075,000 Unlisted Options exercisable at A$0.45 each on or before December 31, 2023; and
1,075,000 Unlisted Options exercisable at A$0.55 each on or before December 31, 2023.
5,698,331 Performance Rights that vest upon achieving a 30-day VWAP of A$2.00 per share, expiring April 23, 2026;
6,698,334 Performance Rights that vest upon achieving a 30-day VWAP of A$3.00 per share, expiring April 23, 2026;
10,808,335 Performance Rights that vest upon achieving a 30-day VWAP of A$4.00 per share, expiring April 23, 2026;
175,000 Performance Rights that vest upon achieving a 30-day VWAP of A$2.00 per share, expiring April 23, 2024;
64

TABLE OF CONTENTS

275,000 Performance Rights that vest upon achieving a 30-day VWAP of A$3.00 per share, expiring April 23, 2024;
125,000 Performance Rights that vest upon achieving a 30-day VWAP of A$4.00 per share, expiring April 23, 2024;
150,000 Performance Rights that vest upon achieving a 30-day VWAP of A$2.00 per share, expiring March 1, 2026;
150,000 Performance Rights that vest upon achieving a 30-day VWAP of A$3.00 per share, expiring March 1, 2026;
150,000 Performance Rights that vest upon achieving a 30-day VWAP of A$4.00 per share, expiring March 1, 2026;
600,000 Unlisted Options exercisable at A$1.33 each on or before September 9, 2025; and
600,000 Restricted Stock Units that vest upon achieving various service-based conditions, expiring September 9, 2025;
19,800,000 Class A Performance Shares expiring on December 1, 2024, that will convert into an equivalent number of ordinary shares upon completion of a positive pre-feasibility study (prepared in accordance with the JORC Code and independently verified by a Competent Person) for heavy mineral sands extraction and processing on any of the Titan Project area which demonstrates a net present value of at least A$200,000,000 before September 17, 2024;
19,800,000 Class B Performance Shares expiring on December 1, 2025, that will convert into an equivalent number of ordinary shares upon the commencement of commercial production from the Titan Project area before September 17, 2025;
50,000 Performance Rights that vest upon achieving a 30-day VWAP of A$2.00 per share, expiring December 22, 2026;
100,000 Performance Rights that vest upon achieving a 30-day VWAP of A$3.00 per share, expiring December 22, 2026;
150,000 Performance Rights that vest upon achieving a 30-day VWAP of A$4.00 per share, expiring December 22, 2026;
259,000 Performance Rights that vest upon achieving various performance conditions, expiring December 22, 2024;
261,000 Performance Rights that vest upon achieving various performance conditions, expiring December 22, 2025; and
265,000 Performance Rights that vest upon achieving various performance conditions, expiring December 22, 2026.
During the period from January 1, 2019 and up to December 31, 2021, 6,126,000 ordinary shares have been issued as a result of the exercise or conversion of Unlisted Options, Restricted Stock Units, Performance Shares and Performance Rights.
Issuances of Securities
Below is information regarding securities sold by us since July 1, 2018, the first day of fiscal 2019. None of the securities sold by us since such date were registered under the Securities Act, and, we have made no public offerings in the United States. All our securities were sold through private placement either (i) outside the United States in reliance on Regulation S, (ii) in the United States to a limited number of investors in transactions not involving any public offering or (iii) in the case of employee compensation, pursuant to Rule 701 of the Securities Act. As discussed below, we believe that each issuance of these securities was exempt from, or not subject to, registration under the Securities Act.
On October 19, 2018, we issued 220,000 ordinary shares to a consultant in lieu of fees for services;
On October 25, 2019, we issued 416,667 ordinary shares representing an exclusive option fee to acquire a portfolio of iron ore tenements. The option was never exercised by the Company;
65

TABLE OF CONTENTS

On September 3, 2020, we issued 15,693,334 listed options pursuant to a pro-rata non-renounceable entitlement issue, with an exercise price of A$0.20 per share and expiring August 31, 2021. As at September 30, 2021, 15,675,824 of these options have been exercised, and 17,510 of these options have lapsed without being exercised;
On December 1, 2020, we issued 25,000,000 ordinary shares as part of a private placement at A$0.08 per share to institutional and sophisticated investors;
On December 1, 2020, we issued 29,150,000 ordinary shares, 5,000,000 unlisted options, 8,000,000 performance options and 39,600,000 performance shares in the Company in relation to the acquisition of the Titan Project;
On January 27 and 29, 2021, we issued 12,150,000 ordinary shares as part of a private placement at A$0.30 per share to institutional and sophisticated investors;
On August 31, 2021, we issued 20,000,000 ordinary shares as part of a private placement at A$1.20 per share to institutional and sophisticated investors;
From time to time since July 1, 2018 through December 31, 2021, we have granted unlisted options to directors, employees, and consultants covering an aggregate of 14,750,000 ordinary shares, with exercise prices ranging from A$0.20 to A$1.33 per share. As at December 31, 2021, 3,126,000 of these options have been exercised;
From time to time since July 1, 2018 through December 31, 2021, we have granted performance rights to directors, employees, and consultants covering an aggregate of 28,315,000 ordinary shares, that each convert into one ordinary share upon the satisfaction of various performance conditions. As at December 31, 2021, 3,000,000 of these performance rights have vested and been converted into ordinary shares.
From time to time since July 1, 2018 through December 31, 2021, we have granted restricted stock units (“RSUs”) to directors covering an aggregate of 600,000 ordinary shares, with a nil exercise price that each convert into one ordinary share upon the satisfaction of various service-based vesting conditions. As at December 31, 2021, none of these RSUs have vested and been converted into ordinary shares and none of these RSUs have lapsed or been forfeited without being exercised.
B. Constitutional Documents
Incorporation
We are a public limited liability company domiciled in Australia and operate under, and are subject to, the Australian Corporations Act. IperionX was originally incorporated in Western Australia as Tao Commodities Limited on May 5, 2017, then changed its name to Hyperion Metals Limited on April 14, 2021, and most recently changed to its current name, IperionX Limited, on February 9, 2022.
Our Constitution
Our constituent document is our Constitution. Our Constitution is subject to the terms of the ASX Listing Rules and the Corporations Act. It does not provide for or prescribe any specific objectives or purposes of IperionX. It may be amended or repealed and replaced by special resolution of shareholders, which is a resolution passed by at least 75% of the votes cast by shareholders entitled to vote on the resolution. Where there is an inconsistency between the provisions of the Constitution and the Corporations Act, the provisions of the Australian Corporation Act will prevail over any inconsistent provisions of the Constitution.
Under Australian law, a company has the legal capacity and powers of an individual both within and outside Australia. The material provisions of our Constitution are summarized below. This summary is not intended to be complete nor to constitute a definitive statement of the rights and liabilities of our shareholders. Our Constitution is filed as an exhibit to this registration statement.
66

TABLE OF CONTENTS

Interested Directors
Except where permitted by the Corporations Act, a director may not vote in respect of any contract or arrangement in which the director has, directly or indirectly, any material interest. Such director must not be counted in a quorum, must not vote on the matter and must not be present at the meeting while the matter is being considered.
Unless a relevant exception applies, the Corporations Act requires our directors to provide disclosure of certain interests and prohibits directors of companies listed on the ASX from voting on matters in which they have a material personal interest and from being present at the meeting while the matter is being considered. In addition, the Corporations Act and the ASX Listing Rules require shareholder approval of any provision of related party benefits to our directors.
Directors’ Compensation
The fixed sum remuneration for non-executive directors may not be increased except at a general meeting of shareholders and the particulars of the proposed increase are required to have been provided to shareholders in the notice convening the meeting. The aggregate, fixed sum for non-executive directors’ remuneration is to be divided among the non-executive directors in such proportion as the Board of Directors agree and in accordance with our Constitution. Remuneration payable to executive directors, such as the Managing Director, does not form part of the aggregate remuneration pool through which non-executive directors are paid. Executive directors may be paid remuneration as employees of IperionX.
Pursuant to our Constitution, any director who performs extra or special services that in the opinion of the Board, are outside the scope of the ordinary duties of a director may be paid additional remuneration or provide benefits to that director, which is determined by the Board.
The Company must also pay all reasonable travel, accommodation and other expenses properly incurred by the directors in attending general meetings, Board meetings, committee meetings or otherwise in connection with our business.
In addition, in accordance with our Constitution, a director may be paid a retirement benefit as determined by the Board, subject to the limits set out in the Corporations Act and the ASX Listing Rules.
Borrowing Powers Exercisable by Directors
Pursuant to our Constitution, the management and control of our business affairs are vested in the Board. Subject to the Corporations Act and the ASX Listing Rules, the Board has the power to raise or borrow money, and charge any of our property or business or any uncalled capital, and may issue debentures or give any other security for any of our debts, liabilities or obligations or of any other person, in each case, in the manner and on terms it deems fit.
Retirement of Directors
Pursuant to our Constitution, one-third of our directors, other than the managing director, must retire from office at every annual general meeting. If the number of directors is not a multiple of three, then the number nearest to, but not exceeding, one-third must retire from office. The directors who retire in this manner are required to be the directors or director longest in office since last being elected. A director, other than the director who is the managing director, must retire from office at the conclusion of the third annual general meeting after which the director was elected. Retired directors are eligible for re-election to the Board of Directors.
Rights and Restrictions on Classes of Shares
Subject to the Corporations Act and the ASX Listing Rules, the rights attaching to our Ordinary Shares are detailed in our Constitution. Subject to the Corporations Act, ASX Listing Rules and any rights or restrictions attached to a class of shares, the Company may issue further shares or grant options over shares on any terms, at any time and for any consideration as the Board resolve. Currently, our outstanding share capital consists of only one class of Ordinary Shares.
Voting Rights
Subject to our Constitution and any rights or restrictions attached to a class of shares, at a meeting of shareholders each shareholder has one vote determined by a show of hands. On a poll vote, each shareholder
67

TABLE OF CONTENTS

shall have one vote for each fully paid share and a fractional vote for each share that is not fully paid, such fraction being equivalent to the proportion of the amount that has been paid to such date on that share. Shareholders may vote by proxy, attorney or representative.
Right to Share in Our Profits
Subject to the Corporations Act, the ASX Listing Rules and the rights of the holders of any shares created or raised under any special arrangements as to dividends, the directors may from time to time declare a dividend to shareholders entitled to the dividend. Under the Corporations Act, we must not pay a dividend unless: (a) our assets exceed our liabilities immediately before the dividend is declared and the excess is sufficient for the payment of the dividend; (b) the payment of the dividend is fair and reasonable to our shareholders as a whole; and (c) the payment of the dividend does not materially prejudice our ability to pay our creditors. Unless any share is issued on terms providing to the contrary, the dividends declared will be payable on all shares according to the proportion that the amount paid (not credited) is of the total amounts paid and payable (excluding amounts credited) in respect of such shares.
Rights to Share in the Surplus in the Event of Liquidation
Our Constitution provides for the right of shareholders to participate in a surplus in the event of our liquidation.
No Redemption Provision for Ordinary Shares
There are no redemption provisions in our Constitution in relation to Ordinary Shares. Under our Constitution and subject to the Corporations Act, any preference shares may be issued on the terms that they are, or may at our option be, liable to be redeemed.
Variation or Cancellation of Share Rights
The rights attached to shares in a particular class of shares may only be varied or cancelled by a special resolution of IperionX, together with either:
a special resolution passed by members holding shares in that class; or
the written consent of members who are entitled to at least 75% of the votes that may be cast in respect of shares in that class.
Liability for Further Capital Calls
According to our Constitution, the Board of Directors may make any calls from time to time upon shareholders in respect of all monies unpaid or partly-paid shares (if any), subject to the terms upon which any of the partly-paid shares have been issued. Each shareholder is liable to pay the amount of each call in the manner, at the time, and at the place specified by the Board of Directors. Calls may be made payable by installment. Failure to pay a call will result in interest becoming payable on the unpaid amount and ultimately, forfeiture of those shares. As of the date of this registration statement, all of our issued shares are fully paid.
Annual General Meetings
Under the Corporations Act, our directors must convene an annual meeting of shareholders at least once every calendar year and within five months after the end of our last financial year. Notice of the proposed meeting of our shareholders is required at least 28 days prior to such meeting under the Corporations Act.
General Meetings of Shareholders
General meetings of shareholders may be called by the Board. Notice of the proposed meeting of our shareholders is required at least 28 days prior to such meeting under the Corporations Act. Except as permitted under the Corporations Act, shareholders may not convene a meeting. Under the Corporations Act, any director or one or more shareholders holding in aggregate at least 5% of the votes that may be cast at a general meeting may call and arrange to hold a general meeting. The meeting must be called in the same way in which general meetings of the company may be called, including the dispatch of a notice of meeting including the matters to be voted upon. The shareholders calling the meeting must pay the expenses of calling and holding the meeting.
68

TABLE OF CONTENTS

The Corporations Act requires the directors to call and arrange to hold a general meeting on the request of shareholders with at least 5% of the votes that may be cast at a general meeting. The request must be made in writing, state any resolution to be proposed at the meeting, be signed by the shareholders making the request and be given to the company. The Board of Directors must call the meeting not more than 21 days after the request is made. The meeting must be held not later than two months after the request is given.
The quorum required for a general meeting of shareholders consists of at least two shareholders present in person, or by proxy, attorney or representative. A meeting (excluding a meeting convened on the requisition of shareholders) which is adjourned for lack of a quorum will be adjourned to the date, time and place as the Directors may by notice to shareholders appoint, or failing any appointment, to the same day in the following week at the same time and place. At the reconvened meeting, the required quorum consists of any two members present in person, or by proxy, attorney or representative appointed pursuant to our Constitution. The meeting is dissolved if a quorum is not present within 30 minutes from the time appointed for the reconvened meeting.
A meeting of shareholders may be held virtually using any technology that gives shareholders as a whole a reasonable opportunity to participate in the meeting.
An ordinary resolution requires approval by the shareholders by a simple majority of votes cast (namely, a resolution passed by more than 50% of the votes cast by shareholders entitled to vote on the resolution). A special resolution (such as in relation to amending our Constitution, approving any variation of rights attached to any class of shares or our voluntary winding-up), requires approval of a special majority (namely, a resolution that has been passed by at least 75% of the votes cast by shareholders entitled to vote on the resolution).
The Foreign Acquisitions and Takeovers Act 1975
Overview
Australia’s foreign investment regime is set out in the Foreign Acquisition and Takeovers Act (the “FATA”) and Australia’s Foreign Investment Policy (the “Policy”). The Australian Treasurer administers the FATA and the Policy with the advice and assistance of the Foreign Investment Review Board (“FIRB”).
In the circumstances set out below in the section entitled ‘Mandatory Notification Requirements’, foreign persons are required to notify and receive a prior statement of no objection, or FIRB clearance, from the Australian Treasurer. In the circumstances set out below in the section entitled ‘Other circumstances in which FIRB may be sought’, it is generally recommended that foreign persons obtain FIRB clearance.
The Australian Treasurer has powers under the FATA to make adverse orders, including prohibition of a proposal, ordering disposal of an interest acquired or imposing conditions on a proposed transaction, in respect of a relevant acquisition if he or she considers it to be contrary to Australia’s national interest.
The obligation to notify and obtain FIRB clearance is upon the acquirer of the interest, and not the Company. The failure to obtain FIRB clearance may be an offence under Australian law.
Investor’s Responsibility
It is the responsibility of any persons who wish to acquire shares of the Company to satisfy themselves as to their compliance with the FATA, regulations made under the FATA, the Policy, guidelines issued by the FIRB and with any other necessary approval and registration requirement or formality, before acquiring an interest in the Company.
Mandatory Notification Requirements
Broadly, FIRB clearance is required for the following transactions involving the acquisition of shares in an Australian corporation:
the acquisition of a substantial interest if the Australian corporation is valued in excess of the applicable monetary threshold (see below);
any direct investment by a foreign government investor;
any acquisition of shares in an Australian land corporation; and
any proposed direct investment in a national security business (including starting such a business) or proposed investment in national security land.
69

TABLE OF CONTENTS

Currently, the prescribed threshold is A$289 million though a higher threshold of A$1.250 billion applies for private foreign investors from the United States, New Zealand, China, Japan, Hong Kong, Peru, South Korea, Singapore and Chile unless the transaction involves certain prescribed sensitive sectors.
Application of these Requirements to the Company
As at June 30, 2021, the Company did not have any interests in Australian land and hence is not an Australian land corporation, and the Company’s gross assets were valued below A$289 million. Accordingly, the only circumstance in which an investor in the Company would currently be subject to the mandatory notification regime is if they are a foreign government investor making a direct investment in the Company. Applications for FIRB clearance may be made by prospective investors in accordance with the information on FIRB’s website.
Other Situations Where FIRB Clearance Might be Sought
In addition to those circumstances where it is mandatory under the FATA for a foreign person to notify FIRB and seek FIRB clearance for a particular transaction (see above), there are other instances where, despite there being no mandatory notification obligation, the Australian Treasurer may make adverse orders under the FATA (e.g., if he or she considers a particular transaction to have national security concerns).
National Security Related Transactions
Under Australia’s foreign investment regime, the Australian Treasurer may ‘call in’ certain transactions for screening on national security grounds and allow investors to voluntarily notify these transactions to obtain certainty about the investment. Where national security concerns are identified, the Australian Treasurer has the power to impose conditions, vary existing conditions, or, as a last resort, force the divestment of any realized investment which was subject to the FATA from January 1, 2021.
Transactions falling within the scope of the national security test are subject to a $0 monetary threshold.
The Company as a Foreign Person
If foreign persons have a substantial interest in the Company, it would be considered to be a foreign person under the FATA. In such event, we would be required to obtain the approval of the Australian Treasurer for our own transactions involving the acquisitions of interests in Australian land and some acquisitions of interests in Australian corporations. FIRB clearance may be required for such acquisitions (which may or may not be given or may be given subject to conditions). If FIRB clearance is required and not given in relation to a proposed investment, we may not be able to proceed with that investment. There can be no assurance that we will be able to obtain any required FIRB clearances in the future.
Defined Terms Used in this Section
Foreign Persons
Under Australia’s foreign investment regime, it is the responsibility of any person (including, without limitation, nominees and trustees) who is:
a natural person not ordinarily resident in Australia;
a corporation in which a natural person not ordinarily resident in Australia, or a corporation incorporated outside of Australia, holds direct or indirect, actual or potential, voting power of 20% or more;
a corporation in which two or more persons, each of whom is either a non-Australian resident or a non-Australian corporation, hold direct or indirect, actual or potential, voting power in aggregate of 40% or more;
a trustee of a trust estate in which a non-Australian resident or non-Australian corporation holds 20% or more of the corpus or income of the trust estate;
70

TABLE OF CONTENTS

a trustee of a trust estate in which two or more persons, each of whom is either a non-Australian resident or a non-Australian corporation, hold in aggregate 40% or more of the corpus or income of the trust estate; or
a foreign government investor,
to ascertain if they may be required to notify the Australian Treasurer of their investment.
Associates
Associate is broadly defined to include:
the person’s spouse or de facto partner, lineal ancestors and descendants, and siblings;
any partner of the person;
any corporation of which the person is an officer, any officer of a corporation (where the person is a corporation), employers and employees, any employee of a natural person of whom the person is an employee;
any corporation whose directors are accustomed or under an obligation, whether formal or informal, to act in accordance with the directions, instructions or wishes of the person or, where the person is a corporation, of the directors of the person;
any corporation in accordance with the directions, instructions or wishes of which, or of the directors of which, the person is accustomed or under an obligation, whether formal or informal, to act;
any corporation in which the person holds a substantial interest;
where the person is a corporation—a person who holds a substantial interest in the corporation;
the trustee of a trust estate in which the person holds a substantial interest;
where the person is the trustee of a trust estate—a person who holds a substantial interest in the trust estate;
any person who is an associate of any other person who is an associate of the person.
Australian Land Corporation
An Australian land corporation (“ALC”), is a corporation where the value of its total assets comprising interests in Australian land exceeds 50% of the value of its total gross assets. An ALC is not necessarily a company registered in Australia. It may be registered anywhere. It is the composition of the assets of the corporation that will make it an ALC for the purposes of the Australian foreign investment regime.
Substantial Interest
A substantial interest is:
control of 20% or more of the actual or potential voting power or issued shares in a target by a single foreign person (together with associates); or
control of 40% or more of the actual or potential voting power or issued shares in a target by multiple foreign persons (together with associates).
Direct Investment
Any investment of an interest of 10% or more is considered to be a direct investment. Investments that involve interests below 10% may also be considered direct investments if the acquiring foreign government investor is building a strategic stake in the target, or can use that investment to influence or control the target. In particular, it includes investments of less than 10% which include any of the following:
preferential, special or veto voting rights;
the ability to appoint directors or asset managers;
71

TABLE OF CONTENTS

contractual agreements including, but not restricted to, agreements for loans, provision of services and off take agreements; or
building or maintaining a strategic or long-term relationship with a target entity.
Foreign Government Issuer
A Foreign Government Investor is:
a body politic of a foreign country;
entities in which governments, their agencies or related entities from a single foreign country have an aggregate interest (direct or indirect) of 20% or more;
entities in which governments, their agencies or related entities from more than one foreign country have an aggregate interest (direct or indirect) of 40% or more; or
entities that are otherwise controlled by foreign governments, their agencies or related entities, and any associates, or could be controlled by them including as part of a controlling group.
At this time, our total assets do not exceed any of the above thresholds and therefore no approval would be required from the Australian Treasurer. Nonetheless, should our total assets exceed the threshold in the future, we will need to be mindful of the number of ordinary shares that can be made available, and monitor the 40% aggregate shareholding threshold for foreign persons (together with their associates) to ensure that it will not be exceeded without an application to the Australian Treasurer’s for approval having been contemplated and submitted if considered necessary. Our Constitution does not contain any additional limitations on a nonresident’s right to hold or vote our securities.
National Security Business
A business is a national security business if it:
is a responsible entity (within the meaning of the Security of Critical Infrastructure Act 2018 as enacted) for an asset;
is an entity that is a direct interest holder in relation to a critical infrastructure asset (within the meaning of those terms in the Security of Critical Infrastructure Act 2018 as enacted);
is a carrier or nominated carriage service provider to which the Telecommunications Act 1997 applies;
develops, manufacturers or supplies critical goods or critical technology that are, or are intended to be, for a military use, or an intelligence use, by defense and intelligence personnel, the defense force of another country, or a foreign intelligence agency;
provides, or intends to provide, critical services to defense and intelligence personnel, the defense force of another country, or a foreign intelligence agency;
stores or has access to information that has a security classification;
stores or maintains personal information of defense and intelligence personnel collected by the Australian Defence Force, the Defence Department or an agency in the national intelligence community which, if accessed, could compromise Australia’s national security;
collects, as part of an arrangement with the Australian Defence Force, the Defence Department or an agency in the national intelligence community, personal information on defence and intelligence personnel which , if disclosed, could compromise Australia’s national security; or
stores, maintains or has access to personal information on defense and intelligence personnel which , if disclosed, could compromise Australia’s national security.
72

TABLE OF CONTENTS

National Security Land
Land is national security land if it is:
“Defence” premises within the meaning of section 71A of the Defence Act 1903. This includes all land owned or occupied by Defence, including buildings, structures and Defence prohibited areas. The definition excludes subparagraph (a)(iii) of the definition which relates to vehicles, vessels or aircraft; or
land in which an agency in the national intelligence community has an interest, if the existence of the interest is publicly known or could be known upon the making of reasonable inquiries.
Ownership Threshold
There are no provisions in our Constitution that require a shareholder to disclose ownership above a certain threshold. Under the Corporations Act, in relation to a company, a person has a “substantial holding” if (i) the total votes attached to voting shares in the company in which they (or their associates) have a relevant interest in is 5 percent or more of the total number of votes attached to voting shares in the company or (ii) the person has made a takeover bid for voting shares in the company and the bid period has started but not yet ended.
A person who:
begins to have, or ceases to have, a substantial holding in a listed company;
has a substantial holding in a listed company and there is movement by at least 1 percent in their holding; or
makes a takeover bid for securities of the listed company,
must give notice to the company and to the ASX.
Upon becoming a U.S. public company, our shareholders will also be subject to disclosure requirements under U.S. securities laws.
Issues of Shares and Change in Capital
Subject to the Corporations Act, ASX Listing Rules and any rights or restrictions attached to a class of shares, the Company may issue further shares or grant options over shares on any terms, at any time and for any consideration as the Board resolve. Pursuant to the ASX Listing Rules, we may in our discretion issue securities without the approval of shareholders, if such issue of securities, when aggregated with securities issued by us during the previous 12 month period would be an amount that would not exceed 15% of our issued capital at the commencement of the 12 month period. The Company may seek shareholder approval by special resolution at its annual general meeting to increase its capacity to issue equity securities by an additional 10% for the proceeding 12 month period. Issues of securities in excess of this limit or the issue of securities to our related parties require approval of shareholders (unless otherwise permitted under the ASX Listing Rules or unless we have obtained a waiver from the ASX in relation to the 15% limit).
Subject to the requirements of our Constitution, the Corporations Act, the ASX Listing Rules and any other applicable law, including relevant shareholder approvals, we may consolidate or divide our share capital into a larger or smaller number by resolution, reduce our share capital (provided that the reduction is fair and reasonable to our shareholders as a whole and does not materially prejudice our ability to pay creditors) or buy back our Ordinary Shares whether under an equal access buy-back or on a selective basis.
Member Approval to Significant Changes
We must not make a significant change (either directly or indirectly) to the nature and scale of our activities except after having disclosed full details to the ASX in accordance with the requirements of the ASX Listing Rules (and, if required by ASX, subject to us obtaining the approval of shareholders in a general meeting). We must not sell or otherwise dispose of the main undertaking of our company without the approval of shareholders in a general meeting. We need not comply with the above obligations if the ASX grants us an applicable waiver to be relieved of our obligations.
73

TABLE OF CONTENTS

Change of Control
Takeovers of listed Australian public companies, such as IperionX, are regulated by the Corporations Act, which prohibits the acquisition of a “relevant interest” in issued voting shares in a listed company if the acquisition will lead to that person’s or someone else’s voting power in IperionX increasing from 20% or below to more than 20% or increasing from a starting point that is above 20% and below 90%, subject to a range of exceptions.
Generally, a person will have a relevant interest in securities if the person:
is the holder of the securities;
has power to exercise, or control the exercise of, a right to vote attached to the securities; or
has the power to dispose of, or control the exercise of a power to dispose of, the securities (including any indirect or direct power or control).
If, at a particular time, a person has a relevant interest in issued securities and the person:
has entered or enters into an agreement with another person with respect to the securities;
has given or gives another person an enforceable right, or has been or is given an enforceable right by another person, in relation to the securities; or
has granted or grants an option to, or has been or is granted an option by, another person with respect to the securities, and the other person would have a relevant interest in the securities if the agreement were performed, the right enforced or the option exercised, the other person is taken to already have a relevant interest in the securities.
There are a number of exceptions to the above prohibition on acquiring a relevant interest in issued voting shares above 20%. In general terms, some of the more significant exceptions include:
when the acquisition results from the acceptance of an offer under a formal takeover bid;
when the acquisition is conducted on market by or on behalf of the bidder under a takeover bid and the acquisition occurs during the bid period;
when shareholders of IperionX approve the takeover by resolution passed at general meeting;
an acquisition by a person if, throughout the six months before the acquisition, that person or any other person has had voting power in IperionX of at least 19% and, as a result of the acquisition, none of the relevant persons would have voting power in IperionX more than three percentage points higher than they had six months before the acquisition;
as a result of a rights issue;
as a result of dividend reinvestment schemes;
as a result of underwriting arrangements;
through operation of law;
an acquisition that arises through the acquisition of a relevant interest in another listed company;
arising from an auction of forfeited shares conducted on market; or
arising through a compromise, arrangement, liquidation or buy-back.
Breaches of the takeovers provisions of the Corporations Act are criminal offenses. ASIC and the Australian Takeover Panel have a wide range of powers relating to breaches of takeover provisions, including the ability to make orders cancelling contracts, freezing transfers of, and rights attached to, securities, and forcing a party to dispose of securities. There are certain defenses to breaches of the takeover provisions provided in the Corporations Act.
Access to and Inspection of Documents
Inspection of our records is governed by the Corporations Act. Any member of the public has the right to inspect or obtain copies of our registers on the payment of a prescribed fee. Shareholders are not required to pay a fee for inspection of our registers or minute books of the meetings of shareholders. Other corporate records,
74

TABLE OF CONTENTS

including minutes of directors’ meetings, financial records and other documents, are not open for inspection by shareholders. Where a shareholder is acting in good faith and an inspection is deemed to be made for a proper purpose, a shareholder may apply to the court to make an order for inspection of our books.
C. Material Contracts
There are no other contracts, other than those disclosed in this registration statement on Form 20-F and those entered into in the ordinary course of our business, that are material to us, and which were entered into in the last two completed fiscal years or which were entered into before the two most recently completed fiscal years but are still in effect as of the date of this registration statement on Form 20-F.
D. Exchange Controls
Australia has largely abolished exchange controls on investment transactions. The Australian dollar is freely convertible into U.S. dollars or other currencies. In addition, there are currently no specific rules or limitations regarding the export from Australia of profits, dividends, capital or similar funds belonging to foreign investors, except that certain payments to non-residents must be reported to the Australian Cash Transaction Reports Agency, which monitors such transaction, and amounts on account of potential Australian tax liabilities may be required to be withheld unless a relevant taxation treaty can be shown to apply and under such there are either exemptions or limitations on the level of tax to be withheld.
E. Taxation
The following is a summary of material U.S. federal and Australian income tax considerations to U.S. Holders, as defined below, of the acquisition, ownership and disposition of ADSs and ordinary shares. This discussion is based on the laws in force as of the date of this registration statement, and is subject to changes in the relevant income tax law, including changes that could have retroactive effect. The following summary does not take into account or discuss the tax laws of any country or other taxing jurisdiction other than the United States and Australia. Holders are advised to consult their tax advisors concerning the overall tax consequences of the acquisition, ownership and disposition of ADSs and ordinary shares in their particular circumstances. This discussion is not intended, and should not be construed, as legal or professional tax advice.
This summary does not address the 3.8% U.S. federal Medicare Tax on net investment income, the effects of U.S. federal estate and gift tax laws, the alternative minimum tax, or any state and local tax considerations within the United States, and is not a comprehensive description of all U.S. federal or Australian income tax considerations that may be relevant to a decision to acquire or dispose of ADSs or ordinary shares. Furthermore, this summary does not address U.S. federal or Australian income tax considerations relevant to holders subject to taxing jurisdictions other than, or in addition to, the United States and Australia, and does not address all possible categories of holders, some of which may be subject to special tax rules.
Material U.S. Federal Income Tax Considerations
The following summary, subject to the limitations set forth below, describes the material U.S. federal income tax consequences to a U.S. Holder (as defined below) of the acquisition, ownership and disposition of our ADSs and ordinary shares as of the date hereof. This summary is limited to U.S. Holders that hold our ADSs or ordinary shares as capital assets within the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended, or the Code.
This section does not discuss the tax consequences to any particular holder, nor any tax considerations that may apply to U.S. Holders subject to special tax rules, such as:
insurance companies;
banks or other financial institutions;
individual retirement and other tax-deferred accounts;
regulated investment companies;
real estate investment trusts;
individuals who are former U.S. citizens or former long-term U.S. residents;
75

TABLE OF CONTENTS

brokers, dealers or traders in securities, commodities or currencies;
traders that elect to use a mark-to-market method of accounting;
persons holding our ADSs or ordinary shares through a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) or S corporation;
persons that received ADSs or ordinary shares as compensation for the performance of services;
grantor trusts;
tax-exempt entities;
persons that hold ADSs or ordinary shares as a position in a straddle or as part of a hedging, constructive sale, conversion or other integrated transaction for U.S. federal income tax purposes;
persons that have a functional currency other than the U.S. dollar;
persons that own (directly, indirectly or constructively) 10% or more of our equity (by vote or value); or
persons that are not U.S. Holders.
In this section, a “U.S. Holder” means a beneficial owner of ADSs or ordinary shares that is, for U.S. federal income tax purposes:
an individual who is a citizen or resident of the United States;
a corporation (or any other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States or any state thereof or the District of Columbia;
an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
a trust (i) the administration of which is subject to the primary supervision of a court in the United States and for which one or more U.S. persons have the authority to control all substantial decisions or (ii) that has an election in effect under applicable income tax regulations to be treated as a U.S. person for U.S. federal income tax purposes.
In addition, we have not received, nor do we expect to seek a ruling from the U.S. Internal Revenue Service, or the IRS, regarding any matter discussed herein. No assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to any of those set forth below. Each prospective investor should consult its own tax advisors with respect to the U.S. federal, state and local and non-U.S. tax consequences of acquiring, owning and disposing of our ADSs and ordinary shares.
If an entity or arrangement treated as a partnership for U.S. federal income tax purposes acquires, owns or disposes of ADSs or ordinary shares, the U.S. federal income tax treatment of a partner in such partnership generally will depend on the status of the partner and the activities of the partnership. Such a partner or partnership should consult its own tax advisor as to the U.S. federal income tax consequences of acquiring, owning and disposing of our ADSs or ordinary shares.
The discussion below is based upon the provisions of the Code, and the U.S. Treasury regulations, rulings and judicial decisions thereunder as of the date hereof, and such authorities may be replaced, revoked or modified, possibly with retroactive effect, so as to result in U.S. federal income tax consequences different from those discussed below. In addition, this summary is based, in part, upon representations made by the depositary to us and assumes that the deposit agreement, and all other related agreements, will be performed in accordance with their terms.
You are urged to consult your own tax advisor with respect to the U.S. federal, as well as state, local and non-U.S., tax consequences to you of acquiring, owning and disposing of ADSs or ordinary shares in light of your particular circumstances, including the possible effects of changes in U.S. federal and other tax laws.
76

TABLE OF CONTENTS

ADSs
If you hold ADSs, you generally will be treated for U.S. federal income tax purposes as the owner of the underlying ordinary shares that are represented by such ADSs. Accordingly, no gain or loss will be recognized for U.S. federal income tax purposes if you exchange ADSs for the underlying shares represented by those ADSs.
The U.S. Treasury has expressed concern that parties to whom ADSs are released before shares are delivered to the depositary or intermediaries in the chain of ownership between holders and the issuer of the security underlying the ADSs, may be taking actions that are inconsistent with the claiming of foreign tax credits by U.S. Holders of ADSs. These actions would also be inconsistent with the claiming of the reduced rate of tax, described below, applicable to dividends received by certain non-corporate U.S. Holders. Accordingly, the creditability of non-U.S. withholding taxes (if any), and the availability of the reduced tax rate for dividends received by certain non-corporate U.S. Holders, each described below, could be affected by actions taken by such parties or intermediaries. For purposes of the discussion below, we assume that intermediaries in the chain of ownership between the holder of an ADS and us are acting consistently with the claim of U.S. foreign tax credits by U.S. Holders.
Certain Tax Consequences If We Are a PFIC
The rules governing PFICs can result in adverse tax consequences to U.S. Holders. We generally will be classified as a PFIC for any taxable year if (i) at least 75% of our gross income for the taxable year consists of certain types of passive income or (ii) at least 50% of our gross assets during the taxable year, based on a quarterly average and generally determined by value, produce or are held for the production of passive income. Passive income for this purpose generally includes, among other things, dividends, interest, rents, royalties, gains from commodities and securities transactions and gains from the disposition of assets that produce or are held for the production of passive income. In determining whether a foreign corporation is a PFIC, a pro-rata portion of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. Under this rule, we should be deemed to own the assets and to receive the income of our wholly-owned subsidiaries for purposes of the PFIC determination. If we are classified as a PFIC in any taxable year with respect to which you own ADSs or ordinary shares, we generally will continue to be treated as a PFIC with respect to you in all succeeding taxable years, regardless of whether we continue to meet the tests described above, unless you make the “deemed sale election” described below.
Because we did not have active business income in the taxable year ended June 30, 2021, we believe we were a PFIC in tax year 2021, and, because we do not expect to begin active business operations in the current taxable year ending June 30, 2022, we expect to be a PFIC in tax year 2022. The determination of our PFIC status for any taxable year, however, will not be determinable until after the end of the taxable year, and will depend on, among other things, the composition of our income and assets (which could change significantly during the course of a taxable year) and the market value of our assets for such taxable year, which may be, in part, based on the market price of our ADSs or ordinary shares (which may be especially volatile). The PFIC determination will depend, in part, on whether we are able to generate gross income from minerals extraction operations. If we are able to generate sufficient income from such operations more quickly than is currently anticipated, we may not be a PFIC for taxable year 2022. You should consult your own tax advisor regarding our PFIC status.
U.S. Federal Income Tax Treatment of a Shareholder of a PFIC
If we are a PFIC for any taxable year during which you hold ADSs or ordinary shares, absent certain elections (including the mark-to-market election or qualified electing fund election described below), you generally will be subject to adverse rules (regardless of whether we continue to be classified as a PFIC) with respect to (1) any “excess distribution” (generally, any distributions you receive on your ADSs or ordinary shares in a taxable year that are greater than 125% of the average annual distributions you receive in the three preceding taxable years or, if shorter, your holding period) and (2) any gain recognized from a sale or other disposition (including a pledge) of such ADSs or ordinary shares. Under these special tax rules:
the excess distribution or gain will be allocated ratably over your holding period for the ADSs or ordinary shares;
77

TABLE OF CONTENTS

the amount allocated to the current taxable year, and any taxable year prior to the first taxable year in which we were classified as a PFIC in your holding period, will be treated as ordinary income arising in the current taxable year (and would not be subject to the interest charge discussed below); and
the amount allocated to each other taxable year during your holding period in which we were classified as a PFIC (i) will be subject to income tax at the highest rate in effect for that year and applicable to you and (ii) will be subject to an interest charge generally applicable to underpayments of tax with respect to the resulting tax attributable to each such year.
In addition, if you are a non-corporate U.S. Holder, you will not be eligible for reduced rates of taxation on any dividends that we pay if we are a PFIC for either the taxable year in which the dividend is paid or the preceding year.
If we are a PFIC, the tax liability for amounts allocated to years prior to the year of disposition or excess distribution cannot be offset by any net operating losses, and gains (but not losses) recognized on the transfer of the ADSs or ordinary shares cannot be treated as capital gains, even if the ADSs or ordinary shares are held as capital assets. Furthermore, unless otherwise provided by the U.S. Treasury Department, if we are a PFIC, you will be required to file an annual report (currently Form 8621) describing your interest in us, making an election on how to report PFIC income, and providing other information about your share of our income.
If we are classified as a PFIC and then cease to be so classified, a U.S. Holder may make an election (a “deemed sale election”) to be treated for U.S. federal income tax purposes as having sold such U.S. Holder’s ADSs or ordinary shares on the last day of our taxable year during which we were a PFIC. A U.S. Holder that makes a deemed sale election would then cease to be treated as owning stock in a PFIC. However, gain recognized as a result of making the deemed sale election would be subject to the adverse rules described above, and loss would not be recognized.
PFIC “Mark-to-market” Election
In certain circumstances, a holder of “marketable stock” of a PFIC can avoid certain of the adverse rules described above by making a mark-to-market election with respect to such stock. For purposes of these rules, “marketable stock” is stock which is “regularly traded” (traded in greater than de minimis quantities on at least 15 days during each calendar quarter) on a “qualified exchange” or other market within the meaning of applicable U.S. Treasury Regulations. A “qualified exchange” includes a national securities exchange that is registered with the SEC.
If you make a mark-to-market election, you must include in gross income, as ordinary income, for each taxable year that we are a PFIC an amount equal to the excess, if any, of the fair market value of your ADSs or ordinary shares that are “marketable stock” at the close of the taxable year over your adjusted tax basis in such ADSs or ordinary shares. If you make such election, you may also claim a deduction as an ordinary loss in each such year for the excess, if any, of your adjusted tax basis in such ADSs or ordinary shares over their fair market value at the end of the year, but only to the extent of the net amount previously included in income as a result of the mark-to-market election. The adjusted tax basis of your ADSs or ordinary shares with respect to which the mark-to-market election applies would be adjusted to reflect amounts included in gross income or allowed as a deduction because of such election. If you make an effective mark-to-market election, any gain you recognize upon the sale or other disposition of your ADSs or ordinary shares in a year that we are a PFIC will be treated as ordinary income and any loss will be treated as ordinary loss, but only to the extent of the net amount previously included in income as a result of the mark-to-market election.
Under current law, the mark-to-market election may be available to U.S. Holders of ADSs if the ADSs are listed on Nasdaq, which constitutes a qualified exchange, although there can be no assurance that the ADSs will be “regularly traded” for purposes of the mark-to-market election. While we would expect the ASX, on which the ordinary shares are listed, to be considered a qualified exchange, no assurance can be given as to whether the ASX is a qualified exchange, or that the ordinary shares would be traded in sufficient frequency to be considered regularly traded for these purposes.
78

TABLE OF CONTENTS

If you make a mark-to-market election, it will be effective for the taxable year for which the election is made and all subsequent taxable years unless the ADSs or ordinary shares are no longer regularly traded on a qualified exchange or the IRS consents to the revocation of the election. You are urged to consult your tax advisors about the availability of the mark-to-market election, and whether making the election would be advisable in your particular circumstances.
PFIC “QEF” election
Alternatively, in certain cases a U.S. Holder can avoid the interest charge and the other adverse PFIC tax consequences described above by obtaining certain information from the PFIC and electing to treat the PFIC as a “qualified electing fund” under Section 1295 of the Code. However, we do not anticipate that this option will be available to you because we do not intend to provide the information regarding our income that would be necessary to permit you to make this election.
You are urged to contact your own tax advisor regarding the determination of whether we are a PFIC and the tax consequences of such status.
Certain Tax Consequences If We Are Not a PFIC
Distributions
If you are a U.S. Holder of our ADSs or ordinary shares in a taxable year in which we are a PFIC (and any subsequent taxable years), then this section generally will not apply to you. Instead, see “—Certain Tax Consequences If We Are A PFIC.”
We do not currently anticipate paying any distributions on our ADSs or ordinary shares in the foreseeable future. However, to the extent there are any distributions made with respect to our ADSs or ordinary shares in the foreseeable future, and subject to the PFIC rules discussed above, the gross amount of any such distributions (without deduction for any withholding tax)made out of our current or accumulated earnings and profits (as determined for U.S. federal income tax purposes) will generally be taxable to you as ordinary dividend income on the date such distribution is actually or constructively received. Distributions in excess of our current and accumulated earnings and profits, as so determined, will be treated first as a tax-free return of capital to the extent of your adjusted tax basis in the ADSs or ordinary shares, as applicable, and thereafter as capital gain. Notwithstanding the foregoing, we do not intend to maintain calculations of earnings and profits, as determined for U.S. federal income tax purposes. Consequently, you should expect to treat any distributions paid with respect to our ADSs or ordinary shares as dividend income. See “—Backup Withholding Tax and Information Reporting Requirements” below. If you are a corporate U.S. Holder, dividends paid to you generally will not be eligible for the dividends-received deduction generally allowed under the Code.
If you are a non-corporate U.S. Holder, dividends paid to you by a “qualified foreign corporation” may be subject to taxation at a maximum rate of 20% if the dividends are “qualified dividends.” Dividends will be treated as qualified dividends if (a) certain holding period requirements are satisfied, (b) we are eligible for benefits under the Convention between the Government of the United States of America and the Government of Australia for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income, as amended (the “Treaty”), or our ADSs or ordinary shares are readily tradable on an established U.S. securities market, and (c) we were not, in the taxable year prior to the year in which the dividend was paid, and are not, in the taxable year in which the dividend is paid, a PFIC.
The Treaty has been approved for the purposes of the qualified dividend rules and we intend to submit an application to list the ADSs on Nasdaq. Although IRS guidance indicates that our ADSs (which are expected to be listed on Nasdaq) will be readily tradeable for purposes of satisfying the conditions required for these reduced tax rates, but there can be no assurance that our ADSs will be considered readily tradeable on an established securities market in subsequent years. As discussed above, we believe we were a PFIC in our taxable year ending June 30, 2021 and expect to be a PFIC in our taxable year ending June 30, 2022. Therefore, the reduced rate of taxation available to U.S. Holders of a “qualified foreign corporation” is not expected to be available for such years or any subsequent year in which we are classified as a PFIC. See the discussion above under “—Certain Tax Consequences If We Are a PFIC.” You should consult your tax advisor regarding the availability of the reduced tax rate on any dividends paid with respect to our ADSs or ordinary shares.
Distributions paid in Australian dollars, including any Australian taxes withheld, will be included in your gross income in a U.S. dollar amount calculated by reference to the spot exchange rate in effect on the date of actual
79

TABLE OF CONTENTS

or constructive receipt, regardless of whether the Australian dollars are converted into U.S. dollars at that time. If Australian dollars are converted into U.S. dollars on the date of actual or constructive receipt, your tax basis in those Australian dollars should be equal to their U.S. dollar value on that date and, as a result, you generally should not be required to recognize any foreign exchange gain or loss.
If Australian dollars so received are not converted into U.S. dollars on the date of receipt, you will have a tax basis in the Australian dollars equal to their U.S. dollar value on the date of receipt. Any gain or loss on a subsequent conversion or other disposition of the Australian dollars generally will be treated as ordinary income or loss to you and generally will be income or loss from sources within the United States for foreign tax credit limitation purposes.
Dividends you receive with respect to ADSs or ordinary shares generally will be treated as foreign source income, which may be relevant in calculating your foreign tax credit limitation. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For these purposes, dividends generally will be categorized as “passive” income. A foreign tax credit for foreign taxes imposed on distributions may be denied if you do not satisfy certain minimum holding period requirements or if you engage in certain risk reduction transactions. Subject to certain limitations, you generally will be entitled, at your option, to claim either a credit against your U.S. federal income tax liability or a deduction in computing your U.S. federal taxable income in respect of any Australian taxes withheld. If you elect to claim a deduction, rather than a foreign tax credit, for Australian taxes withheld for a particular taxable year, the election will apply to all foreign taxes paid or accrued by you or on your behalf in the particular taxable year.
The availability of the foreign tax credit and the application of the limitations on its availability are fact specific and are subject to complex rules. You are urged to consult your own tax advisor as to the consequences of Australian withholding taxes and the availability of a foreign tax credit or deduction. See “—Australian Tax Considerations—Taxation of Dividends.” You should also consult your tax advisor regarding the application of the foreign tax credit rules to the QEF and mark-to-market regimes described above in the event we are a PFIC (as we believe to be the case with respect to taxable years 2021 and 2022).
Sale, Exchange or Other Disposition of ADSs or Ordinary Shares
If you are a U.S. Holder of our ADSs or ordinary shares in a taxable year in which we are a PFIC (and any subsequent taxable years), then this section generally will not apply to you—instead, see the discussion above under “—Certain Tax Consequences If We Are A PFIC.”
Subject to the PFIC rules discussed above, you generally will, for U.S. federal income tax purposes, recognize capital gain or loss on a sale, exchange or other disposition of ADSs or ordinary shares equal to the difference between the amount realized on the disposition (determined in the case of sales or exchanges in currencies other than U.S. dollars by reference to the spot exchange rate in effect on the date of the sale or exchange or, if sold or exchanged on an established securities market and you are a cash basis taxpayer or an electing accrual basis taxpayer, the spot exchange rate in effect on the settlement date) and your adjusted tax basis (as determined in U.S. dollars) in the ADSs or ordinary shares. Your initial tax basis will be your U.S. dollar purchase price for such ADSs or ordinary shares.
Assuming we are not a PFIC and have not been treated as a PFIC during your holding period for your ADSs or ordinary shares, this recognized gain or loss will generally be long-term capital gain or loss if you have held the ADSs or ordinary shares for more than one year. Generally, if you are a non-corporate U.S. Holder, long-term capital gains are subject to U.S. federal income tax at preferential rates. For foreign tax credit limitation purposes, gain or loss recognized upon a disposition generally will be treated as from sources within the United States. However, in limited circumstances, the Treaty can re-source U.S. source income as Australian source income. The deductibility of capital losses is subject to limitations for U.S. federal income tax purposes.
You should consult your own tax advisor regarding the availability of a foreign tax credit or deduction in respect of any Australian tax imposed on a sale or other disposition of ADSs or ordinary shares. See “Australian Tax Considerations—Tax on Sales or other Dispositions of Shares.”
Backup Withholding Tax and Information Reporting Requirements
Payments of dividends with respect to the ADSs or ordinary shares and proceeds from the sale, exchange or other disposition of the ADSs or ordinary shares, by a U.S. paying agent or other U.S. intermediary, or made into the United States, will be reported to the IRS and to you as may be required under applicable Treasury
80

TABLE OF CONTENTS

regulations. Backup withholding may apply to these payments if you fail to provide an accurate taxpayer identification number or certification of exempt status or otherwise fail to comply with applicable certification requirements. Certain U.S. Holders are not subject to backup withholding and information reporting. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to you will be refunded (or credited against your U.S. federal income tax liability, if any), provided the required information is timely furnished to the IRS. Prospective investors should consult their own tax advisors as to their qualification for exemption from backup withholding and the procedure for establishing an exemption.
Certain individual U.S. Holders (and under Treasury regulations, certain entities) may be required to report to the IRS (on Form 8938) information with respect to their investment in the ADSs or ordinary shares not held through an account with a U.S. financial institution. If you acquire any of the ADSs or ordinary shares for cash, you may be required to file an IRS Form 926 with the IRS and to supply certain additional information to the IRS if (i) immediately after the transfer, you own directly or indirectly (or by attribution) at least 10% of our total voting power or value or (ii) the amount of cash transferred to us in exchange for the ADSs or ordinary shares when aggregated with all related transfers under applicable regulations, exceeds an applicable dollar threshold. You are urged to consult with your own tax advisor regarding the reporting obligations that may arise from the acquisition, ownership or disposition of our ADSs or ordinary shares.
The discussion above is not intended to constitute a complete analysis of all tax considerations applicable to an investment in ADSs or ordinary shares. You should consult with your own tax advisor concerning the tax consequences to you in your particular situation.
Australian Tax Considerations
In this section, we discuss the material Australian income tax, stamp duty and goods and services tax considerations related to the acquisition, ownership and disposal by the absolute beneficial owners of the ADSs.
It is based upon existing Australian tax law as of the date of this registration statement, which is subject to change, possibly retrospectively. This discussion does not address all aspects of Australian tax law which may be important to particular investors in light of their individual investment circumstances, such as shares held by investors subject to special tax rules (for example, financial institutions, insurance companies or tax exempt organizations). In addition, this summary does not discuss any foreign or state tax considerations, other than stamp duty and goods and services tax.
Prospective investors are urged to consult their tax advisors regarding the Australian and foreign income and other tax considerations of the acquisition, ownership and disposition of the shares. As used in this summary a “Non-Australian Shareholder” is a holder that is not an Australian tax resident and is not carrying on business in Australia through a permanent establishment.
Taxation of Dividends
Australia operates a dividend imputation system under which dividends may be declared to be “franked” to the extent of tax paid on company profits. Fully franked dividends are not subject to dividend withholding tax. An exemption for dividend withholding tax can also apply to unfranked dividends that are declared to be conduit foreign income, or CFI, and paid to Non-Australian Shareholders. Dividend withholding tax will be imposed at 30%, unless a shareholder is a resident of a country with which Australia has a double taxation agreement and qualifies for the benefits of the Treaty. Under the provisions of the current Treaty, the Australian tax withheld on unfranked dividends that are not declared to be CFI paid by us to a resident of the United States which is beneficially entitled to that dividend is limited to 15% where that resident is a qualified person for the purposes of the Treaty.
If a Non-Australian Shareholder is a company and owns a 10% or more interest, the Australian tax withheld on dividends paid by us to which a resident of the United States is beneficially entitled is limited to 5%. In limited circumstances the rate of withholding can be reduced to zero.
Tax on Sales or other Dispositions of Shares—Capital gains tax
Non-Australian Shareholders will not be subject to Australian capital gains tax on the gain made on a sale or other disposal of ADSs, unless they, together with associates, hold 10% or more of our issued capital, at the time of disposal or for 12 months of the last 2 years prior to disposal.
81

TABLE OF CONTENTS

Non-Australian Shareholders who own a 10% or more interest would be subject to Australian capital gains tax if more than 50% of our direct or indirect assets, determined by reference to market value, consists of Australian land, leasehold interests or Australian extraction, quarrying or prospecting rights. The Treaty is unlikely to limit Australia’s right to tax any gain in these circumstances. Net capital gains are calculated after reduction for capital losses, which may only be offset against capital gains.
Tax on Sales or other Dispositions of Shares—Shareholders Holding Shares on Revenue Account
Some Non-Australian Shareholders may hold shares on revenue rather than on capital account for example, share traders. These shareholders may have the gains made on the sale or other disposal of the shares included in their assessable income under the ordinary income taxing provisions of the income tax law, if the gains are sourced in Australia.
Non-Australian Shareholders assessable under these ordinary income provisions in respect of gains made on shares held on revenue account would be assessed for such gains at the Australian tax rates for non-Australian residents, which start at a marginal rate of 32.5%. This rate does not include the Temporary Budget Repair Levy of 2% that applies in certain circumstances. Some relief from Australian income tax may be available to Non-Australian Shareholders under the Treaty. Non-Australian Shareholders that are companies will be assessed at a rate of 30%.
To the extent an amount would be included in a Non-Australian Shareholder’s assessable income under both the capital gains tax provisions and the ordinary income provisions, the capital gain amount would generally be reduced, so that the shareholder would not be subject to double tax on any part of the income gain or capital gain.
Dual Residency
If a shareholder is a resident of both Australia and the United States under those countries’ domestic taxation laws, that shareholder may be subject to tax as an Australian resident. If, however, the shareholder is determined to be a U.S. resident for the purposes of the Treaty, the Australian tax would be subject to limitation by the Treaty. Shareholders should obtain specialist taxation advice in these circumstances.
Stamp Duty
No stamp duty is payable by Australian residents or non-Australian residents on the issue and trading of shares that are quoted on the ASX or Nasdaq at all relevant times and the shares do not represent 90% or more of all of our issued shares.
Australian Death Duty
Australia does not have estate or death duties. As a general rule, no capital gains tax liability is realized upon the inheritance of a deceased person’s shares. The disposal of inherited shares by beneficiaries may, however, give rise to a capital gains tax liability if the gain falls within the scope of Australia’s jurisdiction to tax.
Goods and Services Tax
The issue or transfer of shares to a non-Australian resident investor will not incur Australian goods and services tax.
F. Dividends and Paying Agents
We have not declared any dividends during fiscal 2021, 2020 or 2019 and do not anticipate that we will do so in the foreseeable future. We currently intend to retain future earnings, if any, to finance the development of our business. Dividends, if any, on our outstanding ordinary shares will be declared by and subject to the discretion of our Board of Directors on the basis of our earnings, financial requirements and other relevant factors, and subject to Australian law.
Any dividend we declare will be paid to the holders of ADSs, subject to the terms of the deposit agreement, to the same extent as holders of our ordinary shares, to the extent permitted by applicable law and regulations, less
82

TABLE OF CONTENTS

the fees and expenses payable under the deposit agreement. Any dividend we declare will be distributed by the depositary bank to the holders of the ADSs, subject to the terms of the deposit agreement. See “Item 12. Description of Securities Other Than Equity Securities—D. American Depositary Shares.”
G. Statement by Experts
The consolidated financial statements of IperionX Limited (formerly Hyperion Metals Limited and Tao Commodities Limited) as of June 30, 2021 and the period ended June 30, 2021 included in this Form 20-F have been so included in reliance on the report of PricewaterhouseCoopers, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.
The consolidated financial statements of IperionX Limited (formerly Hyperion Metals Limited and Tao Commodities Limited) as of December 1, 2020 for the period July 1, 2020 to December 1, 2020 and as of June 30, 2020 and for the period July 1, 2019 to June 30, 2020 included in this Form 20-F have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company's change in accounting principle as described in Note 1(d) to the consolidated financial statements) of PricewaterhouseCoopers, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.
H. Documents on Display
When this registration statement on Form 20-F becomes effective, we will be subject to the information reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements will file reports with the SEC. You may read and copy the registration statement on Form 20-F, including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC’s public reference room at 100 F Street, N.E., Room 1580, Washington, DC 20549. You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, DC 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC will also be available to the public through the SEC’s website at www.sec.gov.
As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities are registered under the Exchange Act. However, we will file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and may submit to the SEC, on a Form 6-K, unaudited quarterly financial information.
In addition, since our ordinary shares are traded on the ASX, we have filed annual and semi-annual reports with, and furnish information to, the ASX, as required under the ASX Listing Rules and the Corporations Act. Copies of our filings with the ASX can be retrieved electronically at www.asx.com.au under our symbol “IPX”. We also maintain a web site at www.iperionx.com. The information contained on our website or available through our website is not incorporated by reference into and should not be considered a part of this registration statement on Form 20-F, and the reference to our website in this registration statement on Form 20-F is an inactive textual reference only.
I. Subsidiary Information.
Not applicable.
83

TABLE OF CONTENTS

ITEM 11.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our principal financial instruments comprise receivables, payables, and cash. The main risks arising from our financial instruments are interest rate risk, foreign currency risk, credit risk and liquidity risk.
We manage our exposure to key financial risks in accordance with our financial risk management policy. Key risks are monitored and reviewed as circumstances change (e.g., acquisition of a new project) and policies are revised as required. The overall objective of our financial risk management policy is to support the delivery of our financial targets while protecting future financial security.
Given the nature and size of the business and uncertainty as to the timing and amount of cash inflows and outflows, we do not enter into derivative transactions to mitigate the financial risks. In addition, our policy is that no trading in financial instruments shall be undertaken for the purposes of making speculative gains. As our operations change going forward, we expect that our Board will review this policy periodically.
Our Board has overall responsibility for the establishment and oversight of the risk management framework. The Board reviews and agrees policies for managing our financial risks as summarized below. For additional information about our financial risk management objectives and policies, see note 20 to our audited consolidated financial statements for the period ended June 30, 2021, incorporated by reference in this registration statement.
Interest Rate Risk
Our exposure to the risk of changes in market interest rates relates primarily to the cash and short-term deposits with a floating interest rate. These financial assets with variable rates expose us to cash flow interest rate risk. All other financial assets and liabilities are either non-interest bearing (for example, receivables and payables) or have fixed interest rates (for example, lease liabilities, sub-lease receivables, and loans and borrowings).
Our cash at bank and on hand and short-term deposits had a weighted average floating interest rate at June 30, 2021 of 0.25%.
We currently do not engage in any hedging or derivative transactions to manage interest rate risk.
Foreign Currency Risk
Foreign currency risk is the risk that the fair value of future cash outflows of an exposure will fluctuate because of changes in foreign currency exchange rates.
Our exposure to the risk of changes in foreign exchange rate relates primarily to assets and liabilities that are denominated in currencies other than U.S. dollars. We also have transactional currency exposures relating to transactions denominated in currencies other than U.S. dollars. The currency in which these transactions primarily are denominated is Australian dollars.
It is our policy not to enter into any hedging or derivative transactions to manage foreign currency risk.
Credit Risk
Credit risk is the risk of financial loss to us if a customer or counterparty to a financial instrument fails to meet its contractual obligations. This arises principally from cash and cash equivalents and receivables.
We did not have significant concentrations of credit risk as of June 30, 2021. With respect to credit risk arising from cash and cash equivalents, our exposure arises from default of the counter party, with a maximum exposure equal to the carrying amount of these instruments.
Trade and other receivables comprise primarily deposits, accrued interest and goods and services tax refunds due. Where possible we trade only with recognized, creditworthy third parties. It is our policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis with the result that our exposure to bad debts is not significant. At June 30, 2021, none of our receivables were past due.
Liquidity Risk
Liquidity risk is the risk that we will not be able to meet our financial obligations as they fall due. The Board’s approach to managing liquidity is to ensure, as far as possible, that we will have sufficient liquidity to meet our liabilities when due. At June 30, 2021, we determined that we had sufficient liquid assets to meet our financial obligations.
84

TABLE OF CONTENTS

ITEM 12.
DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
A. Debt Securities.
Not applicable.
B. Warrants and rights.
Not applicable.
C. Other Securities.
Not applicable.
D. American Depositary Shares
The Bank of New York Mellon, as depositary, will register and deliver American Depositary Shares, also referred to as ADSs. Each ADS will represent 10 shares (or a right to receive 10 shares) deposited with The Hongkong and Shanghai Banking Corporation Limited, as custodian for the depositary in Sydney, Australia. Each ADS will also represent any other securities, cash or other property that may be held by the depositary. The deposited shares together with any other securities, cash or other property held by the depositary are referred to as the deposited securities. The depositary’s office at which the ADSs will be administered and its principal executive office are located at 240 Greenwich Street, New York, New York 10286.
You may hold ADSs either (A) directly (i) by having an American Depositary Receipt, also referred to as an ADR, which is a certificate evidencing a specific number of ADSs, registered in your name, or (ii) by having uncertificated ADSs registered in your name, or (B) indirectly by holding a security entitlement in ADSs through your broker or other financial institution that is a direct or indirect participant in The Depository Trust Company, also called DTC. If you hold ADSs directly, you are a registered ADS holder, also referred to as an ADS holder. This description assumes you are an ADS holder. If you hold the ADSs indirectly, you must rely on the procedures of your broker or other financial institution to assert the rights of ADS holders described in this section. You should consult with your broker or financial institution to find out what those procedures are.
Registered holders of uncertificated ADSs will receive statements from the depositary confirming their holdings.
As an ADS holder, we will not treat you as one of our shareholders and you will not have shareholder rights. Australian law governs shareholder rights. The depositary will be the holder of the shares underlying your ADSs. As a registered holder of ADSs, you will have ADS holder rights. A deposit agreement among us, the depositary, ADS holders and all other persons indirectly or beneficially holding ADSs sets out ADS holder rights as well as the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs.
The following is a summary of the material provisions of the deposit agreement. For more complete information, you should read the entire deposit agreement and the form of ADR. Directions on how to obtain copies of those documents are provided on page 83 of this registration statement.
Dividends and Other Distributions
How will you receive dividends and other distributions on the shares?
The depositary has agreed to pay or distribute to ADS holders the cash dividends or other distributions it or the custodian receives on shares or other deposited securities, upon payment or deduction of its fees and expenses. You will receive these distributions in proportion to the number of shares your ADSs represent.
Cash. The depositary will convert any cash dividend or other cash distribution we pay on the shares into U.S. dollars, if it can do so on a reasonable basis and can transfer the U.S. dollars to the United States. If that is not possible or if any government approval is needed and cannot be obtained, the deposit agreement allows the depositary to distribute the foreign currency only to those ADS holders to whom it is possible to do so. It will hold the foreign currency it cannot convert for the account of the ADS holders who have not been paid. It will not invest the foreign currency and it will not be liable for any interest.
Before making a distribution, any withholding taxes, or other governmental charges that must be paid will be deducted. See “Item 10. Additional Information—E. Taxation.” The depositary will distribute only whole U.S.
85

TABLE OF CONTENTS

dollars and cents and will round fractional cents to the nearest whole cent. If the exchange rates fluctuate during a time when the depositary cannot convert the foreign currency, you may lose some of the value of the distribution.
Shares. The depositary may distribute additional ADSs representing any shares we distribute as a dividend or free distribution. The depositary will only distribute whole ADSs. It will sell shares which would require it to deliver a fraction of an ADS (or ADSs representing those shares) and distribute the net proceeds in the same way as it does with cash. If the depositary does not distribute additional ADSs, the outstanding ADSs will also represent the new shares. The depositary may sell a portion of the distributed shares (or ADSs representing those shares) sufficient to pay its fees and expenses in connection with that distribution.
Rights to purchase additional shares. If we offer holders of our securities any rights to subscribe for additional shares or any other rights, the depositary may (i) exercise those rights on behalf of ADS holders, (ii) distribute those rights to ADS holders or (iii) sell those rights and distribute the net proceeds to ADS holders, in each case after deduction or upon payment of its fees and expenses. To the extent the depositary does not do any of those things, it will allow the rights to lapse. In that case, you will receive no value for them. The depositary will exercise or distribute rights only if we ask it to and provide satisfactory assurances to the depositary that it is legal to do so. If the depositary will exercise rights, it will purchase the securities to which the rights relate and distribute those securities or, in the case of shares, new ADSs representing the new shares, to subscribing ADS holders, but only if ADS holders have paid the exercise price to the depositary. U.S. securities laws may restrict the ability of the depositary to distribute rights or ADSs or other securities issued on exercise of rights to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.
Other Distributions. The depositary will send to ADS holders anything else we distribute on deposited securities by any means it thinks is legal, fair and practical. If it cannot make the distribution in that way, the depositary has a choice. It may decide to sell what we distributed and distribute the net proceeds, in the same way as it does with cash. Or, it may decide to hold what we distributed, in which case ADSs will also represent the newly distributed property. However, the depositary is not required to distribute any securities (other than ADSs) to ADS holders unless it receives satisfactory evidence from us that it is legal to make that distribution. The depositary may sell a portion of the distributed securities or property sufficient to pay its fees and expenses in connection with that distribution. U.S. securities laws may restrict the ability of the depositary to distribute securities to all or certain ADS holders, and the securities distributed may be subject to restrictions on transfer.
The depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any ADS holders. We have no obligation to register ADSs, shares, rights or other securities under the Securities Act. We also have no obligation to take any other action to permit the distribution of ADSs, shares, rights or anything else to ADS holders. This means that you may not receive the distributions we make on our shares or any value for them if it is illegal or impractical for us to make them available to you.
Deposit, Withdrawal and Cancellation
How are ADSs issued?
The depositary will deliver ADSs if you or your broker deposits shares or evidence of rights to receive shares with the custodian. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will register the appropriate number of ADSs in the names you request and will deliver the ADSs to or upon the order of the person or persons that made the deposit.
How can ADS holders withdraw the deposited securities?
You may surrender your ADSs to the depositary for the purpose of withdrawal. Upon payment of its fees and expenses and of any taxes or charges, such as stamp taxes or stock transfer taxes or fees, the depositary will deliver the shares and any other deposited securities underlying the ADSs to the ADS holder or a person the ADS holder designates at the office of the custodian. Or, at your request, risk and expense, the depositary will
86

TABLE OF CONTENTS

deliver the deposited securities at its office, if feasible. However, the depositary is not required to accept surrender of ADSs to the extent it would require delivery of a fraction of a deposited share or other security. The depositary may charge you a fee and its expenses for instructing the custodian regarding delivery of deposited securities.
How do ADS holders interchange between certificated ADSs and uncertificated ADSs?
You may surrender your ADR to the depositary for the purpose of exchanging your ADR for uncertificated ADSs. The depositary will cancel that ADR and will send to the ADS holder a statement confirming that the ADS holder is the registered holder of uncertificated ADSs. Upon receipt by the depositary of a proper instruction from a registered holder of uncertificated ADSs requesting the exchange of uncertificated ADSs for certificated ADSs, the depositary will execute and deliver to the ADS holder an ADR evidencing those ADSs.
Voting Rights
How do you vote?
ADS holders may instruct the depositary how to vote the number of deposited shares their ADSs represent. If we request the depositary to solicit your voting instructions (and we are not required to do so), the depositary will notify you of a shareholders’ meeting and send or make voting materials available to you. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the depositary how to vote. For instructions to be valid, they must reach the depositary by a date set by the depositary. The depositary will try, as far as practical, subject to the laws of Australia and the provisions of our constitution or similar documents, to vote or to have its agents vote the shares or other deposited securities as instructed by ADS holders. If we do not request the depositary to solicit your voting instructions, you can still send voting instructions, and, in that case, the depositary may try to vote as you instruct, but it is not required to do so.
Except by instructing the depositary as described above, you won’t be able to exercise voting rights unless you surrender your ADSs and withdraw the shares. However, you may not know about the meeting enough in advance to withdraw the shares. In any event, the depositary will not exercise any discretion in voting deposited securities and it will only vote or attempt to vote as instructed.
We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote the shares represented by your ADSs. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying out voting instructions. This means that you may not be able to exercise voting rights and there may be nothing you can do if the shares represented by your ADSs are not voted as you requested.
In order to give you a reasonable opportunity to instruct the depositary as to the exercise of voting rights relating to Deposited Securities, if we request the Depositary to act, we agree to give the depositary notice of any such meeting and details concerning the matters to be voted upon at least 30 days in advance of the meeting date.
Fees and Expenses
Persons depositing or withdrawing ordinary shares or ADS holders must pay the depositary:
For:
 
 
 
US$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)
Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property
 
Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates
 
 
 
US$0.05 (or less) per ADS
Any cash distribution to ADS holders
87

TABLE OF CONTENTS

 
 
 
A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs
Distribution of securities distributed to holders of deposited securities (including rights) that are distributed by the depositary to ADS holders
 
 
 
US$0.05 (or less) per ADS per calendar year
Depositary services
 
 
 
Registration or transfer fees
Transfer and registration of shares on our share register to or from the name of the depositary or its agent when you deposit or withdraw shares
 
 
 
Expenses of the depositary
Cable (including SWIFT) and facsimile transmissions (when expressly provided in the deposit agreement)
 
Converting foreign currency to U.S. dollars
 
 
 
Taxes and other governmental charges the depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes
As necessary
 
 
 
Any charges incurred by the depositary or its agents for servicing the deposited securities
As necessary
The depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The depositary may collect any of its fees by deduction from any cash distribution payable (or by selling a portion of securities or other property distributable) to ADS holders that are obligated to pay those fees. The depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.
From time to time, the depositary may make payments to us to reimburse us for costs and expenses generally arising out of establishment and maintenance of the ADS program, waive fees and expenses for services provided to us by the depositary or share revenue from the fees collected from ADS holders. In performing its duties under the deposit agreement, the depositary may use brokers, dealers, foreign currency dealers or other service providers that are owned by or affiliated with the depositary and that may earn or share fees, spreads or commissions.
The depositary may convert currency itself or through any of its affiliates, or the custodian or we may convert currency and pay U.S. dollars to the depositary. Where the depositary converts currency itself or through any of its affiliates, the depositary acts as principal for its own account and not as agent, advisor, broker or fiduciary on behalf of any other person and earns revenue, including, without limitation, transaction spreads, that it will retain for its own account. The revenue is based on, among other things, the difference between the exchange rate assigned to the currency conversion made under the deposit agreement and the rate that the depositary or its affiliate receives when buying or selling foreign currency for its own account. The depositary makes no representation that the exchange rate used or obtained by it or its affiliate in any currency conversion under the deposit agreement will be the most favorable rate that could be obtained at the time or that the method by which that rate will be determined will be the most favorable to ADS holders, subject to the depositary’s obligation to act without negligence or bad faith. The methodology used to determine exchange rates used in currency conversions made by the depositary is available upon request. Where the custodian converts currency, the custodian has no obligation to obtain the most favorable rate that could be obtained at the time or to ensure that the method by which that rate will be determined will be the most favorable to ADS holders, and the depositary makes no representation that the rate is the most favorable rate and will not be liable for any direct or indirect
88

TABLE OF CONTENTS

losses associated with the rate. In certain instances, the depositary may receive dividends or other distributions from us in U.S. dollars that represent the proceeds of a conversion of foreign currency or translation from foreign currency at a rate that was obtained or determined by us and, in such cases, the depositary will not engage in, or be responsible for, any foreign currency transactions and neither it nor we make any representation that the rate obtained or determined by us is the most favorable rate and neither it nor we will be liable for any direct or indirect losses associated with the rate.
Payment of Taxes
You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until those taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.
Tender and Exchange Offers; Redemption, Replacement or Cancellation of Deposited Securities
The depositary will not tender deposited securities in any voluntary tender or exchange offer unless instructed to do so by an ADS holder surrendering ADSs and subject to any conditions or procedures the depositary may establish.
If deposited securities are redeemed for cash in a transaction that is mandatory for the depositary as a holder of deposited securities, the depositary will call for surrender of a corresponding number of ADSs and distribute the net redemption money to the holders of called ADSs upon surrender of those ADSs.
If there is any change in the deposited securities such as a sub-division, combination or other reclassification, or any merger, consolidation, recapitalization or reorganization affecting the issuer of deposited securities in which the depositary receives new securities in exchange for or in lieu of the old deposited securities, the depositary will hold those replacement securities as deposited securities under the deposit agreement. However, if the depositary decides it would not be lawful and practical to hold the replacement securities because those securities could not be distributed to ADS holders or for any other reason, the depositary may instead sell the replacement securities and distribute the net proceeds upon surrender of the ADSs.
If there is a replacement of the deposited securities and the depositary will continue to hold the replacement securities, the depositary may distribute new ADSs representing the new deposited securities or ask you to surrender your outstanding ADSs in exchange for new ADSs identifying the new deposited securities.
If there are no deposited securities underlying ADSs, including if the deposited securities are cancelled, or if the deposited securities underlying ADSs have become apparently worthless, the depositary may call for surrender of those ADSs or cancel those ADSs upon notice to the ADS holders.
Amendment and Termination
How may the deposit agreement be amended?
We may agree with the depositary to amend the deposit agreement and the ADRs without your consent for any reason. If an amendment adds or increases fees or charges, except for taxes and other governmental charges or expenses of the depositary for registration fees, facsimile costs, delivery charges or similar items, or prejudices a substantial right of ADS holders, it will not become effective for outstanding ADSs until 30 days after the depositary notifies ADS holders of the amendment. At the time an amendment becomes effective, you are considered, by continuing to hold your ADSs, to agree to the amendment and to be bound by the ADRs and the deposit agreement as amended.
How may the deposit agreement be terminated?
The depositary will initiate termination of the deposit agreement if we instruct it to do so. The depositary may initiate termination of the deposit agreement if:
60 days have passed since the depositary told us it wants to resign but a successor depositary has not been appointed and accepted its appointment;
89

TABLE OF CONTENTS

we delist the ADSs from an exchange in the United States on which they were listed and do not list the ADSs on another exchange in the United States or make arrangements for trading of ADSs on the U.S. over-the-counter market;
we delist our shares from an exchange outside the United States on which they were listed and do not list the shares on another exchange outside the United States;
the depositary has reason to believe the ADSs have become, or will become, ineligible for registration on Form F-6 under the Securities Act of 1933;
we appear to be insolvent or enter insolvency proceedings;
all or substantially all the value of the deposited securities has been distributed either in cash or in the form of securities;
there are no deposited securities underlying the ADSs or the underlying deposited securities have become apparently worthless; or
there has been a replacement of deposited securities.
If the deposit agreement will terminate, the depositary will notify ADS holders at least 90 days before the termination date. At any time after the termination date, the depositary may sell the deposited securities. After that, the depositary will hold the money it received on the sale, as well as any other cash it is holding under the deposit agreement, unsegregated and without liability for interest, for the pro rata benefit of the ADS holders that have not surrendered their ADSs. Normally, the depositary will sell as soon as practicable after the termination date.
After the termination date and before the depositary sells, ADS holders can still surrender their ADSs and receive delivery of deposited securities, except that the depositary may refuse to accept a surrender for the purpose of withdrawing deposited securities or reverse previously accepted surrenders of that kind that have not settled if it would interfere with the selling process. The depositary may refuse to accept a surrender for the purpose of withdrawing sale proceeds until all the deposited securities have been sold. The depositary will continue to collect distributions on deposited securities, but, after the termination date, the depositary is not required to register any transfer of ADSs or distribute any dividends or other distributions on deposited securities to the ADSs holder (until they surrender their ADSs) or give any notices or perform any other duties under the deposit agreement except as described in this paragraph.
Limitations on Obligations and Liability
Limits on our Obligations and the Obligations of the Depositary; Limits on Liability to Holders of ADSs
The deposit agreement expressly limits our obligations and the obligations of the depositary. It also limits our liability and the liability of the depositary. We and the depositary:
are only obligated to take the actions specifically set forth in the deposit agreement without negligence or bad faith, and the depositary will not be a fiduciary or have any fiduciary duty to holders of ADSs;
are not liable if we are or it is prevented or delayed by law or by events or circumstances beyond our or its ability to prevent or counteract with reasonable care or effort from performing our or its obligations under the deposit agreement;
are not liable if we or it exercises discretion permitted under the deposit agreement;
are not liable for the inability of any holder of ADSs to benefit from any distribution on deposited securities that is not made available to holders of ADSs under the terms of the deposit agreement, or for any special, consequential or punitive damages for any breach of the terms of the deposit agreement;
have no obligation to become involved in a lawsuit or other proceeding related to the ADSs or the deposit agreement on your behalf or on behalf of any other person;
may rely upon any documents we believe or it believes in good faith to be genuine and to have been signed or presented by the proper person;
are not liable for the acts or omissions of any securities depository, clearing agency or settlement system; and
90

TABLE OF CONTENTS

the depositary has no duty to make any determination or provide any information as to our tax status, or any liability for any tax consequences that may be incurred by ADS holders as a result of owning or holding ADSs or be liable for the inability or failure of an ADS holder to obtain the benefit of a foreign tax credit, reduced rate of withholding or refund of amounts withheld in respect of tax or any other tax benefit.
In the deposit agreement, we and the depositary agree to indemnify each other under certain circumstances.
Requirements for Depositary Actions
Before the depositary will deliver or register a transfer of ADSs, make a distribution on ADSs, or permit withdrawal of shares, the depositary may require:
payment of stock transfer or other taxes or other governmental charges and transfer or registration fees charged by third parties for the transfer of any shares or other deposited securities;
satisfactory proof of the identity and genuineness of any signature or other information it deems necessary; and
compliance with regulations it may establish, from time to time, consistent with the deposit agreement, including presentation of transfer documents.
The depositary may refuse to deliver ADSs or register transfers of ADSs when the transfer books of the depositary or our transfer books are closed or at any time if the depositary or we think it advisable to do so.
Your Right to Receive the Shares Underlying your ADSs
ADS holders have the right to cancel their ADSs and withdraw the underlying shares at any time except:
when temporary delays arise because: (i) the depositary has closed its transfer books, or we have closed our transfer books; (ii) the transfer of shares is blocked to permit voting at a shareholders’ meeting; or (iii) we are paying a dividend on our ordinary shares;
when you owe money to pay fees, taxes and similar charges; or
when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.
This right of withdrawal may not be limited by any other provision of the deposit agreement.
Direct Registration System
In the deposit agreement, all parties to the deposit agreement acknowledge that the Direct Registration System, also referred to as DRS, and Profile Modification System, also referred to as Profile, will apply to the ADSs. DRS is a system administered by DTC that facilitates interchange between registered holding of uncertificated ADSs and holding of security entitlements in ADSs through DTC and a DTC participant. Profile is a feature of DRS that allows a DTC participant, claiming to act on behalf of a registered holder of uncertificated ADSs, to direct the depositary to register a transfer of those ADSs to DTC or its nominee and to deliver those ADSs to the DTC account of that DTC participant without receipt by the depositary of prior authorization from the ADS holder to register that transfer.
In connection with and in accordance with the arrangements and procedures relating to DRS/Profile, the parties to the deposit agreement understand that the depositary will not determine whether the DTC participant that is claiming to be acting on behalf of an ADS holder in requesting registration of transfer and delivery as described in the paragraph above has the actual authority to act on behalf of the ADS holder (notwithstanding any requirements under the Uniform Commercial Code). In the deposit agreement, the parties agree that the depositary’s reliance on and compliance with instructions received by the depositary through the DRS/Profile system and in accordance with the deposit agreement will not constitute negligence or bad faith on the part of the depositary.
Shareholder Communications; Inspection of Register of Holders of ADSs
The depositary will make available for your inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. The
91

TABLE OF CONTENTS

depositary will send you copies of those communications or otherwise make those communications available to you if we ask it to. You have a right to inspect the register of holders of ADSs, but not for the purpose of contacting those holders about a matter unrelated to our business or the ADSs.
Jury Trial Waiver
The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws. If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law.
You will not, by agreeing to the terms of the deposit agreement, be deemed to have waived our or the depositary’s compliance with U.S. federal securities laws or the rules and regulations promulgated thereunder.
92

TABLE OF CONTENTS

IperionX Limited (formerly Hyperion Metals Limited and Tao Commodities Limited)
ANNUAL CONSOLIDATED FINANCIAL STATEMENTS
for the period ended June 30, 2021
 
PAGE
FINANCIAL STATEMENTS
 
IperionX Limited (formerly Hyperion Metals Limited and Tao Commodities Limited)
CONSOLIDATED FINANCIAL STATEMENTS
for the periods July 1, 2020 to December 1, 2020 and July 1, 2019 to June 30, 2020
 
PAGE
FINANCIAL STATEMENTS
 
IperionX Limited (formerly Hyperion Metals Limited)
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
for the interim periods ended December 31, 2021 and 2020
 
PAGE
FINANCIAL STATEMENTS
 
F-1

TABLE OF CONTENTS

Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of IperionX Limited
Opinion on the Financial Statements
We have audited the accompanying consolidated statement of financial position of IperionX Limited (formerly Hyperion Metals Limited and Tao Commodities Limited) and its subsidiaries (the “Company”) as of 30 June 2021, and the related consolidated statements of profit or loss and other comprehensive income, of changes in equity and of cash flows for the period ended 30 June 2021, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of 30 June 2021, and the results of its operations and its cash flows for the period ended 30 June 2021 in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ PricewaterhouseCoopers
PricewaterhouseCoopers
Perth, Australia
17 February 2022, except for the effects of the revision discussed in Note 1(x) to the consolidated financial statements, as to which the date is 29 March 2022
We have served as the Company's auditor since 2021
F-2

TABLE OF CONTENTS

CONSOLIDATED STATEMENT OF PROFIT OR LOSS
AND OTHER COMPREHENSIVE INCOME
FOR THE PERIOD ENDED JUNE 30, 2021
 
Notes
2021
US$
Continuing operations
 
 
Exploration and evaluation expenses
 
(2,568,386)
Corporate and administrative expenses
 
(852,944)
Business development expenses
 
(581,200)
Share-based payment expenses
17(a)
(4,084,764)
Finance income
2
5,075
Finance costs
2
(7,492)
Cost of listing on reverse acquisition
14
(5,141,126)
Loss before income tax
 
(13,230,837)
Income tax expense
3
Loss for the period
 
(13,230,837)
Loss attributable to members of IperionX Limited
 
(13,230,837)
 
 
 
Other comprehensive income/(loss)
 
 
Items that may be reclassified subsequently to profit or loss:
 
 
Exchange differences arising on translation of foreign operations
 
(2,419)
Other comprehensive loss for the period, net of tax
 
(2,419)
Total comprehensive loss for the period
 
(13,233,256)
Total comprehensive loss attributable to members of IperionX Limited
 
(13,233,256)
 
 
 
Basic loss per share (US$ per share)
13
(0.22)
Diluted loss per share (US$ per share)
13
(0.22)
The above Consolidated Statement of Profit or Loss and other Comprehensive Income should be read in conjunction with the
accompanying notes.
F-3

TABLE OF CONTENTS

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AT JUNE 30, 2021
 
Notes
2021
US$
ASSETS
 
 
Current Assets
 
 
Cash and cash equivalents
5
1,697,904
Trade and other receivables
 
341
Prepayments
 
49,069
Total Current Assets
 
1,747,314
 
 
 
Non-Current Assets
 
 
Exploration and evaluation assets
6
504,750
Property, plant and equipment
7
539,619
Total Non-Current Assets
 
1,044,369
TOTAL ASSETS
 
2,791,683
 
 
 
LIABILITIES
 
 
Current Liabilities
 
 
Trade and other payables
8
544,842
Lease liabilities
 
81,104
Provisions
 
11,069
Total Current Liabilities
 
637,015
 
 
 
Non-Current Liabilities
 
 
Lease liabilities
 
394,548
Total Non-Current Liabilities
 
394,548
TOTAL LIABILITIES
 
1,031,563
 
 
 
NET ASSETS
 
1,760,120
 
 
 
EQUITY
 
 
Contributed equity
10
10,255,369
Reserves
11
4,735,588
Accumulated losses
12
(13,230,837)
TOTAL EQUITY
 
1,760,120
The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.
F-4

TABLE OF CONTENTS

CONSOLIDATED STATEMENT CHANGES IN EQUITY
FOR THE PERIOD ENDED JUNE 30, 2021
 
Contributed
Equity
US$
Share-Based
Payments
Reserve
US$
Foreign
Currency
Translation
Reserve
US$
Accumulated
Losses
US$
Total
Equity
US$
Balance at incorporation
Net loss for the period
(13,230,837)
(13,230,837)
Exchange differences arising on translation of foreign operations
(2,419)
(2,419)
Total comprehensive loss for the period
(2,419)
(13,230,837)
(13,233,256)
Issue of shares – incorporation
1
1
Issue of shares – seed placement
54,011
54,011
Reverse acquisition
6,433,752
967,582
7,401,334
Issue of shares – share placement
2,819,340
2,819,340
Issue of shares – exercise of options and performance rights
1,033,732
(314,339)
719,393
Share issue costs
(85,467)
(85,467)
Share-based payment expense
4,084,764
4,084,764
Balance at June 30, 2021
10,255,369
4,738,007
(2,419)
(13,230,837)
1,760,120
The above Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.
F-5

TABLE OF CONTENTS

CONSOLIDATED STATEMENT CASH FLOWS
FOR THE PERIOD ENDED JUNE 30, 2021
 
Notes
2021
US$
Operating activities
 
 
Payments to suppliers and employees
 
(3,562,589)
Interest paid
 
(511)
Interest received
 
5,075
Net cash flows used in operating activities
5
(3,558,025)
 
 
 
Investing activities
 
 
Purchase of exploration and evaluation assets
6
(504,750)
Purchase of property, plant and equipment
 
(66,818)
Net cash flows from investing activities
 
(571,568)
 
 
 
Financing activities
 
 
Proceeds from issue of shares
 
3,592,745
Share issue costs
10(a)
(85,467)
Payment of principal portion of lease liabilities
 
(6,473)
Net cash inflow on reverse acquisition
14
2,329,111
Net cash flows from financing activities
 
5,829,916
 
 
 
Net increase in cash and cash equivalents
 
1,700,323
Net foreign exchange differences
 
(2,419)
Cash and cash equivalents at beginning of period
 
Cash and cash equivalents at the end of the period
5
1,697,904
The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.
F-6

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES
The significant accounting policies adopted in preparing the consolidated financial statements of IperionX Limited (formerly Hyperion Metals Limited and Tao Commodities Limited) (“IperionX” or “Company”) and its consolidated entities (“Consolidated Entity” or “Group”) for the period ended June 30, 2021 are stated to assist in a general understanding of the consolidated financial statements.
IperionX is a for-profit company limited by shares, incorporated and domiciled in Australia. Our ordinary shares are listed on the Australian Securities Exchange, or ASX, under the symbol “HYM”.
The principal activities of the Group during the period ended June 30, 2021 consisted of the exploration and development of mineral resource projects.
The consolidated financial statements of the Group for the period ended June 30, 2021 were authorised for issue in accordance with a resolution of the Directors on February 17, 2022.
(a)
Basis of preparation
The consolidated financial statements are general purpose financial statements, which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).
The financial statements comprise the consolidated financial statements of the Group. For the purposes of preparing the consolidated financial statements, the Company is a for-profit entity.
The consolidated financial statements are the first annual financial statements of the newly merged entity formed as a result of the reverse takeover of the Company by Hyperion Metals (Australia) Pty Ltd (“HMAPL”). Refer to Note 14 for accounting treatment of the acquisition.
As outlined in Note 14, as a result of the reverse acquisition the former shareholders of HMAPL effectively obtained control of the combined entity. Therefore, while the Company is the legal acquirer of HMAPL, for accounting purposes HMAPL is deemed to be the acquirer of IperionX Limited and these consolidated financial statements are presented as a continuation of the operations of HMAPL. As such, no comparative period is presented throughout the consolidated financial statements because HMAPL was incorporated during the financial period on July 20, 2020. Accordingly, the financial reporting period as presented in these financial statements reflects the period from July 20, 2020 to June 30, 2021.
The consolidated financial statements have also been prepared on a historical cost basis.
The consolidated financial statements are presented in United States dollars (US$).
The financial statements have been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the normal course of business.
(b)
New standards, interpretations and amendments
In the current period, the Group has adopted all Accounting Standards and Interpretations effective from July 1, 2020. New and revised standards and amendments thereof and interpretations effective for the current reporting period that are relevant to the Group include:
Definition of a Business (Amendments to IFRS 3)
Definition of Material (Amendments to IAS 1 and IAS 8)
Amendments to References to the Conceptual Framework in IFRS Standards
The adoption of the aforementioned standards has no impact on the financial statements of the Company as at June 30, 2021. The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.
F-7

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
(c)
Issued standards and interpretations not early adopted
Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet effective have not been adopted by the Group for the reporting period ended June 30, 2021. Those which may be relevant to the Group are set out in the table below, but these are not expected to have any significant impact on the Group's financial statements:
Standard/Interpretation
Application Date of
Standard
Application Date for
the Group
Annual Improvements to IFRS Standards 2018–2020
January 1, 2022
July 1, 2022
Classification of Liabilities as Current or Non-Current (Amendments to IAS 1)
January 1, 2023
July 1, 2023
Classification of Liabilities as Current or Non-current — Deferral of Effective Date (Amendment to IAS 1)
January 1, 2023
July 1, 2023
(d)
Principles of Consolidation
The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of the Company as at June 30, 2021.
Control is achieved when the Company has power over the investee, is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to use its power to affect its returns. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. When the Company has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company's voting rights in an investee are sufficient to give it power.
Subsidiaries are all those entities (including special purpose entities) over which the Company has the power to govern the financial and operating policies, so as to obtain benefits from its activities, generally accompanying a shareholding of more than one-half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Company controls another entity.
The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company.
Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are de-consolidated from the date that control ceases.
Intercompany transactions and balances, income and expenses and profits and losses between Group companies, are eliminated. Investments in subsidiaries are accounted for at cost in the Statement of Financial Position of the Company.
(e)
Foreign Currencies
(i)
Functional and presentation currency
The functional currency of each of the Group's entities is measured using the currency of the primary economic environment in which that entity operates.
The consolidated financial statements are presented in United States dollars which is the Group's presentation currency.
F-8

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
(ii)
Transactions and balances
Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the period-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.
Exchange differences arising on the translation of monetary items are recognised in the income statement, except where deferred in equity as a qualifying cash flow or net investment hedge.
Exchange differences arising on the translation of non-monetary items are recognised directly in equity to the extent that the gain or loss is directly recognised in equity, otherwise the exchange difference is recognised in the income statement.
(iii)
Group companies
The financial results and position of foreign operations whose functional currency is different from the group's presentation currency are translated as follows:
assets and liabilities are translated at period-end exchange rates prevailing at that reporting date;
income and expenses are translated at average exchange rates for the period; and
retained earnings are translated at the exchange rates prevailing at the date of the transaction.
Exchange differences arising on translation of foreign operations are transferred directly to the group's foreign currency translation reserve in equity. These differences are recognised in profit or loss in the period in which the operation is disposed.
(f)
Cash and Cash Equivalents
Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of 3 months or less, and bank overdrafts.
(g)
Trade and Other Receivables
Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less allowance for expected credit losses, applying the simplified approach. If collection of the amounts is expected in one year or less, they are classified as current assets. If not, they are presented as non-current assets. Trade receivables are generally due for settlement within 30 days and therefore are all classified as current.
As the majority of receivables are short term in nature, their carrying amount is assumed to be the same as their fair value.
(h)
Property, Plant and Equipment
All classes of property, plant and equipment are measured at cost.
Depreciation is provided on a straight-line basis over the estimated useful lives of the assets, except for land which is not depreciated. Currently the Group only has plant and equipment which is depreciated over a period of 5 years.
(i)
Exploration and Development Expenditure
Expenditure on exploration and evaluation is accounted for in accordance with the 'area of interest' method and with IFRS 6 Exploration for and Evaluation of Mineral Resources.
F-9

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
Exploration and evaluation expenditure encompasses expenditures incurred by the Group in connection with the exploration for and evaluation of mineral resources before the technical feasibility and commercial viability of extracting a mineral resource are demonstrable.
For each area of interest, expenditure incurred in the acquisition of rights to explore is capitalised and recognised as an exploration and evaluation asset. This includes option payments made to landowners under the Group’s option agreements with local landowners which are considered part of the acquisition costs. Exploration and evaluation assets are measured at cost at recognition and are recorded as an asset if:
(i)
the rights to tenure of the area of interest are current; and
(ii)
at least one of the following conditions is also met:
the exploration and evaluation expenditures are expected to be recouped through successful development and exploitation of the area of interest, or alternatively, by its sale; and
exploration and evaluation activities in the area of interest have not at the reporting date reached a stage which permits a reasonable assessment of the existence or otherwise of economically recoverable reserves, and active and significant operations in, or in relation to, the area of interest are continuing.
All other exploration and evaluation expenditures are expensed as incurred. Once the technical feasibility and commercial viability of a program or project has been demonstrated with a bankable feasibility study, the carrying amount of the exploration and evaluation expenditure in respect of the area of interest is reclassified as a “mine development property”.
Where a decision is made to proceed with development, accumulated expenditure is tested for impairment and transferred to development properties, and then amortised over the life of the reserves associated with the area of interest once mining operations have commenced. Recoverability of the carrying amount of the exploration and evaluation assets is dependent on successful development and commercial exploitation, or alternatively, sale of the respective areas of interest.
Impairment
Capitalised exploration costs are reviewed each reporting date to establish whether an indication of impairment exists. If any such indication exists, the recoverable amount of the capitalised exploration costs is estimated to determine the extent of the impairment loss (if any). Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but only to the extent that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset.
(j)
Trade and other payables
These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial period which are unpaid. The amounts are unsecured and are usually paid within 60 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting date.
They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method.
The carrying amounts of trade and other payables are considered to be the same as their fair values, due to their short-term nature.
(k)
Provisions
Provisions are recognised when the Group has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured.
F-10

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
(l)
Interest income
Interest income is recognised on a time proportionate basis that takes into account the effective yield on the financial asset.
(m)
Income Tax
The income tax expense for the period is the tax payable on the current period's taxable income based on the national income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses.
Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates which are enacted or substantively enacted for each jurisdiction. The relevant tax rates are applied to the cumulative amounts of deductible and taxable temporary differences to measure the deferred tax asset or liability. An exception is made for certain temporary differences arising from the initial recognition of an asset or a liability. No deferred tax asset or liability is recognised in relation to these temporary differences if they arose on goodwill or in a transaction, other than a business combination, that at the time of the transaction did not affect either accounting profit or taxable profit or loss.
Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in controlled entities where the Company is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.
Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.
The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised.
Unrecognised deferred income tax assets are reassessed at each balance date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.
Current and deferred tax balances attributable to amounts recognised directly in equity are also recognised directly in equity.
Deferred tax assets and deferred tax liabilities are offset only if a legally enforceable right exists to set off current tax assets against tax liabilities and the deferred tax liabilities relate to the same taxable entity and the same taxation authority.
(n)
Employee Entitlements
Provision is made for the Group's liability for employee benefits arising from services rendered by employees to balance date. Employee benefits that are expected to be settled wholly within 12 months have been measured at the amounts expected to be paid when the liability is settled, plus related on-costs. Employee benefits payable later than 12 months have been measured at the present value of the estimated future cash outflows to be made for those benefits.
(o)
Earnings per Share
Basic earnings per share (“EPS”) is calculated by dividing the net profit attributable to members of the Company for the reporting period, after excluding any costs of servicing equity, by the weighted average number of ordinary shares of the Company, adjusted for any bonus issue.
Diluted EPS is calculated by dividing the basic EPS earnings, adjusted by the after tax effect of financing costs associated with dilutive potential Ordinary Shares and the effect on revenues and expenses of conversion to
F-11

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
Ordinary Shares associated with dilutive potential Ordinary Shares, by the weighted average number of Ordinary Shares and dilutive Ordinary Shares adjusted for any bonus issue.
(p)
Goods and Services Tax
Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Tax Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables in the Statement of Financial Position are shown inclusive of GST. Cash flows are presented in the Statement of Cash Flows on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.
(q)
Use and Revision of Accounting Estimates, Judgements and Assumptions
The preparation of the financial report requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
In particular, information about significant areas of estimation uncertainty and critical judgements in applying accounting policies that have the most significant effect on the amount recognised in the financial statements are described in the following note:
Recognition of tax losses (Notes 1(m) and 3);
Impairment of exploration and evaluation assets (Note 6);
Determination of the accounting acquirer in reverse acquisition and fair value of the consideration paid (Note 14); and
Share-based payments (Note 17).
(r)
Operating Segments
An operating segment is a component of an entity that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity), whose operating results are regularly reviewed by the entity's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance and for which discrete financial information is available. This includes start up operations which are yet to earn revenues. Management will also consider other factors in determining operating segments such as the existence of a line manager and the level of segment information presented to the board of directors.
Operating segments have been identified based on the information provided to the chief operating decision makers, being the board of directors.
The group aggregates two or more operating segments when they have similar economic characteristics, and the segments are similar in each of the following respects:
Nature of the products and services,
Nature of the production processes,
Type or class of customer for the products and services,
Methods used to distribute the products or provide the services, and if applicable,
Nature of the regulatory environment.
F-12

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
Operating segments that meet the quantitative criteria as prescribed by IFRS 8 Operating Segments are reported separately. However, an operating segment that does not meet the quantitative criteria is still reported separately where information about the segment would be useful to users of the financial statements.
Information about other business activities and operating segments that are below the quantitative criteria are combined and disclosed in a separate category for “all other segments”.
Currently, the Group has only one operating segment.
(s)
Impairment of Assets
The Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, or when annual impairment testing for an asset is required, the Group makes an estimate of the asset's recoverable amount. An asset's recoverable amount is the higher of its fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets and the asset's value in use cannot be estimated to be close to its fair value. In such cases the asset is tested for impairment as part of the cash-generating unit to which it belongs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or cash-generating unit is considered impaired and is written down to its recoverable amount.
In assessing the value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.
An assessment is also made at each reporting date as to whether there is any indication that previously recognised impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognised impairment loss is reversed only if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised. If that is the case the carrying amount of the asset is increased to its recoverable amount. That increased amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. After such a reversal the depreciation charge is adjusted in future periods to allocate the asset's revised carrying amount, less any residual value, on a systematic basis over its remaining useful life.
(t)
Fair Value Estimation
The fair value of financial assets and financial liabilities must be estimated for recognition and measurement or for disclosure purposes.
The fair value of financial instruments traded in active markets (such as publicly traded derivatives, and equity securities classified as fair value through other comprehensive income) is based on quoted market prices at the reporting date. The quoted market price used for financial assets held by the Group is the current bid price; the appropriate quoted market price for financial liabilities is the current ask price.
The fair value of financial instruments that are not traded in an active market (for example, over the counter derivatives) is determined using valuation techniques. The Group uses a variety of methods and makes assumptions that are based on market conditions existing at each balance date. Quoted market prices or dealer quotes for similar instruments are used for long-term debt instruments held. Other techniques, such as discounted cash flows, are used to determine fair value for the remaining financial instruments. The fair value of interest-rate swaps is calculated as the present value of the estimated future cash flows. The fair value of forward exchange contracts is determined using forward exchange market rates at the reporting date.
The nominal value less estimated credit adjustments of trade receivables and payables are assumed to approximate their fair values. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Group for similar financial instruments.
F-13

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
(u)
Issued and Unissued Capital
Ordinary Shares and Performance Shares are classified as equity. Issued and paid up capital is recognised at the fair value of the consideration received by the Company. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.
(v)
Dividends
Provision is made for the amount of any dividend declared on or before the end of the year but not distributed at balance date.
(w)
Share-Based Payments
Equity-settled share-based payments are provided to officers, employees, consultants and other advisors. These share-based payments are measured at the fair value of the equity instrument at the grant date. Fair value is determined using the Black Scholes option pricing model. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the Company's estimate of equity instruments that will eventually vest. At each reporting date, the Company revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognised in profit or loss over the remaining vesting period, with a corresponding adjustment to the share-based payments reserve.
Equity-settled share-based payments may also be provided as consideration for the acquisition of assets. Where ordinary shares are issued, the transaction is recorded at fair value based on the quoted price of the ordinary shares at the date of issue. The acquisition is then recorded as an asset or expensed in accordance with accounting standards.
(x)
Revisions
In the year ended June 30, 2021, the Group reclassified the net cash inflow on reverse acquisition from investing to financing cash flows in the consolidated statement of cash flows. This change had no impact on the Group’s net loss or financial position for the period ended June 30, 2021.
2.
INCOME AND EXPENSES
 
Note
2021
US$
Finance income
 
 
Interest income
 
5,075
 
 
5,075
 
 
 
Finance costs
 
 
Interest on lease liabilities
 
(3,097)
Other finance costs
 
(4,395)
 
 
(7,492)
 
 
 
Depreciation and amortisation
 
 
Amortisation of right-of-use assets
7
(8,364)
Depreciation of property, plant and equipment
7
(960)
 
 
(9,324)
 
 
 
F-14

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
2.
INCOME AND EXPENSES (Continued)
 
Note
2021
US$
Employee benefits expense
 
 
Wages and salaries
 
(509,474)
Employee benefits
 
(44,325)
Post-employment benefits
 
(8,929)
Share-based payment expenses
 
(4,084,764)
 
 
(4,647,492)
3.
INCOME TAX
 
2021
US$
Recognised in profit or loss
 
Current income tax:
 
Current income tax benefit in respect of the current period
Deferred income tax:
 
Origination and reversal of temporary differences
Income tax expense reported in profit or loss
 
 
Reconciliation between tax expense and accounting loss before income tax
 
Accounting loss before income tax
(13,230,837)
At the Australian income tax rate of 30%
(3,969,251)
Effect of lower income tax rate in the United States
124,391
Expenditure not allowable for income tax purposes
2,942,127
Exchange differences
(5,365)
Effect of deferred tax assets not brought to account
908,098
Income tax expense reported in profit or loss
 
 
Deferred tax assets and liabilities
 
Deferred tax liabilities:
 
Right-of-use assets
142,128
Deferred tax assets used to offset deferred tax liabilities
(142,128)
 
Deferred tax assets:
 
Accrued expenditures
53,997
Provisions
2,893
Lease liabilities
142,695
Tax losses available to offset against future taxable income
1,260,669
Deferred tax assets used to offset deferred tax liabilities
(142,128)
Deferred tax assets acquired on reverse acquisition not brought to account (1)
(410,028)
Other deferred tax assets not brought to account (1)
(908,098)
 
Notes:
(1)
The benefit of deferred tax assets not brought to account will only be brought to account if: (a) future assessable income is derived of a nature and of an amount sufficient to enable the benefit to be realised; (b) the conditions for deductibility imposed by tax legislation continue to be complied with; and (c) no changes in tax legislation adversely affect the Group in realising the benefit.
F-15

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
4.
DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES
No dividends have been paid or proposed for the period ended June 30, 2021.
5.
CASH AND CASH EQUIVALENTS
 
2021
US$
Cash at bank and on hand
1,697,904
 
1,697,904
 
 
Reconciliation of loss before income tax to net cash flows from operations
 
Loss for the period
(13,230,837)
Adjustment for non-cash income and expense items
 
Share-based payments expense
4,084,764
Cost of listing on reverse acquisition
5,141,126
Amortisation of right-of-use assets
8,364
Depreciation of property, plant and equipment
960
Changes in assets and liabilities
 
Increase in receivables and prepayments
(34,405)
Increase in payables and provisions
472,003
Net cash outflow from operating activities
(3,558,025)
6.
EXPLORATION AND EVALUATION ASSETS
 
Titan
Project(1)
US$
2021
 
Carrying amount at incorporation
Additions
504,750
Carrying amount at June 30, 2021(2)
504,750
Notes:
(1)
At June 30, 2021, the Titan Project comprised of approximately 6,111 acres of surface and associated mineral rights in Tennessee prospective for heavy mineral sands, including titanium, rare earth minerals, high grade silica sand, and zircon, of which approximately 137 acres are owned and approximately 5,974 acres are subject to exclusive option agreements. These exclusive option agreements, upon exercise, allow the Group to purchase or, in some cases lease, the surface property and associated mineral rights.
(2)
The ultimate recoupment of costs carried forward for exploration and evaluation is dependent on the successful development and commercial exploitation or sale of the respective areas of interest.
7.
PROPERTY, PLANT AND EQUIPMENT
 
Plant and
equipment
US$
Right-of-use
assets
US$
Total
US$
2021
 
 
 
Carrying amount at incorporation
Additions
66,818
482,125
548,943
Depreciation and amortization
(960)
(8,364)
(9,324)
Carrying amount at June 30, 2021
65,858
473,761
539,619
- at cost
66,818
482,125
548,943
- accumulated depreciation
(960)
(8,364)
(9,324)
F-16

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
8.
TRADE AND OTHER PAYABLES
 
2021
US$
Current
 
Trade payables
286,846
Accruals
255,965
Payroll liabilities
2,031
Total trade and other payables
544,842
9.
LEASES
The Group leases office premises in the United States. The carrying amounts of right-of-use assets (included under property, plant and equipment) and the movements during the period are in Note 7. The carrying amounts of lease liabilities are set out in the Statement of Financial Position. The following are the amounts recognised in profit or loss in respect of leases:
 
Note
2021
US$
Amortisation of right-of-use assets
2
(8,364)
Interest expense on lease liabilities
2
(3,097)
Net amount recognised in profit or loss
(11,461)
10.
CONTRIBUTED EQUITY
 
Note
2021
US$
Issued capital
 
 
105,105,787 fully paid ordinary shares
10(a)
10,255,369
(a)
Movements in issued capital
 
Number of
Ordinary
Shares
Number of
Class A
Performance
Shares
Number of
Class B
Performance
Shares
US$
2021
 
 
 
 
Opening balance at incorporation
Issue of shares – incorporation (July 2020)
1
1
Issue of shares – seed placement (August-October 2020)
99,999
54,011
Reverse acquisition – exchange of ordinary shares of HMAPL for ordinary shares and performance shares of IperionX, adjusted to reflect the exchange ratio set forth in the merger agreement
26,400,000
18,000,000
18,000,000
Reverse acquisition – shares issued to facilitators of reverse acquisition
2,650,000
1,800,000
1,800,000
Reverse acquisition – recognition of legal acquirer shares
57,386,667
6,433,752
Issue of shares – share placement (January 2021)
12,150,000
2,819,340
Issue of shares – exercise of options and performance rights
6,419,120
1,033,732
Share issue costs
(85,467)
Closing balance at June 30, 2021
105,105,787
19,800,000
19,800,000
10,255,369
F-17

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
10.
CONTRIBUTED EQUITY(Continued)
(b)
Rights attaching to Ordinary Shares
The rights attaching to fully paid ordinary shares (“Ordinary Shares”) arise from a combination of the Company's Constitution, statute and general law:
(i)
Shares - The issue of shares in the capital of the Company and options over unissued shares by the Company is under the control of the directors, subject to the Corporations Act 2001, ASX Listing Rules and any rights attached to any special class of shares.
(ii)
Meetings of Members - Directors may call a meeting of members whenever they think fit. Members may call a meeting as provided by the Corporations Act 2001.The Constitution contains provisions prescribing the content requirements of notices of meetings of members and all members are entitled to a notice of meeting. A meeting may be held in two or more places linked together by audio-visual communication devices. A quorum for a meeting of members is 2 shareholders. The Company holds annual general meetings in accordance with the Corporations Act 2001 and the Listing Rules.
(iii)
Voting - Subject to any rights or restrictions at the time being attached to any shares or class of shares of the Company, each member of the Company is entitled to receive notice of, attend and vote at a general meeting. Resolutions of members will be decided by a show of hands unless a poll is demanded. On a show of hands each eligible voter present has one vote. However, where a person present at a general meeting represents personally or by proxy, attorney or representative more than one member, on a show of hands the person is entitled to one vote only despite the number of members the person represents. On a poll each eligible member has one vote for each fully paid share held and a fraction of a vote for each partly paid share determined by the amount paid up on that share.
(iv)
Changes to the Constitution - The Company's Constitution can only be amended by a special resolution passed by at least three quarters of the members present and voting at a general meeting of the Company. At least 28 days' written notice specifying the intention to propose the resolution as a special resolution must be given.
(v)
Listing Rules - Provided the Company remains admitted to the Official List, then despite anything in its Constitution, no act may be done that is prohibited by the Listing Rules, and authority is given for acts required to be done by the Listing Rules. The Company's Constitution will be deemed to comply with the Listing Rules as amended from time to time.
(c)
Rights attaching to Performance Shares
Performance Shares comprise 19,800,000 Class A and 19,800,000 Class B Performance Shares issued in relation to the acquisition of HMAPL (refer Note 14) and are issued based upon the following terms and conditions:
The Performance Shareholders are not entitled to a dividend;
The Performance Shares are not transferable;
The Performance Shareholders shall have no right to vote, subject to the Corporations Act;
The Performance Shares will convert into Ordinary Shares as follows:
Each Class A Performance Share will convert into one (1) Ordinary Share upon completion of a positive pre-feasibility study (prepared in accordance with the JORC Code and independently verified by a Competent Person) for heavy mineral sands mining and processing on any of the Titan Project area which demonstrates a net present value of at least A$200,000,000 before September 17, 2024 (the “Pre-Feasibility Study Milestone”);
Each Class B Performance Share will convert into one (1) Ordinary Share upon the commencement of commercial production from the Titan Project area before September 17, 2025 (the “First Production Milestone”);
All Performance Shares shall automatically convert into Ordinary Shares upon the occurrence of certain change of control events; and
F-18

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
10.
CONTRIBUTED EQUITY(Continued)
To the extent that any Performance Shares have not converted into Ordinary Shares by the applicable expiry date, all such Performance Shares for each holder will automatically lapse be combined into one single Performance Share that will then convert into one single Ordinary Share.
The Ordinary Shares issued on conversion of any Performance Share will rank equally with and confer rights identical with all other Ordinary Shares then on issue and application will be made by the Company to ASX for official quotation of the Ordinary Shares upon the date of conversion.
The Company shall allot and issue Ordinary Shares immediately upon conversion of the Performance Shares for no consideration and shall record the allotment and issue in the manner required by the Corporations Act.
The Performance Shares are unquoted. No application for quotation of the Performance Shares will be made by the Company.
11.
RESERVES
 
Note
2021
US$
Share-based payments reserve
11(b)
4,738,007
Foreign currency translation reserve
11(f)
(2,419)
 
 
4,735,588
(a)
Nature and purpose of reserves
(i)
Share-based payments reserve
The share-based payments reserve is used to record the fair value of Unlisted Options and Performance Rights issued by the Group.
(ii)
Foreign currency translation reserve
Exchange differences arising on translation of entities whose functional currency is different to the Group’s presentation currency are taken to the foreign currency translation reserve, as described in Note 1(e).
(b)
Movements in share-based payments reserve during the period
 
Number of
Listed
Options
(Note 11(c))
Number of
Unlisted
Options
(Note 11(d))
Number of
Performance
Rights
(Note 11(e))
US$
2021
 
 
 
 
Opening balance at incorporation
Reverse acquisition – options issued to vendors of legal acquiree
13,000,000
Reverse acquisition – recognition of legal acquirer options and rights
15,693,334
5,000,000
2,000,000
967,582
Issue of employee options and performance rights
9,150,000
16,325,000(2)
Exercise of options and performance rights
(3,069,120)
(1,350,000)
(2,000,000)
(314,339)
Share-based payment expense
4,084,764
Closing balance at June 30, 2021
12,624,214
25,800,000
16,325,000
4,738,007
Notes:
(1)
For details on the valuation of Unlisted Options and Performance Rights, including models and assumptions used, refer to Note 17 of the financial statements.
(2)
During the period, the Group agreed, subject to shareholder approval, to grant 3,500,000 performance rights to Mr. Hannigan. These performance rights have not been included in this table as they had not been granted at June 30, 2021.
F-19

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
11.
RESERVES(Continued)
(c)
Terms and conditions of Listed Options
Listed Options have the following terms and conditions:
Each Listed Option entitles the holder to the right to subscribe for one Share upon the exercise of each Listed Option;
The Listed Options outstanding at the end of the financial period have the following exercise prices and expiry dates:
12,624,214 Listed Options exercisable at A$0.20 each on or before August 31, 2021;
The Listed Options are exercisable at any time prior to the Expiry Date;
Shares issued on exercise of the Listed Options rank equally with the then Shares of the Company;
Application will be made by the Company to ASX for official quotation of the Shares issued upon the exercise of the Listed Options;
If there is any reconstruction of the issued share capital of the Company, the rights of the Listed Options holders may be varied to comply with the ASX Listing Rules which apply to the reconstruction at the time of the reconstruction; and
The Listed Options are quoted on ASX (ASX code: HYMOA).
(d)
Terms and conditions of Unlisted Options
Unlisted Options granted as share-based payments have the following terms and conditions:
Each Unlisted Option entitles the holder to the right to subscribe for one Share upon the exercise of each Unlisted Option;
The Unlisted Options outstanding at the end of the financial period have the following exercise prices and expiry dates:
6,000,000 Unlisted Options exercisable at A$0.25 each on or before December 31, 2023;
4,650,000 Unlisted Options exercisable at A$0.20 each on or before December 31, 2023;
5,000,000 Unlisted Options exercisable at A$0.20 each on or before December 1, 2025;
4,000,000 Class A Performance Unlisted Options exercisable at A$0.20 each on or before December 1, 2025;
4,000,000 Class B Performance Unlisted Options exercisable at A$0.20 each on or before December 1, 2025;
1,075,000 Unlisted Options exercisable at A$0.45 each on or before December 31, 2023; and
1,075,000 Unlisted Options exercisable at A$0.55 each on or before December 31, 2023.
The Unlisted Options are exercisable at any time prior to the Expiry Date, subject to vesting conditions being satisfied (if applicable);
Shares issued on exercise of the Unlisted Options rank equally with the then Shares of the Company;
Application will be made by the Company to ASX for official quotation of the Shares issued upon the exercise of the Unlisted Options;
If there is any reconstruction of the issued share capital of the Company, the rights of the Unlisted Option holders may be varied to comply with the ASX Listing Rules which apply to the reconstruction at the time of the reconstruction; and
No application for quotation of the Unlisted Options will be made by the Company.
F-20

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
11.
RESERVES(Continued)
(e)
Terms and conditions of Performance Rights
Performance Rights granted as share-based payments have the following terms and conditions:
Each Performance Right automatically converts into one Share upon vesting of the Performance Right;
Each Performance Right is subject to performance conditions (as determined by the Board from time to time) which must be satisfied in order for the Performance Right to vest;
The Performance Rights outstanding at the end of the financial period have the following performance conditions and expiry dates:
5,133,333 performance rights that vest upon a 30-day VWAP of A$2.00 per share, expiring April 23, 2026;
5,133,333 performance rights that vest upon a 30-day VWAP of A$3.00 per share, expiring April 23, 2026;
5,233,334 performance rights that vest upon a 30-day VWAP of A$4.00 per share, expiring April 23, 2026;
125,000 performance rights that vest upon a 30-day VWAP of A$2.00 per share, expiring April 23, 2024;
125,000 performance rights that vest upon a 30-day VWAP of A$3.00 per share, expiring April 23, 2024;
125,000 performance rights that vest upon a 30-day VWAP of A$4.00 per share, expiring April 23, 2024;
150,000 performance rights that vest upon a 30-day VWAP of A$2.00 per share, expiring March 1, 2026;
150,000 performance rights that vest upon a 30-day VWAP of A$3.00 per share, expiring March 1, 2026; and
150,000 performance rights that vest upon achieving a 30-day VWAP of A$4.00 per share, expiring March 1, 2026;
Application will be made by the Company to ASX for official quotation of the Shares issued upon conversion of the Performance Rights;
If there is any reconstruction of the issued share capital of the Company, the rights of the Performance Right holders may be varied to comply with the ASX Listing Rules which apply to the reconstruction at the time of the reconstruction;
No application for quotation of the Performance Rights will be made by the Company; and
Without approval of the Board, Performance Rights may not be transferred, assigned or novated, except, upon death, a participant's legal personal representative may elect to be registered as the new holder of such Performance Rights and exercise any rights in respect of them.
(f)
Movements in foreign currency translation reserve during the period
 
2021
US$
Balance at incorporation
Exchange differences arising on translation of foreign operations
(2,419)
Balance at June 30
(2,419)
F-21

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
12.
ACCUMULATED LOSSES
 
2021
US$
Balance at incorporation
Net loss for the period
(13,230,837)
Balance at June 30
(13,230,837)
13.
LOSS PER SHARE
 
2021
US$
Basic loss per share
(0.22)
Diluted loss per share
(0.22)
The following reflects the loss and share data used in the calculations of basic loss per share:
 
2021
US$
Net loss
(13,230,837)
Loss used in calculating basic and dilutive loss per share
(13,230,837)
 
Number of
Ordinary Shares
2021
Weighted average number of Ordinary Shares used in calculating basic and dilutive loss per share
60,336,252
(a)
Non-Dilutive Securities
As at June 30, 2021, 25,800,000 Unlisted Options and 16,325,000 Performance Rights, which together represent 42,125,000 potential Ordinary Shares, were considered non-dilutive as they would decrease the loss per share.
(b)
Conversions, Calls, Subscriptions or Issues after June 30, 2021
Subsequent to June 30, 2021, the Company has issued:
(i)
20,000,000 ordinary shares pursuant to a share placement to institutional, sophisticated and professional investors;
(ii)
12,606,704 ordinary shares pursuant to the exercise of listed options;
(iii)
1,400,000 ordinary shares pursuant to the exercise of unlisted options;
(iv)
600,000 restricted stock units to new Directors of the Company; and
(v)
600,000 unlisted options to new Directors of the Company.
Other than as above, there have been no other conversions to, calls of, or subscriptions for Ordinary Shares or issues of potential Ordinary Shares since the reporting date and before the completion of this financial report.
14.
REVERSE ACQUISITION ACCOUNTING
On December 1, 2020, IperionX Limited (“Company”) completed its acquisition of Hyperion Metals (Australia) Pty Ltd (“HMAPL”) after issuing 26,500,000 ordinary shares, 5,000,000 unlisted options, 8,000,000 performance options and 36,000,000 performance shares in the Company to the vendors, being the shareholders of HMAPL, following shareholder approval received at the Company’s general meeting held on November 30, 2020.
As a result of the acquisition, the former shareholders of HMAPL effectively obtained control of the combined entity. Accordingly, using the reverse acquisition principles of the business combination accounting standard, while the Company is the legal acquirer of HMAPL, for accounting purposes HMAPL is deemed to be the acquirer of the Company.
F-22

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
14.
REVERSE ACQUISITION ACCOUNTING(Continued)
Therefore, the consolidated financial statements of the Company have been prepared as a continuation of the consolidated financial statements of HMAPL. The deemed acquirer, HMAPL, has accounted for the acquisition of the Company from December 1, 2020. As HMAPL was only incorporated during the financial period on July 20, 2020, there is no comparative period information for HMAPL.
In addition, at the date of the transaction, it was determined that the Company was not a business. Accordingly, for accounting purposes, the acquisition has been treated as a share-based payment transaction.
As a result of the reverse acquisition, during the period the Group has recognised an expense of US$5.1 million in its statement of profit or loss and other comprehensive income, effectively representing the cost of listing. The cost is calculated as the difference in the fair value of the equity instruments that HMAPL is deemed to have issued to acquire the Company and the fair value of the Company’s identifiable net assets, as follows:
 
December 1, 2020
US$
Fair value of consideration:
 
Equity(1)
7,401,334
Direct costs relating to the reverse acquisition
10,875
Cash option fee paid to HMAPL
(25,292)
Pre-acquisition loan to HMAPL
(331,471)
Fair value of consideration
7,055,446
 
 
Fair value of net assets acquired:
 
Cash and cash equivalents
1,983,223
Trade and other receivables
33,523
Trade and other payables
(102,426)
Fair value of net assets acquired
1,914,320
Cost of listing
5,141,126
 
 
Net cash inflow:
 
Net cash acquired on reverse acquisition
1,983,223
Direct costs relating to the reverse acquisition
(10,875)
Cash option fee paid to HMAPL
25,292
Pre-acquisition loan to HMAPL
331,471
Net consolidated cash inflow
2,329,111
Notes:
(1)
The fair value of the equity interests deemed to have been issued by HMAPL has been determined based on the underlying share price of the Company on ASX on the deemed date of acquisition (A$0.26 per share on December 1, 2020), adjusted by the fair value of share-based contingent consideration deemed to have been issued to the existing equity holders of the Company and the fair value of share-based contingent consideration issued to the equity holders of HMAPL, resulting in a deemed value of consideration of US$7,401,334, of which US$6,433,752 has been allocated to issued share capital (i.e. ordinary shares and performance shares) and US$967,582 has been allocated to share-based contingent consideration (i.e. listed options, unlisted options, and unlisted performance rights). Note 17 sets out the key assumptions adopted in the valuation of the unlisted options (Series 2-5) included as contingent consideration. In addition, a probability adjustment has been applied to the valuation of the performance shares and performance options included as contingent consideration reflecting the likelihood that the non-market performance conditions associated with them will vest (80% likelihood that the Pre-Feasibility Study Milestone will be achieved and a 20% likelihood that the First Production Milestone will be achieved).
F-23

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
15.
RELATED PARTIES
(a)
Subsidiaries
 
Country of
Incorporation
Equity Interest
2021
%
Hyperion Metals (Australia) Pty Ltd
Australia
100
TN Exploration LLC
United States
100
Hyperion Materials & Technologies LLC
United States
100
Calatos Pty Ltd LLC
United States
100
(b)
Ultimate Parent
IperionX Limited is the ultimate parent of the Group.
(c)
Key Management Personnel
The aggregate compensation made to Key Management Personnel of the Group is set out below:
 
2021
US$
Short-term employee benefits
275,246
Post-employment benefits
6,079
Share-based payments
3,681,159
Total compensation
3,962,484
No loans were provided to or received from Key Management Personnel during the period ended June 30, 2021.
Focus Capital Partners, LLC (“Focus Capital”), a company of which Mr Smith is a partner, was paid: (a) US$67,792 for the provision of services in relation to business development activities during the period, which has been recognised as an expense through profit or loss; and (b) US$25,493 in share placement fees during the period, which has been recognised as a share issue costs in equity.
(d)
Other transactions with Related Parties
Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note.
16.
PARENT ENTITY DISCLOSURES
 
2021
US$
2020
US$
(a) Financial Position
 
 
Assets
 
 
Current Assets
1,530,089
1,264,716
Non-Current Assets
340,969
868,521
Total Assets
1,871,058
2,133,237
 
 
 
Liabilities
 
 
Current Liabilities
110,938
69,672
Total Liabilities
110,938
69,672
 
 
 
F-24

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
16.
PARENT ENTITY DISCLOSURES(Continued)
 
2021
US$
2020
US$
Equity
 
 
Contributed equity
13,360,608
3,372,855
Reserves
5,723,616
845,282
Accumulated losses
(17,324,104)
(2,154,572)
Total Equity
1,760,120
2,063,565
 
 
 
(b)  Financial Performance
 
 
Loss for the period
(15,169,532)
(549,740)
Other comprehensive income
96,762
Total comprehensive loss
(15,072,770)
(549,740)
(c)
Other
No guarantees have been entered into by the parent entity in relation to its subsidiaries.
Refer to note 21 for details of contingent assets and liabilities.
17.
SHARE-BASED PAYMENTS
(a)
Recognised share-based payment expense
From time to time, the Group grants Restricted Stock Units, Unlisted Options and Performance Rights to officers, employees, consultants and other key advisors as part of remuneration and incentive arrangements. The number of Restricted Stock Units, Unlisted Options and Performance Rights granted, and the terms of the options or rights granted are determined by the Board. Shareholder approval is sought where required.
In addition, the Group has determined that the deemed consideration in respect of the reverse acquisition of the Company by HMAPL represents a share-based payment in accordance with IFRS 2 Share-based payments. The Group has determined the fair value of the deemed consideration to be US$7,055,446, of which US$1,914,320 of this has been allocated to the fair value of the net assets acquired and US$5,141,126 has been recognised as a share-based expense in the statement of profit and loss for the period, representing the cost of the listing. See note 14 for further details.
During the period, the following equity-settled share-based payments have been recognised:
 
2021
US$
Expense arising from staff remuneration arrangements
(4,084,764)
Expense arising from cost of listing on reverse acquisition
(5,141,126)
Total expense arising from equity-settled share-based payment transactions
(9,225,890)
F-25

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
17.
SHARE-BASED PAYMENTS(Continued)
(b)
Summary of securities granted as share-based payments
The following table illustrates the number and weighted average exercise prices (“WAEP”) of Unlisted Options and Performance Rights granted as share-based payments at the beginning and end of the financial period:
 
2021
Number
2021
WAEP
Outstanding at beginning of period
Recognition of legal acquirer Listed Options on reverse acquisition
15,693,334
A$0.20
Recognition of legal acquirer Unlisted Options on reverse acquisition
5,000,000
A$0.20
Recognition of legal acquirer Performance Rights on reverse acquisition
2,000,000
Unlisted Options granted to vendors of legal acquiree on reverse acquisition
13,000,000
A$0.20
Unlisted Options granted during the period
9,150,000
A$0.31
Performance Rights granted during the period
16,325,000
Listed Options exercised during the period
(3,069,120)
(A$0.20)
Unlisted Options exercised during the period
(1,350,000)
(A$0.24)
Performance Rights converted during the period
(2,000,000)
Outstanding at end of period
54,749,214
A$0.19
The following Unlisted Options and Performance Rights were granted as share-based payments during the period:
2021
Security Type
Number
Grant Date
Expiry Date
Exercise Price
A$
Vesting Hurdle
(30-day VWAP)
A$
Fair Value
A$
Series 1
Options
7,000,000
01-Dec-20
31-Dec-23
$0.25
$0.163
Series 2
Options
5,000,000
01-Dec-20
01-Dec-25
$0.20
$0.201
Series 3
Options
4,000,000
01-Dec-20
01-Dec-25
$0.20
$0.201
Series 4
Options
4,000,000
01-Dec-20
01-Dec-25
$0.20
$0.201
Series 5
Options
5,000,000
01-Dec-20
31-Dec-23
$0.20
$0.174
Series 6
Rights
150,000
03-Mar-21
01-Mar-26
$2.00
$0.694
Series 7
Rights
150,000
03-Mar-21
01-Mar-26
$3.00
$0.643
Series 8
Rights
150,000
03-Mar-21
01-Mar-26
$4.00
$0.602
Series 9
Rights
2,000,000
14-Apr-21
23-Apr-26
$2.00
$0.745
Series 10
Rights
2,000,000
14-Apr-21
23-Apr-26
$3.00
$0.693
Series 11
Rights
2,000,000
14-Apr-21
23-Apr-26
$4.00
$0.651
Series 12
Options
875,000
14-Apr-21
31-Dec-23
$0.45
$0.605
Series 13
Options
875,000
14-Apr-21
31-Dec-23
$0.55
$0.575
Series 14
Rights
125,000
15-Apr-21
23-Apr-24
$2.00
$0.599
Series 15
Rights
125,000
15-Apr-21
23-Apr-24
$3.00
$0.510
Series 16
Rights
125,000
15-Apr-21
23-Apr-24
$4.00
$0.445
Series 17
Rights
2,875,000
15-Apr-21
23-Apr-26
$2.00
$0.705
Series 18
Rights
2,875,000
15-Apr-21
23-Apr-26
$3.00
$0.654
Series 19
Rights
2,975,000
15-Apr-21
23-Apr-26
$4.00
$0.613
Series 20
Options
200,000
15-Apr-21
31-Dec-23
$0.45
$0.570
Series 21
Options
200,000
15-Apr-21
31-Dec-23
$0.55
$0.540
Series 22
Rights
258,333
22-Jun-21
23-Apr-26
$2.00
$0.821
Series 23
Rights
258,333
22-Jun-21
23-Apr-26
$3.00
$0.763
Series 24
Rights
258,334
22-Jun-21
23-Apr-26
$4.00
$0.716
F-26

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
17.
SHARE-BASED PAYMENTS(Continued)
(c)
Weighted Average Remaining Contractual Life
At June 30, 2021, the weighted average remaining contractual life of Listed Options, Unlisted Options and Performance Rights on issue that had been granted as share-based payments was 3.16 years.
(d)
Weighted Average Fair Value
The weighted average fair value of Unlisted Options and Performance Rights granted as share-based payments by the Group during the period ended June 30, 2021 was A$0.53.
(e)
Range of Exercise Prices
At June 30, 2021, the range of exercise prices of Listed and Unlisted Options on issue that had been granted as share-based payments was A$0.20 to A$0.55.
(f)
Weighted Average Share Price of Exercised Options
The weighted average share price at the date of exercise of Listed and Unlisted Options exercised during the period was A$0.90.
(g)
Option and Right Pricing Models
The fair value of Unlisted Options granted is estimated as at the date of grant using the Black Scholes option valuation model taking into account the terms and conditions upon which the Unlisted Options were granted. The fair value of Performance Rights granted that have market-based vesting conditions is estimated as at the date of grant using trinomial lattice valuation model taking into account the market based vesting criteria upon which the Performance Rights were granted. The fair value of Performance Rights granted that do not have market-based vesting conditions is estimated as at the date of grant on the underlying share price (being the five-day volume weighted average share price prior to issuance).
The tables below list the inputs to the valuation model used for Unlisted Options and Performance Rights granted by the Group during the period:
2021
Series 1
Series 2
Series 3
Series 4
Series 5
Series 6
Fair value at grant date
A$0.163
A$0.201
A$0.201
A$0.201
A$0.174
A$0.694
Share price at grant date
A$0.26
A$0.26
A$0.26
A$0.26
A$0.26
A$0.800
Vesting hurdle (30-day VWAP)
N/A
N/A
N/A
N/A
N/A
A$2.00
Exercise price
A$0.25
A$0.20
A$0.20
A$0.20
A$0.20
Nil
Expected life of options/rights1
3.08 years
5.00 years
5.00 years
5.00 years
3.10 years
5.00 years
Risk-free interest rate
0.10%
0.26%
0.26%
0.26%
0.10%
0.700%
Expected volatility2
100%
100%
100%
100%
100%
100%
Expected dividend yield3
2021
Series 7
Series 8
Series 9
Series 10
Series 11
Series 12
Fair value at grant date
A$0.643
A$0.602
A$0.745
A$0.693
A$0.651
A$0.605
Share price at grant date
A$0.800
A$0.800
A$0.850
A$0.850
A$0.850
A$0.850
Vesting hurdle (30-day VWAP)
A$3.00
A$4.00
A$2.00
A$3.00
A$4.00
N/A
Exercise price
Nil
Nil
Nil
Nil
Nil
A$0.450
Expected life of options/rights1
5.00 years
5.00 years
5.03 years
5.03 years
5.03 years
2.72 years
Risk-free interest rate
0.700%
0.700%
0.680%
0.680%
0.680%
0.105%
Expected volatility2
100%
100%
100%
100%
100%
100%
Expected dividend yield3
F-27

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
17.
SHARE-BASED PAYMENTS(Continued)
2021
Series 13
Series 14
Series 15
Series 16
Series 17
Series 18
Fair value at grant date
A$0.575
A$0.599
A$0.510
A$0.445
A$0.705
A$0.654
Share price at grant date
A$0.850
A$0.810
A$0.810
A$0.810
A$0.810
A$0.810
Vesting hurdle (30-day VWAP)
N/A
A$2.00
A$3.00
A$4.00
A$2.00
A$3.00
Exercise price
A$0.550
Nil
Nil
Nil
Nil
Nil
Expected life of options/rights1
2.72 years
3.02 years
3.02 years
3.02 years
5.02 years
5.02 years
Risk-free interest rate
0.105%
0.105%
0.105%
0.105%
0.690%
0.690%
Expected volatility2
100%
100%
100%
100%
100%
100%
Expected dividend yield3
2021
Series 19
Series 20
Series 21
Series 22
Series 23
Series 24
Fair value at grant date
A$0.613
A$0.570
A$0.540
A$0.821
A$0.763
A$0.716
Share price at grant date
A$0.810
A$0.810
A$0.810
A$0.930
A$0.930
A$0.930
Vesting hurdle (30-day VWAP)
A$4.00
N/A
N/A
A$2.00
A$3.00
A$4.00
Exercise price
Nil
A$0.450
A$0.550
Nil
Nil
Nil
Expected life of options/rights1
5.02 years
2.71 years
2.71 years
4.84 years
4.84 years
4.84 years
Risk-free interest rate
0.690%
0.105%
0.105%
0.820%
0.820%
0.820%
Expected volatility2
100%
100%
100%
100%
100%
100%
Expected dividend yield3
Notes:
(1)
The expected life is based on the expiry date of the options or rights.
(2)
The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome.
(3)
The dividend yield reflects the assumption that the current dividend payout will remain unchanged.
18.
SEGMENT INFORMATION
IFRS 8 requires operating segments to be identified on the basis of internal reports about components of the Consolidated Entity that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance.
The Consolidated Entity operates in one segment, being mineral exploration in the United States of America.
(a)
Reconciliation of non-current assets by geographical location
 
2021
US$
United States of America
1,044,369
 
1,044,369
19.
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES
(a)
Overview
The Group's principal financial instruments comprise receivables, payables, and cash. The main risks arising from the Group's financial instruments are interest rate risk, foreign currency risk, credit risk and liquidity risk.
This note presents information about the Group's exposure to each of the above risks, its objectives, policies and processes for measuring and managing risk, and the management of capital.
The Group manages its exposure to key financial risks in accordance with the Group's financial risk management policy. Key risks are monitored and reviewed as circumstances change (e.g. acquisition of a new project) and policies are revised as required. The overall objective of the Group's financial risk management policy is to support the delivery of the Group's financial targets whilst protecting future financial security.
F-28

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
19.
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES(Continued)
Given the nature and size of the business and uncertainty as to the timing and amount of cash inflows and outflows, the Group does not enter into derivative transactions to mitigate the financial risks. In addition, the Group's policy is that no trading in financial instruments shall be undertaken for the purposes of making speculative gains. As the Group's operations change, the Directors will review this policy periodically going forward.
The Board of Directors has overall responsibility for the establishment and oversight of the risk management framework. The Board reviews and agrees policies for managing the Group's financial risks as summarised below.
(b)
Credit Risk
Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations. This arises principally from cash and cash equivalents and receivables.
There are no significant concentrations of credit risk within the Group. The carrying amount of the Group's financial assets represents the maximum credit risk exposure, as represented below:
 
Note
2021
US$
Cash and cash equivalents
5
1,697,904
Trade and other receivables
 
341
 
 
1,698,245
With respect to credit risk arising from cash and cash equivalents, the Group's exposure arises from default of the counter party, with a maximum exposure equal to the carrying amount of these instruments.
Trade and other receivables comprise primarily deposits, accrued interest and GST refunds due. Where possible the Group trades only with recognised, creditworthy third parties. It is the Group's policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis with the result that the Group's exposure to bad debts is not significant. At June 30, 2021 none of the Group's receivables are past due.
(c)
Liquidity Risk
Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Board's approach to managing liquidity is to ensure, as far as possible, that the Group will always have sufficient liquidity to meet its liabilities when due. At June 30, 2021, the Group had sufficient liquid assets to meet its financial obligations.
The contractual maturities of financial liabilities, including estimated interest payments, are provided below. There are no netting arrangements in respect of financial liabilities.
 
≤1 year
US$
1-5 years
US$
≥5 years
US$
Total
contractual
cash flows
US$
Carrying
amount of
liabilities
US$
2021
 
 
 
 
 
Financial liabilities
 
 
 
 
 
Trade and other payables
544,842
544,842
544,842
Lease liabilities
115,067
461,903
576,970
475,652
 
659,909
461,903
1,121,812
1,020,494
(d)
Interest Rate Risk
The Group's exposure to the risk of changes in market interest rates relates primarily to the cash and short-term deposits with a floating interest rate. These financial assets with variable rates expose the Group to cash flow
F-29

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
19.
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES(Continued)
interest rate risk. All other financial assets and liabilities are either non-interest bearing (for example, receivables and payables) or have fixed interest rates (for example, lease liabilities, sub-lease receivables, and loans and borrowings).
At the reporting date, the interest rate profile of the Group's interest-bearing financial instruments was:
 
Note
2021
US$
Interest-bearing financial instruments
 
 
Cash at bank and on hand
5
1,697,904
Short term deposits
 
 
 
1,697,904
The Group's cash at bank and on hand and short-term deposits had a weighted average floating interest rate at period end of 0.25%.
The Group currently does not engage in any hedging or derivative transactions to manage interest rate risk.
Interest rate sensitivity
A sensitivity of 0.5% (50 basis points) has been selected as this is considered reasonable given the current level of both short term and long-term interest rates. A 0.5% (50 basis points) movement in interest rates at the reporting date would have increased (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency rates, remain constant.
 
Profit or loss
Equity
 
+0.5%
US$
-0.5%
US$
+0.5%
US$
-0.5%
US$
2021
 
 
 
 
Cash and cash equivalents
8,490
(8,490)
8,490
(8,490)
(e)
Foreign Currency Risk
Foreign currency risk is the risk that the fair value of future cash outflows of an exposure will fluctuate because of changes in foreign currency exchange rates.
The Group’s exposure to the risk of changes in foreign exchange rate relates primarily to assets and liabilities that are denominated in currencies other than US$. The Group also has transactional currency exposures relating to transactions denominated in currencies other than US$. The currency in which these transactions primarily are denominated is A$.
It is the Group’s policy not to enter into any hedging or derivative transactions to manage foreign currency risk.
At the reporting date, the Group’s exposure to financial instruments denominated in foreign currencies was:
A$ denominated financial assets and liabilities
2021
A$ exposure
(US$ Equivalent)
Financial assets
 
Cash and cash equivalents
1,560,370
Trade and other receivables
341
Financial liabilities
 
Trade and other payables
(110,938)
Lease liabilities
Net exposure
1,449,773
F-30

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
19.
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES(Continued)
(f)
Commodity Price Risk
The Group is exposed to commodity price risk. These commodity prices can be volatile and are influenced by factors beyond the Group's control. As the Group is currently engaged in exploration and development activities, no sales of commodities are forecast for the next 12 months, and accordingly, no hedging or derivative transactions have been used to manage commodity price risk.
(g)
Capital Management
The Board's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Given the stage of development of the Group, the Board's objective is to minimise debt and to raise funds as required through the issue of new shares. The Group is not subject to externally imposed capital requirements.
There were no changes in the Group's approach to capital management during the period.
(h)
Fair Value
The net fair value of financial assets and financial liabilities approximates their carrying value. The methods for estimating fair value are outlined in the relevant notes to the financial statements.
20.
CONTINGENT ASSETS AND LIABILITIES
At June 30, 2021, the Group had entered into exclusive option agreements with local landowners in Tennessee, United States, in relation to its Titan Project, which upon exercise, allows the Group to purchase or, in some cases lease, approximately 5,974 acres of surface property and the associated mineral rights from the local landowners. Upon exercise, in the case of an option to lease, the Company will pay a production royalty to the landowners, subject to a minimum royalty. Upon exercise, in the case of a purchase, the Company will pay cash consideration approximating the fair market value of the property, excluding the value of any minerals, plus a premium.
21.
EVENTS SUBSEQUENT TO BALANCE DATE
(a)
On 12 July 2021, the Company announced that PricewaterhouseCoopers was appointed as auditor of the Company following the resignation of BDO Audit (WA) Pty Ltd and ASIC’s consent to the resignation in accordance with section 329(5) of the Corporations Act 2001;
(b)
On 22 July 2021, the Company announced the execution of a memorandum of understanding (“MOU”) for a technology partnership with EOS GmbH (“EOS”), the world’s leading solution supplier in the field of industrial 3D printing (known as additive manufacturing, or AM) of metals and plastics;
(c)
On 31 August 2021, the Company completed a placement of 20 million shares at an issue price of A$1.20 per share to institutional, sophisticated and professional investors to raise gross proceeds of A$24.0 million (US$17.6 million) (“Placement”). The Placement was led by cornerstone investor, Fidelity Management & Research Company, an American multinational financial services corporation;
(d)
On October 21, 2021, the Company announced that it had purchased an option to acquire 100% of the ownership interests of Blacksand Technology, LLC on or before December 31, 2022. Blacksand holds the exclusive commercial licensing rights for more than forty global patents through a license agreement with the University of Utah including the global patents for the patented HAMR and GSD technologies that can produce low-cost and low carbon titanium metal;
(e)
On December 6, 2021, the Company announced that it had signed a memorandum of understanding with Chemours to investigate the potential supply to Chemours of up to 50,000 metric tons of ilmenite, 10,000 metric tons of rutile, and 10,000 metric tons of staurolite. Chemours operates one of the largest titanium dioxide plants at its New Johnsonville plant which is located approximately 20 miles from the Company’s Titan Project in Tennessee; and
F-31

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED JUNE 30, 2021(continued)
21.
EVENTS SUBSEQUENT TO BALANCE DATE(Continued)
(f)
On January 6, 2022, the Company announced that it plans to pursue a listing on a national securities exchange in the United States and will change its name to ‘IperionX Limited’;
(g)
On February 9, 2022, the Company changed its name from ‘Hyperion Metals Limited’ to ‘IperionX Limited’; and
(h)
The impact of the Coronavirus (COVID-19) pandemic is ongoing and while it has not significantly impacted the Company up to June 30, 2021, it is not practicable to estimate the potential impact, positive or negative, after the reporting date. The situation is rapidly developing and is dependent on measures imposed by the Australian, United States and other governments, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.
Other than as outlined above, as at the date of this report there are no other matters or circumstances which have arisen since June 30, 2021 that have significantly affected or may significantly affect:
the operations, in financial years subsequent to June 30, 2021, of the Group;
the results of those operations, in financial years subsequent to June 30, 2021, of the Group; or
the state of affairs, in financial years subsequent to June 30, 2021, of the Group.
F-32

TABLE OF CONTENTS

Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of IperionX Limited
Opinion on the Financial Statements
We have audited the accompanying consolidated statement of financial position of IperionX Limited (formerly Hyperion Metals Limited and Tao Commodities Limited) and its subsidiaries (the “Company”) as of 1 December 2020 and 30 June 2020, and the related consolidated statements of profit or loss and other comprehensive income, of changes in equity and of cash flows for the period ended 1 December 2020 and the year ended 30 June 2020, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of 1 December 2020 and 30 June 2020, and the results of its operations and its cash flows for the period ended 1 December 2020 and the year ended 30 June 2020 in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.
Change in Accounting Principle
As discussed in Note 1(d) to the consolidated financial statements, the Company changed the manner in which it accounts for exploration and evaluation expenditure in the year ended 30 June 2020.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ PricewaterhouseCoopers

PricewaterhouseCoopers
Perth, Australia
17 February 2022
We have served as the Company's auditor since 2021
F-33

TABLE OF CONTENTS

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020
 
Notes
1 Jul 2020 to
1 Dec 2020
A$
Restated(1)
1 Jul 2019 to
30 Jun 2020
A$
Continuing operations
 
 
 
Exploration and evaluation expenses
 
(60,828)
(122,778)
Corporate and administrative expenses
 
(366,600)
(678,772)
Share based payment expenses
 
(87,458)
(89,783)
Finance income
2
3,870
22,651
Finance costs
2
(4,775)
Impairment expenses
2
(464,205)
Other income/(expenses)
2
(66,820)
4,560
Loss before income tax
 
(1,042,041)
(868,897)
Income tax expense
3
Loss for the period
 
(1,042,041)
(868,897)
Loss attributable to members of IperionX Limited
 
(1,042,041)
(868,897)
 
 
 
 
Other comprehensive income
 
 
 
Items that may be reclassified subsequently to profit or loss:
 
 
 
Exchange differences arising on translation of foreign operations
 
(33,566)
9,448
Other comprehensive income/(loss) for the period, net of tax
 
(33,566)
9,448
Total comprehensive loss for the period
 
(1,075,607)
(859,449)
Total comprehensive loss attributable to members of IperionX Limited
 
(1,075,607)
(859,449)
 
 
 
 
Basic loss per share (A$ per share)
12
(0.03)
(0.03)
Diluted loss per share (A$ per share)
12
(0.03)
(0.03)
Notes:
(1)
With effect from 1 July 2019, the policy for accounting for exploration expenditure has changed from the policy applied in previous reporting periods (refer Note 1(d)).
The above Consolidated Statement of Profit or Loss and other Comprehensive Income should be read in conjunction with the
accompanying notes.
F-34

TABLE OF CONTENTS

CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AT 1 DECEMBER 2020 AND 30 JUNE 2020
 
Notes
1 Dec 2020
A$
Restated(1)
30 Jun 2020
A$
ASSETS
 
 
 
Current Assets
 
 
 
Cash and cash equivalents
5
2,717,623
1,649,187
Trade and other receivables
 
19,608
42,438
Loan to Hyperion Metals (Australia) Pty Ltd
 
449,879
Prepayments
 
24,875
Total Current Assets
 
3,187,110
1,716,500
 
 
 
 
Non-Current Assets
 
 
 
Exploration and evaluation assets
6
487,743
Property, plant and equipment
 
30,800
Total Non-Current Assets
 
518,543
TOTAL ASSETS
 
3,187,110
2,235,043
 
 
 
 
LIABILITIES
 
 
 
Current Liabilities
 
 
 
Trade and other payables
7
139,075
68,602
Lease liabilities
8
25,960
Total Current Liabilities
 
139,075
94,562
TOTAL LIABILITIES
 
139,075
94,562
 
 
 
 
NET ASSETS
 
3,048,035
2,140,481
 
 
 
 
EQUITY
 
 
 
Contributed equity
9
5,673,818
4,577,708
Reserves
10
1,091,451
1,191,666
Accumulated losses
11
(3,717,234)
(3,628,893)
TOTAL EQUITY
 
3,048,035
2,140,481
Notes:
(1)
With effect from 1 July 2019, the policy for accounting for exploration expenditure has changed from the policy applied in previous reporting periods (refer Note 1(d)).
The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.
F-35

TABLE OF CONTENTS

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020
 
Contributed
Equity
Share Based
Payments
Reserve
A$
Option
Premium
Reserve
A$
Foreign Currency
Translation
Reserve
A$
Accumulated
Losses
A$
Total
Equity
A$
Balance at 1 July 2020 (restated)(1)
4,577,708
993,483
153,750
44,433
(3,628,893)
2,140,481
Net loss for the period
(1,042,041)
(1,042,041)
Exchange differences arising on translation of foreign operations
(33,566)
(33,566)
Total comprehensive loss for the period
(33,566)
(1,042,041)
(1,075,607)
Share placements
2,000,000
2,000,000
Share issue costs
(991,500)
871,500
(120,000)
Conversion of performance rights
87,610
(87,600)
10
Issue of listed options
15,693
15,693
Expiry of unlisted options
(953,700)
953,700
Share based payments
87,458
87,458
Balance at 1 December 2020
5,673,818
911,141
169,443
10,867
(3,717,234)
3,048,035
 
 
 
 
 
 
 
Balance at 1 July 2019
4,527,708
953,700
153,750
56,941
(2,178,110)
3,513,989
Effect of change in accounting policy(1)
(21,956)
(581,886)
(603,842)
Balance at 1 July 2019 (restated)(1)
4,527,708
953,700
153,750
34,985
(2,759,996)
2,910,147
Net loss for the period
(868,897)
(868,897)
Exchange differences arising on translation of foreign operations
9,448
9,448
Total comprehensive loss for the period
9,448
(868,897)
(859,449)
Share based payments
50,000
39,783
89,783
Balance at 30 June 2020
(restated)(1)
4,577,708
993,483
153,750
44,433
(3,628,893)
2,140,481
Notes:
(1)
With effect from 1 July 2019, the policy for accounting for exploration expenditure has changed from the policy applied in previous reporting periods (refer Note 1(d)).
The above Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.
F-36

TABLE OF CONTENTS

CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020
 
Notes
1 Jul 2020
to
1 Dec 2020
A$
Restated(1)
1 Jul 2019 to
30 Jun 2020
A$
Operating activities
 
 
 
Payments to suppliers and employees
 
(393,110)
(809,330)
Interest paid
 
(4,775)
Interest received
 
3,870
22,651
Other income
 
12,456
12,156
Net cash flows used in operating activities
5
(376,784)
(779,298)
 
 
 
 
Investing activities
 
 
 
Loan to Hyperion Metals (Australia) Pty Ltd
 
(449,879)
Purchase of property, plant and equipment
 
(604)
(6,423)
Net cash flows used in investing activities
 
(450,483)
(6,423)
 
 
 
 
Financing activities
 
 
 
Proceeds from issue of shares
9(a)
2,000,000
Share issue costs
9(a)
(120,000)
Proceeds from conversion of performance rights
 
10
Proceeds from issue of options
 
15,693
Payment of principal portion of lease liabilities
 
(31,225)
Net cash flows from financing activities
 
1,895,703
(31,225)
 
 
 
 
Net increase/(decrease) in cash and cash equivalents
 
1,068,436
(816,946)
Net foreign exchange differences
 
Cash and cash equivalents at beginning of period
 
1,649,187
2,466,133
Cash and cash equivalents at the end of the period
5
2,717,623
1,649,187
Notes:
(1)
With effect from 1 July 2019, the policy for accounting for exploration expenditure has changed from the policy applied in previous reporting periods (refer Note 1(d)).
The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.
F-37

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES
The significant accounting policies adopted in preparing the consolidated financial statements of IperionX Limited (formerly Hyperion Metals Limited and ‘Tao Commodities Limited’) (“IperionX” or “Company”) and its consolidated entities (“Consolidated Entity” or “Group”) for the periods from 1 July 2020 to 1 December 2020 and 1 July 2019 to 30 June 2020 are stated to assist in a general understanding of the consolidated financial statements.
IperionX is a for-profit company limited by shares, incorporated and domiciled in Australia. Our registered office is located at Level 9, 28 The Esplanade, Perth, Western Australia, 6000. Our ordinary shares are listed on the Australian Securities Exchange, or ASX, under the symbol “HYM” (formerly under the symbol “TAO”).
The principal activities of the Group during the period 1 July 2020 to 1 December 2020 and the year ended 30 June 2020 consisted of the exploration and development of mineral resource projects.
The consolidated financial statements of the Group for the periods from 1 July 2020 to 1 December 2020 and 1 July 2019 to 30 June 2020 were authorised for issue in accordance with a resolution of the Directors on February 17, 2022.
(a)
Basis of preparation
The consolidated financial statements are general purpose financial statements, which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).
On December 1, 2020, the Company acquired 100% of Hyperion Metals (Australia) Pty Ltd (“HMAPL”). The transaction was accounted for as a reverse acquisition with HMAPL as the accounting acquirer. Therefore, these consolidated financial statements present the results of the Company for the five-month period prior to the acquisition from July 1, 2020 to December 1, 2020, being the date HMAPL is deemed for accounting to have acquired the Company. The comparative financial statements present the results for the twelve-month period from July 1, 2019 to June 30, 2020. As a result, the amounts presented for the current period are not comparable with the prior period amounts.
The financial report has also been prepared on a historical cost basis, except for other financial assets, which have been measured at fair value.
The financial report is presented in Australian dollars (A$), which is also the functional currency of the Company.
The financial statements have been prepared on the going concern basis, which contemplates the continuity of normal business activity and the realisation of assets and the settlement of liabilities in the normal course of business.
(b)
New standards, interpretations and amendments
In the current period, the Group has adopted all Accounting Standards and Interpretations issued by the IASB that are effective from 1 July 2020. New and revised standards and amendments thereof and interpretations effective for the current reporting period that are relevant to the Group include:
Definition of a Business (Amendments to IFRS 3)
Definition of Material (Amendments to IAS 1 and IAS 8)
Amendments to References to the Conceptual Framework in IFRS Standards
The adoption of the aforementioned standards has no impact on the financial statements of the Company as at 1 December 2020. The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective.
F-38

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
(c)
Issued standards and interpretations not early adopted
Accounting Standards and Interpretations that have recently been issued or amended by the IASB but are not yet effective have not been adopted by the Group for the reporting period ended 1 December 2020. Those which may be relevant to the Group are set out in the table below, but these are not expected to have any significant impact on the Group's financial statements:
Standard/Interpretation
Application Date of
Standard
Application Date for
the Group
Annual Improvements to IFRS Standards 2018–2020
January 1, 2022
July 1, 2022
Classification of Liabilities as Current or Non-Current (Amendments to IAS 1)
January 1, 2023
July 1, 2023
Classification of Liabilities as Current or Non-current — Deferral of Effective Date (Amendment to IAS 1)
January 1, 2023
July 1, 2023
(d)
Changes in Accounting Policy
The policy for accounting for exploration and evaluation expenditure has changed from the policy applied in previous reporting periods.
In previous reporting periods, the costs incurred in connection with the exploration and evaluation of areas with current rights of tenure were capitalised to the Statement of Financial Position. The criteria for carrying forward the costs were:
Such costs are expected to be recouped through successful development and exploitation of the area of interest, or alternatively by its sale; or
Exploration and evaluation activities in the area of interest have not yet reached a stage which permits a reasonable assessment of the existence or otherwise of economically recoverable reserves, and active and significant operations in, or in relation to, the area are continuing.
Costs carried forward in respect of an area of interest that was abandoned were written off in the year in which the decision to abandon was made.
The policy has changed, and the new policy has been applied retrospectively (with comparative information restated accordingly). Under the new policy, except as noted below, exploration and evaluation expenditure is expensed to the Statement of Profit or Loss and other Comprehensive Income as and when it is incurred.
Exploration and evaluation costs are only capitalised to the Statement of Financial Position if they result from an acquisition of a project. Exploration and evaluation costs, subsequent to the acquisition of the rights to explore, will now be expensed as incurred, up and until the preparation of a technical feasibility study.
The Directors are of the opinion that the change in accounting policy provides users with more relevant and no less reliable information as the policy is more transparent and less subjective. The policy is common of smaller exploration companies as exploration and evaluation expenditure is viewed as an ongoing expense of discovery, until a technical feasibility study has been completed.
The impact of this change in accounting policy is reflected below:
Consolidated statement of financial position
As previously reported
at 1 July 2019
$
Effect of change in
accounting policy
$
As adjusted at
1 July 2019
$
Exploration and evaluation assets
1,081,149
(603,843)
477,306
Foreign currency translation reserve
56,941
(21,956)
34,985
Accumulated losses
(2,178,110)
(581,886)
(2,759,996)
F-39

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
Consolidated statement of financial position
30 June 2020
A$
Decrease in exploration and evaluation assets
(737,153)
Increase/(decrease) in equity
(737,153)
Consolidated statement of profit or loss and other comprehensive income
Year Ended
30 June 2020
A$
Increase in exploration and evaluation expenses
(122,778)
Increase/(decrease) in profit or loss
(122,778)
Basic and diluted loss per share have also been restated. The amount of the impact on basic and diluted loss per share for the new result for the year ended 30 June 2020 due to the change in accounting policy is an increase in loss per share to 2.8 cents.
The impact of the change in accounting policy has not been quantified for the current period as these accounting records have not been maintained.
(e)
Principles of Consolidation
The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of the Company as at 1 December 2020 and 30 June 2020.
Control is achieved when the Company has power over the investee, is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to use its power to affect its returns. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. When the Company has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company's voting rights in an investee are sufficient to give it power.
Subsidiaries are all those entities (including special purpose entities) over which the Company has the power to govern the financial and operating policies, so as to obtain benefits from its activities, generally accompanying a shareholding of more than one-half of the voting rights. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Company controls another entity.
The financial statements of the subsidiaries are prepared for the same reporting period as the Company, using consistent accounting policies. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Company.
Subsidiaries are fully consolidated from the date on which control is transferred to the Company. They are de-consolidated from the date that control ceases.
Intercompany transactions and balances, income and expenses and profits and losses between Group companies, are eliminated. Investments in subsidiaries are accounted for at cost in the Statement of Financial Position of the Company.
(f)
Foreign Currencies
(i)
Functional and presentation currency
The functional currency of each of the Group's entities is measured using the currency of the primary economic environment in which that entity operates.
F-40

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
(ii)
Transactions and balances
Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the date of the transaction. Foreign currency monetary items are translated at the year-end exchange rate. Non-monetary items measured at historical cost continue to be carried at the exchange rate at the date of the transaction. Non-monetary items measured at fair value are reported at the exchange rate at the date when fair values were determined.
Exchange differences arising on the translation of monetary items are recognised in the income statement, except where deferred in equity as a qualifying cash flow or net investment hedge.
Exchange differences arising on the translation of non-monetary items are recognised directly in equity to the extent that the gain or loss is directly recognised in equity, otherwise the exchange difference is recognised in the income statement.
(iii)
Group companies
The financial results and position of foreign operations whose functional currency is different from the group's presentation currency are translated as follows:
assets and liabilities are translated at year-end exchange rates prevailing at that reporting date;
income and expenses are translated at average exchange rates for the period; and
retained earnings are translated at the exchange rates prevailing at the date of the transaction.
Exchange differences arising on translation of foreign operations are transferred directly to the group's foreign currency translation reserve in equity. These differences are recognised in profit or loss in the period in which the operation is disposed.
(g)
Cash and Cash Equivalents
Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of 3 months or less, and bank overdrafts.
(h)
Trade and Other Receivables
Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less allowance for expected credit losses, applying the simplified approach. If collection of the amounts is expected in one year or less, they are classified as current assets. If not, they are presented as non-current assets. Trade receivables are generally due for settlement within 30 days and therefore are all classified as current.
As the majority of receivables are short term in nature, their carrying amount is assumed to be the same as their fair value.
(i)
Property, Plant and Equipment
All classes of property, plant and equipment are measured at cost.
Depreciation is provided on a straight-line basis over the estimated useful lives of the assets, except for land which is not depreciated.
 
1 Dec 2020
30 Jun 2020
Major depreciation periods are:
 
 
Plant and equipment:
5 years
5 years
(j)
Exploration and Development Expenditure
Expenditure on exploration and evaluation is accounted for in accordance with the 'area of interest' method and with IFRS 6 Exploration for and Evaluation of Mineral Resources.
F-41

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
Exploration and evaluation expenditure encompasses expenditures incurred by the Group in connection with the exploration for and evaluation of mineral resources before the technical feasibility and commercial viability of extracting a mineral resource are demonstrable.
For each area of interest, expenditure incurred in the acquisition of rights to explore is capitalised and recognised as an exploration and evaluation asset. This includes option payments made to landowners under the Group’s option agreements with local landowners which are considered part of the acquisition costs. Exploration and evaluation assets are measured at cost at recognition and are recorded as an asset if:
(i)
the rights to tenure of the area of interest are current; and
(ii)
at least one of the following conditions is also met:
the exploration and evaluation expenditures are expected to be recouped through successful development and exploitation of the area of interest, or alternatively, by its sale; and
exploration and evaluation activities in the area of interest have not at the reporting date reached a stage which permits a reasonable assessment of the existence or otherwise of economically recoverable reserves, and active and significant operations in, or in relation to, the area of interest are continuing.
All other exploration and evaluation expenditures are expensed as incurred. Once the technical feasibility and commercial viability of a program or project has been demonstrated with a bankable feasibility study, the carrying amount of the exploration and evaluation expenditure in respect of the area of interest is reclassified as a “mine development property” and future expenditure incurred in the development of that area of interest is accounted for in accordance with the Group’s policy for Property, Plant & Equipment, as described in Note 1(i).
Impairment
Capitalised exploration costs are reviewed each reporting date to establish whether an indication of impairment exists. If any such indication exists, the recoverable amount of the capitalised exploration costs is estimated to determine the extent of the impairment loss (if any). Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but only to the extent that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset in previous years.
Where a decision is made to proceed with development, accumulated expenditure is tested for impairment and transferred to development properties, and then amortised over the life of the reserves associated with the area of interest once mining operations have commenced. Recoverability of the carrying amount of the exploration and evaluation assets is dependent on successful development and commercial exploitation, or alternatively, sale of the respective areas of interest.
(k)
Trade and other payables
These amounts represent liabilities for goods and services provided to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured and are usually paid within 60 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting date.
They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method.
The carrying amounts of trade and other payables are considered to be the same as their fair values, due to their short-term nature.
(l)
Provisions
Provisions are recognised when the Group has a legal or constructive obligation, as a result of past events, for which it is probable that an outflow of economic benefits will result and that outflow can be reliably measured.
F-42

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
(m)
Interest income
Interest income is recognised on a time proportionate basis that takes into account the effective yield on the financial asset.
(n)
Government grant income
Government grants are recognised when there is reasonable assurance that the Group will comply with the conditions attaching to the grant and that the grant will be received. Government grants are recognised in profit or loss on a systematic basis over the periods in which the entity recognises as expenses the related costs for which grants are intended to compensate. If the grant relates to expenses or losses already incurred by the entity, or to provide immediate financial support to the entity with no future related costs, the income is recognised in the period in which it becomes receivable.
(o)
Income Tax
The income tax expense for the period is the tax payable on the current period's taxable income based on the national income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements, and to unused tax losses.
Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates which are enacted or substantively enacted for each jurisdiction. The relevant tax rates are applied to the cumulative amounts of deductible and taxable temporary differences to measure the deferred tax asset or liability. An exception is made for certain temporary differences arising from the initial recognition of an asset or a liability. No deferred tax asset or liability is recognised in relation to these temporary differences if they arose on goodwill or in a transaction, other than a business combination, that at the time of the transaction did not affect either accounting profit or taxable profit or loss.
Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in controlled entities where the Company is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.
Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.
The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised.
Unrecognised deferred income tax assets are reassessed at each balance date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.
Current and deferred tax balances attributable to amounts recognised directly in equity are also recognised directly in equity.
Deferred tax assets and deferred tax liabilities are offset only if a legally enforceable right exists to set off current tax assets against tax liabilities and the deferred tax liabilities relate to the same taxable entity and the same taxation authority.
(p)
Employee Entitlements
Provision is made for the Group's liability for employee benefits arising from services rendered by employees to balance date. Employee benefits that are expected to be settled wholly within 12 months have been measured at the amounts expected to be paid when the liability is settled, plus related on-costs. Employee benefits payable later than 12 months have been measured at the present value of the estimated future cash outflows to be made for those benefits.
F-43

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
(q)
Earnings per Share
Basic earnings per share (“EPS”) is calculated by dividing the net profit attributable to members of the Company for the reporting period, after excluding any costs of servicing equity, by the weighted average number of ordinary shares of the Company, adjusted for any bonus issue.
Diluted EPS is calculated by dividing the basic EPS earnings, adjusted by the after tax effect of financing costs associated with dilutive potential Ordinary Shares and the effect on revenues and expenses of conversion to Ordinary Shares associated with dilutive potential Ordinary Shares, by the weighted average number of Ordinary Shares and dilutive Ordinary Shares adjusted for any bonus issue.
(r)
Goods and Services Tax
Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Tax Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of the expense. Receivables and payables in the Statement of Financial Position are shown inclusive of GST. Cash flows are presented in the Statement of Cash Flows on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.
(s)
Use and Revision of Accounting Estimates, Judgements and Assumptions
The preparation of the financial report requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
In particular, information about significant areas of estimation uncertainty and critical judgements in applying accounting policies that have the most significant effect on the amount recognised in the financial statements are described in the following note:
Recognition of tax losses (Note 3);
Write-off of exploration and evaluation expenditures (Note 2); and
Share-based payments (Note 15).
(t)
Operating Segments
An operating segment is a component of an entity that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity), whose operating results are regularly reviewed by the entity's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance and for which discrete financial information is available. This includes start up operations which are yet to earn revenues. Management will also consider other factors in determining operating segments such as the existence of a line manager and the level of segment information presented to the board of directors.
Operating segments have been identified based on the information provided to the chief operating decision makers, being the board of directors.
The group aggregates two or more operating segments when they have similar economic characteristics, and the segments are similar in each of the following respects:
Nature of the products and services,
Nature of the production processes,
F-44

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
1.
STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES(Continued)
Type or class of customer for the products and services,
Methods used to distribute the products or provide the services, and if applicable,
Nature of the regulatory environment.
Operating segments that meet the quantitative criteria as prescribed by IFRS 8 Operating Segments are reported separately. However, an operating segment that does not meet the quantitative criteria is still reported separately where information about the segment would be useful to users of the financial statements.
Information about other business activities and operating segments that are below the quantitative criteria are combined and disclosed in a separate category for “all other segments”.
(u)
Impairment of Assets
The Group assesses at each reporting date whether there is an indication that an asset may be impaired. If any such indication exists, or when annual impairment testing for an asset is required, the Group makes an estimate of the asset's recoverable amount. An asset's recoverable amount is the higher of its fair value less costs to sell and its value in use and is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets and the asset's value in use cannot be estimated to be close to its fair value. In such cases the asset is tested for impairment as part of the cash-generating unit to which it belongs. When the carrying amount of an asset or cash-generating unit exceeds its recoverable amount, the asset or cash-generating unit is considered impaired and is written down to its recoverable amount.
In assessing the value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.
An assessment is also made at each reporting date as to whether there is any indication that previously recognised impairment losses may no longer exist or may have decreased. If such indication exists, the recoverable amount is estimated. A previously recognised impairment loss is reversed only if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised. If that is the case the carrying amount of the asset is increased to its recoverable amount. That increased amount cannot exceed the carrying amount that would have been determined, net of depreciation, had no impairment loss been recognised for the asset in prior years. After such a reversal the depreciation charge is adjusted in future periods to allocate the asset's revised carrying amount, less any residual value, on a systematic basis over its remaining useful life.
(v)
Fair Value Estimation
The fair value of financial assets and financial liabilities must be estimated for recognition and measurement or for disclosure purposes.
The fair value of financial instruments traded in active markets (such as publicly traded derivatives, and equity securities classified as fair value through other comprehensive income) is based on quoted market prices at the reporting date. The quoted market price used for financial assets held by the Group is the current bid price; the appropriate quoted market price for financial liabilities is the current ask price.
The fair value of financial instruments that are not traded in an active market (for example, over the counter derivatives) is determined using valuation techniques. The Group uses a variety of methods and makes assumptions that are based on market conditions existing at each balance date. Quoted market prices or dealer quotes for similar instruments are used for long-term debt instruments held. Other techniques, such as discounted cash flows, are used to determine fair value for the remaining financial instruments. The fair value of interest-rate swaps is calculated as the present value of the estimated future cash flows. The fair value of forward exchange contracts is determined using forward exchange market rates at the reporting date.
F-45

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
The nominal value less estimated credit adjustments of trade receivables and payables are assumed to approximate their fair values. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Group for similar financial instruments.
(w)
Issued and Unissued Capital
Ordinary Shares and Performance Shares are classified as equity. Issued and paid up capital is recognised at the fair value of the consideration received by the Company. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.
(x)
Dividends
Provision is made for the amount of any dividend declared on or before the end of the year but not distributed at balance date.
(y)
Share-Based Payments
Equity-settled share-based payments are provided to officers, employees, consultants and other advisors. These share-based payments are measured at the fair value of the equity instrument at the grant date. Fair value is determined using the Black Scholes option pricing model for options and the barrier up-and-in trinomial pricing model with a Parisian barrier adjustment for rights. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the Company's estimate of equity instruments that will eventually vest. At each reporting date, the Company revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognised in profit or loss over the remaining vesting period, with a corresponding adjustment to the share-based payments reserve.
Equity-settled share-based payments may also be provided as consideration for the acquisition of assets. Where ordinary shares are issued, the transaction is recorded at fair value based on the quoted price of the ordinary shares at the date of issue. The acquisition is then recorded as an asset or expensed in accordance with accounting standards.
2.
INCOME AND EXPENSES
 
1 Dec 2020
A$
30 Jun 2020
A$
Finance income
 
 
Interest income
3,870
22,651
 
3,870
22,651
 
 
 
Finance costs
 
 
Interest on lease liabilities
(4,775)
 
(4,775)
 
 
 
Impairment expenses
 
 
Write-off of exploration and evaluation assets(1)
(454,309)
Write-off of property, plant and equipment
(6,896)
Write-off of trade and other receivables
(3,000)
 
(464,205)
 
 
 
Other income and expenses
 
 
Grant income(2)
12,456
37,368
Gain on derecognition of right-of-use assets
1,453
Depreciation and amortisation
(32,808)
Transaction costs related to acquisition of HMAPL
(80,729)
 
(66,820)
4,560
F-46

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
 
1 Dec 2020
A$
30 Jun 2020
A$
 
 
 
Employee benefits expense
 
 
Wages, salaries and other payroll expenses
(143,400)
(312,611)
Share-based payments expense
(87,458)
(39,784)
 
(230,858)
(352,395)
Notes:
(1)
During the period, the Group made the decision to write-off all capitalised exploration costs associated with the Milford Project on the basis that minimal future exploration and evaluation expenditures are planned for the Milford Project. Refer to Note 6 for further details.
(2)
During the period ended 1 December 2020 and the year ended 30 June 2020, the Group received a cash flow boost from the Australian Government as part of temporary cash flow support to businesses that employ staff during the economic downturn associated with COVID-19.
3.
INCOME TAX
 
1 Dec 2020
A$
30 Jun 2020
A$
Recognised in profit or loss
 
 
Current income tax:
 
 
Current income tax benefit in respect of the current period
Deferred income tax:
 
 
Origination and reversal of temporary differences
Income tax expense reported in profit or loss
 
 
 
Reconciliation between tax expense and accounting loss before income tax
 
 
Accounting loss before income tax
(1,042,041)
(868,897)
At the Australian income tax rate of 30% (2020: 30%)
(312,612)
(260,669)
Expenditure not allowable for income tax purposes
186,749
119,726
Income not assessable for income tax purposes
(11,210)
Other temporary differences
(31,992)
Effect of deferred tax assets not brought to account
125,863
184,145
Income tax expense reported in profit or loss
 
 
 
Deferred Tax Assets and Liabilities
 
 
Deferred Tax Liabilities:
 
 
Other temporary differences
7,462
Deferred tax assets used to offset deferred tax liabilities
(7,462)
 
Deferred Tax Assets:
 
 
Property, plant and equipment
436
Capital allowances
54,459
Other temporary differences
24,300
9,307
Tax losses available to offset against future taxable income
552,891
467,830
Deferred tax assets used to offset deferred tax liabilities
(7,462)
Deferred tax assets not brought to account (1)
(577,191)
(524,570)
 
Notes:
(1)
The benefit of deferred tax assets not brought to account will only be brought to account if: (a) future assessable income is derived of a nature and of an amount sufficient to enable the benefit to be realised; (b) the conditions for deductibility imposed by tax legislation continue to be complied with; and (c) no changes in tax legislation adversely affect the Group in realising the benefit.
F-47

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
4.
DIVIDENDS PAID OR PROVIDED FOR ON ORDINARY SHARES
No dividends have been paid or proposed for the period ended 1 December 2020 (30 June 2020: Nil).
5.
CASH AND CASH EQUIVALENTS
 
1 Dec 2020
A$
30 Jun 2020
A$
Cash at bank and on hand
2,717,623
1,649,187
 
2,717,623
1,649,187
 
 
 
Reconciliation of loss before income tax to net cash flows from operations
 
 
Loss for the period
(1,042,041)
(868,897)
Adjustment for non-cash income and expense items
 
 
Share based payment expenses
87,458
89,783
Write-off of exploration and evaluation assets
454,309
Write-off of property, plant and equipment
6,897
Gain on derecognition of right-of-use assets
(1,453)
Amortisation of right-of-use assets
32,678
Depreciation of property, plant and equipment
130
Change in assets and liabilities
 
 
(Increase)/decrease in trade and other receivables
22,830
(27,307)
(Increase)/decrease in prepayments
24,875
(4,991)
(Decrease)/increase in trade and other payables
70,341
(694)
Net cash outflow from operating activities
(376,784)
(779,298)
6.
EXPLORATION AND EVALUATION ASSETS
 
Milford Project(1)
A$
1 December 2020
 
Carrying amount at 1 July 2020 (restated)
487,742
Foreign exchange differences
(33,433)
Write-off(2)
(454,309)
Carrying amount at 1 December 2020(3)
 
 
30 June 2020
 
Carrying amount at 1 July 2019 (restated)
477,306
Foreign exchange differences
10,436
Carrying amount at 30 June 2020 (restated)(3)
487,742
Notes:
(1)
At 1 December 2020, the Milford Project comprised 100 Mining Rights on U.S. Bureau of Land Management (“BLM”) administered land, situated approximately 6 kilometres west of the town of Milford in Utah, United States. The Milford Project is considered prospective for epithermal and replacement style precious and base metal mineralisation along structural corridors in reactive host rocks.
(2)
During the period, the Group made the decision to write-off all capitalised exploration costs associated with the Milford Project, being a total of A$454,309, on the basis that minimal future exploration and evaluation expenditures are planned for the Milford Project.
(3)
The ultimate recoupment of costs carried forward for exploration and evaluation is dependent on the successful development and commercial exploitation or sale of the respective areas of interest.
F-48

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
7.
TRADE AND OTHER PAYABLES
 
1 Dec 2020
A$
30 Jun 2020
A$
Current
 
 
Trade payables
46,119
11,478
Accruals
81,000
26,404
Payroll liabilities
11,956
30,720
Total trade and other payables
139,075
68,602
8.
LEASES
The Group leases office premises in Australia. The carrying amounts of right-of-use assets are included under property, plant and equipment in the Statement of Financial Position. The carrying amounts of lease liabilities are set out in the Statement of Financial Position. The following are the amounts recognised in profit or loss in respect of leases:
 
1 Dec 2020
A$
30 Jun 2020
A$
Depreciation of right-of-use assets
(32,678)
Interest expense on lease liabilities
(4,775)
Net amount recognised in profit or loss
(37,453)
9.
CONTRIBUTED EQUITY
 
Note
1 Dec 2020
A$
30 Jun 2020
A$
Issued capital
 
 
 
57,386,667 fully paid ordinary shares1 (2020: 31,386,667)
9(a)
5,673,818
4,577,708
Notes:
(1)
Ordinary shares have no par value and the Company does not have a limited amount of authorised capital.
(a)
Movements in issued capital
 
Number of
Ordinary Shares
A$
1 December 2020
 
 
Opening balance at 1 July 2020
31,386,667
4,577,708
Issue of shares – share placement (December 2020)
25,000,000
2,000,000
Issue of shares – conversion of performance rights
1,000,000
87,610
Share issue costs
(991,500)
Closing balance at 1 December 2020
57,386,667
5,673,818
 
 
 
30 June 2020
 
 
Opening balance at 1 July 2019
30,970,000
4,527,708
Issue of shares – option fee
416,667
50,000
Closing balance at 30 June 2020
31,386,667
4,577,708
F-49

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
9.
CONTRIBUTED EQUITY(Continued)
(b)
Rights attaching to ordinary shares
The rights attaching to fully paid ordinary shares (“Shares”) arise from a combination of the Company's Constitution, statute and general law. Shares issued following the exercise of Unlisted Options or conversion of Performance Rights in will rank equally in all respects with the Company's existing Shares.
(i)
Shares - The issue of shares in the capital of the Company and options over unissued shares by the Company is under the control of the directors, subject to the Corporations Act 2001, ASX Listing Rules and any rights attached to any special class of shares.
(ii)
Meetings of Members - Directors may call a meeting of members whenever they think fit. Members may call a meeting as provided by the Corporations Act 2001.The Constitution contains provisions prescribing the content requirements of notices of meetings of members and all members are entitled to a notice of meeting. A meeting may be held in two or more places linked together by audio-visual communication devices. A quorum for a meeting of members is 2 shareholders. The Company holds annual general meetings in accordance with the Corporations Act 2001 and the Listing Rules.
(iii)
Voting - Subject to any rights or restrictions at the time being attached to any shares or class of shares of the Company, each member of the Company is entitled to receive notice of, attend and vote at a general meeting. Resolutions of members will be decided by a show of hands unless a poll is demanded. On a show of hands each eligible voter present has one vote. However, where a person present at a general meeting represents personally or by proxy, attorney or representative more than one member, on a show of hands the person is entitled to one vote only despite the number of members the person represents. On a poll each eligible member has one vote for each fully paid share held and a fraction of a vote for each partly paid share determined by the amount paid up on that share.
(iv)
Changes to the Constitution - The Company's Constitution can only be amended by a special resolution passed by at least three quarters of the members present and voting at a general meeting of the Company. At least 28 days' written notice specifying the intention to propose the resolution as a special resolution must be given.
(v)
Listing Rules - Provided the Company remains admitted to the Official List, then despite anything in its Constitution, no act may be done that is prohibited by the Listing Rules, and authority is given for acts required to be done by the Listing Rules. The Company's Constitution will be deemed to comply with the Listing Rules as amended from time to time.
10.
RESERVES
 
Note
1 Dec 2020
A$
30 Jun 2020
A$
Option premium reserve
10(b)
169,443
153,750
Share-based payments reserve
10(c)
911,141
993,483
Foreign currency translation reserve
10(g)
10,867
44,433
 
 
1,091,451
1,191,666
(a)
Nature and purpose of reserves
(i)
Option premium reserve
The option premium reserve is used to record the value of monies raised from issue of listed options.
(ii)
Share-based payments reserve
The share-based payments reserve is used to record the fair value of Unlisted Options and Performance Rights issued by the Group.
F-50

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
10.
RESERVES(Continued)
(iii)
Foreign currency translation reserve
Exchange differences arising on translation of entities whose functional currency is different to the Group’s presentation currency are taken to the foreign currency translation reserve, as described in Note 1(g).
(b)
Movements in option premium reserve
 
Number of
Listed Options
A$
1 December 2020
 
 
Opening balance at 1 July 2020
15,448,351
153,750
Expiry of listed options
(15,448,351)
Issue of listed options
15,693,334
15,693
Closing balance at 1 December 2020
15,693,334
169,443
 
 
 
30 June 2020
 
 
Opening balance at 1 July 2019
15,448,351
153,750
Closing balance at 30 June 2020
15,448,351
153,750
(c)
Movements in share-based payments reserve
 
Number of
Incentive
Options
Number of
Performance Rights
A$
1 December 2020
 
 
 
Opening balance at 1 July 2020
11,000,000
3,000,000
993,483
Issue of unlisted placement options
5,000,000
871,500
Expiry of unlisted options
(11,000,000)
(953,700)
Conversion of performance rights
(1,000,000)
(87,600)
Share-based payment expense
87,458
Closing balance at 1 December 2020
5,000,000
2,000,000
911,141
 
 
 
 
30 June 2020
 
 
 
Opening balance at 1 July 2019
11,000,000
953,700
Issue of performance rights
4,500,000
Lapse of performance rights
(1,500,000)
Share-based payment expense
39,783
Closing balance at 30 June 2020
11,000,000
3,000,000
993,483
Notes:
(1)
For details on the valuation of Unlisted Options and Performance Rights, including models and assumptions used, refer to Note 16 of the financial statements.
(d)
Terms and conditions of Listed Options
Listed Options have the following terms and conditions:
Each Listed Option entitles the holder to the right to subscribe for one Share upon the exercise of each Listed Option;
F-51

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
10.
RESERVES(Continued)
The Listed Options outstanding at the end of the financial period have the following exercise prices and expiry dates:
15,693,334 Listed Options exercisable at A$0.20 each on or before August 31, 2021;
The Listed Options are exercisable at any time prior to the Expiry Date;
Shares issued on exercise of the Listed Options rank equally with the then Shares of the Company;
Application will be made by the Company to ASX for official quotation of the Shares issued upon the exercise of the Listed Options;
If there is any reconstruction of the issued share capital of the Company, the rights of the Listed Options holders may be varied to comply with the ASX Listing Rules which apply to the reconstruction at the time of the reconstruction; and
The Listed Options are quoted on ASX.
(e)
Terms and conditions of Unlisted Options
Unlisted Options granted as share-based payments have the following terms and conditions:
Each Unlisted Option entitles the holder to the right to subscribe for one Share upon the exercise of each Unlisted Option;
The Unlisted Options granted as share based payments at the end of the financial period have the following exercise prices and expiry dates:
5,000,000 Unlisted Options exercisable at A$0.20 each on or before December 31, 2023.
The Unlisted Options are exercisable at any time prior to the Expiry Date, subject to vesting conditions being satisfied (if applicable);
Shares issued on exercise of the Unlisted Options rank equally with the then Shares of the Company;
Application will be made by the Company to ASX for official quotation of the Shares issued upon the exercise of the Unlisted Options;
If there is any reconstruction of the issued share capital of the Company, the rights of the Unlisted Option holders may be varied to comply with the ASX Listing Rules which apply to the reconstruction at the time of the reconstruction; and
No application for quotation of the Unlisted Options will be made by the Company.
(f)
Terms and conditions of Performance Rights
Performance Rights granted as share-based payments have the following terms and conditions:
Each Performance Right automatically converts into one Share upon vesting of the Performance Right;
Each Performance Right is subject to performance conditions (as determined by the Board from time to time) which must be satisfied in order for the Performance Right to vest;
The Performance Rights outstanding at the end of the financial period have the following performance conditions and expiry dates:
1,000,000 performance rights that vest upon a 20-day VWAP of A$0.40 per share, expiring 24 November 2022; and
1,000,000 performance rights that vest upon a 20-day VWAP of A$0.55 per share, expiring 24 November 2022;
Application will be made by the Company to ASX for official quotation of the Shares issued upon conversion of the Performance Rights;
F-52

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
10.
RESERVES(Continued)
If there is any reconstruction of the issued share capital of the Company, the rights of the Performance Right holders may be varied to comply with the ASX Listing Rules which apply to the reconstruction at the time of the reconstruction;
No application for quotation of the Performance Rights will be made by the Company; and
Without approval of the Board, Performance Rights may not be transferred, assigned or novated, except, upon death, a participant's legal personal representative may elect to be registered as the new holder of such Performance Rights and exercise any rights in respect of them.
(g)
Movements in foreign currency translation reserve
 
1 Dec 2020
A$
30 Jun 2020
A$
Balance at start of period
44,433
34,985
Exchange differences arising on translation of foreign operations
(33,566)
9,448
Balance at end of period
10,867
44,433
11.
ACCUMULATED LOSSES
 
1 Dec 2020
A$
30 Jun 2020
A$
Balance at start of period (restated)
(3,628,893)
(2,759,996)
Net loss for the period (restated)
(1,042,041)
(868,897)
Expiry of options
953,700
Balance at end of period (restated)
(3,717,234)
(3,628,893)
12.
LOSS PER SHARE
 
1 Dec 2020
A$
30 Jun 2020
A$
Basic loss per share
(0.03)
(0.03)
Diluted loss per share
(0.03)
(0.03)
The following reflects the loss and share data used in the calculations of basic loss per share:
 
1 Dec 2020
A$
30 Jun 2020
A$
Net loss
(1,042,041)
(868,897)
Loss used in calculating basic and dilutive loss per share
(1,042,041)
(868,897)
 
Number of
Ordinary Shares
1 Dec 2020
Number of
Ordinary Shares
30 Jun 2020
Weighted average number of Ordinary Shares used in calculating basic and dilutive loss per share
31,737,316
31,340,238
(a)
Non-Dilutive Securities
As at 1 December 2020, 15,693,334 Listed Options, 12,000,000 Unlisted Options and 2,000,000 Performance Rights, which together represent 29,693,334 potential Ordinary Shares, were considered non-dilutive as they would decrease the loss per share.
F-53

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
12.
LOSS PER SHARE(Continued)
(b)
Conversions, Calls, Subscriptions or Issues after 1 December 2020
Subsequent to 1 December 2020, the Company has issued:
(a)
29,150,000 ordinary shares, 5,000,000 unlisted options, 8,000,000 performance options and 39,600,000 performance shares in the Company in regards to the acquisition of the Titan Project;
(b)
12,150,000 ordinary shares pursuant to a share placement to institutional and sophisticated investors in February 2021;
(c)
20,000,000 ordinary shares pursuant to a share placement to institutional, sophisticated and professional investors in August 2021;
(d)
15,675,824 ordinary shares pursuant to the exercise of listed options;
(e)
2,750,000 ordinary shares pursuant to the exercise of unlisted options;
(f)
2,000,000 ordinary shares pursuant to the conversion of performance rights;
(g)
9,150,000 unlisted options and 16,325,000 performance rights to employees and consultants;
(h)
600,000 restricted stock units to new Directors of the Company; and
(i)
600,000 unlisted options to new Directors of the Company.
Other than as above, there have been no other conversions to, calls of, or subscriptions for Ordinary Shares or issues of potential Ordinary Shares since the reporting date and before the completion of this financial report.
13.
RELATED PARTIES
(a)
Subsidiaries
 
Country of
Incorporation
Equity Interest %
 
1 Dec 2020
30 Jun 2020
Calatos Pty Ltd LLC
United States
100%
100%
(b)
Ultimate Parent
IperionX Limited is the ultimate parent of the Group.
(c)
Transactions with Key Management Personnel
The aggregate compensation made to Key Management Personnel of the Group is set out below:
 
1 Dec 2020
A$
30 Jun 2020
A$
Short-term employee benefits
82,075
202,154
Post-employment benefits
7,125
19,205
Share-based payments
87,458
39,784
Total compensation
176,658
261,143
No loans were provided to or received from Key Management Personnel during the period ended 1 December 2020 (2020: nil).
(d)
Other transactions with Related Parties
During the period, GTT Ventures Pty Ltd, a company associated with Mr. Patric Glovac, was paid: (a) consulting fees of A$59,300 (2020: A$126,000) and (b) rent and outgoings of A$19,433 (2020: A$36,000).
During the period, Nova Legal Pty Ltd, a company associated with Mr. Frank Knezovic, was paid A$14,236 (2020: A$33,549) for legal services.
F-54

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
14.
PARENT ENTITY DISCLOSURES
 
1 Dec 2020
A$
30 Jun 2020
A$
(a) Financial Position
 
 
Assets
 
 
Current Assets
3,187,110
1,716,500
Non-Current Assets
518,453
Total Assets
3,187,110
2,235,043
Liabilities
 
 
Current Liabilities
(139,075)
(94,562)
Total Liabilities
(139,075)
(94,562)
Equity
 
 
Contributed equity
5,673,818
4,577,708
Reserves
1,080,584
1,147,233
Accumulated losses
(3,706,369)
(3,584,460)
Total Equity
3,048,035
2,140,481
 
 
 
(b) Financial Performance
 
 
Loss for the period
(1,075,609)
(746,119)
Other comprehensive loss
Total comprehensive loss
(1,075,609)
(746,119)
(c)
Other
No guarantees have been entered into by the parent entity in relation to its subsidiaries.
15.
SHARE-BASED PAYMENTS
(a)
Recognised share-based payment expense
From time to time, the Group grants Unlisted Options and Performance Rights to officers, employees, consultants and other key advisors as part of remuneration and incentive arrangements. The number of options or rights granted, and the terms of the options or rights granted are determined by the Board. Shareholder approval is sought where required.
The following equity-settled share-based payments have been recognised during the periods from 1 July 2020 to 1 December 2020 and 1 July 2019 to 30 June 2020:
 
1 Dec 2020
A$30
Jun 2020
A$
Expense arising from equity-settled share-based payment transactions
(87,458)
(39,783)
F-55

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
15.
SHARE-BASED PAYMENTS(Continued)
(b)
Summary of Unlisted Options and Performance Rights granted as share-based payments
The following table illustrates the number and weighted average exercise prices (“WAEP”) of Unlisted Options and Performance Rights granted as share-based payments at the beginning and end of the financial period:
 
1 Dec 2020
Number
1 Dec 2020
WAEP
30 Jun 2020
Number
30 Jun 2020
WAEP
Outstanding at beginning of period
14,000,000
A$0.24
11,000,000
A$0.30
Lapsed during the period
(11,000,000)
Performance rights converted during the period
(1,000,000)
Unlisted options granted during the period
5,000,000
A$0.20
Performance rights granted during the period
4,000,000
Performance rights forfeited during the period
(1,500,000)
Outstanding at end of period
7,000,000
A$0.14
14,000,000
A$0.24
The following Unlisted Options and Performance Rights were granted as share-based payments during the periods from 1 July 2020 to 1 December 2020 and 1 July 2019 to 30 June 2020:
 
Security Type
Number
Grant Date
Expiry Date
Exercise Price
A$
Fair Value
A$
1 December 2020
 
 
 
 
 
 
Series 1
Options
5,000,000
01-Dec-20
31-Dec-23
$0.20
$0.174
 
 
 
 
 
 
 
30 June 2020
 
 
 
 
 
 
Series 2
Rights
1,000,000
25-Nov-19
25-Nov-22
$0.0876
Series 3
Rights
1,000,000
25-Nov-19
25-Nov-22
$0.0657
Series 4
Rights
1,000,000
25-Nov-19
25-Nov-22
$0.0513
(c)
Weighted Average Remaining Contractual Life
At 1 December 2020, the weighted average remaining contractual life of Unlisted Options and Performance Rights on issue that had been granted as share-based payments was 2.77 years (30 June 2020: 0.58 years).
(d)
Range of Exercise Prices
At 1 December 2020, the range of exercise prices of Unlisted Options on issue that had been granted as share-based payments was A$0.20 to A$0.20 (30 June 2020: A$0.30 to A$0.30).
(e)
Weighted Average Share Price of Exercised Options
There were no Unlisted Options exercised during the period ended 1 December 2020 or year ended 30 June 2020.
(f)
Weighted Average Fair Value
The weighted average fair value of Unlisted Options and Performance Rights granted as share-based payments by the Group during the period ended 1 December 2020 was A$0.174.
(g)
Option and Right Pricing Models
The fair value of Unlisted Options granted is estimated as at the date of grant using the Black Scholes option valuation model taking into account the terms and conditions upon which the Unlisted Options were granted. The fair value of Performance Rights granted that have market-based vesting conditions is estimated as at the date of
F-56

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
15.
SHARE-BASED PAYMENTS(Continued)
grant using trinomial lattice valuation model taking into account the market based vesting criteria upon which the Performance Rights were granted. The fair value of Performance Rights granted that do not have market-based vesting conditions is estimated as at the date of grant on the underlying share price (being the five-day volume weighted average share price prior to issuance).
The tables below list the inputs to the valuation model used for Unlisted Options and Performance Rights granted by the Group during the periods from 1 July 2020 to 1 December 2020 and 1 July 2019 to 30 June 2020:
 
1 December 2020
30 June 2020
 
Series 1
Series 2
Series 3
Series 4
Fair value at grant date
A$0.174
A$0.0876
A$0.0657
A$0.0513
Share price at grant date
A$0.26
A$0.12
A$0.12
A$0.12
Vesting hurdle (20-day VWAP)
N/A
A$0.25
A$0.40
A$0.55
Exercise price
A$0.20
A$0.00001
A$0.00001
A$0.00001
Expected life of options/rights1
3.1 years
3.0 years
3.0 years
3.0 years
Risk-free interest rate
0.10%
0.74%
0.74%
0.74%
Expected volatility2
100%
76%
76%
76%
Expected dividend yield3
Notes:
(1)
The expected life is based on the expiry date of the options or rights.
(2)
The expected volatility reflects the assumption that the historical volatility is indicative of future trends, which may not necessarily be the actual outcome.
(3)
The dividend yield reflects the assumption that the current dividend payout will remain unchanged.
16.
SEGMENT INFORMATION
IFRS 8 Operating Segments requires operating segments to be identified on the basis of internal reports about components of the Consolidated Entity that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance. The Consolidated Entity operates in one segment, being mineral exploration in the United States of America.
(a)
Reconciliation of non-current assets by geographical location
 
1 Dec 2020
30 Jun 2020
 
A$
A$
United States of America
487,742
 
487,742
17.
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES
(a)
Overview
The Group's principal financial instruments comprise receivables, payables, and cash. The main risks arising from the Group's financial instruments are interest rate risk, foreign currency risk, credit risk and liquidity risk.
This note presents information about the Group's exposure to each of the above risks, its objectives, policies and processes for measuring and managing risk, and the management of capital. Other than as disclosed, there have been no significant changes since the previous financial year to the exposure to or management of these risks.
The Group manages its exposure to key financial risks in accordance with the Group's financial risk management policy. Key risks are monitored and reviewed as circumstances change (e.g. acquisition of a new project) and policies are revised as required. The overall objective of the Group's financial risk management policy is to support the delivery of the Group's financial targets whilst protecting future financial security.
F-57

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
17.
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES(Continued)
Given the nature and size of the business and uncertainty as to the timing and amount of cash inflows and outflows, the Group does not enter into derivative transactions to mitigate the financial risks. In addition, the Group's policy is that no trading in financial instruments shall be undertaken for the purposes of making speculative gains. As the Group's operations change, the Directors will review this policy periodically going forward.
The Board of Directors has overall responsibility for the establishment and oversight of the risk management framework. The Board reviews and agrees policies for managing the Group's financial risks as summarised below.
(b)
Credit Risk
Credit risk is the risk of financial loss to the Group if a customer or counterparty to a financial instrument fails to meet its contractual obligations. This arises principally from cash and cash equivalents and receivables.
There are no significant concentrations of credit risk within the Group. The carrying amount of the Group's financial assets represents the maximum credit risk exposure, as represented below:
 
Note
1 Dec 2020
A$
30 Jun 2020
A$
Cash and cash equivalents
5
2,717,623
1,649,187
Trade and other receivables
 
19,605
42,438
Loan to Hyperion Metals (Australia) Pty Ltd
 
449,879
 
 
3,187,107
1,691,625
With respect to credit risk arising from cash and cash equivalents, the Group's exposure arises from default of the counter party, with a maximum exposure equal to the carrying amount of these instruments.
Trade and other receivables comprise primarily deposits, accrued interest and GST refunds due. Where possible the Group trades only with recognised, creditworthy third parties. It is the Group's policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis with the result that the Group's exposure to bad debts is not significant. At 1 December 2020 none (2020: none) of the Group's receivables are past due.
(c)
Liquidity Risk
Liquidity risk is the risk that the Group will not be able to meet its financial obligations as they fall due. The Board's approach to managing liquidity is to ensure, as far as possible, that the Group will always have sufficient liquidity to meet its liabilities when due. At 1 December 2020, the Group had sufficient liquid assets to meet its financial obligations.
The contractual maturities of financial liabilities, including estimated interest payments, are provided below. There are no netting arrangements in respect of financial liabilities.
 
≤1 year
A$
1-5 years
A$
≥5 years
A$
Total
A$
1 December 2020
 
 
 
 
Financial liabilities
 
 
 
 
Trade and other payables
139,075
139,075
 
139,075
139,075
 
 
 
 
 
30 June 2020
 
 
 
 
Financial liabilities
 
 
 
 
Trade and other payables
68,602
68,602
Lease liabilities
25,960
25,960
 
94,562
94,562
F-58

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
17.
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES(Continued)
(d)
Interest Rate Risk
The Group's exposure to the risk of changes in market interest rates relates primarily to the cash and short-term deposits with a floating interest rate. These financial assets with variable rates expose the Group to cash flow interest rate risk. All other financial assets and liabilities are either non-interest bearing (for example, receivables and payables) or have fixed interest rates (for example, lease liabilities, sub-lease receivables, and loans and borrowings).
At the reporting date, the interest rate profile of the Group's interest-bearing financial instruments was:
 
Note
1 Dec 2020
A$
30 Jun 2020
A$
Interest-bearing financial instruments
 
 
 
Cash at bank and on hand
5
2,717,623
1,623,235
Short term deposits
 
25,952
 
 
2,717,623
1,649,187
17.
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (continued)
(d)
Interest Rate Risk (Continued)
The Group's cash at bank and on hand and short-term deposits had a weighted average floating interest rate at year end of 0.61% (2019: 1.05%).
The Group currently does not engage in any hedging or derivative transactions to manage interest rate risk.
Interest rate sensitivity
A sensitivity of 0.5% (50 basis points) has been selected as this is considered reasonable given the current level of both short term and long-term interest rates. A 0.5% (50 basis points) movement in interest rates at the reporting date would have increased (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency rates, remain constant.
 
Profit or loss
Equity
 
+0.5% A$
—0.5% A$
+0.5% A$
—0.5% A$
1 December 2020
 
 
 
 
Cash and cash equivalents
13,588
(13,588)
13,588
(13,588)
(e)
Foreign Currency Risk
Foreign currency risk is the risk that the fair value of future cash outflows of an exposure will fluctuate because of changes in foreign currency exchange rates.
The Group’s exposure to the risk of changes in foreign exchange rate relates primarily to assets and liabilities that are denominated in currencies other than A$. The Group also has transactional currency exposures relating to transactions denominated in currencies other than A$.
It is the Group’s policy not to enter into any hedging or derivative transactions to manage foreign currency risk.
At the reporting date, the Group did not have any material financial instruments denominated in foreign currencies.
(f)
Commodity Price Risk
The Group is exposed to commodity price risk. These commodity prices can be volatile and are influenced by factors beyond the Group's control. As the Group is currently engaged in exploration and development activities, no sales of commodities are forecast for the next 12 months, and accordingly, no hedging or derivative transactions have been used to manage commodity price risk.
F-59

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
17.
FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES(Continued)
(g)
Capital Management
The Board's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Given the stage of development of the Group, the Board's objective is to minimise debt and to raise funds as required through the issue of new shares. The Group is not subject to externally imposed capital requirements.
There were no changes in the Group's approach to capital management during the period.
(h)
Fair Value
The net fair value of financial assets and financial liabilities approximates their carrying value. The methods for estimating fair value are outlined in the relevant notes to the financial statements.
18.
EVENTS SUBSEQUENT TO BALANCE DATE
(a)
On 1 December 2020, the Company completed the acquisition of Hyperion Metals (Australia) Pty Ltd (“HMAPL”) which holds a 100% interest in the Titan Project comprising titanium and zircon prospective HMS properties in Tennessee, United States. The acquisition was accounted for as a reverse acquisition with HMAPL deemed to be the accounting acquirer;
(b)
On 20 January 2021, the Company announced the appointment of Mr. Todd Hannigan as Non-Executive Chairman of the Company, in conjunction with Mr. Hannigan participating in a placement by the Company to raise A$3.6 million;
(c)
On 1 February 2021, the Company announced that it had completed its previously announced placement of 12,150,000 shares to institutional and sophisticated investors to raise gross proceeds of A$3.6 million;
(d)
On 15 February 2021, the Company announced that it had signed a research agreement and option for exclusive licence to develop titanium metal powders using the breakthrough HAMR technology invented by Dr. Z. Zak Fang and his team at the University of Utah with funding from ARPA-E, with Boeing and Arconic (formerly Alcoa, Inc.) as industrial partners;
(e)
On 18 February 2021, the Company announced that experienced U.S. based resource company executive, Mr. Taso Arima, has been appointed Managing Director of the Company, effective from March 1, 2021;
(f)
On 14 April 2021, the Company changed its name from ‘Tao Commodities Limited’ to ‘Hyperion Metals Limited’;
(g)
On 12 July 2021, the Company announced that PricewaterhouseCoopers was appointed as auditor of the Company following the resignation of BDO Audit (WA) Pty Ltd and ASIC’s consent to the resignation in accordance with section 329(5) of the Corporations Act 2001;
(h)
On 22 July 2021, the Company announced the execution of a memorandum of understanding (“MOU”) for a technology partnership with EOS GmbH (“EOS”), the world’s leading solution supplier in the field of industrial 3D printing (known as additive manufacturing, or AM) of metals and plastics;
(i)
On 31 August 2021, the Company completed a placement of 20 million shares at an issue price of A$1.20 per share to institutional, sophisticated and professional investors to raise gross proceeds of A$24.0 million (US$17.6 million) (“Placement”). The Placement was led by cornerstone investor, Fidelity Management & Research Company, an American multinational financial services corporation;
(j)
On October 21, 2021, the Company announced that it had purchased an option to acquire 100% of the ownership interests of Blacksand Technology, LLC on or before December 31, 2022. Blacksand holds the exclusive commercial licensing rights for more than forty global patents through a license agreement with the University of Utah including the global patents for the patented HAMR and GSD technologies that can produce low cost and low carbon titanium metal;
F-60

TABLE OF CONTENTS

NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS
FOR THE PERIODS 1 JULY 2020 TO 1 DECEMBER 2020 AND 1 JULY 2019 TO 30 JUNE 2020(Continued)
18.
EVENTS SUBSEQUENT TO BALANCE DATE(Continued)
(k)
On December 6, 2021, the Company announced that it had signed a memorandum of understanding with Chemours to investigate the potential supply to Chemours of up to 50,000 metric tons of ilmenite, 10,000 metric tons of rutile, and 10,000 metric tons of staurolite. Chemours operates one of the largest titanium dioxide plants at its New Johnsonville plant which is located approximately 20 miles from the Company’s Titan Project in Tennessee; and
(l)
On January 6, 2022, the Company announced that it plans to pursue a listing on a national securities exchange in the United States and will change its name to ‘IperionX Limited’;
(m)
On February 9, 2022, the Company changed its name from ‘Hyperion Metals Limited’ to ‘IperionX Limited’; and
(n)
The impact of the Coronavirus (COVID-19) pandemic is ongoing and while it has not significantly impacted the Company up to 1 December 2020, it is not practicable to estimate the potential impact, positive or negative, after the reporting date. The situation is rapidly developing and is dependent on measures imposed by the Australian, United States and other governments, such as maintaining social distancing requirements, quarantine, travel restrictions and any economic stimulus that may be provided.
Other than as outlined above, as at the date of this report there are no other matters or circumstances which have arisen since 1 December 2020 that have significantly affected or may significantly affect:
the operations, in financial years subsequent to 1 December 2020, of the Group;
the results of those operations, in financial years subsequent to 1 December 2020, of the Group; or
the state of affairs, in financial years subsequent to 1 December 2020, of the Group.
F-61

TABLE OF CONTENTS

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
For the periods ended December 31, 2021 and 2020
 
Note
Six Months Ended
December 31, 2021
US$
Period Ended
December 31, 2020
(restated)
US$
Continuing operations
 
 
 
Exploration and evaluation expenses
 
(3,431,522)
(285,215)
Corporate and administrative expenses
 
(998,378)
(185,031)
Business development expenses
 
(1,501,724)
(71,946)
Share-based payment expense
 
(4,764,135)
(841,896)
Finance income
 
157,435
118
Finance costs
 
(23,831)
Cost of listing on reverse acquisition
9
(5,141,126)
Loss before income tax
 
(10,562,155)
(6,525,096)
Income tax expense
 
Loss for the period
 
(10,562,155)
(6,525,096)
Loss attributable to members of IperionX Limited
 
(10,562,155)
(6,525,096)
 
 
 
 
Other comprehensive income
 
 
 
Items that may be reclassified subsequently to profit or loss:
 
 
 
Exchange differences arising on translation of foreign operations
 
(232,068)
75,680
Other comprehensive loss for the period, net of tax
 
(232,068)
75,680
Total comprehensive loss for the period
 
(10,794,223)
(6,449,416)
Total comprehensive loss attributable to members of IperionX Limited
 
(10,794,223)
(6,449,416)
 
 
 
 
Loss per share
 
 
 
Basic and diluted loss per share (US$ per share)
 
(0.08)
(0.40)
Notes:
(1)
The Condensed Consolidated Statement of Comprehensive Income for the comparative period ended December 31, 2020 has been restated. Refer to Note 9 for further information.
The above Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the
accompanying notes.
F-62

TABLE OF CONTENTS

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As at December 31, 2021 and June 30, 2021
 
Note
December 31, 2021
US$
June 30, 2021
US$
ASSETS
 
 
 
Current Assets
 
 
 
Cash and cash equivalents
 
14,256,359
1,697,904
Trade and other receivables
 
19,722
341
Prepayments
 
37,185
49,069
Total Current Assets
 
14,313,266
1,747,314
 
 
 
 
Non-Current Assets
 
 
 
Exploration and evaluation assets
4
885,725
504,750
Property, plant and equipment
 
714,941
539,619
Financial assets
 
250,000
Total Non-Current Assets
 
1,850,666
1,044,369
TOTAL ASSETS
 
16,163,932
2,791,683
 
 
 
 
LIABILITIES
 
 
 
Current Liabilities
 
 
 
Trade and other payables
 
553,088
544,842
Lease liabilities
 
94,191
81,104
Provisions
 
11,069
Total Current Liabilities
 
647,279
637,015
 
 
 
 
Non-Current Liabilities
 
 
 
Lease liabilities
 
464,696
394,548
Total Non-Current Liabilities
 
464,696
394,548
TOTAL LIABILITIES
 
1,111,975
1,031,563
 
 
 
 
NET ASSETS
 
15,051,957
1,760,120
 
 
 
 
EQUITY
 
 
 
Contributed equity
5
29,669,773
10,255,369
Reserves
6
9,175,176
4,735,588
Accumulated losses
 
(23,792,992)
(13,230,837)
TOTAL EQUITY
 
15,051,957
1,760,120
The above Condensed Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.
F-63

TABLE OF CONTENTS

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the periods ended December 31, 2021 and 2020
 
Contributed
Equity
US$
Share-
Based
Payments
Reserve
US$
Foreign
Currency
Translation
Reserve
US$
Accumulated
Losses
US$
Total
Equity
US$
Balance at July 1, 2021
10,255,369
4,738,007
(2,419)
(13,230,837)
1,760,120
Net loss for the period
(10,562,155)
(10,562,155)
Exchange differences arising on translation of foreign operations
(232,068)
(232,068)
Total comprehensive loss
(232,068)
(10,562,155)
(10,794,223)
Issue of shares - share placement
17,604,000
17,604,000
Issue of shares - exercise of options
2,239,216
(92,479)
2,146,737
Share issue costs
(428,812)
(428,812)
Share-based payment expense
4,764,135
4,764,135
Balance at December 31, 2021
29,669,773
9,409,663
(234,487)
(23,792,992)
15,051,957
 
 
 
 
 
 
Balance at incorporation (restated)
Net loss for the period
(6,525,096)
(6,525,096)
Exchange differences arising on translation of foreign operations
75,680
75,680
Total comprehensive loss
75,680
(6,525,096)
(6,449,416)
Issue of shares – incorporation
1
1
Issue of shares – seed placement
54,011
54,011
Reverse acquisition
6,433,752
967,582
7,401,334
Share-based payment expense
841,896
841,896
Balance at December 31, 2020 (restated)
6,487,764
1,809,478
75,680
(6,525,096)
1,847,826
Notes:
(1)
The Condensed Consolidated Statement of Changes in Equity for the comparative period ended December 31, 2020 has been restated. Refer to Note 9 for further information.
The above Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.
F-64

TABLE OF CONTENTS

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
For the periods ended December 31, 2021 and 2020
 
Note
Six Months Ended
December 31, 2021
US$
Period Ended
December 31, 2020
(restated)
US$
Cash flows from operating activities
 
 
 
Payments to suppliers and employees
 
(5,892,972)
(452,022)
Interest received
 
14,716
118
Interest paid
 
(22,688)
Net cash flows used in operating activities
 
(5,900,944)
(451,904)
 
 
 
 
Cash flows from investing activities
 
 
 
Purchase of exploration and evaluation assets
4
(380,975)
(74,903)
Purchase of property, plant and equipment
 
(113,890)
Purchase of financial assets
 
(250,000)
Net cash flows (used in)/from investing activities
 
(744,865)
(74,903)
 
 
 
 
Cash flows from financing activities
 
 
 
Proceeds from issue of shares
5
19,750,737
54,012
Share issue costs
 
(428,812)
Payment of principal portion of lease liabilities
 
(26,626)
Net cash inflow on reverse acquisition
9
2,329,111
Net cash flows from financing activities
 
19,295,299
2,383,123
 
 
 
 
Net increase in cash and cash equivalents
 
12,649,490
1,856,316
Net foreign exchange differences
 
(91,036)
75,442
Cash and cash equivalents at the beginning of the period
 
1,697,905
Cash and cash equivalents at the end of the period
 
14,256,359
1,931,758
Notes:
(1)
The Condensed Consolidated Statement of Cash Flows for the comparative period ended December 31, 2020 has been restated. Refer to Note 9 for further information.
The above Condensed Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.
F-65

TABLE OF CONTENTS

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the periods ended December 31, 2021 and 2020
1.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Corporate information
IperionX Limited (formerly Hyperion Metals Limited) (“IperionX” or “Company”) is a for-profit company limited by shares, incorporated and domiciled in Australia. Our registered office is located at Level 9, 28 The Esplanade, Perth, Western Australia, 6000. Our ordinary shares are listed on the Australian Securities Exchange, or ASX, under the symbol “IPX” (formerly under the symbol “HYM”).
The principal activities of the Group during the six months ended December 31, 2021 and the period from July 20, 2020 to December 31, 2021 consisted of the exploration and development of mineral resource projects.
The unaudited interim condensed consolidated financial statements of IperionX and its subsidiaries (the “Consolidated Entity” or the "Group") for the six months ended December 31, 2021 and the period from July 20, 2020 to December 31, 2020 (the "Interim Financial Statements") were authorised for issue in accordance with a resolution of the Directors on March 11, 2022.
Basis of preparation
The Interim Financial Statements have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting issued by the International Accounting Standard Board (“IASB”). The preparation of the Interim Financial Statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year-to-date basis. Actual results may differ from those estimates.
The Interim Financial Statements do not include all the notes of the type normally included in annual financial statements and are not necessarily indicative of the results of operations and cash flows expected for the year ended June 30, 2022. Accordingly, the Interim Financial Statements are to be read in conjunction with the annual consolidated financial statements of the Group for the year ended June 30, 2021. In the opinion of management, the accompanying Interim Financial Statements reflect all adjustments consisting only of normal recurring adjustments, which are necessary for a fair presentation of the financial results of such period.
The financial report has been prepared on a historical cost basis and is presented in United States dollars ($).
The accounting policies and methods of computation adopted in the preparation of the interim financial report are consistent with those adopted and disclosed in the Group’s annual financial statements for the financial year ended June 30, 2021, except as disclosed below. These accounting policies are consistent with International Financial Reporting Standards.
New and amended standards and interpretations
In the current period, the Group has adopted all of the new and revised standards, interpretations and amendments that are relevant to its operations and effective for annual reporting periods beginning on or after July 1, 2021.
There are no new or revised standards, interpretations or amendments that are effective for the current period that are relevant to the Group.
The Group has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective. The new standards have not had a material effect on the Group’s financial statements.
2.
SEGMENT INFORMATION
IFRS 8 Operating Segments requires operating segments to be identified on the basis of internal reports about components of the Consolidated Entity that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance.
The Consolidated Entity operates in one segment, being exploration and development of minerals and metals in the United States of America.
F-66

TABLE OF CONTENTS

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the periods ended December 31, 2021 and 2020(Continued)
3.
DIVIDENDS PAID OR PROVIDED FOR
No dividend has been paid or provided for during the six months ended December 31, 2021 (December 31, 2020: nil).
4.
EXPLORATION AND EVALUATION ASSETS
 
Titan Project
US$
Carrying value at July 1, 2021
504,750
Additions
380,975
Carrying amount at December 31, 2021(1)
885,725
 
 
Carrying value at incorporation
Additions
504,750
Carrying amount at June 30, 2021
504,750
Notes:
(1)
The ultimate recoupment of costs carried forward for exploration and evaluation is dependent on the successful development and commercial exploitation or sale of the respective areas of interest.
5.
CONTRIBUTED EQUITY
Issued capital
 
December 31, 2021
US$
June 30, 2021
US$
139,488,491 ordinary shares (June 30, 2021: 105,105,787)
29,669,773
10,255,369
 
29,669,773
10,255,369
Movements in issued capital
 
No. of
Ordinary Shares
No. of
Performance Shares
US$
Opening balance at July 1, 2021
105,105,787
39,600,000
10,255,369
Issue of shares - share placement
20,000,000
17,604,000
Issue of shares - exercise of listed options
12,606,704
1,857,559
Issue of shares - exercise of unlisted options
1,776,000
381,657
Share issue costs
(428,812)
Closing balance at December 31, 2021
139,488,491
39,600,000
29,669,773
6.
RESERVES
Reserves
 
December 31, 2021
US$
June 30, 2021
US$
Share based payments reserve
9,409,663
4,738,007
Foreign currency translation reserve
(234,478)
(2,419)
Total Reserves
9,175,185
4,735,588
F-67

TABLE OF CONTENTS

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the periods ended December 31, 2021 and 2020(Continued)
6.
RESERVES(Continued)
Movements share based payments reserve
 
No. of
Listed
Options
No. of
Unlisted
Options
No. of
Performance
Rights
No. of
RSUs
US$
Opening balance at July 1, 2021
12,624,214
25,800,000
16,325,000
4,738,007
Grant of employee incentive securities
600,000
8,990,000
600,000
Exercise of options
(12,606,704)
(1,776,000)
(92,479)
Expiry of options
(17,510)
Share-based payments expense
4,764,135
Closing balance at December 31, 2021
24,624,000
25,315,000
600,000
9,409,663
7.
SUBSIDIARIES
The consolidated financial statements include the financial statements of IperionX Limited and the subsidiaries listed in the following table.
 
Country of
Incorporation
December 31, 2021
June 30, 2021
Parent Entity
 
 
 
IperionX Limited
Australia
 
 
Subsidiaries
 
 
 
IperionX Inc.
USA
100%
IperionX Critical Minerals LLC
USA
100%
100%
IperionX Materials & Technologies LLC
USA
100%
100%
Hyperion Metals (Australia) Pty Ltd
Australia
100%
100%
Calatos Pty Ltd LLC
USA
100%
100%
8.
CONTINGENT ASSETS AND LIABILITIES
At December 31, 2021, the Group had entered into exclusive option agreements with local landowners in Tennessee, United States, in relation to its Titan Project, which upon exercise, allows the Group to lease or purchase approximately 10,934 acres of surface property and the associated mineral rights from the local landowners. Upon exercise, in the case of an option to lease, the Company will pay a production royalty to the landowners, subject to a minimum royalty. Upon exercise, in the case of a purchase, the Company will pay cash consideration approximating the fair market value of the property, excluding the value of any minerals, plus a premium.
9.
REVERSE ACQUISITION
December 31, 2020
On December 1, 2020, the Company completed its acquisition of Hyperion Metals (Australia) Pty Ltd (“HMAPL”) after issuing 26,500,000 ordinary shares, 5,000,000 unlisted options, 8,000,000 performance options and 36,000,000 performance shares in the Company to the vendors, following shareholder approval received at the Company’s general meeting held on November 30, 2020.
As a result of the acquisition, the former shareholders of HMAPL effectively obtained control of the combined entity. Accordingly, using the reverse acquisition principles of the business combination accounting standard, while the Company is the legal acquirer of HMAPL, for accounting purposes HMAPL is deemed to be the acquirer of the Company.
Therefore, the consolidated financial statements of the Company have been prepared as a continuation of the consolidated financial statements of HMAPL. The deemed acquirer, HMAPL, has accounted for the acquisition of the Company from December 1, 2020.
F-68

TABLE OF CONTENTS

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
For the periods ended December 31, 2021 and 2020(Continued)
9.
REVERSE ACQUISITION(Continued)
In addition, at the date of the transaction, it was determined that the Company was not a business. Accordingly, for accounting purposes, the acquisition has been treated as a share-based payment transaction.
As a result of the reverse acquisition, during the comparative period from July 20, 2020 to December 31, 2020 the Group recognised an expense of US$5.1 million in its condensed consolidated statement of profit or loss and other comprehensive income, effectively representing the cost of listing. The cost is calculated as the difference in the fair value of the equity instruments that HMAPL is deemed to have issued to acquire the Company and the fair value of the Company’s identifiable net assets, as follows:
 
Period Ended
December 31, 2020
US$
Fair value of consideration:
 
Equity
7,401,334
Direct costs relating to the reverse acquisition
10,875
Cash option fee paid to HMAPL
(25,292)
Pre-acquisition loan to HMAPL
(331,471)
Fair value of consideration
7,055,446
Fair value of net assets acquired:
 
Cash and cash equivalents
1,983,223
Trade and other receivables
33,523
Trade and other payables
(102,426)
Fair value of net assets acquired
1,914,320
Cost of listing
5,141,126
 
 
Net cash inflow:
 
Net cash acquired on reverse acquisition
1,983,223
Direct costs relating to the reverse acquisition
(10,875)
Cash option fee paid to HMAPL
25,292
Pre-acquisition loan to HMAPL
331,471
Net consolidated cash inflow
2,329,111
10.
SUBSEQUENT EVENTS AFTER BALANCE DATE
(a)
On January 6, 2022, the Company announced that it plans to pursue a listing on a national securities exchange in the United States; and
(b)
On February 9, 2022, the Company changed its name from ‘Hyperion Metals Limited’ to ‘IperionX Limited’.
Other than as outlined above, at the date of this report there are no other significant events occurring after balance date requiring disclosure.
F-69

TABLE OF CONTENTS

PART II.
As set forth in General Instruction E(a) to Form 20-F, the information called for by Part II of Form 20-F is not applicable because this Form 20-F is filed as an Exchange Act registration statement.
PART III.
ITEM 17.
FINANCIAL STATEMENTS
We have elected to provide financial statements and related information pursuant to Item 18.
ITEM 18.
FINANCIAL STATEMENTS
The consolidated financial statements and the related notes required by this Item are included in this registration statement on Form 20-F beginning on page F-1.
ITEM 19.
EXHIBITS.
Exhibit
Number
Description
Certificate of the Registration of IperionX Limited (formerly Hyperion Metals Limited)
Constitution of IperionX Limited (formerly Hyperion Metals Limited)
2.1*
Form of Deposit Agreement among IperionX Limited, The Bank of New York Mellon, and Owners and Holders of American Depositary Shares
2.2*
Form of American Depositary Receipt evidencing American Depositary Shares (included in Exhibit 2.1)
Option Agreement by and among Hyperion Materials & Technologies, LLC, IperionX Limited (formerly Hyperion Metals Limited) and Blacksand Technology, LLC and its members, dated October 20, 2021
Option of Exclusive License Agreement between Hyperion Materials & Technologies, LLC and Blacksand Technology, LLC, dated February 13, 2021
Master Services Agreement between Blacksand Technology, LLC and Hyperion Materials & Technologies, LLC, dated February 13, 2021, and related statements of work
IperionX Limited (formerly Hyperion Metals Limited) Employee Incentive Plan
Form of Indemnity, Insurance and Access for Directors
List of Subsidiaries of IperionX Limited
Consent of PricewaterhouseCoopers
*
To be filed by amendment.
+
Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
II-1

TABLE OF CONTENTS

SIGNATURES
The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this registration statement on Form 20-F filed on its behalf.
IPERIONX LIMITED
 
By:
/s/ Anastasios Arima
 
 
Anastasios Arima
 
 
Chief Executive Officer and Managing Director
Date: March 29, 2022

 

 Exhibit 1.1

 

   

Certificate of Registration

on Change of Name

 

This is to certify that

 

HYPERION METALS LIMITED

 

Australian Company Number 618 935 372

 

did on the ninth day of February 2022 change its name to

 

IPERIONX LIMITED

 

Australian Company Number 618 935 372

 

The company is a public company.

 

The company is limited by shares.

 

The company is registered under the Corporations Act 2001 and is taken to be registered in Western Australia and the date of commencement of registration is the fifth day of May, 2017.

 

 

 

 

Issued by the

Australian Securities and Investments Commission

on this ninth day of February 2022.

 

 

Joseph Longo

Chair

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

Exhibit 1.2

 

IperionX Limited

 

ACN 618 935 372

 

Constitution

 

Dated: 25 September 2021

 

 

 

 

 

 

Table of contents

 

1 Preliminary 1
       
  1.1 Definitions and interpretation 1
  1.2 Nature of the Company 1
  1.3 Replaceable rules 1
  1.4 Transitional provisions 1
       
2 Shares 1
       
  2.1 Issue of Shares and options 1
  2.2 Preference Shares 2
  2.3 Variation of classes and class rights 2
  2.4 Converting Shares 2
  2.5 Reductions of capital and buy backs 2
  2.6 Ancillary powers regarding distributions 3
  2.7 Unmarketable parcels of Shares 3
  2.8 Registered holder is absolute owner 3
  2.9 Holding statements and certificates 4
       
3 Restricted Securities 4
       
4 Calls, Company Payments, Forfeiture and Liens 4
       
5 Transfer of Shares 5
       
  5.1 Electronic transfer systems 5
  5.2 Forms of transfer 5
  5.3 Instrument of transfer 5
  5.4 Transferor is holder until transfer registered 5
  5.5 Refusal to register transfers 5
  5.6 No registration fee 6
  5.7 Transmission of Shares 6
       
6 Proceeding of Members 6
       
  6.1 Who can call meetings of Members 6
  6.2 Annual general meeting 6
  6.3 How to call meetings of Members 6
  6.4 Right to attend meetings of Members 7
  6.5 Meeting of Members at more than one place 8
  6.6 Meeting of Member by Virtual Meeting 8
  6.7 Quorum 8
  6.8 Chairperson 9
  6.9 General conduct of meetings 9
  6.10 Resolutions of Members 10
  6.11 Direct Voting 10
  6.12 Polls 11
  6.13 Adjourned, cancelled and postponed meetings 11
  6.14 Number of votes 12
  6.15 Objections to qualification to vote 13
  6.16 Proxies, attorneys and representatives 14
       
7 Directors 16
       
  7.1 Number of Directors 16
  7.2 Appointment of Directors 16
  7.3 Retirement of Directors and vacation of office 16
  7.4 Alternate Directors 17
  7.5 Remuneration of Directors 18
  7.6 Interests of Directors 19
       
8 Officers 20
       
  8.1 Managing director 20
  8.2 Secretary 21
  8.3 Indemnity and insurance 21

 

IperionX Limited

 

 

 

 

9 Powers of the Company and Directors 22
       
  9.1 General powers 22
  9.2 Execution of documents 22
  9.3 Committees and delegates 22
  9.4 Attorney or agent 23
       
10 Proceedings of Directors 23
       
  10.1 Written resolutions of Directors 23
  10.2 Meetings of Directors 23
  10.3 Who can call meetings of Directors 24
  10.4 How to call meetings of Directors 24
  10.5 Quorum 24
  10.6 Chairperson 24
  10.7 Resolutions of Directors 25
       
11 Dividends and Profits 25
       
  11.1 Who may determine Dividends 25
  11.2 Dividends for different classes 26
  11.3 Dividends proportional to paid up capital 26
  11.4 Effect of a transfer on Dividends 27
  11.5 No interest on Dividends 27
  11.6 Unpaid amounts 27
  11.7 Capitalisation of profits 27
  11.8 Distributions of assets 27
  11.9 Dividend plans 27
       
12 Notices and Payments 28
       
  12.1 Notice to Members 28
  12.2 Notice to Directors 29
  12.3 Notice to the Company 29
  12.4 Time of service 29
  12.5 Signatures 30
  12.6 Payments 30
       
13 Winding up 30
       
  13.1 Distributions proportional to paid up capital 30
  13.2 Distributions of assets 30
       

Schedule 1 32
   
  Definitions and Interpretation 32
   
Schedule 2 36
   
  Calls, Company payments, Forfeiture and Liens 36
   
Schedule 3 42
   
  Transmission 42
   
Schedule 4 43
   
  Unmarketable Parcels 43
   
Schedule 5 46
   
  Proportional Takeover Bid Approval 46
   
Schedule 6 47
   
  Preference Shares 47

 

IperionX Limited

 

  Page ii 
   

 

This Constitution is made on 25 September 2021

  

by IperionX Limited ACN 618 935 372 (Company)

 

It is agreed:

 

1Preliminary

 

1.1Definitions and interpretation

 

Schedule 1 applies and forms part of this constitution.

 

1.2Nature of the Company

 

The Company is a public company limited by shares.

 

1.3Replaceable rules

 

The replaceable rules in the Corporations Act do not apply to the Company.

 

1.4Transitional provisions

 

This constitution has the effect that:

 

(a)every Director, Alternate Director, senior manager and Secretary in office as at the Adoption Date continues in office subject to, and is taken to have been appointed or elected under, this constitution;

 

(b)any register maintained by the Company immediately before the Adoption Date is taken to be a register maintained under this constitution;

 

(c)any common seal adopted by the Company before the Adoption Date is taken to be the common seal until another common seal is adopted by the Company under this constitution;

 

(d)for the purposes of article 12.6(a)(ii), a cheque issued under a corresponding provision of the Previous Constitution is taken to have been issued under article 12.6(a)(ii); and

 

(e)unless a contrary intention appears in this constitution, all persons, things, agreements and circumstances appointed, approved, created or delegated by or under the Previous Constitution continue to have the same status, operation and effect as if they had occurred under this constitution on and after the Adoption Date.

 

2Shares

 

2.1Issue of Shares and options

 

(a)Subject to any rights and restrictions attached to a class of Shares, the Company may:

 

(i)allot and issue unissued Shares; and

 

(ii)grant options over unissued Shares,

 

on any terms, at any time and for any consideration, as the Directors resolve.

 

(b)The powers of the Company under article 2.1 may only be exercised by the Directors.

 

IperionX Limited

 

 

 

 

2.2Preference Shares

 

(a)The Company may issue any Shares as preference Shares including:

 

(i)preference Shares which are liable to be redeemed in a manner permitted by the Corporations Act; and

 

(ii)preference Shares in accordance with the terms of Schedule 6,

 

provided that such preference Shares are convertible into ordinary Shares in accordance with their terms.

 

(b)Holders of preference Shares have the same rights as holders of ordinary Shares in relation to receiving Notices, reports and audited accounts, and attending meetings of Members.

 

(c)A holder of a preference Share only has the right to vote:

 

(i)during a period during which a Dividend (or part of a Dividend) in respect of the Share is in arrears;

 

(ii)on a proposal to reduce the share capital of the Company;

 

(iii)on a resolution to approve the terms of a buy back agreement;

 

(iv)on a proposal that affects rights attached to the Share;

 

(v)on a proposal to wind up the Company;

 

(vi)on a proposal for the disposal of the whole of the property, business and undertaking of the Company; and

 

(vii)during the winding up of the Company.

 

2.3Variation of classes and class rights

 

(a)Subject to the terms of issue of Shares in a particular class, the Company may:

 

(i)vary or cancel rights attached to Shares in that class; or

 

(ii)convert Shares from one class to another,

 

by a special resolution of the Company and:

 

(iii)a special resolution passed at a meeting of the Members holding Shares in that class; or

 

(iv)the written consent of Members who are entitled to at least 75 per cent of the votes that may be cast in respect of Shares in that class.

 

(b)The provisions in this constitution concerning meetings of Members (with the necessary changes) apply to a meeting held under article 2.3(a)(iii).

 

2.4Converting Shares

 

The Company may by ordinary resolution passed at a meeting of Members convert all or any of its Shares into a larger or smaller number of Shares.

 

2.5Reductions of capital and buy backs

 

(a)Subject to the Corporations Act and the Listing Rules, the Company may:

 

(i)reduce its share capital; and

 

(ii)buy back Shares in itself,

 

on any terms and at any time.

 

IperionX Limited

 

  Page 2 
   

 

(b)The method of distribution of a reduction of the share capital of the Company may include any or all of the payment of cash, the issue of shares, the grant of Company options or other Company securities, the distribution of securities in any other body corporate or the transfer of any other assets.

 

(c)If a distribution of a reduction of the share capital of the Company includes a distribution of shares or other securities in another body corporate:

 

(i)each Member is deemed to have agreed to become a member of that body corporate and be bound by the constitution of that body corporate; and

 

(ii)each Member appoints the Company and each Director as its agent to execute an instrument of transfer or other document required to give effect to the distribution transfer those shares or other securities to that Member; and

 

(iii)any binding or notification between the Member and the Company (including any instructions relating to payment of dividends or to communications from the Company) will be deemed to be a similarly binding instruction or notification to the other body corporate until that instruction or notification is revoked or amended in writing addressed to the other body corporate (to the maximum extent permitted under Australian law, or the other body corporate's constitution).

 

2.6Ancillary powers regarding distributions

 

Instead of making a distribution or issue of specific assets, shares, debentures or other securities to a particular Member, the Directors may make a cash payment to that Member, or allocate some or all of the assets, shares, debentures or other securities to a trustee or nominee to be sold (at the Member's risk and expense, including as to brokerage and withholding tax) on behalf of, and for the benefit of, or in respect of, that Member, if:

 

(a)the distribution or issue would otherwise be illegal or unlawful;

 

(b)the distribution or issue would give rise to parcels of securities which do not constitute a Marketable Parcel;

 

(c)in the Directors' discretion, the distribution or issue would be unreasonable having regard to:

 

(i)the number of Members in the place where the distribution or issue would be made; and/or

 

(ii)the number and value of securities that would be offered; and/or

 

(iii)the cost of complying with the legal requirements, and requirements of a regulatory authority, in the place; or

 

(d)the Member so agrees.

 

2.7Unmarketable parcels of Shares

 

Schedule 4 applies and forms part of this constitution.

 

2.8Registered holder is absolute owner

 

Except as required by Applicable Law, the Company is not required to recognise any interest in, or right in respect of, a Share except an absolute right of legal ownership of the Member registered as the holder of that Share.

 

IperionX Limited

 

  Page 3 
   

 

2.9Holding statements and certificates

 

(a)The Directors will not, unless they determine otherwise or are required by any Applicable Law, issue a certificate to a Member for any Shares registered in the Member's name.

 

(b)The Company must issue to each Member, in accordance with Applicable Law, statements of the holdings of Shares registered in the Member's name.

 

(c)Any certificate for Shares must be issued and despatched in accordance with Applicable Law.

 

(d)If a Share is jointly held:

 

(i)the Company is not required to issue more than one certificate for that Share; and

 

(ii)delivery of a certificate for that Share to any one of the joint holders of that Share is delivery to all the joint holders.

 

(e)Subject to 2.9(a) the Company must issue a replacement certificate for a Share if the Company:

 

(i)receives and cancels the existing certificate; or

 

(ii)is satisfied that the existing certificate is lost or destroyed, and the Member complies with all conditions set out in the Corporations Act and pays any fee as the Directors resolve.

 

3Restricted Securities

 

The Company shall comply in all respects with the requirements of the Listing Rules with respect to restricted securities and the following provisions apply:

 

(a)the Company must refuse to acknowledge a disposal (including registering a transfer) of restricted securities during the escrow period for those securities except as permitted by the Listing Rules or ASX;

 

(b)Members must not dispose of restricted securities during the escrow period for those securities except as permitted by the Listing Rules or ASX;

 

(c)if the restricted securities are in the same class as quoted securities, the holder will be taken to have agreed in writing that the restricted securities are to be kept on the Company's issuer sponsored sub-register and are to have a holding lock applied for the duration of the escrow period applicable to those securities;

 

(d)a holder of restricted securities will not be entitled to participate in any return of capital on those restricted securities during the escrow period applicable to those restricted securities except as permitted by the Listing Rules or ASX; and

 

(e)if a holder of restricted securities breaches a restriction deed or a provision of the constitution restricting a disposal of those restricted securities, the holder will not be entitled to any dividend or distribution or to exercise any voting rights, in respect of those restricted securities for so long as the breach continues.

 

4Calls, Company Payments, Forfeiture and Liens

 

Schedule 2 applies and forms part of this constitution.

 

IperionX Limited

 

  Page 4 
   

 

5Transfer of Shares

 

5.1Electronic transfer systems

 

The Company may do any act, matter or thing permitted under Applicable Law to facilitate involvement by the Company in any clearing and settlement facility provided under Applicable Law for the transfer of securities.

 

5.2Forms of transfer

 

Subject to this constitution, a Member may transfer one or more Shares the Member holds by:

 

(a)a proper ASX Settlement transfer;

 

(b)an instrument of transfer in compliance with this constitution; or

 

(c)any other method permitted by Applicable Law.

 

5.3Instrument of transfer

 

An instrument of transfer of a Share referred to in article 5.2(b) must be:

 

(a)in writing;

 

(b)in any usual form or in any other form approved by the Directors that is otherwise permitted by law;

 

(c)subject to the Corporations Act, executed by or on behalf of the transferor, and if required by the Company, the transferee;

 

(d)stamped, if required by a law about stamp duty; and

 

(e)delivered to the Company, at the place where the Register is kept, together with the certificate (if any) of the Share to be transferred and any other evidence as the Directors require to prove:

 

(i)the title of the transferor to that Share;

 

(ii)the right of the transferor to transfer that Share; and

 

(iii)the proper execution of the instrument of transfer.

 

5.4Transferor is holder until transfer registered

 

Subject to the ASX Settlement Operating Rules, a person transferring a Share remains the registered holder of that Share until the transfer for that Share is registered and the name of the person to whom the Share is being transferred is entered in the Register as the holder of that Share.

 

5.5Refusal to register transfers

 

(a)Subject to:

 

(i)Applicable Law;

 

(ii)article 5.3 and articles 5.5(a) to 5.5(i) (inclusive); and

 

(iii)paragraph 2.1(c) of Schedule 2,

 

the Company must not refuse or fail to register a transfer of Shares.

 

(b)The Company may refuse to register a transfer of Shares where Applicable Law permits the Company to do so.

 

IperionX Limited

 

  Page 5 
   

 

(c)The Company must refuse to register a transfer of Shares where Applicable Law or a law about stamp duty requires the Company to do so.

 

(d)Schedule 5 applies and forms part of this constitution.

 

(e)The Company may apply, or may ask ASX Settlement to apply, a holding lock (including to prevent a transfer, or to refuse to register a paper based transfer document) where Applicable Law permits the Company to do so.

 

(f)The Company must give Notice of any refusal to register a transfer of Shares, and the reasons for the refusal, to the person transferring those Shares and the person who lodged the transfer (if not the same person) within five Business Days after the date on which the transfer was lodged with the Company.

 

(g)The Company must give Notice of any holding lock, and the reasons for the holding lock, to the Member of those Shares within five Business Days after the date on which the Company asked for the holding lock.

 

(h)Failure by the Company to give Notice under article 5.5(f) or 5.5(g) does not invalidate the refusal to register the transfer or the holding lock.

 

(i)The powers of the Company under articles 5.5(b) and 5.5(e) may only be exercised by the Directors.

 

5.6No registration fee

 

The Company must not charge a fee to register a transfer of a Share in compliance with this constitution except as permitted by Applicable Law.

 

5.7Transmission of Shares

 

Schedule 3 applies and forms part of this constitution.

 

6Proceeding of Members

 

6.1Who can call meetings of Members

 

(a)The Directors may call a meeting of Members at a time and place as the Directors resolve.

 

(b)Subject to the Corporations Act, a Director may call a meeting of Members at a time and place as that Director determines.

 

(c)The Directors must call and arrange to hold a meeting of Members on the request of Members made in accordance with the Corporations Act.

 

(d)The Members may call and arrange to hold a meeting of Members as provided by the Corporations Act.

 

6.2Annual general meeting

 

The Company must hold an AGM if required by, and in accordance with, Applicable Law.

 

6.3How to call meetings of Members

 

(a)The Company must give not less than Prescribed Notice of a meeting of Members.

 

(b)Notice of a meeting of Members must be given to ASX, each Member, each Director, each Alternate Director and any auditor of the Company.

 

(c)Holders of preference Shares have the same rights as holders of ordinary Shares to:

 

(i)receive Notice of a meeting of Members; and

 

(ii)receive Notices, reports and financial reports of the Company.

 

IperionX Limited

 

  Page 6 
   

 

(d)Subject to article 6.13(h), a Notice of a meeting of Members must include:

 

(i)date and time for the meeting (and if the meeting is to be held in two or more places, the technology that will be used to facilitate this);

 

(ii)the general nature of the business of the meeting;

 

(iii)the date and time (being not more than 48 hours before the meeting) at which persons will be taken for the purposes of the meeting to hold Shares; and

 

(iv)any other information or documents specified by Applicable Law.

 

(e)A person may waive Notice of any meeting of Members by Notice to the Company to that effect.

 

(f)Anything done (including the passing of a resolution) at a meeting of Members is not invalid because either or both a person does not receive Notice of that meeting or the Company accidentally does not give Notice of that meeting to a person.

 

6.4Right to attend meetings of Members

 

(a)Each Eligible Member and any auditor of the Company is entitled to attend any meetings of Members.

 

(b)Holders of preference Shares have the same rights as holders of ordinary Shares to attend a meeting of Members.

 

(c)Subject to this constitution, each Director is entitled to attend and speak at all meetings of Members.

 

(d)The chairperson of a meeting of Members may refuse any person's admission to, or require a person to leave and remain out of, the meeting if that person:

 

(i)in the opinion of the chairperson, is not complying with the reasonable directions of the chairperson;

 

(ii)has any audio or visual recording device;

 

(iii)has a placard or banner;

 

(iv)has an article the chairperson considers to be dangerous, offensive or liable to cause disruption;

 

(v)refuses to produce or to permit examination of any article, or the contents of any article, in the person's possession;

 

(vi)refuses to comply with a request to turn off a mobile telephone, personal communication or similar device;

 

(vii)behaves or threatens to behave, or who the chairperson has reasonable grounds to believe may behave, in a dangerous, offensive or disruptive manner; or

 

(viii)is not:

 

(A)an Eligible Member;

 

(B)a proxy, attorney or representative of an Eligible Member;

 

(C)a Director; or

 

(D)an auditor of the Company.

 

IperionX Limited

 

  Page 7 
   

 

6.5Meeting of Members at more than one place

 

(a)A meeting of Members may be held in two or more places linked together by any technology that:

 

(i)gives the Eligible Members as a whole in those places a reasonable opportunity to participate in proceedings;

 

(ii)enables the chairperson of that meeting to be aware of proceedings in each place; and

 

(iii)enables the Eligible Members in each place to vote on a show of hands and on a poll.

 

(b)If a meeting of Members is held in two or more places under article 6.5(a):

 

(i)an Eligible Member present at one of the places is taken to be present at that meeting; and

 

(ii)that meeting will be deemed to be held at the place stated in the Notice of meeting, or, failing statement of a place in the Notice of meeting, as determined by the chairperson of that meeting.

 

6.6Meeting of Member by Virtual Meeting

 

A meeting of Member may be held virtually using any technology that gives Members as a whole a reasonable opportunity to participate in the meeting.

 

6.7Quorum

 

(a)Two Eligible Members present (including virtually) and entitled to vote at a meeting of Members constitute a quorum.

 

(b)In determining whether a quorum for a meeting of Members is present:

 

(i)where more than one proxy, attorney or representative of an Eligible Member is present, only one of those persons is counted;

 

(ii)where a person is present as an Eligible Member and as a proxy, attorney or representative of another Eligible Member, that person is counted separately for each appointment provided that there is at least one other Eligible Member present; and

 

(iii)where a person is present as a proxy, attorney or representative for more than one Eligible Member, that person is counted separately for each appointment provided that there is at least one other Eligible Member present.

 

(c)A quorum for a meeting of Members must be present at the commencement of that meeting. If a quorum is present at the commencement of a meeting of Members, it is taken to be present throughout that meeting unless the chairperson of that meeting otherwise determines.

 

(d)If a quorum is not present within 30 minutes after the time appointed for a meeting of Members:

 

(i)if that meeting was called under article 6.1(c) or article 6.1(d), that meeting is dissolved; and

 

(ii)any other meeting is adjourned to the date, time and place as the Directors may by Notice to the Members appoint, or failing any appointment, to the same day in the next week at the same time and place as that meeting adjourned.

 

(iii)If a quorum is not present within 30 minutes after the time appointed for an adjourned meeting of Members, that meeting is dissolved.

 

IperionX Limited

 

  Page 8 
   

 

6.8Chairperson

 

(a)The chairperson of Directors (if any) must (if present within 15 minutes after the time appointed for the holding of the meeting and willing to act) chair each meeting of Members.

 

(b)If there is no chairperson of Directors or the chairperson of Directors will be unable to attend a meeting of Members or not willing to chair the meeting, the Directors may, by majority vote at any time prior to a meeting of Members, elect a person to chair a meeting of Members.

 

(c)If at a meeting of Members:

 

(i)there is no chairperson of Directors;

 

(ii)the chairperson of Directors is not present within 15 minutes after the time appointed for the holding of that meeting; or

 

(iii)the chairperson of Directors is present within that time but is not willing to chair all or part of that meeting,

 

the Directors present may, by majority vote, elect a person present to chair all or part of that meeting.

 

(d)Subject to articles 6.8(a) to 6.8(c) (inclusive), if at a meeting of Members:

 

(i)a chairperson of that meeting has not been elected by the Directors under article 6.8(a), 6.8(b) or 6.8(c); or

 

(ii)the chairperson of that meeting elected by the Directors is not willing to chair all or part of that meeting,

 

the Eligible Members present must elect another person present and willing to act to chair all or part of that meeting.

 

6.9General conduct of meetings

 

(a)The chairperson of a meeting of Members (including any person acting with authority of the chairman):

 

(i)has charge of the general conduct of each meeting of Members and the procedures to be adopted at the meeting (including the procedure for the conduct of the election of Directors);

 

(ii)may require any person wishing to attend the meeting to comply with searches, restrictions or other security arrangements considered appropriate;

 

(iii)if there is insufficient room at the meeting venue, may arrange another or a second venue (without giving notice or putting the matter to a vote), even if the Members present in the separate room are not able to participate in the conduct of the meeting, the meeting will nevertheless be treated as validly held in the main room;

 

(iv)may make rulings or adjourn a meeting of Members without putting the question (or any question) to the vote if that action is required to ensure the orderly conduct of that meeting

 

(v)may require the adoption of any procedure which is in the chairman's opinion necessary or desirable for proper and orderly debate or discussion and the proper and orderly casting or recording of votes at the meeting of Members;

 

IperionX Limited

 

  Page 9 
   

 

(vi)determine any dispute concerning the admission, validity or rejection of a vote at that meeting;

 

(vii)terminate debate or discussion on any matter being considered at that meeting and require that matter be put to a vote;

 

(viii)refuse to allow debate or discussion on any matter which is not business referred to in the Notice of that meeting or is not business allowed to be discussed in accordance with the Corporations Act;

 

(ix)subject to the Corporations Act, refuse to allow any amendment to be moved to a resolution set out in the Notice of that meeting;

 

(x)may withdraw from consideration by the meeting any resolution that is set out in the notice of that meeting (other than those requisitioned by Members or required by law); and

 

(xi)determine who may speak at that meeting.

 

(b)A decision by the chairman under article 6.9(a) (including any person acting with the chairman's authority) is final.

 

(c)The powers conferred on the chairperson of a meeting of Members under article 6.9(a) do not limit the powers conferred by law.

 

6.10Resolutions of Members

 

(a)A resolution at a meeting of Members is passed if the number of votes cast in favour of the resolution by Members entitled to vote on the resolution exceeds the number of votes cast against the resolution by Members entitled to vote on the resolution.

 

(b)Unless a poll is requested in accordance with articles 6.12(a) and 6.12(h) (inclusive), a resolution put to the vote at a meeting of Members must be decided on a show of hands.

 

(c)A declaration by the chairperson of a meeting of Members that a resolution on a show of hands is passed, passed by a particular majority, or not passed, and an entry to that effect in the minutes of that meeting, are sufficient evidence of that fact, unless proved incorrect.

 

6.11Direct Voting

 

(a)The Directors may determine that at any meeting of Members or class meeting, a Member who is entitled to attend and vote on a resolution at that meeting is entitled a direct vote in respect of that resolution. A "direct vote" includes a vote delivered to the Company by post, fax or other electronic means approved by Directors. The Directors may prescribe rules to govern direct voting including specifications as to the form, method and timing of giving the direct vote in order for the vote to be valid, and the treatment of direct votes.

 

(b)A direct vote on a resolution at a meeting in respect of a share cast in accordance with article 6.11(a) is of no effect and will be disregarded:

 

(i)if, at the time of the resolution, the person who cast the direct vote:

 

(A)is not entitled to vote on the resolution in respect of the share; or

 

(B)would not be entitled to vote on the resolution in respect of the share if the person were present at the meeting at which the resolution is considered;

 

(ii)if, had the vote been cast in person at the meeting at which the resolution is considered:

 

(A)the vote would not be valid; or

 

(B)the Company would be obliged to disregard the vote;

 

IperionX Limited

 

  Page 10 
   

 

(iii)subject to any rules prescribed by the Directors, if the person who cast the direct vote is present in person at the meeting at any time the resolution is considered; and

 

(iv)if the direct vote was cast otherwise than in accordance with any regulations, rules and procedures prescribed by the Directors under article 6.11(a).

 

(c)Subject to any rules prescribed by the Directors, if the Company receives a valid direct vote on a resolution in accordance with articles 6.11(a) and 6.11(b) and, prior to, after or at the same time as receipt of the direct vote, the Company receives an instrument appointing a proxy, attorney or Personal Representative to vote on behalf of the same Member on that resolution, the Company may regard the direct vote as effective in respect of that resolution and disregard any vote cast by the proxy, attorney or Personal Representative on the resolution at the meeting.

 

6.12Polls

 

(a)A poll may be demanded on any resolution at a meeting of Members.

 

(b)A poll on a resolution at a meeting of Members may be demanded by:

 

(i)at least five Eligible Members present and entitled to vote on that resolution;

 

(ii)one or more Eligible Members present and who are together entitled to at least five per cent of the votes that may be cast on that resolution on a poll; or

 

(iii)the chairperson of that meeting.

 

(c)A poll on a resolution at a meeting of Members may be demanded:

 

(i)before a vote on that resolution is taken; or

 

(ii)before or immediately after the results of the vote on that resolution on a show of hands are declared.

 

(d)A demand for a poll may be withdrawn.

 

(e)A poll demanded on a resolution at a meeting of Members other than for the election of a chairperson of that meeting or the adjournment of that meeting must be taken in the manner and at the time and place the chairperson directs.

 

(f)A poll demanded on a resolution at a meeting of Members for the election of a chairperson of that meeting or the adjournment of that meeting must be taken immediately.

 

(g)The result of a poll demanded on a resolution of a meeting of Members is a resolution of that meeting.

 

(h)A demand for a poll on a resolution of a meeting of Members does not prevent the continuance of that meeting or that meeting dealing with any other business.

 

6.13Adjourned, cancelled and postponed meetings

 

(a)The chairperson of a meeting of Members:

 

(i)may adjourn that meeting to any day, time and place; and

 

(ii)must adjourn that meeting if the Eligible Members present with a majority of votes that may be cast at that meeting agree or direct the chairperson to do so. The chairperson may adjourn that meeting to any day, time and place.

 

The chairman may, but is not required to, seek consent of the meeting to the adjournment.

 

IperionX Limited

 

  Page 11 
   

 

(b)No person other than the chairperson of a meeting of Members may adjourn that meeting.

 

(c)The Company is only required to give Notice of a meeting of Members resumed from an adjourned meeting if the period of adjournment exceeds 28 days.

 

(d)Only business left unfinished is to be transacted at a meeting of Members resumed after an adjournment.

 

(e)Subject to articles 6.13(a) to 6.13(h) (inclusive), the Directors may at any time postpone or cancel a meeting of Members by:

 

(i)the Directors passing a resolution to postpone or cancel that meeting, with such postponement or cancellation taking effect upon the Directors passing that resolution;

 

(ii)giving Notice as soon as practicable to ASX (or, if the Company is not admitted to the Official List at the relevant time, by other publication) of the postponement or cancellation of that meeting ; and

 

(iii)giving Notice as soon as practicable to each person who is, at the date of the Notice:

 

(A)a Member;

 

(B)a Director or Alternate Director; or

 

(C)an auditor of the Company.

 

(f)A meeting of Members called under article 6.1(c) must not be cancelled by the Directors without the consent of the Members who requested that meeting.

 

(g)A meeting of Members called under article 6.1(d) must not be cancelled or postponed by the Directors without the consent of the Members who called that meeting.

 

(h)A Notice under article 6.13(c) of a meeting of Members resumed from an adjourned meeting and a Notice under article 6.13(e)(iii) postponing a meeting of Members must set out the place, date and time for the revised meeting (and if the revised meeting is to be held in two or more places, the technology that will be used to facilitate this).

 

6.14Number of votes

 

(a)Subject to this constitution and any rights or restrictions attached to a class of Shares, on a show of hands at a meeting of Members, every Eligible Member present has one vote.

 

(b)Subject to this constitution and any rights or restrictions attached to a class of Shares, on a poll at a meeting of Members, every Eligible Member present has:

 

(i)one vote for each fully paid up Share (whether the issue price of the Share was paid up or credited or both) that the Eligible Member holds; and

 

(ii)a fraction of one vote for each partly paid up Share that the Eligible Member holds. The fraction is equal to the proportion which the amount paid up on that Share (excluding amounts credited) is to the total amounts paid up and payable (excluding amounts credited) on that Share.

 

(c)Amounts paid in advance of a call on a Share are ignored when calculating the proportion under article 6.14(b)(ii).

 

IperionX Limited

 

  Page 12 
   

 

(d)If the total number of votes to which an Eligible Member is entitled on a poll does not constitute a whole number, the Company must disregard the fractional part of that total.

 

(e)If a Share is held jointly and more than one Member votes in respect of that Share, only the vote of the Member whose name appears first in the Register counts.

 

(f)A person may vote in respect of a Share at a meeting of Members if:

 

(i)the person is entitled to be registered as the holder of that Share because of a Transmission Event; and

 

(ii)the person satisfied the Directors of that entitlement not less than 48 hours before that meeting.

 

(g)A Member who holds restricted securities is not entitled to any voting rights in respect of those restricted securities during:

 

(i)a breach of the Listing Rules relating to those restricted securities; or

 

(ii)a breach of a restriction agreement.

 

(h)An Eligible Member present at a meeting of Members is not entitled to vote on any resolution in respect of any Shares on which any calls due and payable in respect of those Shares have not been paid.

 

(i)An Eligible Member present at a meeting of Members is not entitled to vote on a resolution at that meeting where that vote is prohibited by Applicable Law, an order of a court of competent jurisdiction or ASX.

 

(j)The Company must disregard any vote on a resolution purported to be cast by a Member present at a meeting of Members where that person is not entitled to vote on that resolution.

 

(k)The authority of any proxy or attorney for an Eligible Member to speak or vote at a meeting of Members in respect of the Shares to which the authority relates is suspended while the Eligible Member is present in person at that meeting.

 

(l)If more than one proxy, or more than one attorney authorised to speak or vote at a meeting of Members in respect of a Share is present at a meeting of Members:

 

(i)none of them is entitled to vote on a show of hands; and

 

(ii)on a poll, the vote of each one is of no effect where the aggregate number or proportion of the Eligible Member's votes for which they have been appointed exceeds the total number or proportion of votes that could be cast by the Eligible Member.

 

6.15Objections to qualification to vote

 

(a)An objection to the qualification of any person to vote at a meeting of Members may only be made:

 

(i)before that meeting, to the Directors; or

 

(ii)at that meeting (or any resumed meeting if that meeting is adjourned), to the chairperson of that meeting.

 

(b)Any objection under article 6.15(a) must be decided by the Directors or the chairperson of the meeting of Members (as the case may be), whose decision, made in good faith, is final and conclusive.

 

IperionX Limited

 

  Page 13 
   

 

6.16Proxies, attorneys and representatives

 

(a)An Eligible Member, who is entitled to attend and cast a vote at a meeting of Members, may vote on a show of hands and on a poll:

 

(i)in person or, if the Member is a body corporate, by its representative appointed in accordance with the Corporations Act;

 

(ii)by proxy or, if the Member is entitled to cast two or more votes at that meeting, by not more than two proxies; or

 

(iii)by attorney or, if the Member is entitled to cast two or more votes at that meeting, by not more than two attorneys.

 

(b)A proxy, attorney or representative of a Member need not be a Member.

 

(c)A Member may appoint a proxy, attorney or representative for:

 

(i)all or any number of meetings of Members; or

 

(ii)a particular meeting of Members.

 

(d)A proxy is valid if:

 

(i)the proxy instrument is signed by the Member making the appointment which contains:

 

(A)the name and address of that Member;

 

(B)the name of the Company;

 

(C)the name of the proxy or the name of the office of the proxy; and

 

(D)the meetings of Members at which the proxy may be used; or

 

(ii)submitted by any electronic means approved by the Directors.

 

(e)The chairperson of a meeting of Members may determine that an instrument appointing a proxy is valid even if it contains only some of the information specified in article 6.16(d).

 

(f)The decision of the chairperson of a meeting of Members as to the validity of an instrument appointing a proxy, attorney or representative is final and conclusive.

 

(g)Unless otherwise provided in the Corporations Act or in the instrument appointing a proxy or attorney, a proxy or attorney may:

 

(i)agree to a meeting of Members being called by shorter Notice than is required by the Corporations Act or this constitution;

 

(ii)speak on any resolution at a meeting of Members on which the proxy or attorney may vote;

 

(iii)vote at a meeting of Members (but only to the extent allowed by the appointment);

 

(iv)demand or join in demanding a poll on any resolution at a meeting of Members on which the proxy or attorney may vote; and

 

(v)attend and vote at any meeting of Members which is rescheduled or adjourned.

 

(h)Unless otherwise provided in the instrument appointing a proxy or attorney, a proxy or attorney may vote on:

 

IperionX Limited

 

  Page 14 
   

 

(i)any amendment to a resolution on which the proxy or attorney may vote;

 

(ii)any motion not to put that resolution or any similar motion; and

 

(iii)any procedural motion relating to that resolution, including a motion to elect the chairperson of a meeting of Members, vacate the chair or adjourn that meeting,

 

even if the appointment directs the proxy or attorney how to vote on that resolution.

 

(i)The Company must only send a form of proxy to Eligible Members in respect of a meeting of Members which provides for the Eligible Member:

 

(i)to appoint proxies of the Eligible Member's choice, but may specify who is to be appointed as proxy if the Eligible Member does not choose; and

 

(ii)to vote for or against each resolution, and may also provide for the Eligible Member to abstain from voting on each resolution or for the proxy to exercise a discretion to vote for or against each resolution.

 

(j)If the name of the proxy or the name of the office of the proxy in a proxy form of an Eligible Member is not filled in, the proxy of that Eligible Member is:

 

(i)the person specified by the Company in the form of proxy in the case the Eligible Member does not choose; or

 

(ii)if no person is so specified, the chairperson of that meeting.

 

(k)An Eligible Member may specify the manner in which a proxy or attorney is to vote on a particular resolution at a meeting of Members.

 

(l)The appointment of a proxy or attorney by an Eligible Member may specify the proportion or number of the Eligible Member's votes that the proxy or attorney may exercise.

 

(m)If an Eligible Member appoints two persons as proxy or attorney, and the appointment does not specify the proportion or number of the Eligible Member's votes those persons may exercise, each of those persons may exercise one half of the votes of the Eligible Member.

 

(n)If the total number of votes to which a proxy or attorney is entitled to exercise does not constitute a whole number, the Company must disregard the fractional part of that total.

 

(o)An appointment of proxy or attorney for a meeting of Members is effective only if the Company receives the appointment (and any authority under which the appointment was signed or a certified copy of the authority) not less than:

 

(i)48 hours before the time scheduled for commencement of that meeting; or

 

(ii)in the case of a meeting which has been adjourned or postponed, 48 hours before the time scheduled for resumption or commencement of that meeting.

 

(p)Unless the Company has received Notice of the matter not less than 48 hours before the time scheduled for the commencement of a meeting of Members, a vote cast at that meeting by a person appointed by an Eligible Member as a proxy, attorney or representative is, subject to this constitution valid even if, before the person votes:

 

(i)there is a Transmission Event in respect of that Eligible Member;

 

(ii)that Eligible Member revokes the appointment of that person;

 

(iii)that Eligible Member revokes the authority under which that person was appointed by a third party; or

 

(iv)that Eligible Member transfers the Shares in respect of which the appointment is made.

 

IperionX Limited

 

  Page 15 
   

 

7Directors

 

7.1Number of Directors

 

(a)The Company must have not less than three Directors.

 

(b)The Company may by ordinary resolution passed at a meeting of Members alter the maximum or minimum number of Directors provided that the minimum is not less than three.

 

(c)Subject to articles 7.1(a) to 7.1(d) (inclusive), the Directors must determine the number of Directors provided that the Directors cannot reduce the number of Directors below the number in office at the time that determination takes effect.

 

(d)If the number of Directors is below the minimum fixed by this constitution, the Directors must not act except in emergencies, for appointing one or more Directors in order to make up a quorum for a meeting of Directors, or to call and arrange to hold a meeting of Members.

 

7.2Appointment of Directors

 

(a)The first Directors are the persons specified as Directors in the application for the registration of the Company under the Corporations Act.

 

(b)Subject to articles 7.1(a) to 7.1(d) (inclusive), the Directors may appoint any person as a Director.

 

(c)The Company may by ordinary resolution passed at a meeting of Members elect any person as a Director.

 

(d)A Director need not be a Member.

 

(e)The Company must hold an election of Directors each year.

 

(f)The Company must accept nominations for the election of a Director in the case of a meeting of Members called under article 6.1(c), 30 Business Days, or otherwise, 35 Business Days, before the date of the meeting of Members at which the Director may be elected.

 

(g)A nomination of a person for Director (other than a Director retiring in accordance with this constitution) must be:

 

(i)in writing;

 

(ii)signed by a Member entitled to attend and vote at the meeting of Members at which the election is proposed;

 

(iii)accompanied by a Notice signed by the nominee consenting to the nomination; and

 

(iv)lodged with the Company at its registered office.

 

7.3Retirement of Directors and vacation of office

 

(a)Articles 7.3(b) to 7.3(d) (inclusive) and articles 7.3(i) and 7.3(j) do not apply to the managing director of the Company, or if more than one, the managing director of the Company determined by the Directors.

 

(b)A Director must retire from office no later than the longer of:

 

(i)the third AGM; or

 

(ii)three years following that Director's last election or appointment.

 

IperionX Limited

 

  Page 16 
   

 

(c)If the Company has three or more Directors, one third of the Directors (excluding Directors required to retire under article 7.3(j) and rounded down to the nearest whole number) must retire at each AGM.

 

(d)If the Company has less than three Directors, one Director must retire at each AGM.

 

(e)The Directors to retire under articles 7.3(c) and 7.3(d) are:

 

(i)those who have held their office as Director the longest period of time since their last election or appointment to that office; and

 

(ii)if two or more Directors have held office for the same period of time, those Directors determined by lot, unless those Directors agree otherwise.

 

(f)A Director who retires under articles 7.3(b) to 7.3(d) (inclusive) or article 7.3(l) is eligible for re election.

 

(g)A Director may resign from office by giving the Company Notice.

 

(h)The Company may by ordinary resolution passed at a meeting of Members remove any Director, and if thought fit, appoint another person in place of that Director.

 

(i)A Director appointed under article 7.2(b) may retire at the next meeting of Members and is eligible for election at that meeting.

 

(j)Unless a Director appointed under article 7.2(b) has retired under article 7.3(i), that Director must retire at the next AGM, and is eligible for re election at that meeting.

 

(k)A Director ceases to hold office immediately if:

 

(i)the Director becomes mentally unfit to hold office, or the Director or his or her affairs are made subject to any law relating to mental health or incompetence;

 

(ii)without the consent of the other Directors, the Director is absent from all meetings of the Directors held during a period of six months;

 

(iii)the Director resigns or is removed under this constitution;

 

(iv)the Director is an Executive Director (including a managing director) and ceases and continues not to be to be an employee of the Company or of a related body corporate of the Company (not including being a Non Executive Director);

 

(v)the Director becomes bankrupt; or

 

(vi)the Director becomes disqualified by law from being a Director or the Corporations Act otherwise provides.

 

(l)A Director who ceases to be the managing director must retire at the next AGM following the Director ceasing to be managing director.

 

7.4Alternate Directors

 

(a)With the approval of a majority of the other Directors, a Director may appoint a person as an Alternate Director of that Director for any period.

 

(b)An Alternate Director need not be a Member.

 

(c)The appointing Director may terminate the appointment of his or her Alternate Director at any time.

 

IperionX Limited

 

  Page 17 
   

 

(d)A Notice of appointment, or termination of appointment, of an Alternate Director is effective only if:

 

(i)the Notice is in writing;

 

(ii)the Notice is signed by the Director who appointed that Alternate Director;

 

(iii)the Company is given a copy of the Notice; and

 

(iv)in the case of an appointment of an Alternate Director, the Alternate Director has provided their written consent to act as an Alternate Director.

 

(e)If the Director who appointed an Alternate Director is not present at a meeting of Directors, that Alternate Director may, subject to this constitution and Applicable Law:

 

(i)attend, count in the quorum of, speak at, and vote at that meeting in place of that appointing Director; and

 

(ii)exercise any other powers (except the power under article 7.4(a)) that the appointing Director may exercise.

 

(f)An Alternate Director cannot exercise any powers of his or her appointing Director if that appointing Director ceases to be a Director.

 

(g)A person does not cease to be a Director under article 7.4(f) if that person retires as a Director at a meeting of Members and is re elected as a Director at that meeting.

 

(h)Subject to article 7.5(g), the Company is not required to pay any remuneration to an Alternate Director.

 

(i)An Alternate Director is an officer of the Company and not an agent of his or her appointing Director.

 

7.5Remuneration of Directors

 

(a)The Company may pay to the Non Executive Directors a maximum total amount of Director's fees, determined by the Company in a meeting of Members, or until so determined, as the Directors resolve.

 

(b)The remuneration of the Non Executive Directors must not be calculated as a commission on, or percentage of, profits or operating revenue.

 

(c)The Directors may determine the manner in which all or part of the amount in article 7.5(a) is divided between the Non Executive Directors, or until so determined, the amount in article 7.5(a) must be divided between the Non Executive Directors equally.

 

(d)The remuneration of the Non Executive Directors is taken to accrue from day to day.

 

(e)The remuneration of the Executive Directors:

 

(i)must, subject to the provisions of any contract between each of them and the Company, be fixed by the Directors; and

 

(ii)must not be calculated as a commission on, or percentage of, operating revenue.

 

(f)If a Director performs extra or special services, including being:

 

(i)a member on a committee of Directors; or

 

(ii)the chairperson of Directors or deputy chairperson of Directors,

 

the Company may, subject to articles 7.5(a) to 7.5(i) (inclusive), pay additional remuneration or provide benefits to that Director as the Directors resolve.

 

IperionX Limited

 

  Page 18 
   

 

(g)The Company must pay all reasonable travelling, accommodation and other expenses that a Director or Alternate Director properly incurs:

 

(i)in attending meetings of Directors or any meetings of committees of Directors;

 

(ii)in attending any meetings of Members; and

 

(iii)in connection with the business of the Company.

 

(h)Any Director may participate in any fund, trust or scheme for the benefit of:

 

(i)past or present employees or Directors of the Company or a related body corporate of the Company; or

 

(ii)the dependants of, or persons connected with, any person referred to in article 7.5(h)(i).

 

(i)The Company may give, or agree to give, a person a benefit in connection with that person's, or someone else's, retirement from a board or managerial office in the Company or a related body corporate of the Company.

 

7.6Interests of Directors

 

(a)A Director may:

 

(i)hold an office or place of profit (except as auditor) in the Company, on any terms as the Directors resolve;

 

(ii)hold an office or otherwise be interested in any related body corporate of the Company or other body corporate in which the Company is interested; or

 

(iii)act, or the Director's firm may act, in any professional capacity for the Company (except as auditor) or any related body corporate of the Company or other body corporate in which the Company is interested,

 

and retain the benefits of doing so if the Director discloses in accordance with the Corporations Act the interest giving rise to those benefits.

 

(b)If a Director discloses the interest of the Director in accordance with the Corporations Act:

 

(i)the Director may contract or make an arrangement with the Company, or a related body corporate of the Company or a body corporate in which the Company is interested, in any matter in any capacity;

 

(ii)the Director may, subject to the Corporations Act, be counted in a quorum for a meeting of Directors considering the contract or arrangement;

 

(iii)the Director may, subject to Applicable Law, vote on whether the Company enters into the contract or arrangement, and on any matter that relates to the contract or arrangement;

 

(iv)the Director may sign on behalf of the Company, or witness the affixing of the common seal of the Company to, any document in respect of the contract or arrangement;

 

(v)the Director may retain the benefits under the contract or arrangement; and

 

(vi)the Company cannot avoid the contract or arrangement merely because of the existence of the Director's interest.

 

(c)The Director must give to the Company:

 

(i)at its registered office; or

 

(ii)any other place the Company reasonably notifies the Director in writing,

 

IperionX Limited

 

  Page 19 
   

 

the information which the Company is required by the Listing Rules to disclose to ASX in respect of:

 

(iii)Notifiable Interests of the Director; and

 

(iv)changes to the Notifiable Interests of the Director,

 

in the form which the Company is required to tell ASX under the Listing Rules.

 

(d)The information referred to in article 7.6(c) must be given to the Company as soon as reasonably possible after each of the following dates but in any event no later than three Business Days after each of the following dates:

 

(i)when the Director is appointed as a Director of the Company, the date of appointment;

 

(ii)when a change in a Notifiable Interest of the Director occurs, the date of the change; and

 

(iii)when the Director ceases to be a director of the Company, the date of cessation.

 

(e)Each Director authorises the Company to give the information provided by the Director under article 7.6(c) to ASX on the Director's behalf and as the Director's agent.

 

(f)The Company may enforce after the date a person ceases to be a Director an obligation of that person under article 7.6(c) in respect of events which occurred on or prior to the date that person ceased to be a Director.

 

8Officers

 

8.1Managing director

 

(a)The Directors may appoint one or more of themselves as a managing director, for any period and on any terms (including as to remuneration) as the Directors resolve.

 

(b)Subject to any agreement between the Company and a managing director and without prejudice to any other article in this constitution, the Directors may remove or dismiss a managing director (without removing him as a Director) at any time, with or without cause.

 

(c)The Directors may delegate any of their powers (including the power to delegate) to a managing director.

 

(d)The Directors may revoke or vary:

 

(i)the appointment of a managing director; or

 

(ii)any power delegated to a managing director,

 

without removing him as a Director.

 

(e)A managing director must exercise the powers delegated to him or her in accordance with any directions of the Directors.

 

(f)The exercise of a delegated power by a managing director is as effective as if the Directors exercised the power.

 

(g)A person ceases to be a managing director if the person ceases to be a Director.

 

(h)Subject to article 7.3(k)(iv), removal as managing director under this article 8 does not remove the managing director as a Director.

 

IperionX Limited

 

  Page 20 
   

 

8.2Secretary

 

(a)The first Secretary is the person specified in the application for registration of the Company as company secretary.

 

(b)The Directors may appoint one or more Secretaries, for any period and on any terms (including as to remuneration) as the Directors resolve.

 

(c)Subject to any agreement between the Company and a Secretary, the Directors may remove or dismiss a Secretary at any time, with or without cause.

 

(d)The Directors may revoke or vary the appointment of a Secretary.

 

8.3Indemnity and insurance

 

(a)To the extent permitted by law, the Company must indemnify each Relevant Officer against:

 

(i)a Liability of that person; and

 

(ii)Legal Costs of that person.

 

(b)To the extent permitted by law, the Company may make a payment (whether by way of advance, loan or otherwise) to a Relevant Officer in respect of Legal Costs of that person.

 

(c)To the extent permitted by law, the Company may pay, or agree to pay, a premium for a contract insuring a Relevant Officer against:

 

(i)a Liability of that person; and

 

(ii)Legal Costs of that person.

 

(d)To the extent permitted by law, the Company may enter into an agreement or deed with:

 

(i)a Relevant Officer; or

 

(ii)a person who is, or has been an officer of the Company or a subsidiary of the Company,

 

under which the Company must do all or any of the following:

 

(iii)keep books of the Company and allow either or both that person and that person's advisers access to those books on the terms agreed;

 

(iv)indemnify that person against any Liability of that person;

 

(v)make a payment (whether by way of advance, loan or otherwise) to that person in respect of Legal Costs of that person; and

 

(vi)keep that person insured in respect of any act or omission by that person while a Relevant Officer or an officer of the Company or a subsidiary of the Company, on the terms agreed (including as to payment of all or part of the premium for the contract of insurance).

 

IperionX Limited

 

  Page 21 
   

 

9Powers of the Company and Directors

 

9.1General powers

 

(a)The Company may exercise in any manner permitted by the Corporations Act any power which a public company limited by shares may exercise under the Corporations Act.

 

(b)The business of the Company is managed by or under the direction of the Directors.

 

(c)The Directors may exercise all the powers of the Company except any powers that the Corporations Act or this constitution requires the Company to exercise in meetings of Members.

 

9.2Execution of documents

 

(a)If the Company has a common seal, the Company may execute a document if that seal is fixed to the document and the fixing of that seal is witnessed by:

 

(i)two Directors;

 

(ii)a Director and a Secretary; or

 

(iii)a Director and another person appointed by the Directors for that purpose.

 

(b)The Company may execute a document without a common seal if the document is signed by:

 

(i)two Directors;

 

(ii)a Director and a Secretary; or

 

(iii)a Director and another person appointed by the Directors for that purpose.

 

(c)The Company may execute a document as a deed if the document is expressed to be executed as a deed and is executed in accordance with article 9.2(a) or 9.2(b).

 

(d)The Directors may resolve, generally or in a particular case, that any signature on certificates for securities of the Company may be affixed by mechanical or other means.

 

(e)Negotiable instruments may be signed, drawn, accepted, endorsed or otherwise executed by or on behalf of the Company in the manner and by the persons as the Directors resolve.

 

9.3Committees and delegates

 

(a)The Directors may delegate any of their powers (including this power to delegate) to a committee of Directors, a Director, an employee of the Company or any other person.

 

(b)The Directors may revoke or vary any power delegated under article 9.3(a).

 

(c)A committee or delegate must exercise the powers delegated in accordance with any directions of the Directors.

 

(d)The exercise of a delegated power by the committee or delegate is as effective as if the Directors exercised the power.

 

(e)Article 10 applies with the necessary changes to meetings of a committee of Directors.

 

IperionX Limited

 

  Page 22 
   

 

9.4Attorney or agent

 

(a)The Directors may appoint any person to be attorney or agent of the Company for any purpose, for any period and on any terms (including as to remuneration) as the Directors resolve.

 

(b)The Directors may delegate any of their powers (including the power to delegate) to an attorney or agent.

 

(c)The Directors may revoke or vary:

 

(i)an appointment under article 9.4(a); or

 

(ii)any power delegated to an attorney or agent.

 

10Proceedings of Directors

 

10.1Written resolutions of Directors

 

(a)The Directors may pass a resolution without a meeting of the Directors being held if all of the Directors entitled to vote on the resolution assent to a document containing a statement that they are in favour of the resolution set out in the document. For the avoidance of doubt, a Director who is prohibited from voting on a resolution pursuant to section 195(1)(b) of the Corporations Act will, for the purposes of this article 10.1(a), not be entitled to vote on such resolution.

 

(b)Separate copies of the document referred to in article 10.1(a) may be used for assenting to by Directors if the wording of the resolution and the statement is identical in each copy.

 

(c)A Director may signify assent to a document under articles 10.1(a) to 10.1(e) (inclusive) by signing the document or by notifying the Company of the assent of the Director:

 

(i)in a manner permitted by article 12.3; or

 

(ii)by any technology including telephone or email.

 

(d)Where a Director signifies assent to a document under article 10.1(c) other than by signing the document, the Director must by way of confirmation sign the document before or at the next meeting of Directors attended by that Director.

 

(e)The resolution the subject of a document under article 10.1(a) is not invalid if a Director does not comply with article 10.1(d).

 

10.2Meetings of Directors

 

(a)The Directors may meet, adjourn and otherwise regulate their meetings as they think fit.

 

(b)A meeting of Directors may be held using any technology.

 

(c)If a meeting of Directors is held in two or more places linked together by any technology:

 

(i)a Director present at one of the places is taken to be present at the meeting unless and until the Director states to the chairperson of that meeting that the Director is discontinuing her or her participation in that meeting; and

 

(ii)the chairperson of that meeting may determine at which place the meeting will be taken to have been held.

 

IperionX Limited

 

  Page 23 
   

 

10.3Who can call meetings of Directors

 

(a)A Director may call a meeting of Directors at any time.

 

(b)On request of any Director, a Secretary of the Company must call a meeting of the Directors.

 

10.4How to call meetings of Directors

 

(a)Notice of a meeting of Directors must be given to each Director and Alternate Director.

 

(b)The Company must give not less than 12 hours' Notice of a meeting of Directors, unless all Directors agree otherwise.

 

(c)A Director or Alternate Director may waive Notice of a meeting of Directors by Notice in writing to the Company to that effect.

 

10.5Quorum

 

(a)Subject to the Corporations Act, a quorum for a meeting of Directors is:

 

(i)if the Directors have fixed a number for the quorum, that number of Directors; and

 

(ii)in any other case, two Directors entitled to vote on a resolution that may be proposed at that meeting.

 

(b)In determining whether a quorum for a meeting of Directors is present:

 

(i)where a Director has appointed an Alternate Director, that Alternate Director is counted if the appointing Director is not present;

 

(ii)where a person is present as Director and an Alternate Director for another Director, that person is counted separately provided that there is at least one other Director or Alternate Director present; and

 

(iii)where a person is present as an Alternate Director for more than one Director, that person is counted separately for each appointment provided that there is at least one other Director or Alternate Director present.

 

(c)A quorum for a meeting of Directors must be present at all times during the meeting.

 

(d)If there are not enough persons to form a quorum for a meeting of Directors, one or more of the Directors (including those who have an interest in a matter being considered at that meeting) may call a meeting of Members and the Members may pass a resolution to deal with the matter.

 

10.6Chairperson

 

(a)Subject to article 10.6(b), the Directors may elect a Director as chairperson of Directors or deputy chairperson of Directors for any period they resolve, or if no period is specified, until that person ceases to be a Director.

 

(b)The Directors may remove the chairperson of Directors or deputy chairperson of Directors at any time.

 

(c)The chairperson of Directors must (if present within 15 minutes after the time appointed for the holding of the meeting and willing to act) chair each meeting of Directors.

 

(d)If:

 

(i)there is no chairperson of Directors; or

 

IperionX Limited

 

  Page 24 
   

 

(ii)the chairperson of Directors is not present within 15 minutes after the time appointed for the holding of a meeting of Directors; or

 

(iii)the chairperson of Directors is present within that time but is not willing to chair all or part of that meeting,

 

then if the Directors have elected a deputy chairperson of Directors, the deputy chairperson of Directors must (if present within 15 minutes after the time appointed for the holding of the meeting and willing to act) chair all or part of the meeting of Directors.

 

(e)Subject to articles 10.6(c) and 10.6(d), if:

 

(i)there is no deputy chairperson of Directors; or

 

(ii)the deputy chairperson of Directors is not present within 15 minutes after the time appointed for the holding of a meeting of Directors; or

 

(iii)the deputy chairperson of Directors is present within that time but is not willing to chair all or part of that meeting,

 

the Directors present must elect one of themselves to chair all or part of the meeting of Directors.

 

(f)A person does not cease to be a chairperson of Directors or deputy chairperson of Directors if that person retires as a Director at a meeting of Members and is re elected as a Director at that meeting.

 

10.7Resolutions of Directors

 

(a)A resolution of Directors is passed if more votes are cast in favour of the resolution than against it.

 

(b)Subject to article 7.6(a) to 7.6(f) (inclusive) and articles 10.7(a) to 10.7(d) (inclusive), each Director has one vote on a matter arising at a meeting of the Directors.

 

(c)In determining the number of votes a Director has on a matter arising at a meeting of Directors:

 

(i)where a person is present as Director and an Alternate Director for another Director, that person has one vote as a Director and, subject to article 7.4(e), one vote as an Alternate Director; and

 

(ii)where a person is present as an Alternate Director for more than one Director, that person has, subject to article 7.4(e), one vote for each appointment.

 

(d)Subject to Applicable Law, in case of an equality of votes on a resolution at a meeting of Directors, the chairperson of that meeting has a casting vote on that resolution in addition to any vote the chairperson has in his or her capacity as a Director in respect of that resolution.

 

11Dividends and Profits

 

11.1Who may determine Dividends

 

(a)Subject to and in accordance with the Corporations Act, the Listing Rules, the rights of any preference Shares and to the rights of the holders of any Shares created or raised under any special arrangement as to Dividend, the Directors may from time to time declare a Dividend to be paid to the shareholders entitled to the Dividend. Subject to the rights of any preference Shares and to the rights of the holders of any Shares created or raised under any special arrangement as to a Dividend, the Dividend as declared will be payable on all Shares according to the proportion that the amount paid (not credited) is of the total amounts paid and payable (excluding amounts credited) in respect of such Shares.

 

IperionX Limited

 

  Page 25 
   

 

(b)The Directors may determine that a Dividend is payable on Shares and fix:

 

(i)the amount of the Dividend;

 

(ii)whether the Dividend is franked, the franking percentage and the franking class;

 

(iii)the time for determining entitlements to the Dividend;

 

(iv)the time for the payment of the Dividend; and

 

(v)the method of payment of the Dividend.

 

(c)The method of payment of a Dividend may include any or all of the payment of cash, the issue of Shares, the grant of Company options or other Company securities, the transfer of shares or any other securities in any other body corporate or units in any unit trust or the transfer of any other assets.

 

(d)If the method of payment of a Dividend includes an issue or transfer of shares in a body corporate, each Member:

 

(i)is deemed to have agreed to become a member of that body corporate and be bound by the constitution of that body corporate; and

 

(ii)in the case of a transfer, appoints the Company and each Director as its agent to execute instrument of transfer or other document required to transfer those shares to that Member.

 

(e)A Dividend in respect of a Share must be paid to the person whose name is entered in the Register as the holder of that Share:

 

(i)where the Directors have fixed a time under article 11.1(b)(iii), at that time; or

 

(ii)in any other case, on the date the Dividend is paid.

 

(f)Subject to article 11.1(g), a Member who holds restricted securities is entitled to any Dividends in respect of those restricted securities.

 

(g)A Member who holds restricted securities is not entitled to any Dividends in respect of those restricted securities during a breach of:

 

(i)the Listing Rules relating to those restricted securities; or

 

(ii)a restriction agreement.

 

11.2Dividends for different classes

 

The Directors may determine that Dividends be paid:

 

(a)on Shares of one class but not another class; and

 

(b)at different rates for different classes of Shares.

 

11.3Dividends proportional to paid up capital

 

(a)Subject to any rights or restrictions attached to a class of Shares, the person entitled to a Dividend on a Share is entitled to:

 

(i)if the Share is fully paid (whether the issue price of the Share was paid or credited or both), the entire Dividend; or

 

(ii)if the Share is partly paid, a proportion of that Dividend equal to the proportion which the amount paid (excluding amounts credited) on that Share is of the total amounts paid or payable (excluding amounts credited) on that Share.

 

IperionX Limited

 

  Page 26 
   

 

(b)Amounts paid in advance of a call on a Share are ignored when calculating the proportion under article 11.3(a)(ii).

 

11.4Effect of a transfer on Dividends

 

If a transfer of a Share is registered after the time determined for entitlements to a Dividend on that Share but before the Dividend is paid, the person transferring that Share is, subject to the ASX Settlement Operating Rules, entitled to that Dividend.

 

11.5No interest on Dividends

 

The Company is not required to pay any interest on a Dividend.

 

11.6Unpaid amounts

 

The Company may retain the whole or part of any Dividend on which the Company has a lien and apply that amount in total or part satisfaction of any amount secured by that lien.

 

11.7Capitalisation of profits

 

(a)The Directors may capitalise any profits of the Company and distribute that capital to the Members, in the same proportions as the Members are entitled to a distribution by Dividend.

 

(b)The Directors may fix the time for determining entitlements to a capitalisation of profits.

 

(c)The Directors may decide to apply capital under article 11.7(a) in either or both of the following ways:

 

(i)in paying up an amount unpaid on Shares already issued; and

 

(ii)in paying up in full any unissued Shares or other securities in the Company.

 

(d)The Members must accept an application of capital under article 11.7(c) in full satisfaction of their interests in that capital.

 

11.8Distributions of assets

 

The Directors may settle any problem concerning a distribution under article 11 in any way, including:

 

(a)rounding amounts up or down to the nearest whole number;

 

(b)ignoring fractions;

 

(c)valuing assets for distribution;

 

(d)paying cash to any Member on the basis of that valuation; and

 

(e)vesting assets in a trustee on trust for the Members entitled.

 

11.9Dividend plans

 

(a)The Directors may establish a dividend selection plan or bonus share plan on any terms, under which participants may elect in respect of all or part of their Shares:

 

(i)to receive a Dividend from the Company paid in whole or in part out of a particular fund or reserve or out of profits derived from a particular source; or

 

(ii)to forego a Dividend from the Company and receive some other form of distribution or entitlement (including securities) from the Company or another body corporate or a trust.

 

IperionX Limited

 

  Page 27 
   

 

(b)The Directors may establish a dividend reinvestment plan on any terms, under which participants may elect in respect of all or part of their Shares to apply the whole or any part of a Dividend from the Company in subscribing for securities of the Company or a related body corporate of the Company.

 

(c)Subject to the Listing Rules, the Directors may implement, amend, suspend or terminate a plan established under articles 11.9(a) to 11.9(c) (inclusive).

 

12Notices and Payments

 

12.1Notice to Members

 

(a)The Company may give Notice to a Member:

 

(i)in person;

 

(ii)by sending it by post to the address of the Member in the Register or the alternative address (if any) nominated by that Member;

 

(iii)by sending it to the fax number or electronic address (if any) nominated by that Member; or

 

(iv)by notifying the Member by any electronic means nominated by the Member:

 

(A)that the Notice is available; and

 

(B)how the Member may access the Notice;

 

(v)by posting (pursuant to rule 12.1(a)(ii)) or faxing (pursuant to 12.1(a)(iii)), a document notifying the Member:

 

(A)that the Notice is available; and

 

(B)how the Member may access the Notice; or

 

(vi)such other means as permitted by the Corporations Act.

 

(b)If the address of a Member in the Register is not within Australia, the Company must send all documents to that Member by air mail, air courier, fax or by electronic means.

 

(c)The Company must give any Notice to Members who are joint holders of a Share to the person named first in the Register in respect of that Share, and that Notice is Notice to all holders of that Share.

 

(d)The Company may give Notice to a person entitled to a Share because of a Transmission Event in any manner specified in article 12.1.

 

(e)Notice to a person entitled to a Share because of a Transmission Event is taken to be Notice to the Member of that Share.

 

(f)A Notice to a Member is sufficient, even if:

 

(i)a Transmission Event occurs in respect of that Member (whether or not a joint holder of a Share); or

 

(ii)that Member is an externally administered body corporate,

 

and regardless of whether or not the Company has Notice of that Transmission Event.

 

IperionX Limited

 

  Page 28 
   

 

(g)A person entitled to a Share because of a transfer, Transmission Event or otherwise, is bound by every Notice given in respect of that Share.

 

(h)Any Notice required or allowed to be given by the Company to one or more Members by advertisement is, unless otherwise stipulated, sufficiently advertised if advertised once in a daily newspaper circulating in the states and territories of Australia.

 

12.2Notice to Directors

 

The Company may give Notice to a Director or Alternate Director:

 

(a)in person;

 

(b)by sending it by post to the usual residential address of that person or the alternative address (if any) nominated by that person;

 

(c)by sending it to the fax number or electronic address (if any) nominated by that person; or

 

(d)by any other means agreed between the Company and that person.

 

12.3Notice to the Company

 

A person may give Notice to the Company by:

 

(a)leaving it at the registered office of the Company during a time when the registered office is open;

 

(b)sending it by post to the registered office of the Company;

 

(c)sending it to a fax number at the registered office of the Company nominated by the Company for that purpose;

 

(d)sending it to the electronic address (if any) nominated by the Company for that purpose; or

 

(e)any other means permitted by the Corporations Act.

 

12.4Time of service

 

(a)A Notice sent by post to an address within Australia is taken to be given:

 

(i)in the case of a Notice of meeting, one day after it is posted; or

 

(ii)in any other case, at the time at which the Notice would be delivered in the ordinary course of post.

 

(b)A Notice sent by post or air mail to an address outside Australia is taken to be given:

 

(i)in the case of a Notice of meeting, one day after it is posted; or

 

(ii)in any other case, at the time at which the Notice would be delivered in the ordinary course of post.

 

(c)A Notice sent by air courier to a place outside Australia is taken to be given one day after delivery to the air courier.

 

(d)A Notice sent by fax is taken to be given on the day it is sent, provided that the sender's transmission report shows that the whole Notice was sent to the correct fax number.

 

(e)A Notice sent to an electronic address is taken to be given on the date it is sent unless a delivery failure message is received by the Company.

 

IperionX Limited

 

  Page 29 
   

 

(f)The giving of a Notice by post, air mail or air courier is sufficiently proved by evidence that the Notice:

 

(i)was addressed to the correct address of the recipient; and

 

(ii)was placed in the post or delivered to the air courier.

 

(g)A certificate by a Director or Secretary of a matter referred to in article 12.4(f) is sufficient evidence of the matter, unless it is proved to the contrary.

 

12.5Signatures

 

The Directors may decide, generally or in a particular case, that a Notice given by the Company be signed by mechanical or other means.

 

12.6Payments

 

(a)The Company may pay a person entitled to an amount payable in respect of a Share (including a Dividend) by:

 

(i)crediting an account nominated in writing by that person;

 

(ii)cheque made payable to bearer, to the person entitled to the amount or any other person the person entitled directs in writing; or

 

(iii)any other manner as the Directors resolve.

 

(b)The Company may post a cheque referred to in article 12.6(a)(ii) to:

 

(i)the address in the Register of the Member of the Share;

 

(ii)if that Share is jointly held, the address in the Register of the Member named first in the Register in respect of the Share; or

 

(iii)any other address which that person directs in writing.

 

(c)Any joint holder of a Share may give effective receipt for an amount (including a Dividend) paid in respect of the Share.

 

13Winding up

 

13.1Distributions proportional to paid up capital

 

Subject to any rights or restrictions attached to a class of Shares, on a winding up of the Company, any surplus must be divided among the Members in the proportions which the amount paid (including amounts credited) on the Shares of a Member is of the total amounts paid and payable (including amounts credited) on the Shares of all Members.

 

13.2Distributions of assets

 

(a)Subject to any rights or restrictions attached to a class of Shares, on a winding up of the Company, the liquidator may, with the sanction of a special resolution of the Members:

 

(i)distribute among the Members the whole or any part of the property of the Company; and

 

(ii)decide how to distribute the property as between the Members or different classes of Members.

 

IperionX Limited

 

  Page 30 
   

 

(b)The liquidator of the Company may settle any problem concerning a distribution under article 13 in any way, including:

 

(i)rounding amounts up or down to the nearest whole number;

 

(ii)ignoring fractions;

 

(iii)valuing assets for distribution;

 

(iv)paying cash to any Member on the basis of that valuation; and

 

(v)vesting assets in a trustee on trust for the Members entitled.

 

(c)A Member need not accept any property, including shares or other securities, carrying a liability.

 

IperionX Limited

 

  Page 31 
   

 

Schedule 1

 

Definitions and Interpretation

 

1Definitions

 

In this constitution, unless the context otherwise requires:

 

Adoption Date means the date on which this constitution is adopted by the Company as its constitution.

 

Alternate Director means a person for the time being holding office as an alternate Director of the Company under articles 7.4(a) to 7.4(i) (inclusive).

 

Applicable Law means the Corporations Act, the Listing Rules and the ASX Settlement Operating Rules.

 

AGM means an annual general meeting of Members.

 

ASX means ASX Limited (ACN 008 624 691) and where the context permits the Australian Securities Exchange operated by ASX Limited.

 

ASX Settlement means ASX Settlement Pty Limited (ACN 008 504 532).

 

ASX Settlement Operating Rules mean the operating rules of ASX Settlement.

 

Business Day:

 

(a)if the Company is admitted to the Official List at the time, has the meaning given in the Listing Rules; or

 

(b)otherwise, means a day except a Saturday, Sunday or public holiday in Western Australia;

 

Company means the company named IperionX Limited (ACN 618 935 372), or whatever its name may be from time to time.

 

Corporations Act means the Corporations Act 2001 (Cth), except to the extent of any exemption, modification, declaration or order made in respect of that legislation which applies to the Company.

 

Directors means the directors of the Company for the time being.

 

Dividend includes an interim dividend and a final dividend.

 

Eligible Member means, in respect of a meeting of Members:

 

(a)the date and time specified in the Notice of that meeting, a person who is a Member at that time; or

 

(b)as otherwise determined by the party calling that meeting,

 

provided that the time is not more than 48 hours prior to that meeting.

 

Executive Director means a Director who is an employee (whether full time or part time) of the Company or of any related body corporate of the Company other than by virtue of being a Director of the Company.

 

Legal Costs of a person means legal costs incurred by that person in defending an action for a Liability of that person.

 

Liability of a person means any liability incurred by that person as an officer of the Company or a subsidiary of the Company.

 

IperionX Limited

 

  Page 32 
   

 

Listing Rules means the listing rules of ASX and any other rules of ASX which are applicable while the Company is admitted to the Official List, each as amended or replaced from time to time, except and to the extent of any express written waiver by ASX.

 

Marketable Parcel has the meaning as defined under the ASX Listing Rules.

 

Member means a person whose name is entered in the Register as the holder of a Share.

 

Non Executive Directors means all Directors other than Executive Directors.

 

Notice means a notice given pursuant to, or for the purposes of, this constitution or Applicable Law.

 

Notifiable Interest has the meaning given by paragraph (a) of the definition of notifiable interest of a director in the Listing Rules.

 

Official List means the official list of ASX.

 

Personal Representative means the legal personal representative, executor or administrator of the estate of a deceased person.

 

Prescribed Notice means 28 days or any shorter period of Notice for a meeting of Members of the Company allowed under the Corporations Act.

 

Previous Constitution means the constitution of the Company immediately before the Adoption Date.

 

Register means the register of Members kept under Applicable Law and, where appropriate, includes any sub register and branch register.

 

Relevant Officer means a person who is, or has been, a Director or Secretary.

 

Secretary means a company secretary of the Company for the time being.

 

Share means a share in the capital of the Company.

 

Transmission Event means:

 

(c)if a Member is an individual:

 

(i)death or bankruptcy of that Member; or

 

(ii)that Member becoming of unsound mind or becoming a person whose property is liable to be dealt with under a law about mental health;

 

(d)if a Member is a body corporate, the deregistration of that Member under the laws of the jurisdiction of its registration; or

 

(e)in any case, the vesting in, or transfer to, a person of the Shares of a Member without that person becoming a Member.

 

Unmarketable Parcel means a holding of Shares which is less than a "marketable parcel" as defined under the ASX Listing Rules.

 

2Interpretation

 

(a)In this constitution, unless the context otherwise requires:

 

(i)a reference to a partly paid Share is a reference to a Share on which there is an amount unpaid;

 

IperionX Limited

 

  Page 33 
   

 

(ii)a reference to a call or an amount called in respect of a Share includes an amount that, by the terms of issue of a Share or otherwise, is payable at one or more fixed times;

 

(iii)a reference to a Share which is jointly held is a reference to a Share for which there is more than one Member;

 

(iv)a reference to a meeting of Members includes a meeting of any class of Members;

 

(v)a Member is taken to be present at a meeting of Members if the Member is present in person or by proxy, attorney or representative; and

 

(vi)a reference to a notice or document in writing includes a notice or document given by fax or another form of written communication.

 

(b)In this constitution, headings are for convenience only and do not affect interpretation, and unless the context indicates a contrary intention:

 

(i)words importing the singular include the plural (and vice versa);

 

(ii)words indicating a gender include every other gender;

 

(iii)the word person includes an individual, the estate of an individual, a corporation, an authority, an association or a joint venture (whether incorporated or unincorporated), a partnership and a trust;

 

(iv)where a word or phrase is given a defined meaning, any other part of speech or grammatical form of that word or phrase has a corresponding meaning; and

 

(v)the word includes in any form is not a word of limitation.

 

(c)In this constitution, unless the context otherwise requires:

 

(i)a reference to an article or a schedule is to an article or a schedule of this constitution;

 

(ii)a reference in a schedule to a paragraph is to a paragraph of that schedule;

 

(iii)a schedule is part of this constitution; and

 

(iv)a reference to this constitution is to this constitution (and where applicable any of its provisions) as modified or repealed from time to time.

 

(d)In this constitution, unless the context otherwise requires:

 

(i)a reference to any statute or to any statutory provision includes any statutory modification or re enactment of it or any statutory provision substituted for it, and all ordinances, by laws, regulations, rules and statutory instruments (however described) issued under it; and

 

(ii)a reference to the Listing Rules or the ASX Settlement Operating Rules includes any amendment or replacement of those rules from time to time.

 

(e)Unless the context indicates a contrary intention:

 

(i)an expression in a provision of this constitution which deals with a matter dealt with by a provision of Applicable Law has the same meaning as in that provision of Applicable Law; and

 

(ii)an expression in a provision of this constitution that is defined in section 9 of the Corporations Act has the same meaning as in that section.

 

(f)In this constitution, a reference to the Listing Rules, the ASX Settlement Operating Rules or ASX has effect only if at that time the Company is included in the Official List.

 

IperionX Limited

 

  Page 34 
   

 

3Exercise of Powers

 

Where this constitution confers a power or imposes a duty, then, unless the contrary intention appears, the power may be exercised and the duty must be performed from time to time as the occasion requires.

 

4Articles of this Constitution

 

(a)Unless Applicable Law provides that this constitution may contain a provision contrary to Applicable Law, the articles of this constitution are subject to Applicable Law such that any article of this constitution that is inconsistent with or contrary to Applicable Law will be read down to the extent of the inconsistency with Applicable Law.

 

(b)If an article is inconsistent with or contrary to Applicable Law and is not capable of being read down to the extent of the inconsistency under paragraph 4(c)(i), the relevant article will be severed from this constitution.

 

(c)If at any time any provision of this constitution is or becomes illegal, invalid or unenforceable in any respect under the law of any jurisdiction, that does not affect or impair:

 

(i)the legality, validity or enforceability in that jurisdiction of any other provision of this constitution; or

 

(ii)the legality, validity or enforceability under the law of any other jurisdiction of that or any other provision of this constitution.

 

5Provisions required by Listing Rule 15.11.1

 

If the Company is admitted to the Official List, the following provisions apply:

 

(a)notwithstanding anything contained in this constitution, if the Listing Rules prohibit an act being done, the act must not be done;

 

(b)nothing contained in this constitution prevents an act being done that the Listing Rules require to be done;

 

(c)if the Listing Rules require an act to be done or not to be done, authority is given for that act to be done or not to be done (as the case may be);

 

(d)if the Listing Rules require this constitution to contain a provision and it does not contain such a provision, this constitution is deemed to contain that provision;

 

(e)if the Listing Rules require this constitution not to contain a provision and it contains such a provision, this constitution is deemed not to contain that provision; and

 

(f)if any provision of this constitution is or becomes inconsistent with the Listing Rules, this constitution is deemed not to contain that provision to the extent of the inconsistency.

 

IperionX Limited

 

  Page 35 
   

 

Schedule 2

 

Calls, Company payments, Forfeiture and Liens

 

1Exercise of Powers

 

The powers of the Company under this Schedule 2 may only be exercised by the Directors.

 

2CALLS

 

2.1Making a call

 

(a)Subject to the terms of issue of a Share, the Company may at any time make calls on the Members of a Share for all or any part of the amount unpaid on the Share as the Directors resolve.

 

(b)The Company may make calls payable for one or more Members for different amounts and at different times.

 

(c)Subject to the terms of issue of a Share, a call may be made payable by instalments.

 

(d)Subject to Applicable Law, the Company may revoke or postpone a call or extend the time for payment of a call.

 

(e)A call is made when the Directors resolve to make the call.

 

2.2Notice of a call

 

(a)The Company must give Members at least 10 Business Days' Notice of a call.

 

(b)A Notice of a call must be in writing and specify the amount of the call, the due date for payment, the manner in which payment of the call must be made, the consequences of non payment of the call and any other information required by the Listing Rules.

 

(c)A call is not invalid if:

 

(i)a Member does not receive Notice of the call; or

 

(ii)the Company accidentally does not give Notice of the call to a Member.

 

2.3Payment of a call

 

(a)A Member must pay to the Company the amount of each call made on the Member on the date and in the manner specified in the Notice of the call.

 

(b)If an amount unpaid on a Share is payable, by the terms of issue of the Share or otherwise, in one or more fixed amounts on one or more fixed dates, the Member of that Share must pay to the Company those amounts on those dates.

 

(c)A Member must pay to the Company:

 

(i)interest at the rate specified in paragraph 7(a) on any amount referred to in paragraph 2.3(a) or 2.3(b) which is not paid on or before the time appointed for its payment, from the time appointed for payment to the time of the actual payment; and

 

(ii)expenses incurred by the Company because of the failure to pay or late payment of that amount.

 

IperionX Limited

 

  Page 36 
   

 

(d)The Company may waive payment of all or any part of an amount payable under paragraph 2.3(c).

 

(e)The joint holders of a Share are jointly and severally liable for the payment of all calls due in respect of that Share.

 

2.4Recovery of a call

 

(a)The Company may recover an amount due and payable under this paragraph 2 from a Member by:

 

(i)commencing legal action against the Member for all or part of the amount due;

 

(ii)enforcing a lien on the Share in respect of which the call was made; or

 

(iii)forfeiting the Share in respect of which the call was made.

 

(b)The debt due in respect of an amount payable under this paragraph 2 in respect of a Share is sufficiently proved by evidence that:

 

(i)the name of the Member sued is entered in the Register as one or more of the holders of that Share; and

 

(ii)there is a record in the minute books of the Company of:

 

(A)in the case of an amount referred to in paragraph 2.3(b), that amount; or

 

(B)in any other case, the resolution making the call.

 

2.5Payment in advance of a call

 

(a)The Company may:

 

(i)accept from any Member all or any part of the amount unpaid on a Share held by the Member before that amount is called for;

 

(ii)pay interest at any rate the Directors resolve, on the amount paid before it is called, from the date of payment until and including the date the amount becomes actually payable; and

 

(iii)repay the amount paid to that Member.

 

(b)An amount paid pursuant to 2.5(a)(i) does not confer a right to participate in:

 

(i)a Dividend determined to be paid from the profits of the Company; or

 

(ii)any surplus of the Company in a winding up of the Company,

 

for the period before the date when the amount paid would have otherwise become payable.

 

3Company Payments on behalf of a member

 

3.1Rights of the Company

 

(a)A Member or, if the Member is deceased, the Member's Personal Representative, must indemnify the Company against any liability which the Company has under any law to make a payment (including payment of a tax) in respect of:

 

(i)a Share held by that Member (whether solely or jointly);

 

(ii)a transfer or transmission of Shares by that Member;

 

IperionX Limited

 

  Page 37 
   

 

(iii)a Dividend or other money which is, or may become, due or payable to that Member; or

 

(iv)that Member.

 

(b)A Member or, if the Member is deceased, the Member's Personal Representative, must pay to the Company immediately on demand:

 

(i)the amount required to reimburse the Company for a payment referred to in paragraph 3.1; and

 

(ii)pay to the Company interest at the rate specified in paragraph 7(a) on any amount referred to in paragraph 3.1(a) paid by the Company, from the date of payment by the Company until and including the date the Company is reimbursed in full for that payment.

 

(c)Subject to Applicable Law, the Company may refuse to register a transfer of any Shares by a Member referred to in paragraph 3.1(a) to 3.1(d), or that Member's Personal Representative, until all money payable to the Company under paragraphs 3.1 to 3.4 (inclusive) has been paid.

 

(d)The powers and rights of the Company under paragraphs 3.1(a) to 3.1(d) (inclusive) are in addition to any right or remedy that the Company may have under the law which requires the Company to make a payment referred to in paragraph 3.1(a).

 

3.2Recovery of Company payments

 

(a)The Company may recover an amount due and payable under paragraphs 3.1(a) to 3.1(d) (inclusive) from the Member or the Member's Personal Representative by any or all of:

 

(i)deducting all or part of that amount from any other amount payable by the Company to that person in respect of the Shares of that person;

 

(ii)commencing legal action against that person for all or part of that amount; or

 

(iii)enforcing a lien on one or more of the Shares of that person.

 

(b)The Company may waive any or all its rights under paragraph 3.

 

4Forfeiture

 

4.1Forfeiture procedure

 

(a)The Company may forfeit a Share of a Member by a resolution of the Directors if:

 

(i)that Member does not pay a call or instalment on that Share on or before the date for its payment;

 

(ii)the Company gives that Member Notice:

 

(A)requiring the Member to pay that call or instalment, any interest on it and all expenses incurred by the Company by reason of the non payment; and

 

(B)stating that the Share is liable to be forfeited if that Member does not pay to the Company, at the place specified in the Notice, the amount specified in the Notice, within 10 Business Days (or any longer period specified) after the date of the Notice; and

 

(b)that Member does not pay that amount in accordance with that Notice.

 

IperionX Limited

 

  Page 38 
   

 

4.2Notice of forfeiture

 

(a)When any Share has been forfeited, the Company must:

 

(i)give Notice of the forfeiture to the Member registered as its holder before the forfeiture; and

 

(ii)record the forfeiture with the date of forfeiture in the Register.

 

(b)Failure by the Company to comply with any requirement in paragraph 4.2 does not invalidate the forfeiture.

 

4.3Effect of forfeiture

 

(a)The forfeiture of a Share extinguishes:

 

(i)all interests in that Share of the former Member; and

 

(ii)all claims against the Company in respect of that Share by the former Member, including all Dividends determined to be paid in respect of that Share and not actually paid.

 

(b)A former Member of a forfeited Share must pay to the Company:

 

(i)all calls, instalments, interest and expenses in respect of that Share at the time of forfeiture; and

 

(ii)interest at the rate specified in paragraph 7(a) on those amounts from the time of forfeiture until and including the date of payment of those amounts.

 

4.4Sale or reissue of forfeited Shares

 

The Company may sell, otherwise dispose of or reissue, a Share which has been forfeited on any terms and in any manner as the Directors resolve.

 

4.5Cancellation of forfeited Shares

 

The Company may by ordinary resolution passed at a meeting of Members cancel a Share which has been forfeited under the terms on which the Share is on issue.

 

4.6Proof of forfeiture

 

A certificate in writing from the Company signed by a Director or Secretary that a Share was forfeited on a specified date is sufficient evidence of:

 

(a)the forfeiture of that Share; and

 

(b)the right and title of the Company to sell, dispose or reissue that Share.

 

4.7Waiver or cancellation of forfeiture

 

The Company may:

 

(a)waive any or all of its rights under paragraph 4; and

 

(b)at any time before a sale, disposition, reissue or cancellation of a forfeited Share, cancel the forfeiture on any terms as the Directors resolve.

 

5Liens

 

5.1First ranking lien

 

(a)The Company has a first ranking lien on:

 

IperionX Limited

 

  Page 39 
   

 

(i)each Share registered in the name of a Member;

 

(ii)the proceeds of sale of those Shares; and

 

(iii)all Dividends determined to be payable in respect of those Shares,

 

for:

 

(iv)each unpaid call or instalment which is due but unpaid on those Shares;

 

(v)if those Shares were acquired under an employee incentive scheme, all amounts payable to the Company by the Member under loans made to enable those Shares to be acquired;

 

(vi)all amounts which the Company is required by law to pay, and has paid, in respect of those Shares (including any payment under paragraph 3) or the forfeiture or sale of those Shares; and

 

(vii)all interest and expenses due and payable to the Company under this Schedule 2.

 

5.2Enforcement by sale

 

The Company may sell a Share of a Member to enforce a lien on that Share if:

 

(a)an amount secured by that lien is due and payable;

 

(b)the Company gives that Member or the Member's Personal Representative Notice:

 

(i)requiring payment to the Company of that amount, any interest on it and all expenses incurred by the Company by reason of the non payment; and

 

(ii)stating that the Share is liable to be sold if that person does not pay to the Company, in the manner specified in the Notice, the amount specified in the Notice within 10 Business Days (or any longer period specified) after the date of the Notice; and

 

(c)that Member or the Member's Personal Representative does not pay that amount in accordance with that Notice.

 

5.3Release or waiver of lien

 

(a)Registration of a transfer of a Share by the Company releases any lien of the Company on that Share in respect of any amount owing on that Share, unless the Company gives Notice, to the person to whom that Share is transferred, of the amount owing.

 

(b)The Company may waive any or all of its rights under paragraph 5.

 

6Sales, Disposals and Reissues

 

6.1Sale procedure

 

(a)The Company may:

 

(i)receive the purchase money or consideration for Shares sold or disposed of under this Schedule 2;

 

(ii)appoint a person to sign a transfer of Shares sold or disposed of under this Schedule 2;

 

(iii)do all things necessary or desirable under Applicable Law to effect a transfer of Shares sold or disposed of under this Schedule 2; and

 

(iv)enter in the Register the name of the person to whom Shares are sold or disposed.

 

IperionX Limited

 

  Page 40 
   

 

(b)The person to whom a Share is sold or disposed under this Schedule 2 need not enquire whether the Company:

 

(i)properly exercised its powers under this Schedule 2 in respect of that Share; or

 

(ii)properly applied the proceeds of sale or disposal of those Shares,

 

and the title of that person is not affected by those matters.

 

(c)The remedy (if any) of any person aggrieved by a sale or other disposal of Shares under this Schedule 2 is in damages only and against the Company exclusively.

 

(d)A certificate in writing from the Company signed by a Director or Secretary that a Share was sold, disposed of or reissued in accordance with this Schedule 2 is sufficient evidence of those matters.

 

6.2Application of proceeds

 

The Company must apply the proceeds of any sale, other disposal or reissue of any Shares under this Schedule 2 in the following order:

 

(a)the expenses of the sale, other disposal or reissue;

 

(b)the amounts due and unpaid in respect of those Shares; and

 

(c)the balance (if any) to the former Member or the former Member's Personal Representative, on the Company receiving the certificate (if any) of those Shares or other evidence satisfactory to the Company regarding the ownership of those Shares.

 

7Interest

 

(a)A person must pay interest under this Schedule 2 to the Company:

 

(i)at a rate the Directors resolve; or

 

(ii)if the Directors do not resolve, at 15 per cent per annum.

 

(b)Interest payable to the Company under this Schedule 2 accrues daily.

 

(c)The Company may capitalise interest payable under this Schedule 2 at any interval the Directors resolve.

 

IperionX Limited

 

  Page 41 
   

 

Schedule 3

 

Transmission

 

1Deceased Members

 

1.1Effect of death

 

(a)If a Member in respect of a Share which is not jointly held dies, the Company must recognise only the Personal Representative of that Member as having any title to or interest in, or any benefits accruing in respect of, that Share.

 

(b)If a Member in respect of a Share which is jointly held dies, the Company must recognise only the surviving Members of that Share as having any title to or interest in, or any benefits accruing in respect of, that Share.

 

1.2Estates and Personal Representatives

 

(a)The estate of a deceased Member is not released from any liability in respect of the Shares registered in the name of that Member.

 

(b)Where two or more persons are jointly entitled to any Share as a consequence of the death of the registered holder of that Share, they are taken to be joint holders of that Share.

 

2TRANSMISSION EVENTS

 

2.1Transmittee right to register or transfer

 

(a)Subject to the Bankruptcy Act 1966 (Cth) if a person entitled to a Share because of a Transmission Event gives the Directors the information they reasonably require to establish the person's entitlement to be registered as the holder of the Share, that person may:

 

(i)elect to be registered as a Member in respect of that Share by giving a signed Notice to the Company; or

 

(ii)transfer that Share to another person.

 

(b)On receiving a Notice under paragraph 2.1(a)(i), the Company must register the person as the holder of that Share.

 

(c)A transfer under paragraph 2.1(a)(ii) is subject to all provisions of this constitution relating to transfers of Shares.

 

2.2Other transmute rights and obligations

 

(a)A person registered as a Member as a consequence of paragraphs 2.1(a) to 2.1(c) (inclusive) must indemnify the Company to the extent of any loss or damage suffered by the Company as a result of that registration.

 

(b)A person who has given to the Directors the information referred to in paragraph 2.1(a) in respect of a Share is entitled to the same rights to which that person would be entitled if registered as the holder of that Share.

 

IperionX Limited

 

  Page 42 
   

 

Schedule 4

 

Unmarketable Parcels

 

1Definitions

 

In this schedule, unless the context otherwise requires, Sale Share means a Share which is sold or disposed of in accordance with this schedule.

 

2Power to sell unmarketable parcels

 

2.1Existing unmarketable parcels

 

(a)The Company may sell the Shares of a Member if:

 

(i)the total number of Shares of a particular class held by that Member is less than a marketable parcel;

 

(ii)the Company gives that Member Notice stating that the Shares are liable to be sold or disposed of by the Company; and

 

(iii)that Member does not give Notice to the Company, by the date specified in the Notice of the Company (being not less than 42 days after the date of the Company giving that Notice), stating that all or some of those Shares are not to be sold or disposed of.

 

(b)The Company may only exercise the powers under paragraph 2.1(a), in respect of one or more Members, once in any 12 month period.

 

(c)The power of the Company under paragraph 2.1(a) lapses following the announcement of a takeover bid. However, the procedure may be started again after the close of the offers made under the takeover bid.

 

2.2New unmarketable parcels

 

(a)The Company may sell the Shares of a Member if:

 

(i)the Shares of a particular class held by that Member are in a new holding created by a transfer on or after 1 September 1999; and

 

(ii)that transfer is of a number of Shares of that class that was less than a marketable parcel at the time the transfer document was initiated, or in the case of a paper based transfer document, was lodged with the Company.

 

(b)The Company may give a Member referred to in paragraph 2.2(a) Notice stating that the Company intends to sell or dispose of the Shares.

 

3Exercise of power of sale

 

3.1Extinguishment of interests and claims

 

(a)The exercise by the Company of its powers under paragraph 2 extinguishes, subject to this Schedule 4:

 

(i)all interests in the Sale Shares of the former Member; and

 

(ii)all claims against the Company in respect of the Sale Shares by that Member, including all Dividends determined to be paid in respect of those Share and not actually paid.

 

IperionX Limited

 

  Page 43 
   

 

3.2Manner of sale

 

(a)The Company may sell or dispose of any Shares under paragraph 2 at any time:

 

(i)using a financial services licensee on the basis that person obtains the highest possible price for the sale of the Shares; or

 

(ii)in any other manner and on any terms as the Directors resolve.

 

(b)The Company may:

 

(i)exercise any powers permitted under Applicable Law to enable the sale or disposal of Shares under this schedule;

 

(ii)receive the purchase money or consideration for Sale Shares;

 

(iii)appoint a person to sign a transfer of Sale Shares; and

 

(iv)enter in the Register the name of the person to whom Sale Shares are sold or disposed.

 

(c)The person to whom a Sale Share is sold or disposed need not enquire whether the Company:

 

(i)properly exercised its powers under this schedule in respect of that Share; or

 

(ii)properly applied the proceeds of sale or disposal of those Shares,

 

and the title of that person is not affected by those matters.

 

(d)The remedy of any person aggrieved by a sale or disposal of Sale Shares is in damages only and against the Company exclusively.

 

(e)A certificate in writing from the Company signed by a Director or Secretary that a Share was sold or disposed of in accordance with this Schedule 4 is sufficient evidence of those matters.

 

3.3Application of proceeds

 

(a)If the Company exercises the powers under paragraphs 2.1(a) to 2.1(c) (inclusive), either the Company or the person to whom a Sale Share is sold or disposed of must pay the expenses of the sale or disposal.

 

(b)The Company must apply the proceeds of any sale or disposal of any Sale Shares in the following order:

 

(i)in the case of an exercise of the powers under paragraphs 2.2(a) and 2.2(b), the expenses of the sale or disposal;

 

(ii)the amounts due and unpaid in respect of those Shares; and

 

(iii)the balance (if any) to the former Member or the former Member's Personal Representative, on the Company receiving the certificate (if any) for those Shares or other evidence satisfactory to the Company regarding the ownership of those Shares.

  

IperionX Limited

 

  Page 44 
   

 

3.4Voting and dividend rights pending sale

 

(a)If the Company is entitled to exercise the powers under paragraphs 2.2(a) and 2.2(b), the Company may by resolution of the Directors remove or change either or both:

  

(i)the right to vote; and

 

(ii)the right to receive Dividends,

 

of the relevant Member in respect of some or all of the Shares liable to be sold or disposed of.

 

(b)After the sale of the relevant Sale Shares, the Company must pay to the person entitled any Dividends that have been withheld under paragraph 3.4(a).

 

IperionX Limited

 

  Page 45 
   

 

Schedule 5

 

Proportional Takeover Bid Approval

 

1Definitions

 

In this schedule, unless the context otherwise requires:

 

Approving Resolution means a resolution to approve a proportional takeover bid in accordance with this Schedule 5.

 

Deadline means the 14th day before the last day of the bid period for a proportional takeover bid.

 

Voter means a person (other than the bidder under a proportional takeover bid or an associate of that bidder) who, as at the end of the day on which the first offer under that bid was made, held bid class securities for that bid.

 

2Refusal of Transfers

 

2.1Requirement for an Approving Resolution

 

(a)The Company must refuse to register a transfer of Shares giving effect to a takeover contract for a proportional takeover bid unless and until an Approving Resolution is passed in accordance with this Schedule 5.

 

(b)This Schedule 5 ceases to apply on the third anniversary of its last adoption, or last renewal, in accordance with the Corporations Act.

 

2.2Voting on an Approving Resolution

 

(a)Where offers are made under a proportional takeover bid, the Directors must, call and arrange to hold a meeting of Voters for the purpose of voting on an Approving Resolution before the Deadline.

 

(b)The provisions of this constitution concerning meetings of Members (with the necessary changes) apply to a meeting held under paragraph 2.2(a).

 

(c)Subject to this constitution, every Voter present at the meeting held under paragraph 2.2(a) is entitled to one vote for each Share in the bid class securities that the Voter holds.

 

(d)To be effective, an Approving Resolution must be passed before the Deadline.

 

(e)An Approving Resolution that has been voted on is taken to have been passed if the proportion that the number of votes in favour of the resolution bears to the total number of votes on the resolution is greater than 50 per cent, and otherwise is taken to have been rejected.

 

(f)If no Approving Resolution has been voted on as at the end of the day before the Deadline, an Approving Resolution is taken, for the purposes of this schedule, to have been passed in accordance with this Schedule 5.

 

IperionX Limited

 

  Page 46 
   

 

Schedule 6

 

Preference Shares

 

1Definitions

 

In this schedule, unless the context otherwise requires:

 

Conversion Circumstances means, in respect of a Converting Preference Share, whether the Preference Share is liable to be converted or convertible:

 

(a)at the option of the Holder, or of the Company, or both;

 

(b)upon the happening of a particular event; or

 

(c)at a fixed time.

 

Conversion Date means, in respect of a Converting Preference Share, the date (if any) specified in the Issue Resolution for the conversion of that Preference Share or the date upon which an event specified in the Issue Resolution occurs which results in the conversion of that Preference Share.

 

Conversion Number means the number, or formula for determining the number, of ordinary Shares into which a Converting Preference Share will convert upon conversion.

 

Converting Preference Share means a Preference Share which is specified in the Issue Resolution as being liable to be converted or convertible into ordinary Shares in a manner permitted by the Corporations Act, whether at the option of the Holder or otherwise.

 

Dividend means any distribution of any property (including without limitation, money, Paid Up shares, debentures, debenture stock or other securities of the Company or of any other Corporation) to a Holder in respect of a Preference Share as a dividend, whether interim or final

 

Dividend Date means, in respect of a Preference Share, a date specified in the Issue Resolution on which a Dividend in respect of that Preference Share is payable.

 

Dividend Rate means, in respect of a Preference Share, the terms specified in the Issue Resolution for the calculation of the amount of Dividend to be paid in respect of that Preference Share on any Dividend Date, which calculation may be wholly or partly established by reference to an algebraic formula.

 

Franked Dividend has the meaning given in the Income Tax Assessment Act 1936 (Cth).

 

Holder means, in respect of a Preference Share, the registered holder of that Share.

 

Issue Resolution means the resolution specified in paragraph 3.

 

Preference Share means a Share issued under articles 2.2(a) to 2.2(c) (inclusive).

 

Redeemable Preference Share means a Preference Share which is specified in the Issue Resolution as being liable to be redeemed in a manner permitted by the Corporations Act.

 

Redemption Amount means, in respect of a Redeemable Preference Share, the amount specified in the Issue Resolution to be paid on redemption of the Redeemable Preference Share.

 

Redemption Circumstances means, in respect of a Redeemable Preference Share, whether the Preference Share is liable to be redeemed:

 

(d)at the option of the Holder, or of the Company, or both;

 

(e)upon the happening of a particular event; or

 

(f)at a fixed time.

 

IperionX Limited

 

  Page 47 
   

 

Redemption Date means, in respect of a Redeemable Preference Share, the date specified in the Issue Resolution for the redemption of that Preference Share or the date upon which an event specified in the Issue Resolution occurs which results in the redemption of that Preference Share.

 

Specified Date means, in respect of a Redeemable Preference Share, the date (if any) specified in the Issue Resolution before which that Redeemable Preference Share may not be redeemed by the Holder.

 

2Rights of Holders

 

Each Preference Share confers upon its Holder:

 

(a)the rights referred to in articles 2.2(b) and 2.2(c);

 

(b)the right in winding up to payment in cash of the amount then paid up on it, and any arrears of Dividend in respect of that Preference Share in priority to any other class of Shares;

 

(c)the right in priority to any payment of a Dividend to any other class of Shares, to a cumulative preferential dividend payable on each Dividend Date in relation to that Preference Share calculated in accordance with the Dividend Rate in relation to that Preference Share; and

 

(d)no right to participate beyond the extent elsewhere specified in this paragraph 2 in surplus assets or profits of the Company, whether in winding up or otherwise.

 

3Issue Resolution

 

3.1The Directors may allot a Preference Share by a resolution of the Directors specifying:

 

(a)the Dividend Date;

 

(b)the Dividend Rate;

 

(c)whether the Preference Share is or is not a Redeemable Preference Share;

 

(d)if the Preference Share is a Redeemable Preference Share, the Redemption Amount, the Redemption Date, the Redemption Circumstances and any Specified Date for that Redeemable Preference Share;

 

(e)that the Preference Share is a Converting Preference Share;

 

(f)the Conversion Circumstances, the Conversion Number and any Conversion Date; and

 

(g)any other terms and conditions to apply to that Preference Share.

 

3.2The Issue Resolution in establishing the Dividend Rate for a Preference Share may specify that the Dividend is to be:

 

(a)fixed;

 

(b)variable depending upon any variation of the respective values of any factors in an algebraic formula specified in the Issue Resolution; or

 

(c)variable depending upon such other factors as the Directors may specify in the Issue Resolution,

 

and may also specify that the Dividend is to be a Franked Dividend or not a Franked Dividend.

 

IperionX Limited

 

  Page 48 
   

 

Where the Issue Resolution specifies that the Dividend to be paid in respect of the Preference Share is to be a Franked Dividend the Issue Resolution may also specify:

 

(d)the extent to which such Dividend is to be franked; and

 

(e)the consequences of any Dividend paid not being so franked, which may include a provision for an increase in the amount of the Dividend to such an extent or by reference to such factors as may be specified in the Issue Resolution.

 

4REDEMPTION

 

4.1The Company must redeem a Redeemable Preference Share on issue:

 

(a)in the case where the Redeemable Preference Share is liable to be redeemed at the option of the Company, on the specified date where the Company, not less than 10 Business Days before that date, has given a Notice to the Holder of that Redeemable Preference Share stating that the Redeemable Preference Share will be redeemed on the specified date;

 

(b)in the case where the Redeemable Preference Share is liable to be redeemed at the option of the Holder, on the specified date where the Holder of that Redeemable Preference Share, not less than 10 Business Days before that date, has given a Notice to the Company stating that the Redeemable Preference Share will be redeemed on the specified date; and

 

(c)in any event, on the Redemption Date,

 

but no Redeemable Preference Share may be redeemed by the Holder before the Specified Date unless the Redemption Date occurs before that date.

 

4.2On redemption of a Redeemable Preference Share, the Company, after the Holder has surrendered to the Company the Certificate (if any) in respect of that Redeemable Preference Share, must pay to the Holder the Redemption Amount by:

 

(a)directly crediting the account nominated in writing by the Holder from time to time; or

 

(b)cheque made payable to the Holder or such other person nominated in writing by the Holder sent through the post to:

 

(i)in the case where the Holder is a joint holder of the Redeemable Preference Share, the address in the Register of the person whose name stands first on the Register in respect of the joint holding; or

 

(ii)otherwise, to the address of the Holder in the Register.

 

5CONVERSION

 

5.1The Company must convert a Converting Preference Share on issue:

 

(a)in the case where the Converting Preference Share is liable to be redeemed at the option of the Company, on the specified date where the Company, not less than 10 Business Days before that date, has given a Notice to the Holder of that Converting Preference Share stating that the Converting Preference Share will be converted on the specified date;

 

(b)in the case where the Converting Preference Share is liable to be redeemed at the option of the Holder, on the specified date where the Holder of that Converting Preference Share, not less than 10 Business Days before that date, has given a Notice to the Company stating that the Converting Preference Share will be converted on the specified date; and

 

(c)in any event, on the Conversion Date.

 

IperionX Limited

 

  Page 49 
   

 

5.2On conversion of a Converting Preference Share the Company must allot to the Holder additional ordinary Shares such that following conversion the Holder holds that number of ordinary Shares in accordance with the Conversion Number. Conversion of a Converting Preference Shares does not constitute a cancellation, redemption or termination of a Converting Preference Share or the issue, allotment or creation of a new Share.

 

5.3The allotment of additional ordinary Shares on Conversion does not constitute a cancellation, redemption or termination of a Converting Preference Share. Conversion is the taking effect of existing rights of a Converting Preference Share and the ending of the special rights attached to the Converting Preference Share.

 

5.4Following Conversion, each Converting Preference Share will rank equally with and will confer rights identical with and impose obligations identical with all other fully paid ordinary Shares then on issue.

 

6CERTIFICATE

 

The Certificate (if any) issued by the Company in relation to any Preference Share, must specify in relation to that Preference Share:

 

(a)the date of issue of the Preference Share;

 

(b)the Dividend Rate and Dividend Dates;

 

(c)whether the Preference Share is a Redeemable Preference Share;

 

(d)if the Preference Share is a Redeemable Preference Share, the:

 

(i)Redemption Circumstances;

 

(ii)Redemption Amount; and

 

(iii)Redemption Date to the extent possible or if not, the event which if it occurs will result in redemption of that Redeemable Preference Share;

 

(e)the:

 

(i)Conversion Circumstances;

 

(ii)Conversion Number; and

 

(iii)Conversion Date to the extent possible or if not, the event which if it occurs will result in conversion of that Concerting Preference Share; and

 

(f)any other matter the Directors determine.

 

IperionX Limited

 

  Page 50 

 

 

 


Exhibit 4.1

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”.

OPTION AGREEMENT

THIS OPTION AGREEMENT (this “Agreement”) is made and entered into effective as of October 20th, 2021 (the “Effective Date”), by and among Hyperion Materials & Technologies, LLC, a North Carolina limited liability company (“Hyperion”), Hyperion Metals Limited, an Australian public limited liability company listed on the Australian Securities Exchange (ASX: HYM) ("HYM"), Blacksand Technology, LLC, a Utah limited liability company (“Blacksand”), Zhigang Zak Fang (“Zak”), Wenfang Bian Fang, Pei Sun, and Madapusi K. Keshavan (each a “Member” and collectively, the “Members”).  The parties to this Agreement are each referred to as a “Party” and collective the “Parties”.

Background:

A.
Hyperion is engaged in the business of developing commercial uses and applications of titanium and titanium alloy powders and other metals and materials.

B.
Blacksand is engaged in the business of developing proprietary and patented technologies to produce low-cost titanium including the processes for making titanium primary metal from titanium minerals and titanium powders for use with additive manufacturing and near net shape manufacturing of metal parts.

C.
Blacksand is a party to a certain License Agreement, dated August 31, 2015, between the University of Utah Research Foundation (“UURF”) as licensor, and Blacksand as licensee (as amended, the “License Agreement”).

D.
The Members collectively own all of the membership interests of Blacksand as more particularly set forth on Exhibit A (each a “Membership Interest” and collectively, the “Membership Interests”).

E.
The Parties desire to enter into this Agreement to grant Hyperion the option to purchase the Membership Interests and thereby acquire 100% of the ownership interests of Blacksand.

NOW, THEREFORE, in consideration of the mutual representations, warranties, covenants and agreements contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and upon the terms and subject to the conditions hereinafter set forth, the Parties hereto, intending to be legally bound hereby, hereby agree as follows:

1.
Definitions.

(a)
Additional Amount” means 0.5% multiplied by Net Sales after Closing in excess of $300,000,000.

(b)
Affiliate” means with respect to any specified Person, any Person that, directly or indirectly, controls, is controlled by, or is under common control with, such specified Person, through one or more intermediaries or otherwise.

(c)
Agreement” has the meaning set forth in the introductory paragraph.

(d)
Blacksand” has the meaning set forth in the introductory paragraph.



(e)
Blacksand Real Property” means all real property owned, leased, or used by Blacksand, and all other real property for which Blacksand has the option to purchase, lease or otherwise acquire or use, including but not limited to the Covered Property.

(f)
Business Day” means any day other than a Saturday, a Sunday, or a day on which banks in the State of North Carolina are required or authorized to be closed.

(g)
Claim” means any claim, action, demand, lawsuit, or other proceeding of any nature brought against a Person entitled to indemnification in accordance with this Agreement.

(h)
Closing” has the meaning set forth in Section 3(a).

(i)
Closing Date” has the meaning set forth in Section 3(a).

(j)
Company Paid Amount” has the meaning set forth in Section 2(c).

(k)
Conditions Precedent” has the meaning set forth in Section 3(b)(i).

(l)
Confidential Information” has the meaning set forth in Section 11(a).

(m)
Covered Property” means the Blacksand Real Property set forth on Exhibit B.

(n)
Disclosing Party” has the meaning set forth in Section 11(a).

(o)
Dollars” or “$” means United States Dollars.

(p)
Effective Date” has the meaning set forth in the introductory paragraph.

(q)
"Employment Agreement" means any agreement as of the Effective Date between a Member and Blacksand which governs the Member’s terms of employment, consultancy or contractor arrangement with Blacksand (as applicable).

(r)
Encumbrance” means all liens (statutory or otherwise), charges, mortgages, pledges, hypothecations, leases, subleases, occupancy agreements, title retention agreements, adverse interests, title defects, security interests, deeds of trust, claims, licenses, rights of way, servitudes, deemed statutory trusts for taxes,  preferences, priorities, options, warrants, rights of first refusal, rights of first offer, preemptive rights, voting trusts or agreements, proxies, community property interests, security agreements, easements, encroachments, covenants, restrictions, burdens or other encumbrances of any kind or nature whatsoever.

2


(s)
Exercise Date” has the meaning set forth in Section 2(b).

(t)
Governmental Authority” means (i) the United States of America or any other nation, any state, province, local or other political subdivision thereof, (ii) any entity, agency, instrumentality, commission, department, board, bureau, tribunal, court or authority exercising any executive, legislative, judicial, regulatory or administrative functions of government, whether international, foreign, provincial, domestic, federal, state, province, municipal or local, (iii) any arbitrator or mediator, and (iv) any other agency, body, exchange, authority or organization similar to the foregoing having jurisdiction or regulatory authority over Blacksand.

(u)
"Group" means Blacksand (from and after the Closing Date), Hyperion, HYM and any of their Affiliates.

(v)
Hyperion” has the meaning set forth in the introductory paragraph.

(w)
"HYM" has the meaning set forth in the introductory paragraph.

(x)
"HYM Share" means a fully paid ordinary share in HYM.

(y)
"Members HYM Shares" means such number of HYM Shares equal to the Members Paid Amount, with the issue price of each HYM Share being the greater of:

(i)
AUS$0.85; and

(ii)
Seventy five percent (75%) of the volume weighted average price of HYM Shares in the 10-day trading period on the applicable securities exchange (currently the Australian Securities Exchange (“ASX”)) immediately preceding the Closing Date; subject to a maximum issue price for each HYM Share of AUS $3.00.

(z)
Master Services Agreement” means that Master Services Agreement between the Parties dated February 13, 2021.

(aa)
Member” and “Members” have the meaning set forth in the introductory paragraph.

(bb)
Membership Interest” and “Membership Interests” has the meaning set forth in Recital C.

(cc)
Member Paid Amount” has the meaning set forth in Section 2(c).

(dd)
Net Sales” means the cumulative gross revenues—net of taxes, duties, customs and similar fees—relating to or arising from Blacksand, or any of Blacksand’s assets or properties existing as of the Exercise Date, from the period beginning as of the Closing Date until the applicable measurement date.

(ee)
Organizational Document” of any Person means the documents by which such Person (other than an individual) establishes its legal existence or which govern its internal affairs or the rights or obligations of the holders of the equity interests (including the Membership Interests) thereof (including any certificate of formation, certificate of incorporation or other incorporation or formation document, any charters or bylaws, constitution, memorandum and articles of association, other organizational documents, and any operating agreements, partnership agreements, shareholders’ agreement, investor rights agreement, voting agreement, co-sale agreement, registration rights agreement, drag-along agreement, right of first refusal agreement or other similar documents).

(ff)
Option Notice” has the meaning set forth in Section 2(b).

(gg)
Option Payment” has the meaning set forth in Section 5.

(hh)
Option Period” means the period beginning on the Effective Date and terminating upon the earliest to occur of (i) the Closing Date, (ii) termination of the Master Services Agreement, (iii) December 31, 2022, or (iv) the termination of this Agreement.

(ii)
Party” and “Parties” have the meaning set forth in the introductory paragraph.

(jj)
Person” means an individual, corporation (including any non-profit corporation), general partnership, limited partnership, joint venture, association, limited liability company, trust, estate, unincorporated organization, Governmental Authority, or other entity, enterprise, association, organization, or group in any jurisdiction.

(kk)
Pro Rata Share” has the meaning set forth on Exhibit A.

(ll)
Property Agreements” has the meaning set forth in Section 8(e)(i).

(mm)
Purchase Price” has the meaning set forth in Section 2(c)(i).


(nn)
Purchase Option” has the meaning set forth in Section 2(a).

(oo)
Receiving Party” has the meaning set forth in Section 11(a).

(pp)
"Restrained Business" the business of commercializing any granted U.S. patents licensed to Blacksand, or any other Intellectual Property Rights held by Blacksand, as of the Exercise Date; provided that, for the avoidance of doubt, such term shall not include any legal obligation of academic service of Zak to the University of Utah or any affiliate thereof.

3


(qq)
Restrained Customer” means any Person who is during the Restraint Period or was during the twelve (12) month period immediately preceding the Restraint Period, a customer of Blacksand or the Group (as applicable) and with whom, with respect to each Member, such Member had work or other business-related dealings in connection with Blacksand or the Group during the Restraint Period or the during the twelve (12) month period immediately preceding the Restraint Period.

(rr)
Restrained Employee” means any individual who is during the Restraint Period an employee, independent contractor, officer, and/or agent of Blacksand or the Group (as applicable) and with whom, with respect to each Member, such Member had work or other business-related dealings in connection with Blacksand or the Group during the Restraint Period or the during the twelve (12) month period immediately preceding the Restraint Period. “Restrained Supplier” means any Person who is during the Restraint Period or was during the twelve (12) month period immediately preceding the Restraint Period, a supplier of Blacksand or the Group (as applicable) and with whom, with respect to each Member, such Member had work or other business-related dealings in connection with Blacksand or the Group during the Restraint Period or the during the twelve (12) month period immediately preceding the Restraint Period.  "Restraint Area" means the world.

(ss)
"Restraint Period" means, with respect to each Member, the period beginning on the Effective Date and ending on the third (3rd) anniversary of the Closing Date, provided the Restraint Period shall be tolled for a Member during any period in which the Member is in default of its obligations under Section 10 herein.

(tt)
"Shareholder Approval" means the approval of holders of HYM Shares for the issue of the Members HYM Shares to the Members.

(uu)
Transfer” means the sale, assignment, transfer, lease, disposition or other Encumbrance of the Membership Interests.

2.
Purchase Option.

(a)
Grant of Purchase Option.  Subject to and upon the terms and conditions of this Agreement, each Member hereby grants to Hyperion the exclusive and continuing option (but not obligation) to purchase all of the Membership Interests, which Membership Interests shall constitute 100% of the ownership interests in Blacksand (the “Purchase Option”).  The Purchase Option shall be irrevocable for the duration of the Option Period, except as expressly provided for in this Agreement.  If Hyperion does not exercise its Purchase Option for any reason, it shall have no further obligation or liability whatsoever to Blacksand or the Members except as expressly provided for in this Agreement.

(b)
Exercise of Purchase Option.  Hyperion may exercise the Purchase Option at any time during the Option Period, provided that Hyperion is then current in its obligations under the Master Services Agreement.  In the event Hyperion, in its sole and absolute discretion, desires to exercise the Purchase Option, Hyperion shall exercise the Purchase Option by delivering written notice of such exercise (the “Option Notice”) to Blacksand and/or the Members in the manner provided in Section 14(f).  The date on which Hyperion issues the Option Notice shall be the “Exercise Date”.

4


(c)
Purchase Price.  If Hyperion exercises the Purchase Option:

(i)
At the Closing, Hyperion shall:

(1)
Pay or contribute to Blacksand an amount reasonably determined by Blacksand to satisfy certain verified (by written supporting documentation) indebtedness and account payables of Blacksand, not to exceed $3,000,000 (the “Company Paid Amount”); and

(2)
Pay the Members their Pro Rata Share of (i) $12,000,000 (ii) plus the amount of any U.S. federal grant that Blacksand receives between the Effective Date and the Exercise Date, (iii) minus the Company Paid Amount (the “Member Paid Amount”), which shall be paid in the form of seventy percent (70%) cash, and, subject to HYM obtaining Shareholder Approval (which Hyperion shall use its reasonable best efforts to obtain) thirty percent (30%) HYM Shares.

(ii)
If Hyperion obtains Shareholder Approval to satisfy part of the Members Paid Amount through the issue of the Members HYM Shares, each Member agrees to be bound by the constitution of HYM, to the extent that such constitution applies to all owners of HYM Shares.

(iii)
At the Closing, Hyperion shall also commit to donate $1,000,000 towards the establishment of an endowed chair professorship at the University of Utah, which shall be used to support research and development related to Blacksand, Hyperion, other members of the Group, and other related technologies in the field of titanium, critical metals, and minerals. Establishment of the endowed chair professorship shall be subject to the approval/acceptance of the University of Utah, and the Members shall provide support and cooperation and lead the coordination of the endowed chair professorship and the relationship between Blacksand and the University of Utah in that regard. $300,000 of such amount shall be contributed or set aside by the first anniversary of the Effective Date, $300,000 of such amount shall be contributed or set aside by the second anniversary of the Effective Date, and $400,000 of such amount shall be contributed or set aside by the third anniversary of the Effective Date.  In the event the endowed chair professorship has not been approved/accepted by the University of Utah within five (5) years of Closing, the committed funds shall revert back to Hyperion.

(iv)
If, from and after the Closing Date, Net Sales exceed $300,000,000, then Hyperion shall pay the Members their Pro Rata Share of the Additional Amount on an annual basis, within thirty (30) days after the end of each applicable calendar year.

3.
Closing of Purchase Option.

(a)
Closing Generally.  If Hyperion exercises its Purchase Option, the closing of the purchase and sale of the Membership Interests as described in this Agreement (the “Closing”) shall be held on or before five (5) days after the satisfaction or waiver of the Conditions Precedent and the deliverables and actions required under Section 3(c) below (the “Closing Date”).  For purposes of clarity, the Closing Date may extend beyond the Option Period as long as the Option Notice was delivered during the Option Period.   Unless otherwise agreed, Closing shall take place by the exchange of signatures by facsimile, electronic mail or other electronic transmission or, if such electronic exchange is not practicable, at the offices of Johnston, Allison & Hord, P.A., 1065 E. Morehead Street, Charlotte, North Carolina, USA.

5


(b)
Conditions Precedent.

(i)
Closing is conditional on the satisfaction or waiver of the following conditions precedent (“Conditions Precedent”):

(1)
no material adverse change in the business, results, operations, prospects, condition (financial or otherwise) or assets of Blacksand between the date of the Exercise Date and the Closing Date;

(2)
all necessary governmental and other third party approvals and consents are obtained, including without limitation an Estoppel and Consent from the UURF under the License Agreement;

(3)
all necessary shareholder approvals are obtained by Hyperion and, if Hyperion elects to satisfy all or part of the Members Paid Amount through the issuance of the Members HYM Shares, HYM;

(4)
no law, regulation, or order exists that renders it impossible or impracticable to commercially exploit titanium and titanium alloy powders;

(5)
no material liabilities of Blacksand exist other than liabilities under the Master Services Agreement or other liabilities entered into in the ordinary course of Blacksand’s operations;

(6)
Blacksand has the ongoing right to own, occupy, or have the option to purchase all of the Blacksand Real Property;

(7)
Blacksand is in compliance with its obligations under the Master Services Agreement; and

(8)
no material breach of warranty or other terms and provisions of this Agreement.

(ii)
The Conditions Precedent are for the benefit of Hyperion and can only be waived by Hyperion.

6


(c)
Closing Deliverables and Actions.

(i)
On the Closing Date, Hyperion shall contribute the Company Paid Amount and pay to each Member its Pro Rata Share of the Member Paid Amount, in accordance with clause 2(c)(i);

(ii)
On or before the Closing Date, Blacksand must hold a meeting of the Members pursuant to Blacksand’s Organizational Documents and applicable law to approve, and provide Hyperion reasonably satisfactory written resolutions and/or duly executed minutes of each such meeting relating to, the following matters:

(1)
transfer of the Blacksand Membership Interests to Hyperion and the documenting of Hyperion as the sole legal and beneficial owner of the Blacksand Membership Interests to the extent legally permissible and otherwise in such form as approved by Hyperion;

(2)
issuance of written confirmation of Hyperion as the sole owner of the Blacksand Membership Interests;

(3)
resignation of all managers and officers of Blacksand and appointment of Hyperion’s nominees as managers and officers of Blacksand (in the manner specified by Hyperion in writing prior to Closing);

(4)
revocation of each existing authority to operate any bank account of Blacksand and approval of such new authority as may be requested by Hyperion before Closing;

(5)
revocation of any existing powers of attorney granted by Blacksand; and

(6)
any other reasonable business of which Hyperion has given notice to Blacksand prior to Closing.


(iii)
Blacksand and the Members must deliver to Hyperion:

(1)
completed transfers of the Blacksand Membership Interests in favor of Hyperion as transferee duly executed by each Member as transferor, to the extent legally permissible and otherwise in such form as approved by Hyperion;

(2)
all registers, resolutions, minute books and other record books and financial records of Blacksand, including asset registers, management accounts, budgets, ledgers, journals, books of account and other records of Blacksand, and the common seal, if any, of Blacksand;

7


(3)
possession of all title documents relating to the Blacksand Real Property and other documents held by Blacksand in connection with the Blacksand Real Property; and

(4)
if requested by Hyperion, executed escrow agreements (in the form provided by Hyperion) to give effect to any ASX-imposed escrow in relation to the Members HYM Shares.

4.
Access and Rights of Hyperion. Hyperion shall have the following rights.

(a)
Access to Blacksand Real Property.  From the Effective Date to the Closing Date, in each case subject to the conditions in the applicable Property Agreement, reasonable confidentiality (including as set forth in the MSA) and intellectual property-related limitations as Blacksand may reasonably request (the “Limitations”), Blacksand shall grant Hyperion and its representatives, as Blacksand’s agent, reasonable access, with advance notice and during reasonable business hours, to the Blacksand Real Property for purposes of inspecting and reviewing material analyses, intellectual property, reports, service contracts, purchase orders, customer lists, and periodic financial reports in Blacksand’s possession relating to Blacksand’s business, products or services (the “Materials”).

(b)
Access to Blacksand Materials. From the Effective Date to the Closing Date, subject to Blacksand’s confidentiality obligations to third parties and the Limitations, Blacksand shall provide Hyperion, and its representatives, copies of the Materials.

5.
Purchase Option Consideration.

Upon the Effective Date, as consideration for the Purchase Option, Hyperion shall pay Blacksand $250,000, in cash or other immediately available funds to an account designated by Blacksand (“Option Payment”).

It is acknowledged and agreed that, as the Members own all of the Membership Interests, such Option Payment paid by Hyperion to Blacksand shall provide substantial economic and other benefits to the Members, and therefore such Option Payment shall be deemed adequate consideration for the Members’ grant of the Purchase Option to Hyperion.

6.
Obligations of Blacksand and the Members.  During the Option Period, without the prior written consent of Hyperion where relevant, which shall not be unreasonably withheld, delayed or conditioned:

(a)
Blacksand and the Members shall provide Hyperion with copies of all Organizational Documents and any amendments and restatements to or of the Organizational Documents.

(b)
Neither Blacksand nor any Member shall, or shall attempt, agree or purport to: (i) create, authorize, designate, reclassify, modify, or issue any class or series of new Membership Interests or any rights, options, warrants, or other securities convertible into or exchangeable for any Membership Interests, to any Person or (ii) voluntarily or involuntarily Transfer all or any of the Membership Interests.

8


(c)
Each of Blacksand and the Members shall use commercially reasonable efforts not to allow any Encumbrance upon the Membership Interests or upon the properties or assets of Blacksand.

(d)
Blacksand shall be and remain, and the Members shall cause Blacksand to be and remain, in good standing and duly qualified to do business under the laws of the State of Utah, and any other jurisdiction where the nature of the property owned or leased by it or the nature of the business conducted by it makes such qualification necessary.

(e)
Blacksand shall use commercially reasonable efforts to comply, and the Members shall use commercially reasonable efforts to cause Blacksand to comply, in all material respects with all applicable laws and permits issued by Governmental Authorities.

(f)
Blacksand shall use commercially reasonable efforts to comply, and the Members shall cause Blacksand to use commercially reasonable efforts to comply, in all material respects with all Property Agreements, as they may be amended, modified, or supplemented from time to time (provided that no such amendment may be made without the consent of Hyperion).

(g)
Blacksand and the Members  shall promptly notify Hyperion: (i) of any fact, circumstances, event or action the existence, occurrence, or taking of which has had, or could reasonably be expected to expected to have, individually or in the aggregate, a material adverse effect on Blacksand or Blacksand’s business, and (ii) of any material change in zoning or environmental regulations affecting the Blacksand Real Property to the extent such change may reasonably interfere with Blacksand’s business.

(h)
The Members shall, and shall cause Blacksand to: (i) conduct Blacksand’s business in the ordinary course of business consistent with past practice and (ii) use commercially reasonable efforts to maintain and preserve intact the current organization and business of Blacksand and to preserve the rights, goodwill, and relationships of its employees, customers, lenders, suppliers, regulators, and others having business relationships with Blacksand.

(i)
Blacksand shall file all applicable tax returns as and when due and shall pay all local, state, and federal taxes owed by it.

(j)
Blacksand shall not:

(i)
alter or agree to alter its Organizational Documents;

(ii)
distribute any material assets outside of the ordinary course of its business or distribute any cash other than (a) distributions to allow Members to pay tax consequences of ownership in Blacksand, and (b) distributions that do not impair Blacksand’s ability to continue its operations in the ordinary course;

(iii)
cause to occur, by act or omission, an event or series of events, whether related or not, which would have a material adverse effect on the business, assets or financial condition of Blacksand or on the transactions contemplated by this Agreement; or



(iv)
sell, assign or dispose of any legal or beneficial interest in Blacksand’s assets other than in the ordinary course of business consistent with past practice.

9


(k)
Blacksand covenants that it will and the Members agree to ensure that Blacksand will:

(i)
During the Option Period, use commercially reasonable efforts to observe and perform all material stipulations and conditions relating to the Property Agreements (including, without limitation, expenditure conditions prescribed under any applicable laws or regulations), all statutory obligations relating to activities on the Covered Property and all agreements related to Blacksand’s Intellectual Property Rights, including without limitation the License Agreement;

(ii)
During the Exercise Period, work with Hyperion to obtain all necessary governmental approvals and consents required for transfer of the Membership Interests;

(iii)
Not relinquish any portion of any of the Property Agreements except with the agreement of Hyperion, such agreement not to be unreasonably withheld;

(iv)
During the Option Period, use commercially reasonable efforts to promptly pass to Hyperion any notice or communication from any third party or government authority in any way affecting the Property Agreements, the Covered Property or the License Agreement; and

(v)
Maintain in good standing and free from Encumbrance, all of Blacksand’s Intellectual Property Rights.

(l)
Blacksand shall not grant licenses or sublicenses for any technology or other property owned or licensed by Blacksand, including, without limitation, any Intellectual Property Rights.

(m)
Blacksand shall use good faith efforts to pursue an amendment to the License Agreement with UURF as deemed reasonably necessary by Hyperion to insure that all of Blacksand’s Intellectual Property Rights as shown and designated as “U-No.” on Exhibit C hereto are covered and properly referenced in the License Agreement.  Otherwise, Blacksand shall not amend, alter, expand or terminate the License Agreement.

(n)
Blacksand shall use good faith efforts to pursue execution and recording by the original inventors and/or the University of Utah, as the case may be, of any assignment deemed reasonably necessary by Hyperion to confirm that Blacksand’s Intellectual Property Rights as shown and designated as “U-No.” on Exhibit C hereto are currently owned by UURF, including assignments of provisional patent applications, formal patent applications, issued patents, divisionals, continuations, continuations in part and foreign applications.

(o)
Blacksand shall use good faith efforts to license the intellectual property known as “Production of Titanium Dioxide Pigment” and having University of Utah and UURF reference number U-4606, pursuant to a license agreement to be approved by Hyperion.
10


7.
Representations of the Members.  Each Member hereby represents and warrants to Hyperion solely as to such Member and not with respect to any other Member (on the Effective Date and each day until Closing or the termination of this Agreement), as follows:

(a)
Member Authority.  Such Member has the capacity to execute, deliver and perform or consummate the transactions contemplated by this Agreement. This Agreement has been duly and validly executed and delivered by such Member and constitutes the valid and binding obligation of such Member, enforceable against such Member in accordance with their respective terms, except as such enforcement shall be limited by bankruptcy, insolvency, moratorium or similar law affecting creditors’ rights generally and subject to general principles of equity.

(b)
No Member Conflicts.  The execution, delivery and performance by such Member of this Agreement, and the consummation by such Member of the transactions contemplated hereby does not and will not violate any provision of any law to which such Member is subject.  The execution, delivery and performance by such Member of this Agreement, and the consummation by such Member of the transactions contemplated hereby does not and will not, with or without the giving of notice or the lapse of time, or both, (i) violate or result in a breach of or constitute a default under, conflict with, require the consent of (or notice to) any third party under any contract or permit issued by a Governmental Authority, or (ii) result in the creation or imposition of any Encumbrance of any nature whatsoever upon any of any portion of the Membership Interest held by such Member.  No notices to, filings with, or authorizations, consents or approvals of any Governmental Authority or any other Person are necessary for the execution, delivery or performance by such Member of this Agreement or the consummation by such Member of the transactions contemplated hereby.

(c)
Title to Membership Interests.  Such Member is the record and beneficial owner of the Membership Interest set forth opposite such Member’s name on Exhibit A, and has good and valid title to his or its Membership Interest, as applicable, free and clear of all Encumbrances and other any restrictions imposed by applicable United States securities laws.

(d)
Intellectual Property Rights.  Such Member does not own, license or otherwise control patents, patent applications or other intellectual property related to Blacksand’s Intellectual Property Rights.

8.
Representations of Blacksand.  Blacksand hereby represents and warrants to Hyperion (on the Effective Date, and each day until the Closing Date, as follows:

(a)
Organization. Blacksand is a limited liability company, duly formed, validly existing and in good standing under the laws of the State of Utah.  Blacksand has all requisite power and authority to own, lease and operate its properties and carry on its business as it is now being conducted.  Blacksand is duly qualified to do business and is in good standing in all other jurisdictions where the nature of the property owned or leased by it or the nature of the business conducted by it makes such qualification necessary.

11

 
(b)
Company Authority.  Blacksand has all requisite power and authority to execute, deliver and perform this Agreement and to perform its obligations hereunder and to consummate the transactions contemplated hereby.  The execution, delivery and performance by Blacksand of this Agreement, and the consummation by Blacksand of the transactions contemplated hereby have been duly authorized by all necessary action on the part of Blacksand.  No other limited liability company proceedings on the part of Blacksand are necessary to authorize such execution, delivery or performance or to consummate the transactions contemplated by this Agreement.  This Agreement has been duly and validly executed and delivered by Blacksand and constitutes the valid and binding obligation of Blacksand, enforceable against Blacksand in accordance with its terms, except as such enforcement shall be limited by bankruptcy, insolvency, moratorium or similar law affecting creditors’ rights generally and subject to general principles of equity.

(c)
No Company Conflicts.  The execution, delivery and performance by Blacksand of this Agreement and the consummation by Blacksand of the transactions contemplated hereby does not and will not (i) violate any provision of any law to which Blacksand is subject, or (ii) violate or breach any provision of any Organizational Document of Blacksand.  The execution, delivery and performance by Blacksand of this Agreement, and the consummation by Blacksand of the transactions contemplated hereby does not and will not, with or without the giving of notice or the lapse of time, or both, (x) violate or result in a breach of or constitute a default under, conflict with, require the consent of (or notice to) any third party under, or result in or permit the termination, cancellation, modification, or amendment of any provision of, or result in or permit the acceleration of the maturity or cancellation of performance of any obligation under any contract (including any Property Agreement) or any permit issued by a Governmental Authority to which Blacksand is a party or by which Blacksand may be bound or affected, or (y) result in the creation or imposition of any Encumbrance of any nature whatsoever upon any of the assets or properties of Blacksand or give to others any interests or rights therein.  No notices to, filings with, or authorizations, consents or approvals of any Governmental Authority or any other Person are necessary for the execution, delivery or performance by Blacksand of this Agreement or the consummation by Blacksand of the transactions contemplated hereby.

(d)
Capitalization.  All of the issued and outstanding Membership Interests have been duly authorized and validly issued, fully paid and non-assessable, and none of the issued and outstanding Membership Interests are subject to or were issued in violation of any applicable securities laws, purchase option, call option, right of first refusal, preemptive right, subscription right or any similar right under any provision of applicable law, the Organizational Documents of Blacksand or any contract to which Blacksand is a party.  All of the issued and outstanding membership interests of Blacksand are held of record and beneficially owned by the Members as set forth on Exhibit A, in each case in the class and amounts so indicated thereon. There are no obligations or commitments for Blacksand to issue any additional membership interests or equity interests beyond those already issued and outstanding. There are no outstanding or authorized options, warrants, purchase rights, subscription rights, conversion rights, convertible securities, exchange rights, calls, puts, preemptive rights, rights of first refusal, tag-along right, drag-along rights or other contracts, rights, agreements, arrangements or commitments of any character that would require Blacksand to issue, sell, purchase or otherwise cause to become outstanding, or cause to be repurchased or redeemed, any Membership Interests or any other membership or equity interest in Blacksand.  There are no voting trusts, equityholder agreements, shareholders agreements, proxies or other agreements or understandings in effect with respect to the voting or Transfer of any Membership Interests.

12

 
(e)
Real Property.

(i)
Exhibit B sets forth a true, correct and complete list of all property owned by Blacksand and all written or oral leases, subleases, licenses, option agreements, rights to purchase, rights of first refusal, or other occupancies of the Blacksand Real Property (including all amendments, extensions, renewals and guaranties with respect thereto) (collectively, the “Property Agreements”) to which Blacksand is a party (as lessor, lessee, sublessee, licensee, option holder, or otherwise).  Blacksand has delivered or made available to Hyperion a true, correct and complete copy of each of the Property Agreements and all amendments, modifications and supplemental agreements thereto.  Each of the Property Agreements is in full force and effect and is valid, binding and enforceable against the Blacksand and each of the other parties thereto, in accordance with its terms and has not been modified or amended except as disclosed on Exhibit B.

(ii)
(1) Blacksand has not received from the other party to any Property Agreement any notice claiming that Blacksand is in default thereunder for which such default has not been cured; (2) all payments required to be paid by Blacksand pursuant to the Property Agreements have been paid prior to such payments becoming delinquent; (3) there has not occurred any event which would constitute a breach of or default in the performance of any covenant, agreement or condition contained in any Property Agreement which has not been cured, nor has there occurred any uncured event which with the passage of time or the giving of notice or both would constitute such a breach or default;  and (4) Blacksand has not received any written notice from the other party to any Property Agreement of the termination or proposed termination thereof.

(iii)
Blacksand presently enjoys peaceful and undisturbed possession of the Blacksand Real Property.  There are no matters affecting the right, title and interest of Blacksand in and to the Blacksand Real Property which, in the aggregate, would adversely affect the ability to carry on the Business upon the Blacksand Real Property substantially in the manner in which such operations are currently carried on.  No Person other than Blacksand has any right to use or occupy the Blacksand Real Property.

(iv)
The current use of the Blacksand Real Property in the conduct of Blacksand’s business does not violate any Property Agreement in any respect.  Blacksand is not in violation of any covenant, condition, restriction, easement or order of any Governmental Authority having jurisdiction over the Blacksand Real Property or the use or occupancy thereof.  Blacksand has not received written notice from any Governmental Authority, with respect to the Blacksand Real Property, of any violation or claimed violation by Blacksand of applicable building, zoning, subdivision, conservation, fire, health and safety and other land use and similar applicable laws, rules and regulations, permits, licenses, and certificates of occupancy.

(v)
None of the transactions contemplated by this Agreement constitutes an assignment of Blacksand’s rights under any Property Agreement, and such transactions do not require the consent of any Person under any Property Agreement.

(vi)
Each use of the Blacksand Real Property by Blacksand is and has been valid, permitted and conforming uses in accordance with the current zoning classification of the Blacksand Real Property, and there are no outstanding variances or special use permits affecting the Blacksand Real Property or their uses.  The operation of the Business on the Blacksand Real Property complies with all applicable laws, all applicable permits issued by Governmental Authorities, and all Property Agreements.
13


 
(f)
Intellectual Property:

(i)
Exhibit C sets forth a true, correct and complete list, reference or link to all the intellectual property and software legally and beneficially owned or licensed by Blacksand, including all registered or unregistered business names, trade or service marks, patents, and patent applications, other than off-the-shelf and shrink-wrap or click-wrap software requiring payments of less than $2,500 per year (“Intellectual Property Rights”).

(ii)
Blacksand owns or is legally entitled to use all the assets, systems, hardware and software required to operate the information technology functions of Blacksand.

(iii)
Blacksand does not require the use of any Intellectual Property Rights other than those specified in Exhibit C in the course of conducting its business.

(iv)
The information technology systems, including hardware and software, utilized by Blacksand in the operations of its business as of the Effective Date are sufficient for the conduct of the business Blacksand as currently conducted.

(v)
Neither Blacksand nor any of its Affiliates are in material breach of a material term of any agreement or license relating to the Intellectual Property Rights to which it is a party (whether as licensor or licensee) and so far as Blacksand is aware no third party is in breach of any such agreement.

(vi)
To Blacksand’s knowledge, neither Blacksand nor any of its Affiliates have infringed any Intellectual Property Rights of any third party or is aware of any circumstances which is likely to give rise to any infringement.

(vii)
Blacksand is not aware of any unauthorized use by any person of any Intellectual Property Rights or confidential information of Blacksand or any of its Affiliates.

(viii)
There is not currently any unresolved challenge, dispute or claim which has been made or threatened by any person with respect to any of the Intellectual Property Rights used in connection with Blacksand's business.

(g)
Compliance with Laws; Permits.  Blacksand has been, during the three (3) year period prior to the Effective Date, and is currently in compliance in all material respects with all applicable laws and permits issued by Governmental Authorities.

(h)
Legal Proceedings.  There are no actions pending or threatened against or by Blacksand: (a) relating to or affecting Blacksand’s business or the Membership Interests; or (b) that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement.  No event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such action.  There are no outstanding orders of Governmental Authorities and no unsatisfied judgments, penalties or awards against, relating to or affecting Blacksand’s business.

14


 
(i)
Taxes.

(i)
From and after Blacksand’s date of formation (September 3, 2013), Blacksand has been taxed as a partnership or as a disregarded entity.

(ii)
All tax returns required to be filed by Blacksand for any period prior to the Effective Date have been, or will be, timely filed.  Such tax returns are, or will be, true, complete, and correct in all respects. All taxes due and owing by Blacksand (whether or not shown on any tax return) have been, or will be, timely paid.

(iii)
Blacksand has withheld and paid each tax required to have been withheld and paid in connection with amounts paid or owing to any of its employees, independent contractors, creditors, customers, shareholders or other persons, and has complied with all information reporting and backup withholding provisions of applicable law.

(iv)
No extensions or waivers of statutes of limitations have been given or requested with respect to any taxes of Blacksand.

(v)
All deficiencies asserted, or assessments made, against Blacksand as a result of any examinations by any taxing authority have been fully paid.

(vi)
Blacksand is not a party to any action by any taxing authority.  There are no pending or threatened actions by any taxing authority.

(vii)
There are no Encumbrances for taxes upon any of the Membership Interests nor is any taxing authority in the process of imposing any Encumbrances for taxes on any of the Membership Interests (other than for current taxes not yet due and payable).

(j)
Subsidiaries:  Blacksand does not have any subsidiaries.

(k)
No other operations or assets: Other than the business described in the Recitals above, Blacksand does not have any operations, assets or agreements.

(l)
Employees and contractors: Other than as disclosed to Hyperion, Blacksand does not have any employees and contractors.

(m)
Liabilities: Other than as disclosed to the Hyperion, Blacksand does not have any liabilities, other than the Company Paid Amounts, obligations to UURF, and other payables and similar obligations incurred in the ordinary course of Blacksand’s business.

(n)
Consistency with other agreements: The terms of this Agreement are not inconsistent with and do not contravene the provisions of any other agreements or contract to which Blacksand is a party.

15


9.
Employee/Advisor/Consultant Retention.

During the period commencing from the Effective Date to the Closing Date, Blacksand and the Members will:

(i)
use commercially reasonable efforts to maintain the services of all of the officers, employees and consultants of Blacksand;

(ii)
without the prior written consent of Hyperion, not terminate, vary or amend any agreements with or encourage the resignation of any of the officers, employees and consultants of Blacksand; and

(iii)
work in good faith with Hyperion to conduct a review to determine key officers and employees of Blacksand who will be offered continued employment and the terms and conditions of such employment, including without limitation any covenants similar to the covenants set forth in Section 10 below.

In addition, by execution of this Agreement, Zak agrees to remain as an advisor and consultant to Hyperion for at least twenty-four (24) months following Closing, obligated to continue providing the level of service, assistance and support currently being provided to Blacksand/Hyperion for compensation in the amount as set forth in any then current Consulting Agreement between Zak and Hyperion, subject to the terms and conditions of any such then current Consulting Agreement.

10.
Non-Compete Covenants.

(a)
Each Member agrees that he will not, either d irectly or by, with, or through any other Person, do any of the following:

(i)
during the Restraint Period and within the Restraint Area, carry on, promote, participate in, operate, engage in or be involved in any way (whether as an employee, agent, director, consultant, partner, promoter, owner, investor, lender, financier, guarantor, co-obligor, or however otherwise) in any Restrained Business;

(ii)
to the extent not covered in the immediately preceding clause, during the Restraint Period and within the Restraint Area, act as an adviser, independent contractor, consultant, director, manager, agent, employee or in any other capacity whatsoever in or to any Restrained Business;

(iii)
during the Restraint Period, solicit, provide and/or accept business that is or is similar to the Restrained Business or goods or services of a similar type to those provided by Blacksand or the Group to any Restrained Customer;

(iv)
during the Restraint Period, solicit, any Restrained Supplier, to cease to supply, or to restrict or vary the terms of supply to, Blacksand or the Group (as applicable), attempt to do any of the foregoing with respect to any such Restrained Supplier, or otherwise interfere with any relationship between Blacksand or the Group (as applicable) and any such Restrained Supplier;

16


(v)
during the Restraint Period, solicit, lure, entice, call, and/or induce any Restrained Customer, to cease purchasing goods and/or services from, or the restrict or vary the terms of the purchase of goods and/or services from, Blacksand or the Group, attempt to do any of the foregoing with respect to any such Restrained Customer, or otherwise interfere with any relationship between Blacksand or the Group (as applicable) and any such Restrained Customer;

(vi)
during the Restraint Period, solicit, lure, entice, call, and/or induce any Restrained Employee to leave the employment of, cease providing services to, reduce or lessen the provision of services to, or otherwise vary the terms of such Restrained Employee’s provision of services to, Blacksand or the Group (as applicable), or otherwise interfere with the relationship between Blacksand or the Group (as applicable) and any such Restrained Employee;

(vii)
reveal, report, publish, disclose or transfer any Confidential Information of Blacksand or the Group to any Person (other than Blacksand and/or the Group), use any such Confidential Information for any purpose, or use any such Confidential Information for the benefit of any Person (other than Blacksand and/or the Group); or

(viii)
procure any other Person to do or assist any other Person in doing any of the things referred to in clauses 10(a)(i) to 10(a)(vii) inclusive.

(b)
Prior written consent: The covenants in this clause 10 do not apply in circumstances where the Member has obtained the prior written consent of Blacksand and Hyperion.

(c)
Acknowledgment: The Members agree and acknowledge that:

(i)
the Members will obtain Confidential Information during the Employment, the disclosure of which could materially harm the Group;

(ii)
the covenants in clause 10(a) are fair and reasonable and necessary for the protection of the Confidential Information and the Group's goodwill and legitimate business interests, particularly in relation to the Group's core business activities;

(iii)
the remuneration and other benefits provided to the Members by virtue of the Option Payment and the Company Paid Amount constitute adequate consideration for the Members' agreement to be bound by the covenants under this clause 10;

(iv)
their willingness to be bound by the covenants in clause 10(a) was and is a material inducement to Hyperion’s willingness to enter into this Agreement and potentially exercise the Purchase Option, and Hyperion would not have entered into this Agreement and would not be willing to exercise the Purchase Option but for the Members’ willing to be bound by the covenants in clause 10;

17


(v)
the covenants in clause 10(a) do not unreasonably restrict the Members' right to practice in their profession or calling;

(vi)
damages may be inadequate to protect the Group's interests and the Group is entitled to seek and obtain injunctive relief, or any other remedy, in any court for any breach or threatened breach of the Members' obligations under this clause 10, without the need to post bond or any other form of security therefor;

(vii)
each covenant contained in clause 10(a) (resulting from any combination of the wording in clause 10(a) and the definitions of Restraint Period and Restraint Area) constitutes a separate and independent covenant, severable from the other covenants therein; and

(viii)
if any covenants are determined to be unenforceable in whole or in part, the enforceability of the remaind er of that restraint and any other restraint will not be affected.

(d)
Continuing Obligations: For the avoidance of doubt, the Members' obligations under this clause 10 survive termination of any Employment Agreement.

11.
Other Agreements.

(a)
Confidentiality.  From time to time during the term of this Agreement, a Party (as the “Disclosing Party”) may disclose or make available to another Party (as the “Receiving Party”) information about its business affairs, products, services, confidential intellectual property, trade secrets, third-party confidential information and other sensitive or proprietary information (collectively, “Confidential Information”).  Confidential Information shall not include information that, at the time of disclosure: (i) is or becomes generally available to and known by the public other than as a result of, directly or by, with, or through any other Person, any breach by the Receiving Party or any of its representatives; (ii) is or becomes available to the Receiving Party on a non-confidential basis from a third-party source, provided that such third party is not and was not prohibited from disclosing such Confidential Information; (iii) was known by or in the possession of the Receiving Party or its representatives before being disclosed by or on behalf of the Disclosing Party; or (iv) was or is independently developed by the Receiving Party without reference to or use, in whole or in part, of any of the Disclosing Party’s Confidential Information.  The Receiving Party shall: (A) protect and safeguard the confidentiality of the Disclosing Party’s Confidential Information with at least the same degree of care as the Receiving Party would protect its own Confidential Information, but in no event with less than a commercially reasonable degree of care; (B) not use the Disclosing Party’s Confidential Information, or permit it to be accessed or used, for any purpose other than to exercise its rights or perform its obligations under this Agreement; and (C) not disclose any such Confidential Information to any person or entity, except to the Receiving Party’s representatives who need to know the Confidential Information to assist the Receiving Party, or act on its behalf, to exercise its rights or perform its obligations under the Agreement.  The Receiving Party shall be responsible for any breach of this Section 11(a) caused by any of its representatives.  In the event the Disclosing Party’s Confidential Information is required to be disclosed under applicable federal, state or local law, regulation or a valid order issued by a court or Governmental Authority of competent jurisdiction, the Receiving Party shall promptly notify the Disclosing Party of such requirement and reasonably assist the Disclosing Party (at the Disclosing Party’s expense) to enable it to obtain a protective order or otherwise take appropriate measures to prevent the disclosure of its Confidential Information.  In the event the Disclosing Party is unable to prevent the disclosure of such Confidential Information, the Receiving Party shall disclose only that portion of such Confidential Information that the Receiving Party is legally required to disclose.  On the expiration or termination of the Agreement, at the Disclosing Party’s written request, the Receiving Party shall promptly return, and shall require its representatives to return to the Disclosing Party all copies, whether in written, electronic or other form or media, of the Disclosing Party’s Confidential Information, or destroy all such copies and certify in writing to the Disclosing Party that such Confidential Information has been destroyed. Notwithstanding this clause, (a) Hyperion may use any Confidential Information they require for the purposes of raising capital or pursuing an Exchange listing, and (b) Zak may use and disclose certain Confidential Information as required by, or consistent with, Zak’s academic obligations to the University of Utah and its affiliates.






18


(b)
Exclusivity.  During the Option Period, the Parties agree that Hyperion is and shall be the exclusive holder of the Purchase Option.  In light of the foregoing, during the Option Period, Blacksand and/or the Members shall not, directly or by, with, or through any other Person, in any capacity whatsoever: (i) solicit, initiate, entertain, encourage, accept any inquiries, proposals, or offers from any Person other than Hyperion for the acquisition of the Membership Interests or to engage in transactions similar to the transactions contemplated hereby; (ii) grant any Person other than Hyperion any right or option to purchase the Membership Interests, all or substantially all of the assets of Blacksand, or otherwise to acquire or succeed to the Business;  (iii) grant any Person other than Hyperion the right to access the Covered Property for purposes exploring, evaluating, mining, or removing Mineral Products; (iv) provide any Person other than Hyperion with access to any  reports, surveys, historical exploration results, and data relating to the Covered Property, Mineral Products that may be located on or under the Covered Property, and other geological attributes of the Covered Property, or relating to the Business; or (v) otherwise circumvent, avoid, bypass, or obviate the intent of this Agreement and the observance and performance of all the terms and provisions hereof.  The Parties agree that this Section shall be strictly construed and the violation of this Section 11(b) shall be an incurable material breach of this Agreement.

(c)
Further Assurances.  If Hyperion exercises the Purchase Option, following the Closing, the Parties shall, and shall cause their respective representatives to, execute and deliver such additional documents, instruments, conveyances, and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement.

12.
Indemnification.

Indemnification by Blacksand and MembersBlacksand (during the term of this Agreement) and the Members (during and thereafter), jointly and severally, shall indemnify, defend, and hold harmless Hyperion, and its officers, directors, employees, agents, representatives, affiliates, successors, and permitted assigns, from and against any and all losses, damages, liabilities, costs, or expenses arising out of or resulting from any breach by Blacksand or any Member of any representation, warranty, or covenant set forth in this Agreement.

Indemnification by Hyperion.  Hyperion shall indemnify, defend, and hold harmless Blacksand, the Members, and Blacksand’s officers, managers, employees, agents, representatives, affiliates, successors, and permitted assigns, from and against any and all losses, damages, liabilities, costs, or expenses arising out of or resulting from any breach by Hyperion of any representation, warranty, or covenant set forth in this Agreement.

13.
Termination.

(a)
Events of Termination.

(i)
This Agreement may be terminated at any time by the mutual agreement of all Parties.

(ii)
This Agreement shall terminate upon the expiration of the Option Period (unless the Option Notice has been given).

(iii)
This Agreement may be terminated by Hyperion at any time and for any reason (or for no reason), upon sixty (60) days’ notice to Blacksand.

(iv)
This Agreement may be terminated by Hyperion if there has been a breach, inaccuracy in, or failure to perform any representation, warranty, covenant or agreement made by Blacksand or any Member pursuant to this Agreement, and such breach, inaccuracy, or failure has not been cured by Blacksand or the Members (as applicable) within thirty (30) days of receipt of written notice of such breach from Hyperion.  Notwithstanding the foregoing, there shall be no cure period for a breach of Section 11(a) (Confidentiality) or Section 11(b) (Exclusivity).

(v)
This Agreement may be terminated by Blacksand if there has been a breach, inaccuracy in, or failure to perform any representation, warranty, covenant or agreement made by Hyperion pursuant to this Agreement, and such breach, inaccuracy, or failure has not been cured by Hyperion within thirty (30) days of receipt of written notice of such breach from Blacksand.

19


(b)
Effects of Termination.

(i)
Following the termination of this Agreement, the Parties shall have no further rights, obligations, duties under this Agreement, except pursuant to Section 11(a) (Confidentiality), Section 12 (Indemnification), Section 13(b) (Effects of Termination), and Section 14 (Miscellaneous), all of which shall survive the termination of this Agreement.  The Parties’ indemnification obligations under Section 12, and the representations and warranties set forth herein, shall survive for a period of one (1) year following the termination of this Agreement.

(ii)
Upon termination of this Agreement, Hyperion shall have no further obligations to make the Option Payment under Section 5.

(iii)
Following the termination of this Agreement, Hyperion shall have thirty (30) days from the date of termination to remove all of its representatives, vehicles, and other property from the Covered Property.

(iv)
If this Agreement is terminated due to the uncured breach of one Party, the non-breaching party shall retain all of its rights and remedies at law and in equity.

14.
Miscellaneous.

(a)
Entire Agreement.  This Agreement (including the Exhibits attached hereto) constitutes the entire understanding and agreement of the Parties with respect to the transactions contemplated by this Agreement and supersedes any other agreements, whether written or oral, that may have been made or entered into by or among any of the Parties or any of its respective Affiliates relating to the transactions contemplated hereby or thereby or the subject matter hereof or thereof.

(b)
Successors and Assigns.  The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and permitted assigns of the Parties hereto; provided, however, that this Agreement may not be assigned by any Party hereto without the prior written consent of the other parties hereto, except that Hyperion and HYM may without the consent of any other Party (A) assign this Agreement (in whole or in part) and their rights and obligations hereunder to (i) one or more Affiliates of Hyperion, or (ii) to an acquirer to all or a substantial portion of the capital stock (or other equity interests) or all or a substantial portion of the assets or business of Hyperion in any form of transaction, or (B) change the legal name of Hyperion or HYM.  Any assignment in violation of this Section is be void ab initio.

(c)
Modification and Waiver.  No amendment, modification, or alteration of the terms or provisions of this Agreement shall be binding unless the same shall be in writing and duly executed by the Parties.  Notwithstanding the foregoing, Exhibit B and the corresponding definition of “Covered Property” may be amended by a writing executed solely by Blacksand and Hyperion.  Any of the terms or provisions of this Agreement may be waived in writing at any time by the Party that is entitled to the benefits of such waived term or provision.  No single waiver of any of the provisions of this Agreement shall be deemed to or shall constitute, absent an express statement otherwise, a continuous waiver of such provision or a waiver of any other provision hereof (whether or not similar).  No delay on the part of any Party in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, and no course of dealing between or among the Parties shall be deemed effective to modify, amend or discharge any part of this Agreement or any rights or obligations of any party hereto under or by reason of this Agreement.

20

 
(d)
Severability.  Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Agreement.

(e)
Expenses. Except as otherwise expressly provided in this Agreement, all costs and expenses, including, without limitation, fees and disbursements of counsel, financial advisors and accountants, incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the party incurring such costs and expenses.

(f)
Notices.  Any notice, request, instruction, or other document to be given hereunder by any Party hereto to any other Party shall be in writing and shall be given by delivery in person, by electronic mail, by electronic facsimile transmission, by overnight courier or by registered or certified mail, postage prepaid (and shall be deemed given when delivered if delivered by hand or by electronic mail, when transmission confirmation is received if delivered by facsimile, one Business Day after deposited with an overnight courier service if delivered by overnight courier and three days after mailing if mailed), as follows:

 
If to Hyperion or HYM:
 
[***]
       
 
with copy to:
 
[***]
       
 
If to Blacksand:
 
[***]
       
       
 
If to Member Zhigang Zak Fang:
 
[***]
       
 
If to Wenfang Bien Fang:
 
[***]
       
 
If to Pei Sun:
 
[***]
       
 
If to Madapusi K. Keshavan:
 
[***]

(g)
Specific Performance.  The Parties agree that irreparable damage would occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the Parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy to which they are entitled at law or in equity.

(h)
Attorneys’ Fees and Expenses.  In the event any suit, action, or other proceeding arising out of or relating to this Agreement or any transaction contemplated hereby is commenced by any Party hereto, the prevailing Party in such suit, action, or proceeding shall be entitled to recover its reasonable attorneys’ fees and expenses from the other Party(s) as determined by the court in accordance with N.C. Gen. Stat. § 6-21.6.  The parties to this Agreement hereby acknowledge this agreement is a contract entered into primarily for business or commercial purposes.

(i)
Governing Law.  This Agreement shall be governed by and interpreted and enforced in accordance with the laws of the State of North Carolina, without giving effect to any choice of law or conflict of laws rules or provisions (whether of the State of North Carolina or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of North Carolina.

 
(j)
No Third Party Beneficiaries. This Agreement is intended and agreed to be solely for the benefit of the Parties and their successors and permitted assigns, and no other party or Person shall be entitled to rely on this Agreement or accrue any benefit, claim, or right of any kind whatsoever pursuant to, under, by, or through this Agreement

(k)
Counterparts; Electronic Signatures.  This Agreement may be executed in multiple counterparts, each of which shall for all purposes be deemed to be an original and all of which shall constitute the same instrument.  This Agreement and any amendments hereto, to the extent signed and delivered by electronic transmission in portable document format (pdf), or by other electronic transmission, shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.

21


IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized representatives as of the Effective Date.

 
HYPERION:
   
 
Hyperion Materials & Technologies, LLC
   
   
 
By:
/s/ Anastasios Arima
     
 
Name:  
Anastasios Arima
     
 
Title:
Manager


 
Blacksand:
   
 
Blacksand Technology, LLC
   
   
 
By:
/s/ Madapusi K. Keshavan
   
 
Name:  
Madapusi K. Keshavan
   
 
Title:
President



 
MEMBERS:
   
   
 
/s/ Zhigang Zak Fang
 
Zhigang Zak Fang
   
   
 
/s/ Wenfang Bian Fang
 
Wenfang Bian Fang
   
   
 
/s/ Pei Sun
 
Pei Sun
   
   
 
/s/ Madapusi K. Keshavan
 
Madapusi K. Keshavan






 
 
HYM:
   
   
 
Hyperion Metals Limited
   
   
 
By:
/s/ Anastasios Arima
   
 
Name:  
Anastasios Arima
   
 
Title:
Director
   
   
   
 
By:
/s/ Gregory Swan
   
 
Name:  
Gregory Swan
   
 
Title:
Company Secretary


NOTE:

HYM joins in the execution of this Agreement solely to satisfy any conditions of issuance of the Members HYM Shares in the event Hyperion elects to satisfy all or part of the Members Paid Amount through the issue of the Members HYM Shares.



 

 

Exhibit 4.2

 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”.

 

OPTION OF EXCLUSIVE LICENSE AGREEMENT

 

BETWEEN

 

HYPERION MATERIALS & TECHNOLOGIES, LLC

 

AND

 

BLACKSAND TECHNOLOGY, LLC

 

 

Contents

 

1.   Definitions 3
2.   License Grant 4
3.   Royalties 5
4.   Records, Books, and Examinations 6
5.   Term of the License 6
6.   Licensor’s Performance 6
7.   Sublicensing Rights 6
8.   Representations and Warranties 7
9.   Modification and Termination 9
10.   Liability 10
11.   Infringement and Litigation 11
12.   Confidentiality 11
13.   Miscellaneous 12
APPENDIX A – Master Services Agreement and Statement of Work 14

 

Page 2 of 15

 

 

OPTION OF EXCLUSIVE LICENSE AGREEMENT

 BETWEEN

HYPERION MATERIALS & TECHNOLOGIES, LLC

 AND

BLACKSAND TECHNOLOGY, LLC

 

This Option of Exclusive License Agreement (“Agreement”) is entered into between Blacksand Technology, LLC, a limited liability company organized under the laws of Utah (“Licensor”), with offices at 1782 West 2300 South, West Valley City, Utah 84119, and Hyperion Materials & Technologies, LLC, a limited liability company organized under the laws of North Carolina (“Licensee”), with offices at 32N Main St. Suite 100, Belmont, North Carolina, 28012.

 

RECITATIONS

 

WHEREAS, Licensor is party to a certain License Agreement, dated August 24, 2015, between University of Utah Research Foundation (“UURF”) and Licensor, as amended by Amendment to License Agreement dated March 20, 2016, and as the same may be amended from time to time (the “UURF License Agreement”), pursuant to which Licensor has received an exclusive license and related rights to the Licensed Patents and Licensed Products (as defined herein). The UURF License Agreement is attached to this Agreement for reference only as Appendix A.

 

WHEREAS, pursuant to the UURF License Agreement, UURF granted to Licensor the exclusive right to sublicense the Licensed Patents and Licensed Products to sublicensees provided that Licensor has exclusive rights in the territory being sublicensed, and Licensor currently has such exclusive rights to sublicense the Licensed Patents and Licensed Products to Licensee in the Licensed Territory.

 

WHEREAS, pursuant to the Master Services Agreement (as amended, “MSA”) and Statement of Work #1 of even date herewith (as amended, “Statement of Work”), Licensor has granted Licensee an option (the “Option”) to acquire the License (as defined herein).

 

WHEREAS, each of the MSA and Statement of Work are attached to this Agreement as Appendix B and incorporated by reference.

 

AGREEMENT

 

NOW THEREFORE, in accordance with the aforementioned recitations and in consideration of the release and of the covenants and obligations hereinafter set forth to be well and truly performed, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

1. Definitions

 

As used in this Agreement, the following terms shall have the following meanings and such meanings shall be equally applicable to both the singular and plural forms of the terms defined.

 

1.1.       “Affiliate” means any corporation, firm, partnership, or other entity in which Licensee owns or controls more than fifty percent (50%) of the voting stock or interests thereof.

 

1.2.       “Effective Date” means the date when this Agreement is signed by both parties.

 

Page 3 of 15

 

 

1.3.       “Exclusive Licensed Use” means use of the Licensed Patents and Licensed Products, within the Licensed Territory, to process titanium-bearing ores or titanium feedstocks with a percentage of TiO2 of 96% or below for the production of Ti-metal or Ti-metal alloy powders. The Exclusive Licensed Use includes processing of all Ti-minerals and Ti-slags into Ti-metal powders, but excludes processing of commercial TiO2 powder into Ti-metal powders and excludes the production of TiO2 powder.

 

1.4.       “Licensed Patents” means [***].

 

1.5.       “Licensed Products” mean any and all apparatus, articles of manufacture, compositions of matter, methods, uses, processes or products falling in whole or in part within, or generated in whole or in part from, and including Licensed Products (as defined in the UURF License Agreement) and Licensed Services (as defined in the UURF License Agreement), to the extent within the scope of one or more claims of the Licensed Patents,

 

1.6.       “Licensed Territory” means worldwide.

 

1.7        “Sublicense” means a grant of rights by Licensee to a third party (each a “Sublicensee”) to make, have made, use, have used, sell, import, have imported, export or have exported, Licensed Products for the Exclusive Licensed Use within the Licensed Territory for which Licensee has received an Exclusive License for the Licensed Patents as provided under this Agreement.

 

1.8        “The Point of Practical Application” means the stage of development of the products and methods described and claimed in the Licensed Patents at which the parties determine that the products and methods may be safely and legally utilized and that their benefits are, to the extent permitted by law or government regulations, available to the public on reasonable terms.

 

2. License Grant

 

2.1.      Subject to the terms, covenants, conditions and limitations set forth in this Agreement, Licensee’s full and complete performance and payment of its obligations under the MSA and the Statement of Work, and Licensee’s ongoing compliance with laws and regulations applicable to the Licensed Territory, Licensor hereby grants to Licensee an exclusive use license (the “License”) to the Licensed Patents and Licensed Products solely for Exclusive Licensed Use. This license is non-assignable except as may be permitted pursuant to the terms of Article 7 or Article 13.5 hereof.

 

2.2.      For the avoidance of doubt, Licensor and Licensee acknowledge that nothing in this Agreement shall prohibit or limit Licensee from selling or using the Licensed Products within the Licensed Territory, provided that Licensee will provide Licensor with advance written notice of any such use outside of the United States so that Licensor can coordinate patent or other intellectual property protection for the Licensed Patents and the Licensed Products.

 

2.3.      Licensee acknowledges that, as between Licensee and Licensor, Licensor owns all right, title, and interest, including all intellectual property rights, in and to the Licensed Patents and any intellectual property arising therefrom, directly or indirectly, whether in existence as of the Effective Date or created thereafter, required to enter into this Agreement, and that Licensee’s rights thereto are limited to the License granted pursuant to this Agreement.

 

2.4.      The exclusive nature of the License is at all times subject to Licensee’s ongoing compliance with its obligations hereunder, and at any time Licensee fails to so comply, any and all exclusivity shall, upon fifteen (15) days’ prior written notice to Licensee from Licensor, automatically terminate unless Licensee has cured (and provided evidence thereof to Licensor) any such noncompliance prior to the expiration of such 15-day period.

 

Page 4 of 15

 

 

3. Royalties

 

In consideration of the License:

 

3.1.      Licensee shall pay to Licensor a nonrefundable license fee of (a) $650,000 (Six Hundred Fifty Thousand US Dollars) upon exercise of the Option (the “Initial License Payment”); (b) an additional $750,000 (Seven Hundred Fifty Thousand US Dollars) upon the first anniversary of the Initial License Payment; and (c) an additional $500,000 (Five Hundred Thousand US Dollars) upon the second anniversary of the Initial License Payment.

 

3.2.      Commencing on the third anniversary of the Initial License Payment, and on each subsequent anniversary thereafter, Licensee shall pay Licensor the Annual Minimum License Payment, as defined below. The “Annual Minimum License Payment” shall be (a) with respect to the third, fourth and fifth anniversaries of the Initial License Payment, $150,000, and (b) with respect to the sixth anniversary of the Initial License Payment and each anniversary thereafter until termination of this Agreement, $250,000. The Annual Minimum License Payment shall be nonrefundable but may be credited toward the payment of any other royalties payable by Licensee pursuant to Article 3.3 within the calendar year in which the Annual Minimum License Payment is due.

 

3.3.      Licensee shall pay to Licensor a royalty equal to 3% (three percent) of the Net Value (as defined in Article 3.4 below) of each Licensed Product which is sold, transferred (except to a Sublicensee for the limited purpose of facilitating later sale of Licensed Product to customers), or used internally by Licensee or a Sublicensee until termination of this Agreement (“Annual Earned Royalty”). Payment of the Annual Earned Royalty shall be made not later than by 15 April of each year with respect to all Annual Earned Royalty accrued but unpaid with respect to the preceding calendar year; late payments shall accrue interest at a rate of [***] per month, compounding monthly, until paid in full (and Licensee shall reimburse Licensor for all reasonable collection costs (including reasonable attorneys’ fees) associated with such payment).

 

3.4.      Licensed Products shall be considered to be “sold” when they are shipped, delivered, and paid for by the customer (by purchase, rental, or other transaction), whether by Licensee, an Affiliate of Licensee or Sublicensee. “Net Value” means the sum of all charges billed or invoiced by Licensee, an Affiliate of Licensee or a Sublicensee to customers for sales of Licensed Product, less (a) customary trade, quantity, or discounts actually allowed and taken; (b) amounts paid or credited by reason of rejections or returns; (c) any freight or other transportation costs, insurance charges, duties, tariffs; (d) all sales and excise taxes based directly on sales or turnover or delivery of royalty bearing products; and (e) any commission or fee paid to sales agents or representatives, not to exceed [***] of the gross sales price.

 

3.5.      Licensee shall reimburse Licensor for [***] of all reasonable and documented costs incurred by Licensor prior to and following the Effective Date for the preparation, filing, prosecution, maintenance and defense of the Licensed Patents (including those incurred in furtherance of the MSA and the Statement of Work) within thirty (30) days of Licensee’s receipt of invoice therefor. At Licensee’s request, Licensor will provide information and records concerning invoicing and determination of such reimbursable costs.

 

3.6.      Pursuant to the UURF License Agreement, Licensor is responsible for providing UURF with at least fifteen (15) days advance notice of any material filing related to prosecution of a Licensed Patent so that UURF may provide its input on such filings. Licensor shall provide Licensee the same notice, and shall annually, and upon Licensee’s reasonable written request no more than once a quarter, provide Licensee and UURF with a written report concerning the status of the filing, prosecution, and maintenance of the Licensed Patents in the Licensed Territory.

 

Page 5 of 15

 

 

3.7.      Licensee shall pay, within thirty (30) calendar days from any termination of this Agreement, the royalties accrued or accruable for payment at the time of any such termination.

 

4. Records, Books, and Examinations

 

4.1.      Licensee agrees to make and keep full, accurate, and complete books and records as necessary to establish its compliance with Article 3 of this Agreement. With respect to the Exclusive Licensed Use granted herein, Licensee further agrees to provide reports substantially similar to those required under Article 8 of the UURF License Agreement.

 

4.2.      Licensee agrees that Licensor, upon reasonable prior notice, may have a duly authorized agent or representative on Licensor’s behalf inspect, audit, or verify such books and records that are relevant to establishing Licensee’s compliance with Article 3 of this Agreement, either at Licensee’s place of business or at a place mutually agreed upon by the parties hereto. Any audit conducted hereunder shall be on a dollar-for-dollar basis without the use of statistical methods including but not limited to sampling and extrapolation.

 

5. Term of the License

 

5.1.      The grant of the License shall be in force upon exercise of the Option and shall remain in force as long as Licensee continues to pay when due the amounts due to Licensor pursuant to Article 3 of this Agreement, and for as long as the Licensed Patents remain enforceable.

 

5.2.      This Agreement shall otherwise remain in effect unless it is modified or terminated as provided in Article 9 of this License.

 

6. Licensor’s Performance

 

6.1.      Subject to Article 3.5, Licensor shall pay all maintenance fees to maintain the life of the Licensed Patents. However, in the event that Licensor fails to make said payments, Licensee may pay any maintenance fee when due and likewise be entitled to reimbursement of [***] of such fees under Article 3.5.

 

6.2.      At the request of Licensee, and at the discretion of Licensor, Licensor may provide technical assistance (not involving further research and development) to Licensee on a time and cost basis for the purpose of assisting Licensee in bringing the Licensed Products to the Point of Practical Application; provided, notwithstanding, that Licensor shall be obligated to perform Licensor’s obligations under the MSA and Statement of Work.

 

7. Sublicensing Rights

 

7.1.      Subject to prior written approval by Licensor, not to be unreasonably withheld, conditioned or delayed, Licensee may grant Sublicenses under the Licensed Patents during the term of this Agreement where such Sublicense is consistent with and in furtherance of Licensee’s rights and obligations provided under this Agreement. Each Sublicense relationship will be evidenced by a written agreement and made subject and subordinate to this Agreement, including all rights retained or held by Licensor hereunder, and consistent with the relevant provisions hereof that apply to Sublicenses. A copy of all Sublicenses will be furnished to Licensor prior to the execution thereof for review and approval. The final executed Sublicenses will be promptly provided to Licensor by Licensee. For the avoidance of doubt, Licensor shall be entitled to all royalties, fees and other payments due to Licensor pursuant to Article 3 with respect to Licensed Products sold by Licensee’s Affiliates and Sublicensees as if sold by Licensee itself; Licensee shall be fully responsible to Licensor for any such amounts.

 

Page 6 of 15

 

 

7.2.      In addition to the inclusion of all rights retained or held by Licensor hereunder, Licensee shall specifically include in each Sublicense Licensor’s right to terminate or modify a Sublicense pursuant to Article 9. Licensee shall not grant or exercise any rights that are inconsistent with the rights and obligations of Licensee or act in conflict with the residual rights of Licensor hereunder. Any Sublicense shall include an audit right by Licensor of the same scope as provided under Article 4 with respect to Licensee.

 

7.3.      If a Sublicense request by a third party is made to Licensee, Licensee will use commercially reasonable efforts to grant a Sublicense if Licensee is not and will not be using the Licensed Patents for the requested field of use.

 

7.4.      No other, further, or different power, right, or privilege to grant powers, rights, privileges, or immunities to third parties is granted or implied. Licensee shall remain wholly responsible and liable for the acts or omissions of each Sublicensee in connection with the subject matter hereof and the performance of its obligations as described herein.

 

8. Representations and Warranties

 

8.1       Each party represents and warrants to the other party as follows: (a) that it is a company formed and in good standing as of the Effective Date, (b) that the execution, delivery, and performance of this Agreement by each party has been authorized by all necessary action on the part of such party; (c) that this Agreement has been executed and delivered by each party and constitutes a legal, valid, and binding obligation of such party, enforceable against such party in accordance with its terms; (d) that the execution, delivery, and performance of this Agreement does not: (i) violate, conflict with, or result in, the breach of any provision of the charter or by-laws of such party; (ii) conflict with or violate any law or governmental order applicable to such party or any of its assets, properties, or businesses; or (iii) conflict with, result in any breach of, constitute a default under, require any consent under, or give to others any rights of termination, amendment, revocation, or cancellation of any contract, agreement, or other instrument or arrangement to which it is a party.

 

8.2       Licensor represents and warrants to Licensee that:

 

a. Licensor owns all right, title and interest in, or has sufficient rights to, the Licensed Patents and Licensed Products, including all intellectual property rights related thereto, which are the subject of this Agreement, and has the exclusive right to enter into and perform under this Agreement and grant the License and release contained herein.

 

b. There are no disputes, lawsuits, arbitrations, patent infringement claims or other conflicts of interest, whether active or pending, arising from or in relation to any claim by any third-party, including inventors, against Licensor, its officers, employees, agents, shareholders, or affiliates in connection with any aspect of the Licensed Patents or Licensed Products.

 

c. Licensor is not aware of any disputes, lawsuits, arbitrations, patent infringement claims or other conflicts of interest, whether active or pending, arising from or in relation to any claim by any third-party, including the inventors of the technology related to the Licensed Patents or Licensed Products.

 

Page 7 of 15

 

 

d. Licensor is not aware of any patents, technology, methods, processes, inventions, know-how, intellectual property, or other data or information owned by third parties, which is needed for Licensee to utilize the Licensed Patents for commercial application.

 

e. Licensor has not granted, and during the term of this this Agreement will not grant, any licenses, sub licenses, or any contingent or non-contingent right, title or interest in the Licensed Patents and Licensed Products to any third party.

 

f. Subject to Licensee’s approval, not to be unreasonably withheld, conditioned or delayed, Licensor may work with third parties on matters related to the Licensed Patents and Licensed Products, and share data and information related to the Licensed Patents and Licensed Products with such third parties.

 

8.3      Licensor further represents and warrants that the UURF License Agreement is in full force and effect and that Licensor is in compliance with the UURF License Agreement in all material respects. Licensor further represents and warrants that, before the Effective Date of this Agreement, Licensor has obtained written consent from UURF to enter into this Agreement with Licensee, and Licensor acknowledges and agrees that obtaining such written consent is a condition precedent to Licensee entering into this Agreement. Licensor warrants and covenants that it will use its best efforts to (a) perform all of its obligations in compliance with the UURF License Agreement, and (b) ensure that the UURF License Agreement remains in full force and effect for its term. Licensor warrants and covenants that it will provide written notice immediately to Licensee upon Licensor’s knowledge that (i) Licensor plans to provide notice to UURF of Licensor’s intent to terminate the UURF License Agreement, (ii) UURF plans to provide to Licensor, or Licensor has received from UURF, UURF’s notice to terminate the UURF License Agreement, (iii) or Licensor receives a notice of default under the UURF License Agreement. In the event that the UURF License Agreement is terminated by either UURF or Licensor, Licensor agrees to cooperate with Licensee in converting this Agreement into an exclusive license between Licensee and UURF.

 

8.4       EXCEPT AS EXPRESSLY SET FORTH IN ARTICLE 8, RIGHTS GRANTED HEREUNDER, INCLUDING RIGHTS TO LICENSED PRODUCTS, ARE PROVIDED “AS IS”, WITH NO REPRESENTATIONS OR WARRANTIES OF ANY KIND (EXPRESS, IMPLIED, OR OTHERWISE) IN CONNECTION WITH THIS AGREEMENT OR ITS SUBJECT MATTER. WITHOUT LIMITING THE FOREGOING, LICENSOR EXPRESSLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTIES OF PATENT VALIDITY, NON-INFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE RIGHTS GRANTED HEREUNDER, INCLUDING RIGHTS TO LICENSED PRODUCTS.

 

8.5       UURF Disclaimers and Limitation on Liability. WITHOUT LIMITING ANYTHING IN THIS ARTICLE 8, LICENSEE ACKNOWLEDGES THAT THIS AGREEMENT IS SUBJECT TO THE FOLLOWING PROVISIONS OF THE UURF LICENSE AGREEMENT IN FAVOR OF UURF: (A) SECTION 15.2 (NO REPRESENTATIONS AND WARRANTIES PROVIDED BY UURF), (B) SECTION 15.3 (DISCLAIMER OF SPECIFIC WARRANTIES BY UURF); AND (C) SECTION 15.4 (UURF LIMITATION OF LIABILITY).

 

8.6       Nothing relating to this Agreement nor the license grant itself shall be construed to confer upon Licensee any immunity from or defenses under the antitrust laws or from a charge of patent misuse, and the acquisition and use of the rights pursuant to this license shall not be immunized from the operation of state or Federal law.

 

Page 8 of 15

 

 

8.7       Nothing contained in this Agreement shall be interpreted to grant to Licensee any rights with respect to any invention other than the licensed invention specified herein.

 

9. Modification and Termination

 

9.1.      Licensor may terminate or modify this Agreement in whole or in part if:

 

a. Licensee is in breach of a covenant or agreement contained in this Agreement; or

 

b. Licensee has willfully made a false statement of or willfully omitted a material fact in any report required by this Agreement; or

 

c. Licensee has been found by a court of competent jurisdiction to have violated the Federal antitrust laws in connection with its performance under the License Agreement; or

 

d. Licensee is adjudged as bankrupt or has all or a substantial portion of its assets, relating to or utilized in performing operations herein licensed, placed in the hands of a temporary or permanent receiver or makes any assignment or other accommodation for the benefit of creditors, unless Licensee enters bankruptcy proceedings solely for the purpose of reorganizing and continues to do business during and after the bankruptcy.

 

9.2.      Licensor may directly terminate or modify any Sublicense if Licensor determines that any of the grounds for termination or modification of this Agreement provided under this Article 9 apply to a Sublicensee or to Sublicensee performance under a Sublicense.

 

9.3.      Before modifying or terminating in whole or in part this Agreement or a Sublicense under any of the terms and conditions specified herein permitting modification or termination, other than by mutual agreement, Licensor shall furnish Licensee a written notice of intention to modify or terminate in whole or in part this Agreement or a Sublicense, and Licensee shall be allowed ninety (90) days after such notice to remedy any breach of any covenant or agreement set forth in this Agreement or a Sublicense.

 

9.4.      Licensee may terminate or request modification in whole or in part of this Agreement:

 

a. if the Licensed Patent is ruled by competent authorities not to be patentable in the Licensed Territory; or

 

b. by giving ninety (90) days prior written notice to Licensor.

 

9.5.      This Agreement may be terminated or modified upon mutual agreement of Licensor and Licensee.

 

9.6.      The following rights and obligations survive any termination of this Agreement to the extent necessary to permit their complete fulfillment or discharge:

 

a. Licensee’s obligation to maintain records and Licensor’s right to conduct a final audit as provided in Article 4 of this Agreement;

 

b. Any cause of action or claim of Licensor accrued, or to accrue, because of any breach or default by Licensee; and

 

Page 9 of 15

 

 

c. Licensee shall remain responsible for all royalties and fees accrued prior to its termination (whether or not yet due and payable).

 

9.7.      In the event of termination of this Agreement, Licensee may sell its remaining inventory of Licensed Products after such termination and Licensee may fulfill contractual obligations to supply Licensed Products under contracts entered into before the date of termination provided such obligations can be fulfilled within one calendar year of the date of termination, except for such contracts which contain indefinite delivery, indefinite quantities, or other unexercised options, in which case Licensee may fulfill contractual obligations through the life of the option period and the delivery requirements associated with such options. Licensee agrees to pay royalties on all Licensed Products sold, whether by Licensee or a Sublicensee, after the date of termination as set forth in Article 3 of this Agreement.

 

10. Liability

 

10.1.     Licensee agrees to defend, indemnify, and hold Licensor harmless from and against all claims, liability, demands, damages, expenses for losses and death, personal injury, illness or property damage (each, a “Claim”) arising out of (a) the use, sale, or other disposition by Licensee, a Sublicensee, or any Licensee or Sublicensee customers or any other transferee of any Licensed Products, or (b) any act or omission of Licensee or any Sublicensee in the course of performing its obligations under this Agreement (or pursuant to any Sublicense).

 

10.2.     Licensor agrees to defend, indemnify, and hold Licensee, UURF, The University of Utah, and their Affiliates and respective employees, managers, officers, agents, members, and successors (“Licensor Indemnified Parties”) harmless from and against all Claims arising out of any act or omission of Licensor in the course of performing its obligations under this Agreement.

 

10.3.     Neither party shall be liable for any unforeseeable event beyond its reasonable control not caused by the fault or negligence of such party, which causes such party to be unable to perform its obligations (other than payment obligations) under this Agreement (and which it has been unable to overcome by the exercise of due diligence), including, but not limited to, flood, drought, earthquake, storm, fire, pestilence, lightning and other natural catastrophes, epidemic, war, riot, civic disturbance or disobedience, strikes, labor dispute, or failure, threat or failure, or sabotage, or any order or injunction made by a court or public agency. In the event of the occurrence of such a force majeure event, the party unable to perform shall promptly notify the other party. It shall further use its best efforts to resume performance as quickly as possible and shall suspend performance only for such period of time as is necessary as a result of the force majeure event.

 

10.4.     IN NO EVENT WILL LICENSOR OR LICENSEE BE LIABLE UNDER OR IN CONNECTION WITH THIS AGREEMENT UNDER ANY LEGAL OR EQUITABLE THEORY, INCLUDING BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, AND OTHERWISE, FOR ANY: (a) CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, ENHANCED, OR PUNITIVE DAMAGES; (b) INCREASED COSTS, DIMINUTION IN VALUE OR LOST BUSINESS, PRODUCTION, REVENUES, OR PROFITS; (c) LOSS OF GOODWILL OR REPUTATION; (d) USE, INABILITY TO USE, LOSS, INTERRUPTION, DELAY OR RECOVERY OF ANY DATA, OR BREACH OF DATA OR SYSTEM SECURITY; OR (e) COST OF REPLACEMENT GOODS OR SERVICES, IN EACH CASE REGARDLESS OF WHETHER LICENSOR OR LICENSEE WAS ADVISED OF THE POSSIBILITY OF SUCH LOSSES OR DAMAGES OR SUCH LOSSES OR DAMAGES WERE OTHERWISE FORESEEABLE.IN NO EVENT WILL LICENSOR’S AGGREGATE LIABILITY ARISING OUT OF OR RELATED TO THIS AGREEMENT UNDER ANY LEGAL OR EQUITABLE THEORY, INCLUDING BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, AND OTHERWISE EXCEED THE TOTAL AMOUNTS PAID TO LICENSOR UNDER THIS AGREEMENT IN THE SIX-MONTH PERIOD PRECEDING THE EVENT GIVING RISE TO THE CLAIM OR $1,000, WHICHEVER IS GREATER.

 

Page 10 of 15

 

 

10.5.     UURF as Third Party Beneficiary. UURF shall be a third party beneficiary to the provisions of this Article 10, and shall have the right to enforce such provisions directly to the extent UURF may deem such enforcement necessary or advisable to protect its rights thereunder. Licensee hereby acknowledges and agrees to Article 20 (Indemnification) as it applies to UURF.

 

11. Infringement and Litigation

 

11.1.     Should either party become aware of any infringement or potential infringement of Licensed Patents, it shall give the other party prompt written notice detailing as many facts as possible concerning such infringement or potential infringement.

 

11.2.     If Licensor fails to bring an infringement action or provide Licensee with its written intent to bring an infringement action within three (3) months after receipt of a bona fide notification of infringement of Licensed Patents, Licensee is authorized in the United States to:

 

a. Bring suit in a United States District Court in its own name or, if required by law, jointly with Licensor, at Licensee’s expense and on Licensee’s behalf, for infringement of Licensed Patents;

 

b. Enjoin infringement in any such suit, and to collect for its own benefit, any damages, profits, and awards of whatever nature recoverable for such infringement;

 

c. Settle any claim or suit for infringement of Licensed Patents. However, in no instance shall Licensee(s) be able to settle any such claim or suit by granting a sublicense.

 

11.3.     Licensee’s obligation to pay royalties to Licensor continues during infringement litigation or negotiations; provided, any amounts paid by Licensee to any third party as damages or compensation with respect to infringement of a third party’s rights shall be deducted from royalties due Licensor herein.

 

12. Confidentiality

 

12.1.     From time to time during the term of this Agreement, either party or its Affiliates may disclose or make available to the other party or its Affiliates information about its business affairs, products, confidential intellectual property, trade secrets, third-party confidential information, and other sensitive or proprietary information, whether orally or in written, electronic, or other form or media/in written or electronic form or media, and whether or not marked, designated or otherwise identified as “confidential” (collectively, “Confidential Information”). Confidential Information does not include information that, at the time of disclosure is: (a) in the public domain; (b) known to the receiving party at the time of disclosure; (c) rightfully obtained by the receiving party on a non-confidential basis from a third party; or (d) independently developed by the receiving party. The receiving party shall not disclose the disclosing party’s Confidential Information to any person or entity, except to the receiving party’s employees who have a need to know the Confidential Information for the receiving party to exercise its rights or perform its obligations hereunder. Notwithstanding the foregoing, each party may disclose Confidential Information to the limited extent required (i) in order to comply with the order of a court or other governmental body, or as otherwise necessary to comply with applicable law, provided that the party making the disclosure pursuant to the order shall first have given written notice to the other party and made a reasonable effort to obtain a protective order; or (ii) to establish a party’s rights under this Agreement, including to make required court filings.

 

Page 11 of 15

 

 

12.2.     On the termination of the Agreement, the receiving party shall promptly return to the disclosing party all copies, whether in written, electronic, or other form or media, of the disclosing party’s Confidential Information, or destroy all such copies and certify in writing to the disclosing party that such Confidential Information has been destroyed. Each party’s obligations of non-disclosure with regard to Confidential Information are effective as of the Effective Date and will expire five years from the date first disclosed to the receiving party; provided, however, with respect to any Confidential Information that constitutes a trade secret (as determined under applicable law), such obligations of non-disclosure will survive the termination or expiration of this Agreement for as long as such Confidential Information remains subject to trade secret protection under applicable law.

 

13. Miscellaneous

 

13.1.     Licensee CGL Insurance. Beginning at the time the Licensed Product is first distributed or sold by Licensee, or its Affiliate or a sublicensee pursuant to Article 7, Licensee will, at its sole cost and expense, procure and maintain commercial general liability insurance issued by an insurance carrier with an A.M. Best rating of “A” or better in amounts that provide product liability and other liability coverage, as well as coverage for litigation costs, related to Article 10. Licensee will use reasonable efforts to include Licensor, UURF, and their respective officers, directors, members, employees, and agents, as additional insureds under Licensee’s commercial general liability insurance. All rights of subrogation will be waived against Licensor, UURF, and their respective insurers. Licensee will provide Licensor or UURF, with documentary evidence of such insurance upon written request by Licensor or UURF. Licensee will maintain such commercial general liability insurance beyond the expiration or termination of this Agreement during (a) the period that any Licensed Product is being commercially manufactured, distributed, or sold by Licensee, any Affiliate, or any sublicensee of Licensee, and (b) for one (1) yearafter such period.

 

13.2.     Disputes. Before Licensee or Licensor may bring suit in any court concerning an issue relating to this Agreement, such party must first seek in good faith resolution of the issues through negotiation or other forms of nonbinding alternative dispute resolution mutually acceptable to the parties.

 

13.3.     Governing Law. This Agreement will be interpreted, construed, and enforced in all respects in accordance with the laws of the State of North Carolina, without reference to its choice of law rules. Notwithstanding the foregoing, the courts within Salt Lake County in the State of Utah shall have exclusive jurisdiction and venue for all disputes between Licensor, UURF, or Licensee arising out of the UURF License Agreement to the extent involving rights or responsibilities of UURF. Further, the Parties agree that UURF shall be entitled to any protections, rights, or defenses applicable to it under the Utah Governmental Immunity Act, Utah Code Annotated sections 630-7-101, et. seq., as amended, in the same manner and to the same extent as if Utah law governed this Agreement.

 

13.4.     Notices. All notices pertaining to or required by this Agreement shall be in writing and shall be signed by an authorized representative and shall be delivered by hand or sent by certified mail, return receipt requested, with postage prepaid, addressed as follows (or such mailing address as the parties may specify in writing):

 

For Licensor:

 

[***]

 

Page 12 of 15

 

 

 

For Licensee:

 

[***]

 

For the purposes of Sections 3.6 hereof:

 

[***]

 

13.5.     Assignment. This Agreement may not be assigned or transferred by Licensee without the prior written consent of Licensor (except that no consent shall be required for a successor by merger to, an acquirer of substantially all of the assets of, or an entity affiliated with or controlled by or under common control with, Licensee in connection with that part of Licensee’s business to which the Licensed Patents and this Agreement pertain; however, in no event shall any rights or obligations of this Agreement be assigned or transferred to a party who is not a citizen and resident of the United States of America without the written consent of Licensor, not to be unreasonably withheld, conditioned or delayed).

 

13.6.     Entire Agreement. This Agreement constitutes the entire agreement and understanding between Licensor and Licensee with respect to the subject matter hereof, and any modification of this Agreement shall be in writing and shall be signed by a duly authorized representative of both Licensor and Licensee. There are no understandings, representations, or warranties between Licensor and Licensee concerning the subject matter hereof except as expressly set forth in this Agreement.

 

13.7.     Headings. Titles and headings of the sections and subsections of this Agreement are for the convenience of references only and do not form a part of this Agreement and shall in no way affect the interpretation thereof.

 

13.8.     Severability. The illegality or invalidity of any provisions of this Agreement shall not impair, affect or invalidate the other provisions of this Agreement.

 

13.9.     Proprietary Information. Both parties acknowledge that the terms of this Agreement, as well as Licensee’s plan for bringing the Licensed Patents to the Point of Practical Application, are confidential and shall not be discussed or revealed to third parties.

 

13.10.   Export Regulation. The Licensed Products may be subject to US export control laws, including the Export Control Reform Act and its associated regulations. Licensee shall not, directly or indirectly, export, re-export, or release the Licensed Products to, or make the Licensed Products accessible from, any jurisdiction or country to which export, re-export, or release is prohibited by law, rule, or regulation. Licensee shall comply with all applicable federal laws, regulations, and rules, and complete all required undertakings (including obtaining any necessary export license or other governmental approval), prior to exporting, re-exporting, releasing, or otherwise making the Licensed Products available outside the United States.

 

13.11.   Relationship of the Parties. The relationship between the parties is that of independent contractors. Nothing contained in this Agreement will be construed as creating any agency, partnership, joint venture, or other form of joint enterprise, employment, or fiduciary relationship between the parties.

 

Page 13 of 15

 

 

13.12.   Counterparts. This Agreement may be executed in counterparts, each of which is deemed an original, but all of which together are deemed to be one and the same agreement.

 

13.13.   Marking; Use of Names. Licensee agrees to comply with the provisions of Article 11 (Marking) and Article 25 (Use of Names) as set forth in the UURF License Agreement.

 

The Remainder of this page was intentionally left blank.

 

Page 14 of 15

 

 

IN WITNESS WHEREOF, the parties hereto have caused this instrument to be executed by their duly authorized representatives. For the avoidance of doubt, the Effective Date shall be the last date set forth below.

 

FOR LICENSEE:

 

Hyperion Materials & Technologies, LLC

 

/s/ Anastasios Arima Date: February 13, 2021
 

Name: Anastasios Arima

Title: Manager

 

FOR LICENSOR:

 

Blacksand Technology, LLC

 

/s/ Kesh Keshavan Date: February 13, 2021
 

Name: Kesh Keshavan

Title: President

 

Page 15 of 15

 

 

 

 

 

Exhibit 4.3

 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”.

 

MASTER SERVICES AGREEMENT

 

This Master Services Agreement (this “Agreement”) is made and entered into as of February 13, 2021 (the “Effective Date”) between Blacksand Technology LLC, a Utah limited liability company (“Blacksand”), and Hyperion Materials & Technologies, LLC, a North Carolina limited liability company (“Hyperion”). The parties agree as follows:

 

1.               SERVICES AND STATEMENTS OF WORK

 

1.1      Services. Subject to the terms and conditions of this Agreement, Blacksand will perform the services described in one or more Statements of Work (as defined below) (collectively, the “Services”) and, to the extent applicable, Hyperion will perform the obligations thereof as described in any such Statement of Work. In the process of providing the Services, Blacksand may produce deliverables or other items pursuant to a Statement of Work.

 

1.2      Statements of Work. The specific details of the Services will be described in one or more written Statements of Work, substantially in the form of the Statement of Work set forth in Schedule 1 hereto, to be executed by both parties (each, a “Statement of Work”). Once executed by both parties, each Statement of Work, including Schedule 1, will be a unique agreement that incorporates the terms of this Agreement and stands alone from all other Statements of Work. If there is a conflict between the terms of this Agreement and the terms of a Statement of Work, the terms of this Agreement will control unless the Statement of Work states that a specific provision of this Agreement will be superseded by a specific provision of the Statement of Work.

 

1.3      Delays. The “Delivery Schedule” or any other timeline for Services, if any, set forth in a Statement of Work depends on performance by third parties and Hyperion. If Blacksand determines in its reasonable discretion that the Delivery Schedule or other timeline set forth in a Statement of Work may need to change due to (1) actions or delays of third parties (other than Blacksand’s suppliers, vendors and subcontractors), or (2) actions or delays of Hyperion, then it will notify Hyperion of such determination. If the actions or delays of third parties (other than Blacksand’s suppliers, vendors and subcontractors) or Hyperion causes material changes to the scope or timing of the Delivery Schedule or other timeline for Services or requires, in Blacksand’s reasonable discretion, an increase in Service Fees, then Blacksand shall notify Hyperion of the foregoing, and the parties shall work in good faith to agree on an amended Statement of Work to account for the changes in scope, Delivery Schedule (or other timing), or fees. If the actions or delays of Blacksand or Blacksand’s suppliers, vendors and subcontractors causes material changes to the scope or timing of the Delivery Schedule or other timeline for Services or requires, in Hyperion’s reasonable discretion, a decrease in Service Fees, then Hyperion shall notify Blacksand of the foregoing, and the parties shall work in good faith to agree on an amended Statement of Work to account for the changes in scope, Delivery Schedule (or other timing), or fees. Blacksand shall not be responsible for changes to the Delivery Schedule or other

timeline due to the actions or delays of any third party (other than Blacksand’s suppliers, vendors and subcontractors) or of Hyperion.

 

2.               PERFORMANCE OF SERVICES

 

2.1      Performance Standard. Blacksand will diligently perform the Services in accordance with the applicable Statement of Work, including any specifications in the Statement of Work. Blacksand will use commercially reasonable efforts to complete the Services, including the delivery of any deliverables, in accordance with the Delivery Schedule and other schedule of times and milestones specified in the Statement of Work, and shall perform all Services in accordance with applicable laws and industry standards. To the extent Hyperion has performance obligations under a Statement of Work, Hyperion agrees to diligently perform such obligations in a commercially reasonable manner in accordance with applicable laws and industry standards.

 

2.2      Personnel. Blacksand shall be free to designate the appropriate personnel to accomplish the tasks required by each Statement of Work. However, the Services must be performed in a competent, timely, professional, and workmanlike manner by qualified personnel in accordance with applicable laws and industry standards.

 

2.3      Subcontractors. Blacksand may utilize independent subcontractors to perform all or part of the Services. In the event Blacksand uses subcontractors, Blacksand will remain solely responsible for the performance of all of the Services that are subcontracted.

 

2.4      Materials. Except as otherwise specified in a Statement of Work, Blacksand will be responsible for and supply all necessary equipment, materials, and other resources required to perform the Services.

 

2.5      Government Approvals. Unless otherwise specified in a Statement of Work, Hyperion is responsible for securing all government approvals and licenses necessary to allow the use of any Services and deliverables produced by Blacksand pursuant to a Statement of Work.

 

2.6      Other Work. Hyperion acknowledges that Blacksand is a consultant and may provide services similar to the Services on behalf of other companies in accordance with this Agreement. Subject to Section 8, and unless set forth in a Statement of Work, Blacksand shall be free to work for other companies without restriction, even if such work is done for a potentially competing company or individual, so long as Blacksand does not breach its non-solicitation, confidentiality, and other obligations in this Agreement.


-1-

 

3.               NON-SOLICITATION

 

3.1      Non-Solicitation Agreement. During the term of this Agreement (including any applicable Statement of Work hereunder) and for a period of twelve (12) months following the termination of the Agreement, neither party shall, on its own behalf or on behalf of any other person or entity, without the express written consent of the other party, solicit, induce or attempt to solicit or induce, any then current employee or past employee, representative, contractor or other service provider of the other party to terminate or modify his, her or its employment or business relationship with such party. Notwithstanding the foregoing, general solicitations for employment or contracting shall not be deemed to violate this section.

 

3.2      Reasonableness of Restrictions. Each party regards the restrictions contained in this section as reasonable in scope and term and appropriate to provide the parties with limited, legitimate and reasonable protection against subsequent diminution of the value of the business of one party attributable to any actions of the other party in violation of such restrictions, and each party hereby waives any and all rights to attack the validity of such covenants on the grounds of the breadth of their geographic scope or the length of their term.

 

4.               THIRD PARTY MATERIALS; THIRD PARTY IP. Unless stated otherwise in a Statement of Work, if a Statement of Work requires Blacksand to obtain, for use in connection with the Services, any material, including intellectual property, from a third party, then Blacksand will inform Hyperion of such need, and Hyperion shall be responsible, at its sole expense, to acquire rights to the third party materials.

 

5.               COMPENSATION

 

5.1      Fees and Taxes. Hyperion will pay the fees as set out in each Statement of Work (“Service Fees”). Hyperion will reimburse Blacksand for any costs or expenses that have been disclosed and approved prior to being incurred. Hyperion is responsible for all taxes associated with the performance of the Services and imposed upon the Service Fees. The parties shall each be responsible for all taxes imposed on their net income. Blacksand may, at its sole option, withhold providing Services (and shall not be in breach for doing so), if Hyperion does not make timely payment as provided in this Agreement.

 

5.2      Payment. Unless otherwise specified in a Statement of Work: (a) Blacksand will issue quarterly invoices for Service Fees for Services that have been performed in the previous quarter; and (b) Hyperion will pay any undisputed amount set forth in such invoices no later than thirty (30) days after receipt of Blacksand’s invoice. If Hyperion disputes in good faith any amount invoiced by Blacksand within thirty (30) days after receipt of Blacksand’s invoice, the parties will pursue the escalation procedures set forth in this Agreement. If Hyperion withholds payment pursuant to this Section, Blacksand may also decline to provide further Services until the escalation procedures have been followed.

6.               TERM AND TERMINATION

 

6.1      Term. This Agreement will commence on the Effective Date and will continue until terminated as provided in this Agreement. Any Statement of Work in existence as of the date that this Agreement terminates or expires will continue to be effective unless specifically terminated in accordance with the terms of this Agreement or the terms of the Statement of Work.

 

6.2      Termination. In addition to any other rights of termination in this Agreement, Hyperion may terminate this Agreement: (a) for any or no reason, upon ninety (90) days’ prior written of notice to Blacksand and (b) either party may terminate this Agreement for breach if, provided the parties have met in good faith in accordance with Section 12.4 of this Agreement to resolve any dispute, such party notifies the other party in writing of a breach of this Agreement and such breach is not cured within fifteen (15) days after written notice thereof by the non-breaching party. All of the provisions and terms of this Agreement that by their nature suggest continuance beyond termination shall survive termination of this Agreement. Within thirty (30) days after termination, the parties will return to each other any Confidential Information that belongs to the other party.

 

7.               CONFIDENTIALITY

 

7.1      Definition. “Confidential Information” means any non-public information that relates to the actual or anticipated business, research, or development of either party and any proprietary information, trade secrets, and know-how of either party (the “Disclosing Party”) that are disclosed to the other party (the “Receiving Party”) or its agents, directly or indirectly, in writing, orally, or by inspection or observation of tangible items. Confidential Information includes the terms of this Agreement and any Statement of Work hereunder, research, development, and commercialization plans, customer information, processes, techniques, formulas, prototypes, and any non-public information relating to the project as outlined in any Statement of Work hereunder. Confidential Information also includes information that is defined as “Confidential Information” under any other agreement between the parties, and any other information that the Receiving Party should reasonably know to be confidential based upon its content or the circumstances surrounding its disclosure. Neither party makes any representations or warranties as to the correctness, completeness or accuracy of any Confidential Information.

 

7.2      Exceptions. Confidential Information does not include any information that Receiving Party can demonstrate:  was publicly known and made generally available in the public domain before the Disclosing Party disclosed the information,  became publicly known and made generally available, after disclosure to the Receiving Party, through no wrongful action or inaction of the Receiving Party,  was in the Receiving Party’s possession, without confidentiality restrictions, at the time of disclosure by the Disclosing Party, or was independently developed without use of or reference to the Confidential Information.


-2-

 

7.3      Nondisclosure and Nonuse. The Receiving Party will not, during and after the term of this Agreement, disclose the Confidential Information to any third party or use the Confidential Information for any purpose other than for purposes of performing its obligations under this Agreement. Without limiting the generality of the foregoing, the Receiving Party, its affiliates, and their employees, contractors, agents, representatives, consultants, and advisors (“Representatives”) shall not: (a) use or disclose the Disclosing Party’s Confidential Information for any competitive purpose or (b) otherwise use or disclose the Disclosing Party’s Confidential Information for the pecuniary gain of themselves and/or any of their business partners. The Receiving Party will take all reasonable precautions to prevent any unauthorized use or disclosure of the Confidential Information including, but not limited to, requiring each Representative with access to Confidential Information to execute a nondisclosure agreement or policy containing terms that are substantially similar to the terms contained in this Agreement. In addition, the Receiving Party will promptly notify the Disclosing Party upon the loss or unauthorized use or disclosure of the Disclosing Party’s Confidential Information in the Receiving Party’s possession or under its control. The Receiving Party acknowledges and agrees that it shall be liable for any breach of its confidentiality obligations hereunder by its Representatives.

 

7.4      Existing Obligations. The obligations in this Section 7 are in addition to, and supplement, each party’s obligations of confidentiality and nondisclosure under the terms of any confidentiality or nondisclosure agreement between the parties (referred to herein, collectively, as the “NDA”).

 

7.5      Publications. Articles, papers, bulletins, data, studies, statistics, interim or final reports, oral transmittals or any other materials reporting the plans, progress, analyses, results, or findings of work conducted under this Agreement shall not be presented publicly or published without prior written approval by both parties.

 

7.6      Ownership. Subject to Section 8, each party shall retain all rights, title, and interest in and to its Confidential Information, and this Agreement shall not be construed to grant any license to such Confidential Information.

 

8.               INTELLECTUAL PROPERTY OWNERSHIP

 

8.1      Unless explicitly stated in a Statement of Work or other license agreement between the parties, nothing in this Agreement represents a license of any intellectual property by one party to the other party.

 

8.2      Unless explicitly stated in a Statement of Work, or other license agreement between the parties and/or their affiliates, the parties do not intend for any new intellectual property created under this Agreement to be jointly owned. Each party’s intellectual property as existing as of the date of this Agreement or developed by such party after the date of this Agreement, unless otherwise stated in a Statement of Work, including any adaptions, modifications, and derivative works of the foregoing, and including all works of authorship, inventions, discoveries, improvements, methods, processes, formulas, designs, techniques, know-how, and information  conceived, discovered, developed or otherwise made (as necessary to establish authorship, inventorship, or ownership) by such party (collectively, “Inventions”), will owned by the party that created or developed it. For the avoidance of doubt, Blacksand’s patented technology and all other registered intellectual property of Blacksand, and any adaptions, modifications or derivative

works thereof, shall be, and shall remain, the sole and exclusive property of Blacksand, and Blacksand grants no license or other right with respect to such Inventions to Hyperion hereunder, subject to any Statement of Work or other license agreement between the parties and/or their affiliates.

 

9.               REPRESENTATIONS AND WARRANTIES. Each party represents and warrants: (a) that such party is a duly organized, validly existing organization as stated in the preamble to this Agreement; (b) that the transactions contemplated herein have been duly authorized by all necessary action on such party’s part; (c) that this Agreement constitutes a valid and binding obligation of such party; and (d) the execution and delivery of this Agreement by such party and the performance of such party’s obligations hereunder are not in violation or breach of, and will not conflict with or constitute a default under, any material contract, agreement, or commitment binding upon such party, including, without limitation, any non-disclosure, confidentiality, non-competition, or other similar agreement.

 

10.            INDEMNIFICATION

 

10.1    Hyperion Indemnification. Hyperion agrees to indemnify, defend, and hold harmless Blacksand, its directors, managers, officers, employees, and successors and assigns from and against all taxes, losses, damages, judgments, settlements, liabilities, costs, and expenses, including attorneys’ fees and other legal expenses, arising directly or indirectly from or in connection with: (a) any negligent, reckless, or intentionally wrongful act of Hyperion or its employees or agents; (b) any breach or alleged breach of any representation, warranty or covenant of Hyperion set forth herein; and (c) raw materials provided by Hyperion to Blacksand pursuant to the terms of a Statement of Work.

 

10.2    Blacksand Indemnification. Blacksand agrees to indemnify, defend, and hold harmless Hyperion, its affiliates, and their directors, managers, officers, employees, and successors and assigns from and against all taxes, losses, damages, judgments, settlements, liabilities, costs, and expenses, including attorneys’ fees and other legal expenses, arising directly or indirectly from or in connection with: (a) any negligent, reckless, or intentionally wrongful act of Blacksand or its employees or agents; (b) and breach or alleged breach of any representation, warranty or covenant of Blacksand set forth herein; and (c) any third party claim that Blacksand’s intellectual property and/or materials used or provided hereunder infringes upon, misappropriates, or otherwise violates the intellectual property rights of any third party.

 

11.            LIMITATION OF REMEDIES; DISCLAIMER

 

11.1    Limitation of Remedies. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS AGREEMENT, EACH PARTY WILL NOT, UNDER ANY CIRCUMSTANCES, BE LIABLE TO THE OTHER PARTY FOR CONSEQUENTIAL, INCIDENTAL, SPECIAL, PUNITIVE, OR EXEMPLARY DAMAGES ARISING OUT OF OR RELATED TO THE TRANSACTION CONTEMPLATED UNDER THIS AGREEMENT, INCLUDING BUT NOT LIMITED TO LOST PROFITS OR LOSS OF BUSINESS, EVEN IF A PARTY IS APPRISED OF THE LIKELIHOOD OF SUCH DAMAGES OCCURRING. THIS LIMITATION WILL APPLY EVEN IF THE REMEDIES AVAILABLE IN THIS AGREEMENT HAVE FAILED OF THEIR ESSENTIAL PURPOSE. EACH PARTY’S SOLE AND AGGREGATE LIABILITY UNDER THIS AGREEMENT OR ANY MATTER OR EVENT RELATED THERETO SHALL IN NO EVENT EXCEED THE SERVICE FEES PAID BY HYPERION DURING THE PRECEDING 12 MONTHS PRIOR TO THE EVENT GIVING RISE TO THE LIABILITY.


-3-

 

11.2    Disclaimer of Warranty. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS AND IMPLIED, INCLUDING BUT NOT LIMITED TO ANY IMPLIED WARRANTY OF MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE. EXCEPT AS PROVIDED HEREIN, THE DELIVERABLES AND SERVICES ARE PROVIDED AS-IS AND AS-AVAILABLE. BLACKSAND DOES NOT REPRESENT THAT THE DELIVERABLES WILL MEET HYPERION’S NEEDS OR BE ERROR-FREE.

 

12.            MISCELLANEOUS

 

12.1    Services and Information Prior to Effective Date. All services performed by Blacksand and all information and other materials disclosed between the parties prior to the Effective Date will be governed by the terms of this Agreement, except where the services are covered by a separate agreement between the parties.

 

12.2    Independent Contractor. It is the express intention of the parties that the parties are independent contractors. Without limiting the generality of the foregoing, neither party is authorized to bind the other party to any liability or obligation or to represent that such party has any authority.

 

12.3    Governing Law. This Agreement will be interpreted, construed, and enforced in all respects in accordance with the laws of the State of North Carolina, without reference to its choice of law rules.

 

12.4    Dispute Resolution. Except with regard to disputes under Section 12.5, if a dispute arises under this Agreement, the parties agree to promptly meet, either in person or remotely, to discuss the dispute. If any such dispute cannot be resolved within fifteen (15) days, then either party shall be free to pursue its remedies as provided by law. No dispute, except a dispute under Section 12.5, shall be referred to a court before the provisions of this Section 12.4 have been followed.

 

12.5    Injunctive Relief. Each party acknowledges and agrees that (a) the unauthorized disclosure of the Confidential Information by the Receiving Party or (b) a breach of a party’s obligations under Section 3.1 or Section 8, may cause irreparable harm to the Disclosing Party or non-breaching Party, as applicable. As a result thereof, in addition to any other remedies available, the Disclosing Party or non-breaching Party, as applicable shall be entitled to seek injunctive and other extraordinary relief in a court of competent jurisdiction in order to enforce the breaching Party’s obligations hereunder.

 

12.6    Assignment; Subcontractors. This Agreement and the rights related thereto may not be assigned or otherwise transferred by either party except with the written approval of the other party, which shall not be unreasonably delayed or denied.

Subject to the foregoing, this Agreement will be binding upon and will inure to the benefit of the parties and their respective successors and assigns. Any assignment in violation of the foregoing will be null and void.

 

12.7    Notices. Any notice required or permitted under the terms of this Agreement or required by law must be in writing and must be:  delivered in person, sent by first class registered mail, or air mail, as appropriate, or sent by overnight air courier, in each case properly posted and fully prepaid to the appropriate address as set forth below. Either party may change its address for notices by notice to the other party given in accordance with this Section 12.6. Notices will be deemed given at the time of actual delivery in person, three business days after deposit in the mail as set forth above, or one day after delivery to an overnight air courier service.

 

12.8    Waiver. Any waiver of the provisions of this Agreement or of a party’s rights or remedies under this Agreement must be in writing to be effective. Failure, neglect, or delay by a party to enforce the provisions of this Agreement or its rights or remedies at any time, will not be construed as a waiver of the party’s rights under this Agreement and will not in any way affect the validity of the whole or any part of this Agreement or prejudice the party’s right to take subsequent action. Exercise or enforcement by either party of any right or remedy under this Agreement will not preclude the enforcement by the party of any other right or remedy under this Agreement or that the party is entitled by law to enforce.

 

12.9    Severability. If any term, condition, or provision in this Agreement is found to be invalid, unlawful, or unenforceable to any extent, the parties will endeavor in good faith to agree to amendments that will preserve, as far as possible, the intentions expressed in this Agreement. If the parties fail to agree on an amendment, the invalid term, condition, or provision will be severed from the remaining terms, conditions, and provisions of this Agreement, which will continue to be valid and enforceable to the fullest extent permitted by law.

 

12.10  Counterparts. This Agreement may be executed in counterparts, each of which will be deemed to be an original and together will constitute one and the same agreement. This Agreement may also be delivered by facsimile or e-mail and such delivery will have the same force and effect of an original document with original signatures.

 

12.11  Headings. Headings are used in this Agreement for reference only and will not be considered when interpreting this Agreement.

 

12.12  Integration. This Agreement and all exhibits contain the entire agreement of the parties with respect to the subject matter of this Agreement and supersede all previous communications, representations, understandings, and agreements, either oral or written, between the parties with respect to the subject matter hereof, except that any NDA will remain in effect in accordance with its terms. No terms, provisions, or conditions of any purchase order, acknowledgement, or other business form that either party may use in connection with the transactions contemplated by this Agreement will have any effect on the rights, duties, or obligations of the parties under, or otherwise modify, this Agreement, regardless of any failure of a receiving party to object to these terms, provisions, or conditions. This Agreement may not be amended, except by a writing signed by both parties.

 

12.13          Force Majeure. Neither party will be in breach or default of this Agreement by reason of its delay or failure to meet any obligation hereunder due to any event, circumstance, or cause beyond its control such as but not limited to: governmental regulation, acts of nature or terrorism, or failures of public infrastructure, and similar events, circumstances, or causes, so long as the affected party provides prompt notice thereof to the non-affected party. The affected party will be excused from performance for as long as such force majeure event prevents such party from performing its obligations under this Agreement; provided, however, that in the event a force majeure event exceeds sixty (60) days in duration, the non-affected party may immediately terminate this Agreement and/or any Statement of Work hereunder upon notice to the affected party without any further liability except: (i) to pay any amounts due and payable to the other party as of the date of termination and (ii) with regard to any provisions of this Agreement which survive termination.


-4-

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

 

HYPERION:   BLACKSAND:
     
HYPERION MATERIALS & TECHNOLOGIES, LLC   BLACKSAND TECHNOLOGY LLC

 

Name:   Anastasios Arima   Name:   Kesh Keshavan

 

Title:   Manager   Title:   President
     
Signature:   /s/ Anastasios Arima   Signature:   /s/ Kesh Keshavan
         
Address for Notice:                [***]   Address for Notice: [***]
         

 

-5-

 

 SCHEDULE 1

 

STATEMENT OF WORK

 

Statement of Work #: 1 Effective From: February 13, 2021 (the “SOW Effective Date”)

 

This Statement of Work forms part of the Master Services Agreement dated February 13, 2021 (the “MSA”) by and between Blacksand Technology LLC, a Utah limited liability company (“Blacksand”), and Hyperion Materials & Technologies, LLC, a North Carolina limited liability company (“Hyperion”). Capitalized terms not otherwise defined herein shall have the definitions set forth in the MSA.

 

During the term of this Statement of Work, Blacksand will provide the following R&D services:

 

STATEMENT OF WORK
Task DESCRIPTION OF SERVICES Start End
    Week
1 Evaluate ARH process to convert enriched Ti ore ( UGS provided by Hyperion) to TiO2  
2 Demonstration of conversion of high grade TiO2 derived from Hyperion mineral ore to commercial pure Ti
3 Demonstrate cost analyses to produce 100kg, 1ton and 100ton /year of commercial pure Ti    
       
1.1 Phase 1: 1-5 kg TiO2    
  Evaluate ARH process to convert enriched Ti ore (UGS provided by Hyperion) to TiO2 Q1 Q2
  Report with recommendations    
       
2.1 Phase 1: 1-5 kg Ti Q2 Q3
2.1.1 HAMR process to convert TiO2 to Ti. - use TiO2 produced from task 1.1    
2.1.2 Report results & recommendations    
2.1.3 HAMR process to convert TiO2 to Ti. - using commercial TiO2    
2.1.4 Report results & recommendations    
       
2.2 Phase 2: 10-20 kg Ti Q4 Q5
2.2.1 HAMR Process to convert TiO2 to Ti (using commercial TiO2)    
2.2.2 Report results & recommendations    
       
2.3 Phase 3: 50-100 kg Ti Q6 Q8
2.3.1 HAMR Process to convert TiO2 to Ti (using commercial TiO2)    
2.3.2 Report results & recommendations    
       
3.1 Cost analyses - 100 kg, 1 ton, 1000 ton / year - for commercial titanium Q2 Q7
3.1.1 Set up input on constraints and assumptions mutually agreed upon between Hyperion and Blacksand    
3.1.2 Cost model set up    
3.1.3 Cost model simulation studies for different plant loading    

 

Notes:

 

Hyperion will provide the enriched titanium ore (i.e. the product equivalent to upgraded Ti slag (UGS)), or supply Blacksand commercially available titanium slag; provided that, during Phase 2 and Phase 3, Blacksand shall have the option to purchase enriched titanium ore from a third party at Hyperion’s sole discretion and expense.

 

1. TERM

 

The term of this Statement of Work shall commence on the SOW Effective Date and shall continue until the earlier of (a) termination as provided in the MSA or (b) completion of the scope of R&D services set forth in the table above (the “SOW Term”); provided that, should the SOW Term extend beyond the two year anniversary of the SOW Effective Date, Hyperion shall continue to pay Blacksand $47,500 for each such quarter until expiration of the SOW Term. In addition, either party may terminate this Statement of Work upon thirty (30) days’ written notice to the other party if any phase described in the table above is mutually and reasonably determined to be unsuccessful.

 

-1- 

 

The parties agree that for purposes of interpretation of Section 1.3 of the MSA – “Delays” – the schedule for the R&D Services above is indicative only and subject to change based on input from potential suppliers, vendors and subcontractors to Blacksand. Upon consultation with such third parties, Blacksand and Hyperion will discuss in good faith and agree to update the execution schedule as may be required.

 

2. SERVICE FEES

 

In consideration of the Services performed by Blacksand during the SOW Term, Hyperion shall pay to Blacksand a fixed price of $480,000 (Four Hundred Eighty Thousand US Dollars) (the “Original Amount”) as follows:

 

$72,500 due and payable upon the Effective Date.

$47,500 due and payable quarterly (every three months), beginning May 1, 2021.

$75,000 as a one-time payment upon completion of Phase I and commencement of Phase II, as described below.

 

Additionally, in the event the term of this Statement of Work renews for additional periods under Section 1 above or by mutual agreement of the parties, Hyperion will pay Blacksand the additional compensation set forth in Section 1 above.

 

In addition to the foregoing, Hyperion shall also be responsible for the cost of the ARH equipment that may be required to make 200 kg of TiO2 to yield 100 kg of Ti powder.

 

For the avoidance of doubt:

 

a) The rates stated above are exclusive of taxes.

 

b) Hyperion will be responsible for and will promptly pay all taxes (including but not limited to sales, services, export and use taxes) associated with this Agreement or Hyperion’s receipt of the Services, except taxes based on Blacksand’s net income and taxes related to Blacksand’s employees.

 

c) The rates stated in this Statement of Work shall be valid for a period of two (2) years from the SOW Effective Date. Revised rates shall be mutually agreed by the parties in writing.

 

d) A finance charge shall be imposed on all undisputed account balances outstanding over 30 days. The finance charge is [***] per month or the highest rate allowed by applicable law, whichever is lower.

 

e) Ninety (90) days prior to the commencement of Phase 3 of this Statement of Work, Blacksand will prepare an estimated capital cost for the cost of the ARH equipment which will be required to execute the Phase 3 scope of work. The parties shall work in good faith to agree on an approved budget and the parties will negotiate and execute a change notice to this Statement of Work to cover the cost of the Phase 3 equipment.

 

f) Other than the Phase 3 equipment, Blacksand will perform the Statement of Work on a fixed price basis. Any work not contemplated by this Statement of Work may be completed by change notice, or by a separate Statement of Work. Prior to undertaking any additional work, Blacksand will prepare an estimated cost and schedule for the additional work. Blacksand will obtain prior written approval from Hyperion prior to performing any additional work, otherwise Hyperion shall have no obligation to reimburse Blacksand for such unapproved expense.

 

3. OPTION/LICENSE AGREEMENT

 

At any time during the term of the MSA, subject to Hyperion’s compliance with the MSA and this Statement of Work, and conditioned on Hyperion having paid the Original Amount in full, Hyperion shall have the right, but not the obligation, to exercise the option, and acquire the License, as set forth in that certain “Option for Exclusive License Agreement Between Hyperion Materials & Technologies, LLC and Blacksand Technology, LLC” (“License Agreement”), of even date herewith and attached as Exhibit A. In furtherance of this right, during the term of the MSA, Blacksand covenants and agrees (a) not to take any action that would be inconsistent with the License Agreement and (b) to use its reasonable best efforts from taking any action that would prevent Blacksand from making any of the representations or warranties, or making and complying with any of the covenants, set forth in the License Agreement.

 

-2- 

 

IN WITNESS WHEREOF, the parties hereto have executed this Statement of Work as of the SOW Effective Date.

  

HYPERION:   BLACKSAND:
     
HYPERION MATERIALS & TECHNOLOGIES, LLC   BLACKSAND TECHNOLOGY, LLC

 

Name:   Anastasios Arima   Name:   Kesh Keshavan

 

Title:   Manager   Title:   President
     
Signature:   /s/ Anastasios Arima   Signature:   /s/ Kesh Keshavan
         

 

-3- 

 

STATEMENT OF WORK # 2

 

Statement of Work #: 2 Effective From: June 1, 2021 (the “SOW Effective Date”)

 

This Statement of Work forms part of the Master Services Agreement dated February 13, 2021 (the “MSA”) by and between Blacksand Technology LLC, a Utah limited liability company (“Blacksand”), and Hyperion Materials & Technologies, LLC, a North Carolina limited liability company (“Hyperion”). Capitalized terms not otherwise defined herein shall have the definitions set forth in the MSA.

 

During the term of this Statement of Work, Blacksand will provide the following services:

 

Supply to Hyperion 500-900 kg Ti-6Al-4V powder using GSD technology over the course of two (2) years.  Blacksand shall supply 20-45 kg of powder monthly.

Powder shall be made according to widely accepted specifications (ASTM F2924 and AMS 4998, for example) or customized requirements of chemistry and size distributions based on end-user specifications to be provided by Hyperion.  

Blacksand will use existing pilot plant and provide resources to produce the powder.

 

During the term of this Statement of Work Hyperion will provide the following:

 

Define requirements for powder to meet the specifications of end-user/customer needs or inventory build.

Supply raw material (Ti scrap) for use in GSD manufacturing.

 

The parties agree that this scope of services may be expanded upon agreement of the parties to cover recycling of AM powder. The parties also agree that certain pilot scale capital equipment may be required during the execution of this SOW. Hyperion will provide funding for the purchase of such equipment upon mutual agreement of the parties.

 

1. TERM

 

The term of this Statement of Work shall commence on the SOW Effective Date and shall continue until the earlier of (a) termination as provided in the MSA (b) completion of the scope services set forth in the table above, or (c) two (2) years after the SOW Effective Date (the “SOW Term”).

 

2. SERVICE FEES

 

In consideration of the Services performed by Blacksand during the SOW Term, Hyperion shall pay to Blacksand a fixed price of $1,200,000 (One Million Two Hundred Thousand US Dollars) (the “Original Amount”) for two (2) years, with $150,000 due and payable upon the Effective Date, and $150,000 due and payable quarterly thereafter (every three months).

 

For the avoidance of doubt:

 

g) The rates stated above are exclusive of taxes.

 

h) Hyperion will be responsible for and will promptly pay all taxes (including but not limited to sales, services, export and use taxes) associated with this Agreement or Hyperion’s receipt of the Services, except taxes based on Blacksand’s net income and taxes related to Blacksand’s employees.

 

i) The rates stated in this Statement of Work shall be valid for a period of two (2) years from the SOW Effective Date. Revised rates shall be mutually agreed by the parties in writing.

 

j) A finance charge shall be imposed on all undisputed account balances outstanding over 30 days. The finance charge is [***] per month or the highest rate allowed by applicable law, whichever is lower.

 

k) Blacksand will perform the Statement of Work on a fixed price basis. Any work not contemplated by this Statement of Work may be completed by change notice, or by a separate Statement of Work. Prior to undertaking any additional work, Blacksand will prepare an estimated cost and schedule for the additional work. Blacksand will obtain prior written approval from Hyperion prior to performing any additional work, otherwise Hyperion shall have no obligation to reimburse Blacksand for such unapproved expense.

 

-1- 

 

3. OPTION/LICENSE AGREEMENT

 

At any time during the term of the MSA, subject to Hyperion’s compliance with the MSA and this Statement of Work, and conditioned on Hyperion having paid the Original Amount in full, Hyperion shall have the right, but not the obligation, to exercise the option, and acquire the License, as set forth in that certain “Option for Exclusive License Agreement Between Hyperion Materials & Technologies, LLC and Blacksand Technology, LLC” (“License Agreement”), of even date herewith and attached as Exhibit A. In furtherance of this right, during the term of the MSA, Blacksand covenants and agrees (a) not to take any action that would be inconsistent with the License Agreement and (b) to use its reasonable best efforts from taking any action that would prevent Blacksand from making any of the representations or warranties, or making and complying with any of the covenants, set forth in the License Agreement.

 

IN WITNESS WHEREOF, the parties hereto have executed this Statement of Work #2 as of the SOW Effective Date.

 

HYPERION:   BLACKSAND:
     
HYPERION MATERIALS & TECHNOLOGIES, LLC   BLACKSAND TECHNOLOGY, LLC

 

Name:   Anastasios Arima   Name:   Kesh Keshavan

 

Title:   Manager   Title:   President
     
Signature:   /s/ Anastasios Arima   Signature:   /s/ Kesh Keshavan
         

 

-2-

 

 

 

 

 

 

Exhibit 4.4

 

IPERIONX LIMITED
ACN 618 935 372

 

Employee INCENTIVE Plan


Adopted by Shareholders on April 14, 2021

 

 

 

CONTENTS

 

1 PURPOSE 2
     
2 Commencement 2
     
3 Maximum allocation 2
     
4 Eligibility and grant 2
     
5 Operation of Plan 4
     
6 EMPLOYEE SHARE TRUST 5
     
7 Quotation 5
     
8 Lapse of Options and performance rights 5
     
9 Issue of Shares 7
     
10 Rights attaching to Shares 8
     
11 NOMINEE 8
     
12 Good Leaver 8
     
13 Bad Leaver 9
     
14 Fraudulent or dishonest actions 9
     
15 Buy-Back 11
     
16 Buy-Back price 11
     
17 Holding lock 12
     
18 tax liability and withholding 12
     
19 Contravention of Applicable Laws 12
     
20 Contravention of Rules 12
     
21 Administration of the Plan 12
     
22 Plan amendment 14
     
23 Termination or suspension 15
     
24 No employment contract 15
     
25 ASIC relief 16
     
26 Non-exclusivity 16
     
27 General 16
     
28 PROVISIONS SPECIFIC TO UNITED STATES 17
     
29 Definitions and interpretation 20
     
SCHEDULE 1: terms and conditions of options 26
   
SCHEDULE 2: terms and conditions of performance rights 32
   
SCHEDULE 3: PRO-FORMA OFFER LETTER - OPTIONS 36
   
SCHEDULE 4: PRO-FORMA OFFER LETTER - PERFORMANCE RIGHTS 42

 

 

 

1 PURPOSE

 

1.1 The purpose of the Plan is to:

 

1.1.1 assist in the reward, retention and motivation of Eligible Employees;

 

1.1.2 link the reward of Eligible Employees to Shareholder value creation; and

 

1.1.3 align the interests of Eligible Employees with Shareholders by providing an opportunity to Eligible Employees to earn rewards via an equity interest in the Company based on creating Shareholder value.

 

2 Commencement

 

2.1 The Plan will commence on a date determined by resolution of the Board (and if no date is specified, on the date the Plan is approved by the Board).

 

3 Maximum allocation

 

3.1 An Offer of Options or Performance Rights may only be made under this plan if the number of Shares that may be acquired on exercise of the Options and Performance Rights when aggregated with the number of Shares issuable if each outstanding Option and Performance Right were exercised and the number of Shares issued pursuant to the Plan or any other Group employee incentive scheme during the previous 3 years does not exceed 10% of the total number of Shares on issue at the time of the proposed issue.

 

3.2 For the avoidance of doubt, where an Employee Incentive lapses without being exercised, the Employee Incentive concerned shall be excluded from any calculation under this clause 3.

 

3.3 The maximum allocation and allocated pool provided for in this clause 3 may be increased by Board resolution, provided such an increase complies with the Listing Rules.

 

4 Eligibility and grant

 

Participation

 

4.1 The Board may from time to time in its sole and absolute discretion determine that an Eligible Employee may participate in the Plan.

 

Selection

 

4.2 Following determination that an Eligible Employee may participate in the Plan, the Board may at any time, and from time to time, make an Offer to the Eligible Employee.

 

Offer

 

4.3 Subject to clause 4.4, the manner, form, content, timing and frequency of Offers will be as determined by the Board in its sole and absolute discretion.

 

4.4 An Offer must be set out in an Offer Letter delivered to the Eligible Employee. The Offer Letter may specify (as determined by the Board):

 

    2

 

 

4.4.1 the number of Options or Performance Rights;

 

4.4.2 the conditions on the Offer (Offer Conditions);

 

4.4.3 the Grant Date;

 

4.4.4 the Fee (if any);

 

4.4.5 the Performance Criteria (if any);

 

4.4.6 the Vesting Conditions (if any);

 

4.4.7 the Exercise Price (if any);

 

4.4.8 the Exercise Period (if applicable);

 

4.4.9 the Performance Period (if applicable); and

 

4.4.10 the Expiry Date and Term (if applicable).

 

4.5 An Offer must be accompanied by an Application, the terms and conditions of the relevant Employee Incentive and a copy of this Plan.

 

4.6 Pro-forma Offer Letters and pro-forma Applications are attached as Schedules 3 to 4 (as applicable) of this Plan, respectively.

 

Application

 

4.7 Unless otherwise determined by the Board in its sole and absolute discretion, an Eligible Employee that wishes to apply to participate in the Plan in response to an Offer must, on or before the period of time allowed for acceptance of the Offer, give an Application:

 

4.7.1 to the person specified in the Offer Letter; and

 

4.7.2 in accordance with any instructions or conditions set out in the Offer Letter.

 

4.8 An Eligible Employee may accept less than the total number of Employee Incentives in an Offer.

 

Multiple Offers

 

4.9 Unless otherwise determined by the Board in its sole and absolute discretion, the Board may make any number of issues to Eligible Employees, as set out in any Offer, notwithstanding that an issue or issues may have been previously made to any Eligible Employee.

 

Right to Reject Applications

 

4.10 The Board is entitled to reject any Application by an Eligible Employee to participate in this Plan without giving any reason.

 

Acceptance of Offer

 

4.11 A person to whom an Offer is made may accept the Offer by completing the Application and giving it to the Board by 5:00pm on the last day of the acceptance period specified in the Offer Letter.
    3

 

 

4.12 Unless an Eligible Employee is notified otherwise by the Board, an Eligible Employee's Application is accepted by the Board upon receipt.

 

4.13 Once that notice is given, a contract is formed under which an Eligible Employee and Company:

 

4.13.1 become bound by the terms and conditions of the Offer Letter, this Plan, the terms and conditions of the relevant Employee Incentive and the Company's Constitution;

 

4.13.2 the Eligible Employee agrees to the issue of the Employee Incentives from the Company in accordance with the terms and conditions of the Eligible Employee’s Application; and

 

4.13.3 the Company agrees to issue the Employee Incentives to the Eligible Employee in accordance with the terms and conditions of the Eligible Employee’s Application.

 

4.14 In accordance with the Company's reporting obligations under Australian and other tax legislation, each participant consents to the disclosure of information about this Plan and its participants to the Australian Tax Office or another tax authority.

 

5 Operation of Plan

 

5.1 This Plan is administered by the Board, which has power to:

 

5.1.1 determine appropriate procedures for administration of this Plan consistent with this Plan;

 

5.1.2 resolve conclusively all questions of fact or interpretation in connection with this Plan;

 

5.1.3 appoint a person to be the Plan Administrator;

 

5.1.4 delegate to any persons (including, without limitation, a Plan Administrator) for such period and on such terms as it sees fit the exercise of any of its powers or discretions under this Plan; and

 

5.1.5 take and rely on independent professional or expert advice in or in relation to the exercise of any of its powers or discretions under this Plan.

 

5.2 Where the Board is to make a determination, decision, approval or give any opinion under this Plan, the Board or the Company may do so in its absolute discretion.

 

5.3 Any power or discretion which is conferred on the Board or the Company by this Plan may be exercised by the Board in the interests, or for the benefit, of the Company and the Board is not, in exercising any such power or discretion, under any fiduciary or other obligation to any other person including, for the avoidance of doubt, any Eligible Employee or any Participant.

 

    4

 

 

6 EMPLOYEE SHARE TRUST

 

6.1 The Board may in its sole and absolute discretion use an employee share trust or other mechanism for the purposes of holding Shares for Participants under the Plan and delivering Shares to Participants upon exercise of the Options or the vesting of a Performance Right.

 

7 Quotation

 

7.1 The Company will not seek official quotation of any Options or Performance Rights.

 

7.2 The Company must use all reasonable endeavours to obtain the grant of quotation of Shares issued on exercise of Options or conversion of Performance Rights under this Plan on the ASX and, subject to Listing Rules, on any other exchange on which Shares are quoted. This is subject to there being no applicable trading restrictions under:

 

7.2.1 this Plan;

 

7.2.2 the Listing Rules; or

 

7.2.3 the Corporations Act 2001 (Cth).

 

8 Lapse of Options and performance rights

 

When do Options and Performance Rights lapse?

 

8.1 Subject to clause 8.2 or the Board deciding otherwise, a Participant's Options and/or Performance Rights shall automatically be cancelled for no consideration on the earliest to occur of the following:

 

8.1.1 the cessation of employment or office of a Participant with the Company or any member of the Group (other than in accordance with clause 12);

 

8.1.2 where clause 14 applies;

 

8.1.3 if applicable Performance Criteria and/or Vesting Conditions are not achieved by the relevant time;

 

8.1.4 if the Board determines in its reasonable opinion that the applicable Performance Criteria and/or Vesting Conditions have not been met or cannot be met prior to the Expiry Date or the end of the Performance Period (as applicable);

 

8.1.5 the Expiry Date;

 

8.1.6 where the Board has determined that the Participant has, by any act or omission, brought the Group into disrepute or acted contrary to the interests of the Company or the Group;

 

8.1.7 the receipt by the Company of notice from the Participant (after a Special Circumstance has arisen with respect to the Participant) that the Participant has elected to surrender the Employee Incentive; or

 

8.1.8 any other circumstances specified in any Offer Letter pursuant to which the Employee Incentive were issued.
    5

 

 

Discretion of Board

 

8.2 The Board may decide to allow a Participant to:

 

8.2.1 retain and exercise any or all of their Options, whether or not the Vesting Conditions or Performance Criteria (as applicable) have been satisfied, and whether or not the Options would otherwise have lapsed, provided that no Options will be capable of exercise later than the relevant Expiry Date for those Options; and

 

8.2.2 retain any Performance Rights regardless of:

 

8.2.2.1 the expiry of the Performance Period to which those Performance Rights relate; or

 

8.2.2.2 any failure by the Participant to satisfy in part or in full the Performance Criteria or Vesting Conditions (as applicable) specified by the Board in respect of those Performance Rights;

 

in which case, the Board may:

 

8.2.2.3 determine that any or all of those retained Performance Rights shall vest and the corresponding Shares shall be provided to the Eligible Employee; or

 

8.2.2.4 determine a new Performance Period or Vesting Conditions (as applicable) for those retained Performance Rights and notify the Participant of the determination as soon as practicable.

 

Determination Whether to Exercise Discretion

 

8.3 The Board may have regard to whatever matters it thinks reasonable when making a decision about the matters in clause 8.2 with respect to a Participant, including any of the following factors:

 

8.3.1 the reason for the cessation of employment with the Company, or any member of the Group;

 

8.3.2 the length of time between the date of cessation of employment and the Expiry Date;

 

8.3.3 the Participant's reasons for any failure to satisfy any Performance Criteria;

 

8.3.4 the total length of service of the person as an employee with the Company, or any member of the Group;

 

8.3.5 if the cessation of employment is related to the person's performance, then the extent to which the person has been given warning of their performance inadequacies;

 

8.3.6 information provided by the person to the Board to support any claim to exercise the discretion in the person's favour; or

 

8.3.7 Applicable Law.

 

    6

 

 

Effect of Lapse

 

8.4 All rights of a Participant under this Plan in respect of an Option or Performance Right cease upon the Option or Performance Right lapsing. No consideration or compensation will be payable to any person in relation to that lapse.

 

8.5 The Company will, with respect to any Option or Performance Right that has lapsed in accordance with this clause 8:

 

8.5.1 notify the Participant that the relevant Options or Performance Rights held by them have lapsed;

 

8.5.2 arrange for the Participant or the Participant's agent or attorney to sign any transfer documents as may be required to transfer or otherwise deal with the Options or Performance Rights; and

 

8.5.3 not be liable for any damages, compensation or other amounts to the Participant in respect of the Options or Performance Rights.

 

9 Issue of Shares

 

Issue of Shares

 

9.1 The Company will issue Shares or acquire and transfer Shares directly to the Eligible Employee where Shares are to be provided under this Plan, unless the Board determines otherwise.

 

Overriding restrictions on Shares

 

9.2 Participants must not deal with Shares if to do so would contravene Applicable Laws.

 

9.3 The Board must not issue and allot any Shares under this Plan to a person if the issue of the Shares is prohibited or would contravene Applicable Laws, including if prohibited under the Corporations Act without a disclosure document, product disclosure statement or similar document or if the Company is required to obtain shareholder approval for the issue of the Shares.

 

Issuer sponsored holding for Shares

 

9.4 Unless the Board determines otherwise (in its absolute discretion), all Shares issued under this Plan including Shares issued on exercise of any Options or conversion of any Performance Rights:

 

9.4.1 will be issued on the issuer sponsored sub-register maintained by the Company; and

 

9.4.2 the Participant must keep the Shares issued on the issuer sponsored sub-register while they remain employed by the Company or any member of the Group. The Company is entitled to impose a holding lock pursuant to clause 17 if any Participant attempts to transfer their shares from the Company's issued sponsored sub-register in breach of this clause 9.4.2.

 

    7

 

 

10 Rights attaching to Shares

 

Shares to Rank Equally

 

10.1 Any Shares allotted, issued or transferred by the Company to a Participant under the Plan will rank equally with all existing Shares, including those Shares issued, directly, under this Plan, on and from the date of allotment, issue or transfer in respect of all rights and bonus issues, and dividends which have a record date for determining entitlements on or after the date of allotment, issue, or transfer of those Shares.

 

11 NOMINEE

 

11.1 Unless expressly permitted in the Offer or by the Board, an Eligible Employee may only submit an Application in the Eligible Employee's name and not on behalf of any other person.

 

11.2 If an Eligible Employee is permitted in the Offer or by the Board, the Eligible Employee may nominate a Related Party to be issued the Options or Performance Rights the subject of the Offer. The nominated Related Party must execute any documents required by the Company in order to receive the grant of the Options or Performance Rights.

 

11.3 If Options or Performance Rights are granted to a Related Party nominated by an Eligible Employee, then to the extent necessary to give effect to these Rules, the Eligible Employee will continue to be treated as the Participant.

 

11.4 If a Participant ceases to Control its Related Party to whom Options or Performance Rights have been granted under these Rules, then that Related Party must immediately transfer all Options or Performance Rights held by it to the Participant. Each of the Participant and the Related Party will do (and hereby authorise the Company and its officers and agents to do) all things necessary, including executing all documentation necessary, to give effect to this clause.

 

12 Good Leaver

 

12.1 Subject to clause 12.2, where a Participant who holds Employee Incentives becomes a Good Leaver:

 

12.1.1 all vested Options which have not been exercised in accordance with these Rules will continue in force and remain exercisable for 90 days after the date the Participant becomes a Good Leaver, unless the Board determines otherwise in its sole and absolute discretion, after which the Options will lapse; and

 

12.1.2 the Board may at any time, in its sole and absolute discretion (subject to the Corporations Act and ASX Listing Rules), do one or more of the following:

 

12.1.2.1 permit unvested Employee Incentives held by the Good Leaver to vest;

 

12.1.2.2 permit such unvested Employee Incentives held by the Good Leaver or his or her nominee(s) to continue to be held by the applicable holder, with the Board having the discretion to amend the vesting criteria (including any Offer Conditions, Performance Criteria or Vesting Conditions) or reduce the exercise period of such unvested Employee Incentives; or

 

12.1.2.3 determine that the unvested Employee Incentives will lapse.

 

12.2 Where a person is a Good Leaver due to a Special Circumstance, the Nominated Beneficiary shall be entitled to benefit from any exercise of the above discretionary powers by the Board.

 

    8

 

 

13 Bad Leaver

 

13.1 Where a Participant who holds Employee Incentives becomes a Bad Leaver:

 

13.1.1 unless the Board determines otherwise, in its sole and absolute discretion, all vested and unvested Employee Incentives will lapse; and

 

13.1.2 the Board may determine to exercise the right to buy back any Shares issued upon exercise of an Option or conversion of a Performance Rights in accordance with clause 15.

 

14 Fraudulent or dishonest actions

 

Fraudulent or Dishonest Actions

 

14.1 Where, in the reasonable opinion of the Board, a Participant or Former Participant (which for the avoidance of doubt may include a Good Leaver):

 

14.1.1 acts fraudulently or dishonestly;

 

14.1.2 wilfully breaches his or her duties to the Company or any member of the Group; or

 

14.1.3 has, by any act or omission, in the opinion of the Board (determined in its absolute discretion):

 

14.1.3.1 brought the Company, the Group, its business or reputation into disrepute; or

 

14.1.3.2 is contrary to the interest of the Company or the Group.

 

14.1.4 commits any material breach of the provisions of any employment contract entered into by the Participant with any member of the Group;

 

14.1.5 commits any material breach of any of the policies of the Group or procedures or any laws, rules or regulations applicable to the Company or Group;

 

14.1.6 is subject to allegations, has been accused of, charged with or convicted of fraudulent or dishonest conduct in the performance of the Participant's (or Former Participant's) duties, which in the reasonable opinion of the relevant directors of the Group effects the Participant's suitability for employment with that member of the Group, or brings the Participant or the relevant member of the Group into disrepute or is contrary to the interests of the Company or the Group;

 

    9

 

 

14.1.7 is subject to allegations, has been accused of, charged with or convicted of any criminal offence which involves fraud or dishonesty or any other criminal offence which Board determines (in its absolute discretion) is of a serious nature;

 

14.1.8 has committed any wrongful or negligent act or omission which has caused any member of the Group substantial liability;

 

14.1.9 has become disqualified from managing corporations in accordance with Part 2D.6 of the Corporations Act or has committed any act that, pursuant to the Corporations Act, may result in the Participant being banned from managing a corporation;

 

14.1.10 has committed serious or gross misconduct, wilful disobedience or any other conduct justifying termination of employment without notice.

 

14.1.11 has wilfully or negligently failed to perform their duties under any employment contract entered into by the Participant with any member of the Group;

 

14.1.12 has engaged in a transaction which involves a conflict of interest to their employment with the Company resulting in the Participant or Former Participant obtaining a personal benefit;

 

14.1.13 accepts a position to work with a competitor of the Company or Group;

 

14.1.14 acting in such a manner that could be seen as being inconsistent with the culture and values of the Company or the Group; or

 

14.1.15 any other act that the Board determines in its absolute discretion to constitute fraudulent or dishonest by the Participant or Former Participant for the purposes of this clause 14,

 

then the Board may (in its absolute discretion) deem all Employee Incentives held by the Participant or Former Participant will automatically be forfeited.

 

When Forfeiture Occurs

 

14.2 Where any Employee Incentives are subject to forfeiture pursuant to clause 14.1, the Company will:

 

14.2.1 notify the Participant or Former Participant that the relevant Employee Incentives held by them have been forfeited;

 

14.2.2 cancel any Employee Incentives, Buy Back any Employee Incentives pursuant to clause 15 or arrange for the Participant's agent or attorney to sign any transfer documents required to transfer or rely on clauses 21.6 and 21.7 and otherwise deal with the relevant Employee Incentives as the Board determines in its absolute discretion; and

 

14.2.3 not be liable for any damages, compensation or other amounts to the Participant in respect of the relevant Employee Incentives that were subject to such forfeiture.

 

    10

 

 

15 Buy-Back

 

Buy-Back

 

15.1 Subject to any Applicable Laws, Employee Incentives issued pursuant to this Plan will be subject to the Company's right to Buy-Back and may at any time be immediately Bought-Back by the Company if:

 

15.1.1 the Participant holding the Employee Incentives ceases employment or office where the Offer Conditions, Performance Criteria and/or Vesting Conditions attaching to the Employee Incentives have not been met by the time of cessation. The time of cessation of employment or office shall be the time as determined by the Board in its sole discretion;

 

15.1.2 where clause 13 applies;

 

15.1.3 where clause 14 applies;

 

15.1.4 where clause 8 applies; or

 

15.1.5 if the Board determines in its reasonable opinion that the applicable Performance Criteria and/or Vesting Conditions have not been met by the end of the Expiry Date.

 

15.2 The Buy-Back of Employee Incentives under clause 15.1 may occur in one or more tranches within such time, as determined by the Board in its sole and absolute discretion.

 

Buy-Back Mechanism

 

15.3 Each Participant is deemed to agree to sell such Employee Incentives to the Company and will do all acts, matters and things at any time which are necessary or desirable in the sole opinion of the Board to give effect to any Buy-Back of his or her Employee Incentives, including but not limited to:

 

15.3.1 authorising and appointing the company secretary holding office at the relevant time (or their delegate) as their agent or attorney to sell the Employee Incentives; or

 

15.3.2 where any Option, Performance Right, or Share transferred or issued to the Participant or any Shares resulting from exercise of said Options and/or Performance Rights have been sold by the Participant, require the Participant to pay all or part of the proceeds received from the sale of any Employee Incentives to the Company; or

 

15.4 If there are insufficient proceeds received by the Company from the sale of Employee Incentives, the Participant will owe a debt to the Company for the value of the Employee Incentives.

 

16 Buy-Back price

 

16.1 Unless determined otherwise by the Board in its absolute discretion, the total price on which all Employee Incentives held by a Participant may be Bought-Back by the Company is an aggregate of $1.00 for all the relevant Employee Incentives (Buy-Back Price).

 

    11

 

 

17 Holding lock

 

17.1 The Board may at any time request that the Company's share registry to impose a holding lock on any Employee Incentives issued pursuant to this Plan where the Board determines or reasonably believes (in its absolute discretion) that a Participant (or a Former Participant while they were employed by the Company or a member of the Group) has or may breach these Rules. A holding lock shall not be imposed in violation of Code Section 409A, as applicable.

 

18 tax liability and withholding

 

18.1 The ultimate responsibility and liability for any and all taxes belongs to and shall remain with the Participant, and any tax consequences arising from the grant or exercise of any Performance Right or Option, from the payment of Shares covered thereby, or from any other event or act relating to the Performance Rights, Options, or Shares issued upon exercise thereof, shall be borne solely by the Participant. The Company makes no representations or undertaking regarding the tax treatment of any grant, issuance or exercise of any Performance Rights, Options, or Shares.

 

18.2 The Company may withhold any such number of Performance Rights, Options, or Shares to be issued to the Participant which may be required to be withheld by any Applicable Law or to satisfy the Participant's tax obligations under clause 18.1.

 

19 Contravention of Applicable Laws

 

19.1 No act will be done or determination made in accordance with these Rules where to do so would be a breach of any Applicable Laws, and where any such act is done or determination made it will be considered void and to the extent possible be unwound and of no effect in respect of Employee Incentives.

 

20 Contravention of Rules

 

20.1 The Board may at any time, in its sole and absolute discretion, take any action it deems reasonably necessary in relation to any Employee Incentives if it determines or reasonably believes a Participant has breached these Rules or the terms of issue of any Employee Incentives, including but not limited to, signing transfer forms in relation to Employee Incentives, placing a holding lock on Employee Incentives pursuant to clause 17, signing any and all documents and doing all acts necessary to effect a Buy-Back, accounting for the proceeds of the sale of forfeited Employee Incentives, refusing to transfer any Employee Incentives and/or refusing to issue any Shares.

 

21 Administration of the Plan

 

Regulations

 

21.1 The Board may make such regulations for the operation of the Plan as it considers necessary, provided such regulations are consistent with these Rules.

 

    12

 

 

Delegation

 

21.2 The Board may delegate any of its powers or discretions conferred on it by these Rules to a committee of the Board or to any one or more persons selected by it, including but not limited to the company secretary.

 

21.3 Any delegation will be for such period and upon such terms and conditions as determined by the Board from time to time.

 

Decisions Final

 

21.4 Subject to clause 21.5, every exercise of a discretion by the Board (or its delegates) and any decision by the Board (or its delegates) regarding the interpretation, effect or application of these Rules will be final, conclusive and binding and may not be subsequently reversed or changed by the Board (or its delegates) without the Participant's or Former Participant's consent.

 

21.5 Unless the Board (or its delegates) has resolved to make an irrevocable exercise of their discretion or made an irrevocable determination, the exercise of any discretion or decision by the Board (or its delegates) under these Rules does not prevent the Board (or its delegates) from subsequently exercising its powers under clauses 14 to 17 (inclusive) if any of the circumstances described in clause 14 is found to apply to a Participant or Former Participant, including, but not limited to, if the Board (or its delegates) has previously determined that a Participant was a Good Leaver under these Rules.

 

Attorney and Agent

 

21.6 Each Participant hereby authorises and appoints the company secretary holding office at the relevant time (or their delegate) as their agent or attorney with power to do all things necessary in the name of and on behalf of the Participant to give effect to these Rules, including and without limitation, signing Option or Share transfer forms, requesting the Company’s share registry to place a holding lock on any Employee Incentives, signing all documents and doing all acts necessary to effect a Buy-Back, and accounting for the proceeds of the sale of forfeited Employee Incentives, but expressly excluding the power to exercise Options granted to the Participant under the Plan.

 

21.7 Each Participant agrees to indemnify and hold harmless any person acting as their agent or attorney in accordance with these Rules in respect of all costs, damages, or losses of whatever nature arising from so acting, other than costs, damages, or losses arising from the agent's or the attorney's dishonesty, fraud, or wilful breach of their duties.

 

Notice

 

21.8 Address for service:

 

21.8.1 Any notice required to be given to the Participants under the Plan will be sent to the address of the Participant as entered in the register unless delivered in person.

 

21.8.2 Any notice required to be given to the Company under the Plan will be sent to the registered office of the Company or such other address as is notified to Participants from time to time.

 

21.9 Delivery of notices:

 

21.9.1 Any notice to be given to Participants may be delivered to the Participant by hand, by prepaid post or email to the last address notified by the Participant to the Company or held on the Company's records.

 

    13

 

 

21.9.2 Any notice to be given to the Company may be delivered by hand, prepaid post, or by email to the address notified by the Company to the Participant.

 

21.9.3 Notices delivered to Participants in accordance with the Constitution will be taken to be delivered in accordance with the Constitution. Notices delivered to the Company by pre-paid post will be taken to be delivered if properly addressed and stamped, forty-eight (48) hours after mailing in Australia and seven days after mailing outside Australia. Notices delivered by facsimile, email or other mode of electronic delivery will be taken to be delivered on receipt of a successful transmission notice, return receipt or such other confirmation by which the sender can reasonably verify delivery.

 

22 Plan amendment

 

Amendment of Plan

 

22.1 Subject to clause 22.2 and the Constitution, the Board may at any time amend these Rules or the terms and conditions upon which any Employee Incentives have been issued under the Plan.

 

22.2 No amendment to these Rules or to Employee Incentives granted under the Plan may be made if the amendment, in the opinion of the Board, materially reduces the rights of any Participant in respect of Employee Incentives granted to them prior to the date of the amendment, other than:

 

22.2.1 an amendment introduced primarily:

 

22.2.1.1 for the purposes of complying with or conforming to present or future legislation governing or regulating the Plan or like plans;

 

22.2.1.2 to correct any manifest error or mistake;

 

22.2.1.3 to allow the implementation of a trust arrangement in relation to the holding of Shares granted under the Plan;

 

22.2.1.4 for the purpose of complying with the Applicable Laws; and/or

 

22.2.1.5 to take into consideration possible adverse taxation implications in respect of the Plan including changes to applicable taxation legislation or the interpretation of that legislation by a court of competent jurisdiction or any rulings from taxation authorities administering such legislation; or

 

22.2.2 an amendment agreed to in writing by the Participant(s).

 

22.3 The Board may determine that any amendment to these Rules or the terms of Employee Incentives granted under the Plan be given retrospective effect.

 

22.4 Amendment of these Rules or the terms and conditions upon which Employee Incentives are granted under the Plan by the Board will be of immediate effect unless otherwise determined by the Board.

 

    14

 

 

22.5 As soon as reasonably practicable after making any amendment to these Rules or the terms and conditions of Employee Incentives granted under the Plan, the Board will give notice of the amendment to any Participant affected by the amendment. Failure by the Board to notify a Participant of any amendment will not invalidate the amendment as it applies to that Participant.

 

Amendment by Addendum

 

22.6 Subject to any other provision of these Rules, the Board may from time to time amend the terms of this Plan as they will apply in particular jurisdictions or circumstances by means of an addendum to these Rules.

 

23 Termination or suspension

 

Termination or Suspension

 

23.1 Subject to clause 23.2, the Board may at any time terminate or amend the Plan or suspend the operation of the Plan for such period or periods as it thinks fit.

 

Resolution to Terminate, Suspend, Supplement or Amend

 

23.2 In passing a resolution to terminate, amend or suspend the operation of the Plan, the Board must consider and endeavour to ensure that there is fair and equitable treatment of all Participants.

 

24 No employment contract

 

24.1 Nothing in these Rules or the terms of any Employee Incentives:

 

24.1.1 confers upon an Eligible Employee a right to a grant or offer of a grant of Employee Incentives;

 

24.1.2 confers on an Eligible Employee or a Participant the right to continue as an employee or officer of the Company, or any member of the Group (as the case may be);

 

24.1.3 affects the rights of the Company, or any member of the Group, to terminate the employment or office of an Eligible Employee or a Participant (as the case may be);

 

24.1.4 affects the rights and obligations of any Eligible Employee or Participant under the terms of their office or employment with the Company, or any member of the Group;

 

24.1.5 confers any legal or equitable right on an Eligible Employee or a Participant whatsoever to take action against the Company, or any member of the Group, in respect of their office or employment; or

 

24.1.6 confers on an Eligible Employee or a Participant any rights to compensation or damages in consequence of the termination of their employment or office by the Company, or any member of the Group, for any reason whatsoever including ceasing to have rights under the Plan as a result of such termination.

 

    15

 

 

25 ASIC relief

 

25.1 Notwithstanding any other provisions of the Plan, every covenant or other provisions set out in an exemption or modification granted from time to time by ASIC in respect of the Plan or which applies to the Plan pursuant to its power to exempt and modify the Corporations Act and required to be included in the Plan in order for that exemption or modification to have full effect, is deemed to be contained in the Plan. To the extent that any covenant or other provision deemed by this clause 25 to be contained in the Plan is inconsistent with any other provision in the Plan, the deemed covenant or other provision will prevail.

 

26 Non-exclusivity

 

Non-Exclusivity

 

26.1 This Plan will not be deemed to be the exclusive method of providing incentive compensation to Eligible Employees, nor will it preclude the Company, or any member of the Group, from authorising or approving other forms of incentive compensation for employees of the Company, or any member of the Group.

 

Relationship to Other Equity Plans

 

26.2 Participation in this Plan will not affect or be affected by any participation in any other employee equity plan operated by the Company, except as specifically provided in the terms of that other plan.

 

27 General

 

No Fiduciary Capacity

 

27.1 The Board may exercise any power or discretion conferred on it by these Rules in the interest or for the benefit of the Company, and in so doing the Board is not required to act in the interests of another person or as requested by another person and will not be under any fiduciary obligation to another person.

 

Listing Rules

 

27.2 On the Company being admitted to the list of companies quoted on a recognised stock exchange, the provisions of the Listing Rules will apply to the Plan, and to the extent that the Plan and the Listing Rules are inconsistent, the provisions of the Listing Rules will apply.

 

Enforcement

 

27.3 These Rules, any determination of the Board made pursuant to the Rules, and the terms of any Shares, Options or Performance Rights granted under the Plan, will be deemed to form a contract between the Company and the Participant.

 

Governing Law

 

27.4 This Plan and any Shares, Options or Performance Rights granted under it will be governed by, and must be construed according to, the laws of the Western Australia and the Commonwealth of Australia.

 

    16

 

 

28 PROVISIONS SPECIFIC TO UNITED STATES

 

Applicable Laws and Persons

 

28.1 This Plan is provided by the Company and not by any of its indirect US subsidiaries (including any corporation that is a subsidiary corporation for purposes of Section 424(f) of the Code).

 

28.2 Any Performance Rights, Options, and Shares granted to an Eligible Employee residing in the U.S. are subject to the applicable provisions of the Code and this clause 28.

 

General Provisions

 

28.3 If the provisions for vesting of Performance Rights or Options, as applicable, are satisfied, the issue of the Shares must not occur later than March 15 of the year following the year in which the Performance Right or Option vests. Such Shares shall be issued subject to any conditions imposed by ASX.

 

28.4 Until the Shares for Performance Rights or Options, as applicable, are issued to the Participant, the Participant shall have no rights as a Shareholder.

 

28.5 In connection with the issuance of Shares and upon the exercise of any Performance Right or Option hereunder, the Participant agrees to execute any and all documents required to be executed by Applicable Law, the Company, and/or the Company’s Constitution.

 

28.6 No Performance Right or Option shall be transferable by the Participant other than by will or by the laws of descent and distribution. Performance Rights and Options issued hereunder may be exercised during the lifetime of the Participant by the Participant only. For the purposes of clarification and the avoidance, of doubt, notwithstanding anything to the contrary in clause 11 of this Plan or otherwise, the Participant is not permitted and shall not attempt to nominate a Related Party to accept any Offer of Performance Rights or Options to such Participant. The transfer of Performance Rights and Options is further limited as set forth in this Plan and any Notice of Exercise.

 

28.7 The terms of the Performance Rights, Options, and Shares shall be final, conclusive and binding upon the beneficiaries, executors, administrators, heirs and successors of the Participant.

 

Certain Provisions Relating to the Grant of Incentive Stock Options and Non-Qualified Stock Options

 

28.8 The Company may grant to the Participant Incentive Stock Options (ISOs) or Non-Qualified Stock Options (NQSOs). If the Options are designated as ISOs in an Offer to the Participant, to the extent the aggregate fair market value (determined as of the time of grant) of Shares with respect to which such ISOs are exercisable for the first time by the Participant during any calendar year under the Plan and/or any other stock option plan of the Company or any of subsidiary or parent thereof exceeds $100,000, such ISOs shall be treated as NQSOs.

 

28.9 Moreover, if for any reason an Option (or portion thereof) shall not qualify as an ISO, then, to the extent of such non-qualification, such Option (or portion thereof) shall be regarded as an NQSO granted under the Plan. In no event shall the Plan Administrator, the Company, any parent, subsidiary, affiliate, or any of their respective employees, directors, members, managers, shareholders, agents, consultants, independent contractors, or other service providers have any liability to the Participant (or any other person) due to the failure of the Options to qualify for any reason as ISOs.
    17

 


28.10 Subject to clause 28.11 below, the Options may be exercised in whole or in part once vested at any time for a period of ten (10) years from the Grant Date, unless otherwise explicitly stated in the Offer; provided, however, that in the case of an ISO granted to a Ten Percent Shareholder, the Term of such ISO shall not exceed (5) years from the Grant Date. The Grant Date, the dates at which the Options vest, and the dates at which they are exercisable shall be set out in the Offer.

 

28.11 The Options shall terminate as set forth in the Plan.

 

Taxes

 

28.12 At the sole discretion of the Board, upon the vesting of a Performance Right or Option, the Participant shall make arrangements to pay an amount equal to the applicable withholding taxes imposed under the Code and applicable state and local laws of the U.S. by either making payment to the Company prior to the issuance of the Shares as an express condition thereto or through payroll withholding after the issuance of the Shares. Notwithstanding the foregoing, the Company and/or its affiliates, parent, or subsidiaries may make such alternative provisions and take such alternative steps as it/they may deem necessary or appropriate for the withholding of all taxes required by applicable U.S. federal, state, or local law to be withheld by (i) deducting the amount so required to be withheld from any other amount then or thereafter payable to the Participant and/or (ii) by causing the exercise and sale of any Performance Right, Options or Shares held on behalf of the Participant to cover such liability up to the amount required to satisfy minimum statutory withholding requirements. In addition, the Participant will be pay any amount, including penalties, that exceeds the tax to be withheld and transferred to the tax authorities, pursuant to applicable tax laws and regulations.

 

28.13 The Company’s rights in clause 28.12 shall not relieve the Participant of the Participant’s obligation to make satisfactory arrangements for satisfaction of withholding obligations as they become due. The ultimate responsibility and liability for any and all taxes belongs to and shall remain with the Participant, and any tax consequences arising from the grant or exercise of any Performance Right or Option, from the payment of Shares covered thereby, or from any other event or act relating to the Performance Rights, Options, or Shares issued upon exercise thereof, shall be borne solely by the Participant. The Company makes no representations or undertaking regarding the tax treatment of any grant, issuance or exercise of any Performance Rights, Options, or Shares.

 

28.14 The Participant agrees to indemnify the Company and/or its affiliates, parent, subsidiaries, and any Related Body Corporate and hold them harmless against and from all liability for any taxes due under this clause 28 or interest or penalty thereon, including without limitation, liabilities relating to the necessity to withhold, or to have withheld, any such tax from any payment made to the Participant for which the Participant is responsible.

 

28.15 It is the intent of the Company that the Performance Rights issued hereunder be exempt from Code Section 409A as short term deferrals and that the Participant’s right to the Performance Rights be subject to the short-term deferral exception. The Company reserves the right to amend the Plan from time to time and at any time to ensure compliance with Code Section 409A. No payment hereunder shall be accelerated, delayed or substituted with another payment nor have vesting accelerated to the extent such change in the rights granted hereunder cause the Performance Rights to fail to be exempt from Code Section 409A. Further, any distribution subject to Code Section 409A to a “specified employee” may be delayed as required by Code Section 409A.

 

    18

 

 

Notice of Disqualifying Disposition of ISO Shares

 

28.16 If an Option granted to the Participant hereunder is an ISO, and if Participant sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the latter of (i) the date two (2) years after the Grant Date or (ii) the date one (1) year after the date of exercise, Participant shall immediately notify the Company in writing of such disposition. Participant agrees that Participant may be subject to income tax withholding by the Company on the compensation income recognized by the Participant.

 

U.S. Securities Laws

 

28.17 The grant of the Performance Rights and Options and any issuance of Shares following vesting shall be in accordance with registration requirements of U.S. federal and state securities law, or shal1be in accordance with an exemption from those registration requirements. Shares shall not be issued pursuant to the exercise of a Performance Right or an Option unless the exercise of such Option and the issuance and delivery of such shares complies with U.S. federal and state securities laws and any other Applicable Law and shall be further subject to the approval of counsel for the Company with respect to such compliance. The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by Company’s counsel to be necessary to the lawful issuance and sale of any Shares hereunder, shall relieve the Company of any liability with respect of the failure to issue or sell such Shares as to which requisite authority shall not have been obtained.

 

28.18 Transferability of such Performance Rights and Options and of the Shares is subject to restrictions imposed by the applicable Performance Right or Option terms, applicable U.S. federal and state (and other) securities law, and one or more restrictive legends will be placed on the share certificates. Such restrictive legends shall indicate that the Shares were granted pursuant to this Plan and that transfer of such Shares is subject to the limitations of this Plan and the terms and provisions hereof governing Performance Rights or Options, as applicable. Participant hereby agrees to strictly adhere to the Company’s written guidelines for converting his or her Shares to American depository receipts prior to attempting to transfer, resell, trade, or otherwise dispose of such Shares via a U.S.-based stock exchange.

 

Data Privacy

 

28.19 Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of the Participant’s personal data as described in this Agreement and any other Performance Right or Option grant materials by and among, as applicable, the Company and its parent, subsidiaries and affiliates for the purpose of implementing, administering and managing the Participant’s participation in the Plan. Participant understands that the Company may hold certain personal information about the Participant, including, but not limited to, Participant’s name, home address and telephone number, date of birth, social security (insurance) number or other identification number, salary, nationality, job title, any shares of stock or directorships held in the Company, details of all options or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor, for the purpose of implementing, administering and managing the Plan (the “Data”). Participant understands that Data may be transferred to any third parties assisting the Company with the implementation, administration and management of the Plan. Participant understands that the recipients of the Data may be located in Australia, the U.S. or elsewhere, and that the recipient’s country may have different data privacy laws and protections than Participant’s country. Participant hereby authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purpose of implementing, administering and managing Participant’s participation in the Plan, including any transfer of such Data as may be necessary or appropriate to a broker, escrow agent or other third party with whom the Shares acquired upon exercise of the Performance Rights or Options may be deposited.

 

    19

 

 

29 Definitions and interpretation

 

Definitions

 

29.1 In these Rules, unless the context otherwise requires, the following terms and expressions will have the following meanings:

 

Applicable Law means any one or more or all, as the context requires of:

 

(a) the Corporations Act;

 

(b) the Listing Rules (as applicable) or the rules of a foreign stock exchange which the Company is listed;

 

(c) the Constitution;

 

(d) the Income Tax Assessment Act 1936 (Cth) and the Income Tax Assessment Act 1997 (Cth), each as amended from time to time;

 

(e) the Code and any regulations thereunder (as applicable);

 

(f) U.S. federal or state securities laws and other laws (as applicable);

 

(g) any practice note, policy statement, regulatory guide, class order, declaration, guideline, policy, procedure, ruling, judicial interpretation or other guidance note made to clarify, expand or amend paragraphs (a), (b), and (d) above; and

 

(h) any other legal requirement that applies to the Plan.

 

Application means an application by an Eligible Employee to participate in the Plan made in response to an Offer substantially in the form set out in Schedules 3 or 4 (as applicable) or any other form as determined by the Board.

 

ASIC means the Australian Securities and Investments Commission.

 

ASX means ASX Limited (ABN 98 008 624 691) or, the context permits, the Australian Securities Exchange operated by ASX Limited.

 

Bad Leaver means, unless otherwise determined by the Board in its sole and absolute discretion, a Participant who ceases employment or office with the Company or a Group Member, including (but not limited to) for any of the circumstances described in clause 14.1.

 

Board means the board of directors of the Company, a committee appointed by the board of directors of the Company as constituted from time to time, or any person who is provided with delegated authority by the board from time to time.

 

    20

 

 

Buy-Back means the buy-back by the Company of Employee Incentives, pursuant to clause 15, and Bought-Back has a similar meaning.

 

Buy-Back Period means, with respect to any Employee Incentive and any Participant, the period of 90 days from the date that the right to Buy-Back arises under clause 15.1 of the Plan.

 

Buy-Back Price means the price at which the Employee Incentives are to be Bought-Back as determined under clause 16.1.

 

Code means the U.S. Internal Revenue Code of 1986, as amended.

 

Company means IperionX Limited (ACN 618 935 372).

 

Control has the meaning given in Section 50AA of the Corporations Act and Controlled has a corresponding meaning.

 

Constitution means the constitution of the Company, as amended from time to time.

 

Corporations Act means the Corporations Act 2001 (Cth), as amended from time to time.

 

Data has the meaning given to that term in clause 28.19.

 

Director means a director of the Company, or any member of the Group.

 

Eligible Employee means:

 

(a) Directors (excluding non-executive Directors) and Employees who are declared by the Board in its sole and absolute discretion to be eligible to receive grants of Employee Incentives under the Plan; or

 

(b) any other person who is declared by the Board in its sole and absolute discretion to be eligible to receive grants of Employee Incentives,

 

under the Plan.

 

Employee means an employee or other consultant or contractor of the Company, or any member of the Group.

 

Employee Incentive means any:

 

(a) Option or Performance Right granted; or

 

(b) Share(s) issued pursuant to the exercise of an Option or conversion of a Performance Rights,

 

under this Plan.

 

Exercise Period means the period up to the Expiry Date during which a vested Option may be exercised, and as determined by the Board.

 

Exercise Price means the exercise price payable (if any) by a Participant to acquire a Share upon the exercise of an Option as specified by the Board in the Offer in its sole and absolute discretion.

 

    21

 

 

Expiry Date means the date determined by the Board and as specified in the Offer with respect to those Options or Performance Rights, after which those Options or Performance Rights lapse and, in the case of Options, may no longer be exercised.

 

Fee means any fee payable by a Participant on the grant of Employee Incentives, and as determined by the Board in its sole and absolute discretion.

 

Former Participant means a Participant who ceases to be an Employee.

 

Good Leaver means a Participant who ceases employment or office with the Company or a Group Member and is determined by the Board to be a Good Leaver.

 

Grant Date means the date on which Employee Incentives are granted to a Participant following the acceptance of an Application.

 

Group means the Company and its Related Bodies Corporate.

 

Incentive Stock Option or ISO shall mean an Option issued hereunder to an Eligible Employee that is intended to be an “incentive stock option” within the meaning of Code Section 422.

 

Liquidity Event means:

 

(a) a sale of all of the ordinary shares in the Company; or

 

(b) a sale of all or substantially all of the assets of the Company.

 

Listing Rules means the listing rules, market rules or operating rules of a financial market in respect of which the Company's shares are quoted or are the subject of an application for quotation, including but not limited to, the official listing rules of the ASX (as relevant).

 

Non-Qualified Stock Option or NQSO means an Option not described in Code Sections 422(b) or 423(b), or which, by its terms, does not qualify or is not intended to qualify as an Incentive Stock Option.

 

Nominated Beneficiary means:

 

(a) if a Participant has included a nominated beneficiary in their Offer Letter, the person nominated by the Participant in their Offer Letter; or

 

(b) if a Participant has not included a nominated beneficiary in their Offer Letter, then the Participant's beneficiary, personal representative or successor in title.

 

Notice of Exercise means a notice of exercise of Options in the form determined by the Board from time to time.

 

Offer means an offer to an Eligible Employee to apply for the grant of Employee Incentives under the Plan, in each case substantially in the form set out in Schedules 3 or 4 (as applicable) to this Plan.

 

Offer Conditions has the meaning given to that term in clause 4.4.2.

 

Offer Letter means a letter containing an Offer to an Eligible Employee that sets out the terms and conditions of the Offer, substantially in the form set out in Schedules 3 or 4 (as applicable).

 

    22

 


 

Option means an option granted under this Plan to subscribe for, acquire and/or be allocated (as determined by the Board in its sole and absolute discretion) one Share subject to the Rules and terms and conditions in Schedule 1.

 

Participant means an Eligible Employee who has been offered Employee Incentives and who has returned a corresponding Application to the Company that has been accepted by the Company pursuant to these Rules, or, as applicable, that Eligible Employee's Related Party nominated in accordance with clause 11.

 

Performance Criteria means any performance requirements (as specified in the Offer Letter and determined by the Board in its sole and absolute discretion) which must be met prior to the vesting of an Employee Incentive.

 

Performance Period means the period in which the Performance Criteria must be satisfied in respect of an Employee Incentive.

 

Performance Right means a right granted under this Plan to be issued one Share subject to the Rules and the terms and conditions in Schedule 2.

 

Plan means the employee incentive plan as administered in accordance with these Rules.

 

Plan Administrator means a person or entity appointed to administer the Plan.

 

Related Body Corporate has the meaning given in section 9 of the Corporations Act.

 

Related Party in relation to an Eligible Employee means:

 

(a) a trustee of a trust, in respect of which the Eligible Employee is the trustee or the Eligible Employee Controls a body corporate which is the trustee; or

 

(b) a body corporate Controlled by such Eligible Employee; or

 

(c) any other person deemed a related party by the Board.

 

Relevant Interest has the meaning given to that term under section 9 of the Corporations Act.

 

Rules means these rules in respect of the operation of the Plan, as amended from time to time.

 

SEC means the U.S. Securities and Exchange Commission.

 

Securities Act means the U.S. Securities Act of 1933, as amended.

 

Security Interest means a mortgage, charge, pledge, lien, encumbrance or other third party interest of any nature.

 

Share means a fully paid ordinary share in the capital of the Company, including those issued pursuant to Performance Rights or Options hereunder.

 

Share Trading Policy means any Company share trading policy as amended from time to time.

 

Shareholder means any holder of a Share.

 

Special Circumstances means any of the following:

 

(a) the death of the Participant; or

 

    23

 


 

(b) the total and permanent disablement of the Participant such that the Participant is unlikely ever to engage in any occupation for which the Participant is reasonably qualified by education, training or experience.

 

Takeover Bid has the meaning given to that term under section 9 of the Corporations Act.

 

Ten Percent Shareholder means any Participant who owns more than ten percent (10%) of the combined voting power of all classes of stock of the Company, within the meaning of Code Section 422.

 

Term means the period commencing on the Grant Date and ending on the Expiry Date (inclusive).

 

Transfer has the meaning given to that term in the Constitution.

 

Vesting Conditions means any time based requirement or condition (as specified in the Offer and determined by the Board in its sole and absolute discretion) which must be met prior to Employee Incentives (as applicable) vesting in a Participant.

 

Vesting Notification means a notice to a Participant informing the Participant that the Participant's Employee Incentives have vested and are exercisable (if applicable).

 

Interpretation

 

29.2 In these Rules, unless otherwise stated or the contrary intention appears:

 

29.2.1 the singular includes the plural and vice versa;

 

29.2.2 a gender includes all genders;

 

29.2.3 a reference to any legislation includes any modification or replacement of it and all regulations and statutory instruments issued under it and a reference to any provision of any legislation includes any modification or substitution of it;

 

29.2.4 a reference to these Rules means these Rules as amended from time to time and includes all recitals, annexures, addendums and schedules to these Rules;

 

29.2.5 a reference to a person includes a reference to the person's executors, administrators and successors or a body corporate including any person taking by way of novation and, in the case of a trustee, includes any substituted or additional trustee; and

 

29.2.6 in these Rules any reference to include means to include without limitation.

 

29.3 In the event of any inconsistency between the terms of an Offer, Options, Performance Rights or the Rules, the terms of the relevant Employee Incentive will be interpreted in the following priority:

 

29.3.1 the terms of the Offer;

 

29.3.2 the terms of the Options in Schedule 1 or the terms of the Performance Rights in Schedule 2 (as applicable); and

 

29.3.3 the Rules.

 

    24

 

 

Applicable Laws

 

29.4 These Rules, the offering and granting of any Options, the issuing and/or transferring of any Shares, including Shares, and the rights attaching to or interests in the Options and Shares, including Shares, will at all times be subject to all Applicable Laws.

 

Share Trading Policy

 

29.5 A Participant must comply with any Share Trading Policy at all times.

 

Rounding

 

29.6 Where any calculation or adjustment to be made pursuant to these Rules produces a fraction of a cent or a fraction of an Option or a Share, the fraction will be eliminated by rounding to the nearest whole number.

 

Headings

 

29.7 Headings are inserted in these Rules for convenience only and do not affect the interpretation of these Rules.

 

Constitution

 

29.8 The entitlements of Eligible Employees and Participants under these Rules are subject to the Constitution.

 

29.9 In the event of any inconsistency between these Rules and either of the Constitution, the terms of the Constitution will prevail to the extent of that inconsistency.

 

    25

 


 

SCHEDULE 1: terms and conditions of options

 

Entitlement

 

1.1 Subject to the Board determining otherwise prior to an Offer, each vested Option entitles the Participant holding the Option to subscribe for, or to be transferred, one Share on payment of the Exercise Price (if any).

 

Exercise Period

 

1.2 The Exercise Period and Expiry Date for Options will be as determined by the Board in its sole and absolute discretion.

 

1.3 If the Participant is prohibited from exercising vested Options under Applicable Law on or in the ten (10) business days before the Expiry Date, the Expiry Date for the Options is automatically extended to the date that is five (5) business days after the Participant is no longer prohibited under Applicable Law from exercising the Option.

 

Conditions for Vesting and Exercise

 

1.4 The Board will determine prior to an Offer being made and specify in the Offer any Performance Criteria and/or Vesting Conditions attaching to the Options.

 

1.5 Options will only vest and be exercisable if the applicable Performance Criteria and/or Vesting Conditions (if any) have been satisfied, waived by the Board, or are deemed to have been satisfied under these Rules.

 

1.6 In the event of a Liquidity Event, the Board in its absolute discretion may waive any vesting or exercise criteria in respect of some or all Options held by a Participant.

 

Method of Exercise

 

1.7 Following the issuing of a Vesting Notification to the Participant, the Option is exercisable by the Participant within the Exercise Period specified by the Board in the Offer, subject to the Participant delivering to the registered office of the Company or such other address as determined by the Board of:

 

1.7.1 a signed Notice of Exercise; and

 

1.7.2 subject to the cashless exercise option, a cheque or cash or such other form of payment determined by the Board in its sole and absolute discretion as satisfactory for the amount of the Exercise Price (if any).

 

No Issue Unless Cleared Funds

 

1.8 Where a cheque is presented as payment of the Exercise Price on the exercise of Options, the Company will not, unless otherwise determined by the Board, allot and issue or transfer Shares until after any cheque delivered in payment of the Exercise Price has been cleared by the banking system.

 

Cashless Exercise of Options

 

1.9 Subject to clause 1.10, a Participant may elect to pay the Exercise Price for each Option by setting off the total Exercise Price against the number of Shares which they are entitled to receive upon exercise (Cashless Exercise Facility). By using the Cashless Exercise Facility, the holder will receive Shares to the value of the surplus after the Exercise Price has been set off.

 

    26

 

 

1.10 If the Participant elects to use the Cashless Exercise Facility, the Participant will only be issued that number of Shares (rounded down to the nearest whole number) as is equal in value to the difference between the total Exercise Price otherwise payable for the Options on the Options being exercised and the then market value of the Shares at the time of exercise calculated in accordance with the following formula:

 

S = O x (MSP - EP)

MSP

 

Where:

 

S = Number of Shares to be issued on exercise of the Options

 

O = Number the Options being exercised

 

MSP = Market value of the Shares calculated using the volume weighted average of the Shares on ASX for the 5 trading days immediately prior to (and excluding) the date of the Notice of Exercise

 

EP = Exercise Price

 

1.11 If the difference between the total Exercise Price otherwise payable for the Options on the Options being exercised and the then market value of the Shares at the time of exercise (calculated in accordance with clause 1.10) is zero or negative, then a Participant will not be entitled to use the Cashless Exercise Facility.

 

Minimum Exercise

 

1.12 Options must be exercised in multiples of one hundred (100) unless fewer than one hundred (100) Options are held by a Participant or the Board otherwise agrees.

 

Actions on Exercise

 

1.13 Following the exercise of Options:

 

1.13.1 the Options will automatically lapse; and

 

1.13.2 the Company will allot and issue, or transfer, the number of Shares for which the Participant is entitled to subscribe for or acquire through the exercise of the Options.

 

Timing of the Issue of Shares on Exercise and Quotation

 

1.14 The Company must within twenty (20) business days after the later of the following:

 

1.14.1 receipt of a Notice of Exercise given in accordance with these terms and conditions and payment of the Exercise Price for each Option being exercised; and

 

1.14.2 when excluded information in respect of the Company (as defined in section 708A(7) of the Corporations Act) (if any) ceases to be excluded information. If there is no such information, the relevant date will be the date of receipt of a Notice of Exercise as detailed in clause 1.14.1 above,

 

    27

 

 

the Company will:

 

1.14.3 allot and issue the Shares pursuant to the exercise of the Options;

 

1.14.4 as soon as reasonably practicable and if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and

 

1.14.5 apply for official quotation on ASX of Shares issued pursuant to the exercise of the Options.

 

1.15 Notwithstanding clause 1.14 above, solely with respect to Participants who are not U.S. residents or to the extent such does not otherwise violate Code Section 409A, the Company’s obligation to issue such Shares shall be postponed if such Participant at any time after the delivery of a Notice of Exercise and payment of the Exercise Price for each Option being exercised (if applicable) elects for the Shares to be issued to be subject to a holding lock for a period of twelve (12) months. Following any such election:

 

1.15.1 the Shares to be issued or transferred will be held by such Participant on the Company's issuer sponsored sub-register (and not in a CHESS sponsored holding);

 

1.15.2 the Company will apply a holding lock on the Shares to be issued or transferred and such Participant is taken to have agreed to that application of that holding lock;

 

1.16 the Company shall release the holding lock on the Shares on the earlier to occur of:

 

1.16.1 the date that is twelve (12) months from the date of issue of the Share; or

 

1.16.2 the date the Company issues a disclosure document that qualifies the Shares for trading in accordance with section 708A(11) of the Corporations Act; or

 

1.16.3 the date a transfer of the Shares occurs pursuant to clause 1.17 of these terms and conditions; and

 

1.17 Shares shall be transferable by such Participant and the holding lock will be lifted provided that the transfer of the Share complies with section 707(3) of the Corporations Act and, if requested by the Company, the transferee of the Shares agrees by way of a deed poll in favour of the Company to the holding lock applying to the Shares following its transfer for the balance of the period in clause 1.16.1.

 

Shares Issued on Exercise

 

1.18 Shares issued on the exercise of the Options rank equally with all existing Shares, including those Shares issued, directly, under the Plan.

 

    28

 

 

Quotation of the Shares Issued on Exercise

 

1.19 If admitted to the official list of ASX at the time, application will be made by the Company to ASX for quotation of the Shares issued upon the exercise of the Options.

 

Adjustment for Reorganisation

 

1.20 Subject to any Applicable Laws, the number of Options held by a Participant under the Plan may, in the sole and absolute discretion of the Board, be determined to be such number as is appropriate and so that the Participant does not suffer any material detriment following any variation in the share capital of the Company arising from:

 

1.20.1 a reduction, subdivision or consolidation of share capital;

 

1.20.2 a reorganisation of share capital;

 

1.20.3 a distribution of assets in specie;

 

1.20.4 the payment of a dividend, otherwise than in the ordinary course, of an amount substantially in excess of the Company's normal distribution policy; or

 

1.20.5 any issue of ordinary shares or other equity securities or instruments which convert into ordinary shares by way of capitalisation of profits or reserves.

 

1.21 Upon any adjustment being made, the Board will notify each Participant (or his or her legal personal representative where applicable) in writing, informing them of the number of Options held by the relevant Participant.

 

1.22 If there is any reorganisation of the issued share capital of the Company, the terms of Options and the rights of the Participant who holds such Options will be varied, including an adjustment to the number of Options and/or the Exercise Price (if any) applicable to Options, in accordance with the Listing Rules that apply to the reorganisation at the time of the reorganisation.

 

Participant in New Issues and Other Rights

 

1.23 A Participant who holds Options is not entitled to:

 

1.23.1 notice of, or to vote or attend at, a meeting of the Shareholders;

 

1.23.2 receive any dividends declared by the Company; or

 

1.23.3 participate in any new issues of securities offered to Shareholders during the term of the Options,

 

unless and until the Options are exercised and the Participant holds Shares.

 

Adjustment for Rights Issue

 

1.24 If the Company makes an issue of Shares pro rata to existing Shareholders (other than an issue in lieu of in satisfaction of dividends or by way of dividend reinvestment) the Exercise Price of an Option will be reduced according to the following formula:

 

New exercise price = O - (E[P-(S+D)] divided by N+1)

    29

 

 

O = the old Exercise Price of the Option.

 

E = the number of underlying Shares into which one Option is exercisable.

 

P = average market price per Share weighted by reference to volume of the underlying Shares during the five (5) trading days ending on the day before the ex rights date or ex entitlements date.

 

S = the subscription price of a Share under the pro rata issue.

 

D = the dividend due but not yet paid on the existing underlying Shares (except those to be issued under the pro rata issue).

 

N = the number of Shares with rights or entitlements that must be held to receive a right to one new share.

 

Adjustment for Bonus Issue of Shares

 

1.25 If the Company makes a bonus issue of Shares or other securities to existing Shareholders (other than an issue in lieu or in satisfaction, of dividends or by way of dividend reinvestment):

 

1.25.1 the number of Shares which must be issued on the exercise of an Option will be increased by the number of Shares which the Participant would have received if the Participant had exercised the Option before the record date for the bonus issue; and

 

1.25.2 no change will be made to the Exercise Price.

 

Change of Control

 

1.26 For the purposes of these terms and conditions, a "Change of Control Event" occurs if:

 

1.26.1 the Company announces that its Shareholders have at a Court convened meeting of Shareholders voted in favour, by the necessary majority, of a proposed scheme of arrangement (excluding a merger by way of scheme of arrangement for the purposes of a corporate restructure (including change of domicile, or any reconstruction, consolidation, sub-division, reduction or return) of the issued capital of the Company) and the Court, by order, approves the scheme of arrangement;

 

1.26.2 a Takeover Bid:

 

1.26.2.1 is announced;

 

1.26.2.2 has become unconditional; and

 

1.26.2.3 the person making the Takeover Bid has a Relevant Interest in fifty percent (50%) or more of the issued Shares;

 

1.26.3 any person acquires a Relevant Interest in fifty and one-tenth percent (50.1%) or more of the issued Shares by any other means; or

  

1.26.4 the announcement by the Company that a sale or transfer (in one transaction or a series of related transactions) of the whole or substantially the whole of the undertaking and business of the Company has been completed.

 

    30

 

 

1.27 Where a Change of Control Event has (i) occurred or (ii) been announced by the Company and, in the opinion of the Board, will or is likely to occur:

 

1.27.1 a Participant may exercise any or all of their Options, regardless of whether the Vesting Conditions have been satisfied, provided that no Option will be capable of exercise later than the Expiry Date; and

 

1.27.2 if the Board has procured an offer for all holders of Options on like terms (having regard to the nature and value of the Options) to the terms proposed under the Change in Control Event and the Board has specified (in its absolute discretion) a period during which the holders of Options may elect to accept the offer and, if the holder has not so elected at the end of that offer period, the Options, if not exercised within 10 days of the end of that offer period, shall expire.

 

Quotation

 

1.28 The Company will not seek official quotation of any Options.

 

No Transfer of Options

 

1.29 Options granted under this Plan may not be assigned, transferred, encumbered with a Security Interest in or over them, or otherwise disposed of by a Participant, unless:

 

1.29.1 the prior consent of the Board is obtained, which consent may impose such terms and conditions on such assignment, transfer, encumbrance with a Security Interest or disposal as the Board sees fit; or

 

1.29.2 such assignment or transfer occurs by force of law upon the death or total and permanent disablement of a Participant to the Participant's legal personal representative.

 

Options to be Recorded

 

1.30 Options will be recorded in the appropriate register of the Company.

 

Rules

 

1.31 The Options are issued under and in accordance with the Plan and the terms and conditions of these Options are subject to the Rules.

 

Options Granted to Eligible Employees Residing in the U.S.

 

1.32 With respect to Options granted to Eligible Employees residing in the U.S, clause 28 of the Plan shall apply, notwithstanding anything to the contrary herein or in clause 28.3 of the Plan, to the extent that there is any inconsistency between this Schedule 1 and the terms, conditions, and provisions hereof and clause 28, the latter will prevail.

 

    31

 

 

SCHEDULE 2: terms and conditions of performance rights

 

Offer of Performance Rights

 

1.1 The Board may offer Performance Rights to any Participant in its sole discretion. Each Performance Right confers an entitlement to be provided with one Share, credited as fully paid, at no cost, upon the full satisfaction of the Performance Criteria and/or Vesting Conditions specified by the Board in relation to that Performance Right.

 

Performance Criteria/Vesting Conditions and Variation to Performance Criteria//Vesting Conditions

 

1.2 The Board will determine prior to an Offer being made and specify in the Offer any Performance Criteria, Vesting Conditions, Performance Period or Expiry Date attaching to the Performance Rights.

 

1.3 Performance Rights will only vest and entitle the Participant to be issued Shares if the applicable Performance Criteria and/or Vesting Conditions (if any) have been satisfied prior to the end of the Performance Period, waived by the Board, or are deemed to have been satisfied under these Rules.

 

Satisfaction of Performance Criteria

 

1.4 The Board will determine in its sole discretion whether (and, where applicable, to what extent) the Participant has satisfied the Performance Criteria and/or Vesting Conditions (if any) applicable to the Performance Rights at the end of the Performance Period. As soon as practicable after making that determination the Board must allot and issue, or transfer, the number of Shares for which the Participant is entitled to acquire upon satisfaction of the Performance Criteria and/or Vesting Conditions for the relevant number of Performance Rights held in accordance with clause 1.6.

 

Lapse of Performance Rights

 

1.5 Where Performance Rights have not satisfied the Performance Criteria within the Performance Period or Expiry Date (whichever occurs earlier) those Performance Rights will automatically lapse.

 

Timing of the Issue of Shares and Quotation

 

1.6 The Company must within twenty (20) business days after the later of the following:

 

1.6.1 the satisfaction of the Performance Criteria and/or Vesting Conditions (if any) applicable to the Performance Rights; and

 

1.6.2 when excluded information in respect of the Company (as defined in section 708A(7) of the Corporations Act) (if any) ceases to be excluded information. If there is no such information, the relevant date will be the date the relevant Performance Criteria and/or Vesting Conditions are satisfied pursuant to clause 1.4,

 

the Company will:

 

1.6.3 allot and issue the Shares pursuant to the vesting of the Performance Rights;

 

    32

 

 

1.6.4 as soon as reasonably practicable and if required, give ASX a notice that complies with section 708A(5)(e) of the Corporations Act, or, if the Company is unable to issue such a notice, lodge with ASIC a prospectus prepared in accordance with the Corporations Act and do all such things necessary to satisfy section 708A(11) of the Corporations Act to ensure that an offer for sale of the Shares does not require disclosure to investors; and

 

1.6.5 apply for official quotation on ASX of Shares issued pursuant to the vesting of the Performance Rights.

 

1.7 Notwithstanding clause 1.6 above, solely with respect to Participants who are not U.S. residents or to the extent such does not otherwise violate Code Section 409A, the Company’s obligation to issue such Shares shall be postponed if such Participant at any time after the relevant Performance Criteria and/or Vesting Conditions are satisfied pursuant to clause 1.4 elects for the Shares to be issued to be subject to a holding lock for a period of twelve (12) months. Following any such election:

 

1.7.1 the Shares to be issued or transferred will be held by such Participant on the Company's issuer sponsored sub-register (and not in a CHESS sponsored holding);

 

1.7.2 the Company will apply a holding lock on the Shares to be issued or transferred and such Participant is taken to have agreed to that application of that holding lock;

 

1.7.3 the Company shall release the holding lock on the Shares on the earlier to occur of:

 

1.7.3.1 the date that is twelve (12) months from the date of issue of the Share; or

 

1.7.3.2 the date the Company issues a disclosure document that qualifies the Shares for trading in accordance with section 708A(11) of the Corporations Act; or

 

1.7.3.3 the date a transfer of the Shares occurs pursuant to clause 1.7.4 of these terms and conditions; and

 

1.7.4 Shares shall be transferable by such Participant and the holding lock will be lifted provided that the transfer of the Share complies with section 707(3) of the Corporations Act and, if requested by the Company, the transferee of the Shares agrees by way of a deed poll in favour of the Company to the holding lock applying to the Shares following its transfer for the balance of the period in clause 1.7.3.1.

 

Shares Issued

 

1.8 Shares issued on the satisfaction of the Performance Criteria and/or Vesting Conditions attaching to the Performance Rights rank equally with all existing Shares, including those Shares issued, directly, under the Plan.

 

Quotation of the Shares Issued on Exercise

 

1.9 If admitted to the official list of ASX at the time, application will be made by the Company to ASX for quotation of the Shares issued upon the vesting of the Performance Rights.
    33

 


 

Reorganisation

 

1.10 If there is any reorganisation of the issued share capital of the Company, the terms of Performance Rights and the rights of the Participant who holds such Performance Rights will be varied, including an adjustment to the number of Performance Rights, in accordance with the Listing Rules that apply to the reorganisation at the time of the reorganisation.

 

Participant Rights

 

1.11 A Participant who holds Performance Rights is not entitled to:

 

1.11.1 notice of, or to vote or attend at, a meeting of the Shareholders; or

 

1.11.2 receive any dividends declared by the Company,

 

1.11.3 participate in any new issues of securities offered to Shareholders during the term of the Performance Rights, or

 

1.11.4 cash for the Performance Rights or any right to participate in surplus assets of profits of the Company on winding up,

 

unless and until the Performance Rights are satisfied and the Participant holds Shares.

 

Pro Rata Issue of Securities

 

1.12 If during the term of any Performance Right, the Company makes a pro rata issue of securities to the Shareholders by way of a rights issue, a Participant shall not be entitled to participate in the rights issue in respect of any Performance Rights, only in respect of Shares issued in respect of vested Performance Rights.

 

1.13 A Participant will not be entitled to any adjustment to the number of Shares they are entitled to or adjustment to any Performance Criteria and/or Vesting Conditions which is based, in whole or in part, upon the Company’s share price, as a result of the Company undertaking a rights issue.

 

Adjustment for Bonus Issue

 

1.14 If, during the term of any Performance Right, securities are issued pro rata to Shareholders generally by way of bonus issue, the number of Shares to which the Participant is then entitled, shall be increased by that number of securities which the Participant would have been issued if the Performance Rights then held by the Participant were vested immediately prior to the record date for the bonus issue.

 

Change of Control

 

1.15 For the purposes of these terms and conditions, a "Change of Control Event" occurs if:

 

1.15.1 the Company announces that its Shareholders have at a Court convened meeting of Shareholders voted in favour, by the necessary majority, of a proposed scheme of arrangement (excluding a merger by way of scheme of arrangement for the purposes of a corporate restructure (including change of domicile, or any reconstruction, consolidation, sub-division, reduction or return) of the issued capital of the Company) and the Court, by order, approves the scheme of arrangement;

  

1.15.2 a Takeover Bid:

 

    34

 

 

1.15.2.1 is announced;

 

1.15.2.2 has become unconditional; and

 

1.15.2.3 the person making the Takeover Bid has a Relevant Interest in fifty percent (50%) or more of the issued Shares;

 

1.15.3 any person acquires a Relevant Interest in fifty and one-tenths percent (50.1%) or more of the issued Shares by any other means; or

 

1.15.4 the announcement by the Company that a sale or transfer (in one transaction or a series of related transactions) of the whole or substantially the whole of the undertaking and business of the Company has been completed.

 

1.16 Where a Change of Control Event has (i) occurred or (ii) been announced by the Company and, in the opinion of the Board, will or is likely to occur, all granted Performance Rights which have not yet vested or lapsed shall automatically and immediately vest, regardless of whether any Performance Criteria or Vesting Conditions have been satisfied.

 

Quotation

 

1.17 The Company will not seek official quotation of any Performance Rights.

 

Performance Rights Not Property

 

1.18 A Participant's Performance Rights are personal contractual rights granted to the Participant only and do not constitute any form of property.

 

No Transfer of Performance Rights

 

1.19 Unless otherwise determined by the Board, Performance Rights cannot be transferred to or vest in any person other than the Participant.

 

Rules

 

1.20 The Performance Rights are issued under and in accordance with the Plan and the terms and conditions of these Performance Rights are subject to the Rules.

 

Performance Rights Granted to Eligible Employees Residing in the U.S.

 

1.21 With respect to Performance Rights granted to Eligible Employees residing in the U.S, clause 28 of the Plan shall apply, notwithstanding anything to the contrary herein or in clause 28.3 of the Plan, to the extent that there is any inconsistency between this Schedule 2 and the terms, provisions, conditions hereof and clause 28, the latter will prevail.

 

    35

 

 

SCHEDULE 3: PRO-FORMA OFFER LETTER - OPTIONS

 

[date]

 

[insert Participant name]
[insert Participant address]

 

Dear Participant

 

Offer To Participate In IperionX Employee Incentive Plan

 

As you are aware, IperionX Limited (“IperionX”) has established an Employee Incentive Plan (“Plan”).

 

To incentivise people important to the development prospects of IperionX and to ensure the interests and motivations of such key persons are aligned with the interests and motivations of shareholders of IperionX, the Board of IperionX (“Board”) have elected to offer equity to some key individuals.

 

As a key member of the IperionX team, IperionX is delighted to offer you the opportunity to participate in the Plan on the terms set out in this letter (“Offer”) and in accordance with the rules of the Plan and the terms of and conditions of the options as enclosed (“Rules”).

 

The offer means such key persons will have an opportunity to be personally rewarded for developing the business of IperionX.

 

The Grant Date of Employee Incentives issued under the Plan is the date of this Offer Letter.

 

Enclosed is a copy of the Rules. Capitalised terms which are defined in the Rules have the same meaning in this Offer Letter.

 

KEY TERMS OF THE OFFER

 

IperionX is offering you the opportunity to acquire the following unlisted options to subscribe for fully paid ordinary shares in IperionX, subject to the satisfaction of certain Vesting Conditions (“Options”) for no consideration:

 

NUMBER OF

OPTIONS OFFERED

EXERCISE PRICE

OF OPTIONS

VESTING

CONDITIONS

EXPIRY DATE OF

OPTIONS

[insert number of options] [insert exercise price of options] [e.g. 12 months continuous service from the Grant Date] [insert expiry date of options]
[insert number of options] [insert exercise price of options] [e.g. 12 months continuous service from the Grant Date] [insert expiry date of options]

  

The Options will only be issued to you if you continue to be employed or engaged by IperionX or one of its subsidiaries at the Grant Date.

 

    36

 

  

Conversion Rate

 

Upon exercise each Option will convert to one fully paid ordinary share in IperionX.

 

Exercise Period

 

Your vested Options will be exercisable at any time before the Expiry Date.

 

Nominee

 

You may nominate a Related Party to receive the Options in accordance with clause 11 of the Plan. In order to do so, you will need to include the nominee’s details in the attached application (“Application”).

 

Notwithstanding the foregoing, if you are an Eligible Employee residing in the U.S., you cannot nominate a Related Party to receive the Options.

 

Quotation

 

The Options will not be quoted on ASX.

 

Other Terms Applicable to the Offer

 

[insert other applicable terms, if applicable, such as Performance Criteria]

 

For Options Granted to Participants residing in the U.S.: PLEASE BE ADVISED that clause 28 of the Plan applies to you. Before accepting this Offer, please read the terms, provisions, and conditions of clause 28 in full (in addition to and in conjunction with the other terms, provisions, and conditions of the Plan, this Offer, and the Rules). If you have any questions regarding the same, please let me know before accepting this Offer.

 

The other terms and conditions applicable to the Options offered to you are described in Schedule 1 of the Plan.

 

Financial and Taxation Consequences

 

This Offer does not purport to provide all of the information you may require in order to evaluate an investment in the Company. The Company in making the Offer is not giving you any financial, legal, tax or investment advice. You should make your own enquiries and evaluations as you deem necessary of the Offer (including your investment objectives, financial situation, and particular needs), and you should seek all necessary financial, legal, tax and investment advice.

 

In the event the Company does provide you with any advice in relation to Shares, such advice does not take into account your objectives, financial situation and needs.

 

    37

 

 

Risk

 

As with any investment in securities there can be no guarantee that the market value of the Company's shares will not fall in the future. There is also no assurance as to future dividends or distributions since these are dependent on earnings and the financial condition of the Company.

 

Market Price of Shares

 

Before deciding whether to accept the Offer, you should refer to the current market price of the Company's shares, which can be obtained from the financial pages of some daily newspapers, your stockbroker, your financial adviser, or the ASX. The Company will also provide you upon request, within a reasonable time, either verbally or in writing, details of the current market price (in Australian dollars) of the Company's shares.

 

Please note that the market price of the Company's shares may rise or fall between the date of this Offer and the date when the Shares are issued to you upon exercise of the Options.

 

Next Steps

 

If you wish to accept the Offer and apply for Options, you must:

 

· complete, sign and date the enclosed Application; and

 

· return the completed Application to IperionX at [insert address].

 

By delivering the attached application form to IperionX, you agree to be bound by the Rules and the terms of this Offer as a Participant in the Plan, as well as giving the acknowledgments contained in the Application.

 

Upon receipt of the Application, provided you remain employed or engaged by IperionX at that time, IperionX will take steps to issue the Options to you and to provide you with an Options Certificate or holding statement confirming the issue.

 

This Offer must be accepted before 5:00pm [insert time zone] on the date fourteen (14) days after the date of this letter and will expire after that time. Please get in contact with me if you need more time to consider the Offer for any reason and we can discuss.

 

Once again, you are a very important member of the IperionX team and we look forward to your participation in the Plan.

 

Yours sincerely

 

 

[Director of the Company]

 

Encl: Application form
  Plan Rules

 

    38

 

 

IPERIONX INCENTIVE PLAN - OPTIONS

APPLICATION

 

A. INSTRUCTIONS

 

Please provide the application form to IperionX at [insert address]. All capitalised terms not otherwise defined herein have the same meaning given to them in the Plan.

 

B. PERSONAL DETAILS

 

Name:  
   
Address:  

 

Pursuant to this Application (“Application”), I hereby accept the offer of Options offered to me pursuant to a Letter of Offer dated ________________ (“Offer Letter”) under the IperionX Employee Incentive Plan (“Plan”) (please check only one (1) of the following boxes):

 

In full.

 

In respect of ____________________________ Options.

 

C. USE OF NOMINEE (NOTE: YOU MAY NOMINATE A RELATED PARTY TO ACCEPT YOUR OPTIONS ONLY IF YOU ARE NOT A U.S. RESIDENT)

 

Please check only one (1) of the following boxes:

 

I do not wish to nominate another person to accept my Options and apply for them personally in my own name.
   
I wish to nominate ___________________________________________________________________ (Insert full name) of ____________________________________________________________ (Insert address) to accept my Options and attach evidence hereto showing that they are a Related Party.

 

D. NOMINATED BENEFICIARY IN THE EVENT OF DEATH (PLEASE COMPLETE)

 

I wish to nominate ____________________________________________________________________ (Insert full name) of ____________________________________________________________ (Insert address) to receive all of my Options in the event of my death.

 

E. ACKNOWLEDGEMENTS

 

By accepting the Offer and delivering this form to IperionX, I agree and acknowledge:

 

1. the Options are issued pursuant to the Plan and the Rules and I agree to be bound by the Rules and the terms of the Offer as a Participant in the Plan;

 

2. participation in the Plan does not create a right to employment or interfere with the ability to terminate my employment or service relationship (if any), subject to applicable law;

 

    39

 

 

3. the future value of the Options and any Shares is uncertain and the value may increase or decrease in value from time to time;

 

4. any rights acquired under the Plan are an extraordinary item of compensation, which is outside the scope of my employment agreement, if any, and are not part of ordinary compensation or salary for any purpose;

 

5. no claim or entitlement to compensation or damages shall arise from forfeiture of Options under the Plan resulting from my service to IperionX coming to an end for any reason;

 

6. the ultimate liability for all taxes payable in respect of my participation in the Plan and the acquisition and disposal of Options and Shares is and remains my responsibility;

 

7. IperionX may be required by law to provide information about me to tax authorities and I will allow IperionX to provide such information; and

 

8. the Offer Letter provided to me is not financial product advice and I have been advised to consult an independent investment or taxation advisor prior to accepting Options if I have any concerns.

 

F. U.S. ACKNOWLEDGEMENTS (if applicable)

 

I further agree and acknowledge that:

 

9. the Offer Letter, the Options, and the Shares that may be obtained in connection therewith are subject to the terms, conditions, and provisions of clause 28 of the Plan, which I have read in full and to which I hereby expressly assent;

 

10. I have read and expressly acknowledge clauses 28.12 through 28.16 of the Plan with respect to their bearing on any tax consequences in connection with the Options, and the exercise thereof;

 

11. as an express condition of exercising the Options, I hereby authorize payroll withholding and otherwise will make adequate provision for all applicable tax withholding of IperionX, all as more completely described in the Plan;

 

12. IperionX does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes my tax liabilities;

 

13. I have read expressly acknowledge those portions of clause 28 of the Plan under the heading “U.S. Securities Laws” with respect to their bearing on any legal consequences related to U.S. federal, state, or other securities laws in connection with the Options and the exercise thereof;

 

14. I am aware of IperionX’s business affairs and financial condition and have acquired sufficient information about IperionX to reach an informed and knowledgeable decision to acquire the Options and the Shares that may be obtained in connection therewith;

 

15. I have received and have access to such information as I consider necessary or appropriate for deciding whether to invest in the Shares that may be obtained in connection with the Options;

 

16. my investment in IperionX is a speculative investment that has limited liquidity and is subject to the risk of complete loss, and I am able to hold the Shares that may be obtained in connection with the Options for an indefinite period and to suffer a complete loss in my investment in such Shares; and

 

17. this Application shall inure to the benefit of and be binding upon my heirs, executors, administrators, successors, and assigns.

 

    40

 

 

G. EXECUTION

 

THIS APPLICATION IS HEREBY EXECUTED BY ____________________________:

 

 
Signature  
   
   
Date  

 

H. If a Related Party is nominated, please also complete the required details below and have the Related Party execute:

 

(NOTE: YOU MAY NOMINATE A RELATED PARTY TO ACCEPT YOUR OPTIONS ONLY IF YOU ARE NOT A U.S. RESIDENT)

 

Please check only one (1) of the following boxes:

 

(if related party is a trust for which you are the trustee in your personal capacity):

 

EXECUTED BY ____________________________________________________________________________ as trustee for the _______________________________________________________Trust:

 

   
Signature of trustee  

 

(if related party is a company you control which is the trustee of a trust):

 

EXECUTED BY ________________________________________________________ ACN _______________ as trustee for the _________________________________________________________Trust in accordance with s127 of the Corporations Act 2001:

 

     
Signature of director   Signature of director/company secretary
     
     
Name of director (print)   Name of director/company secretary (print)

 

(if related party is a company you control, not in the capacity of trustee):

 

EXECUTED BY _______________________________________________ ACN _______________ in accordance with s127 of the Corporations Act 2001:

 

     
Signature of director   Signature of director/company secretary
     
     
Name of director (print)   Name of director/company secretary (print)

 

    41

 

 

SCHEDULE 4: PRO-FORMA OFFER LETTER - PERFORMANCE RIGHTS

 

[date]

 

[insert Participant name]
[insert Participant address]

Dear Participant

 

OFFER TO PARTICIPATE IN IperionX EMPLOYEE INCENTIVE PLAN

 

As you are aware, IperionX Limited (“IperionX”) has established an Employee Incentive Plan (“Plan”).

 

To incentivise people important to the development prospects of IperionX and to ensure the interests and motivations of such key persons are aligned with the interests and motivations of shareholders of IperionX, the Board of IperionX (“Board”) have elected to offer equity to some key individuals.

 

As a key member of the IperionX team, IperionX is delighted to offer you the opportunity to participate in the Plan on the terms set out in this letter (“Offer”) and in accordance with the rules of the Plan and the terms and conditions of the performance rights as enclosed (“Rules”).

 

The offer means such key persons will have an opportunity to be personally rewarded for developing the business of IperionX.

 

The Grant Date of Employee Incentives issued under the Plan is the date of this Offer Letter.

 

Enclosed is a copy of the Rules. Capitalised terms which are defined in the Rules have the same meaning in this Offer Letter.

 

KEY TERMS OF THE OFFER

 

IperionX is offering you the opportunity to acquire the following rights to be issued shares in IperionX, credited as fully paid, at no cost, subject to the satisfaction of certain Performance Criteria and/or Vesting Conditions (“Performance Rights”) for no consideration:

 

NUMBER OF

RIGHTS OFFERED

PERFORMANCE

CONDITIONS

VESTING

CONDITIONS

EXPIRY DATE OF

RIGHTS

[insert number of Performance Rights] [insert performance-based conditions] [e.g. 12 months continuous service from the Grant Date] [insert expiry date of rights]

 

The Performance Right will only be issued to you if you continue to be employed or engaged by IperionX or one of its subsidiaries at the Grant Date.

 

    42

 

 

Conversion Rate

 

Each Performance Right will convert to one fully paid ordinary share in IperionX.

 

Nominee

 

You may nominate a Related Party to receive the Performance Rights in accordance with clause 11 of the Plan. In order to do so, you will need to include the nominee's details in the attached application (“Application”).

 

Notwithstanding the foregoing, if you are an Eligible Employee residing in the U.S. you cannot nominate a Related Party to receive the Performance Rights.

 

Quotation

 

The Performance Rights will not be quoted on ASX.

 

Other Terms Applicable to the Offer

 

[insert other applicable terms, if applicable, such as Performance Criteria]

 

For Performance Rights Granted to Participants Residing in the U.S.: PLEASE BE ADVISED that clause 28 of the Plan applies to you. Before accepting this Offer, please read the terms, provisions, and conditions of clause 28 in full (in addition to and in conjunction with the other terms, provisions, and conditions of the Plan, this Offer, and the Rules). If you have any questions regarding the same, please let me know before accepting this Offer.

 

The other terms and conditions applicable to the Performance Rights offered to you are described in Schedule 2 of the Plan.

 

Financial and Taxation Consequences

 

This Offer does not purport to provide all of the information you may require in order to evaluate an investment in the Company. The Company in making the Offer is not giving you any financial, legal, tax or investment advice. You should make your own enquiries and evaluations as you deem necessary of the Offer (including your investment objectives, financial situation, and particular needs), and you should seek all necessary financial, legal, tax and investment advice.

 

In the event the Company does provide you with any advice in relation to Shares, such advice does not take into account your objectives, financial situation and needs.

 

Risk

 

As with any investment in securities there can be no guarantee that the market value of the Company's shares will not fall in the future. There is also no assurance as to future dividends or distributions since these are dependent on earnings and the financial condition of the Company.

 

    43

 

 

Market Price of Shares

 

Before deciding whether to accept the Offer, you should refer to the current market price of the Company's shares, which can be obtained from the financial pages of some daily newspapers, your stockbroker, your financial adviser, or the ASX. The Company will also provide you upon request, within a reasonable time, either verbally or in writing, details of the current market price (in Australian dollars) of the Company's shares.

 

Please note that the market price of the Company's shares may rise or fall between the date of this Offer and the date when the Shares are issued to you upon conversion of Performance Rights.

 

Next Steps

 

If you wish to accept the Offer and apply for Performance Rights, you must:

 

· complete, sign and date the enclosed Application; and

 

· return the completed Application to IperionX at [insert address].

 

By delivering the attached application form to IperionX, you agree to be bound by the Rules and the terms of this Offer as a Participant in the Plan, as well as giving the acknowledgments contained in the Application.

 

Upon receipt of the Application, provided you remain employed or engaged by IperionX at that time, IperionX will take steps to issue the Performance Rights to you and to provide you with a Certificate or holding statement confirming the issue.

 

This Offer must be accepted before 5:00pm [Insert time zone] on the date fourteen (14) days after the date of this letter and will expire after that time. Please get in contact with me if you need more time to consider the Offer for any reason and we can discuss.

 

Once again, you are a very important member of the IperionX team and we look forward to your participation in the Plan.

 

Yours sincerely

 

[Director of the Company]

 

Encl: Application form
  Plan Rules

 

    44

 

 

Pro-forma acceptance form - PERFORMANCE RIGHTS

 

IPERIONX INCENTIVE PLAN

 

APPLICATION FORM

 

A. INSTRUCTIONS:

 

Please provide the original application form to IperionX at [insert address]. All capitalised terms not otherwise defined herein have the same meaning given to them in the Plan.

 

B. PERSONAL DETAILS

 

Name:  
   
Address:  

 

Pursuant to this Application (“Application”), I hereby accept the offer of Performance Rights offered to me pursuant to a Letter of Offer dated ________________ (“Offer Letter”) under the IperionX Employee Incentive Plan (“Plan”) (please check only one (1) of the following boxes):

 

In full.
   
In respect of ____________________________ Performance Rights.

 

C. USE OF NOMINEE (NOTE: YOU MAY NOMINATE A RELATED PARTY TO ACCEPT YOUR PERFORMANCE RIGHTS ONLY IF YOU ARE NOT A U.S. RESIDENT)

 

I do not wish to nominate another person to accept my Performance Rights and apply for them personally in my own name.
   
I wish to nominate _________________________________________________________________ (Insert full name) of ____________________________________________________________ (Insert address) to accept my Performance Rights and attach evidence showing that they are a Related Party.

 

D. NOMINATED BENEFICIARY IN THE EVENT OF DEATH (PLEASE COMPLETE)

 

I wish to nominate ________________________________________________________________ (Insert full name) of ____________________________________________________________ (Insert address) to receive all of my Performance Rights in the event of my death.

 

E. ACKNOWLEDGEMENT

 

By accepting the Offer and delivering this form to IperionX, I agree and acknowledge:

 

1. the Performance Rights are issued pursuant to the Plan and the Rules and I agree to be bound by the Rules and the terms of the Offer as a Participant in the Plan;
   
2. participation in the Plan does not create a right to employment or interfere with the ability to terminate my employment or service relationship (if any), subject to applicable law;
   
3. the future value of the Performance Rights and any Shares is uncertain and the value may increase or decrease in value from time to time;

 

    45

 

 

4. any rights acquired under the Plan are an extraordinary item of compensation, which is outside the scope of my employment agreement, if any, and are not part of ordinary compensation or salary for any purpose;
   
5. no claim or entitlement to compensation or damages shall arise from forfeiture of Performance Rights under the Plan resulting from my service to IperionX coming to an end for any reason;
   
6. the ultimate liability for all taxes payable in respect of my participation in the Plan and the acquisition and disposal of Performance Rights and Shares is and remains my responsibility;
   
7. IperionX may be required by law to provide information about me to Tax authorities and I will allow IperionX to provide such information; and
   
8. the Offer Letter provided to me is not financial product advice and I have been advised to consult an independent investment or taxation advisor prior to accepting Performance Rights if I have any concerns.

 

F. U.S. ACKNOWLEDGEMENTS (if applicable):

 

I further agree and acknowledge that:

 

9. the Offer Letter, the Performance Rights, and the Shares that may be obtained in connection therewith are subject to the terms, conditions, and provisions of clause 28 of the Plan, which I have read in full and to which I hereby expressly assent;
   
10. I have read and expressly acknowledge clauses 28.12 through 28.16 of the Plan with respect to their bearing on any tax consequences in connection with the Performance Rights, and the exercise thereof;
   
11. as an express condition of exercising the Performance Rights, I hereby authorize payroll withholding and otherwise will make adequate provision for all applicable tax withholding of IperionX, all as more completely described in the Plan;
   
12. IperionX does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes my tax liabilities;
   
13. I have read expressly acknowledge those portions of clause 28 of the Plan under the heading “U.S. Securities Laws” with respect to their bearing on any legal consequences related to U.S. federal, state, or other securities laws in connection with the Performance Rights and the exercise thereof;
   
14. I am aware of IperionX’s business affairs and financial condition and have acquired sufficient information about IperionX to reach an informed and knowledgeable decision to acquire the Performance Rights and the Shares that may be obtained in connection therewith;
   
15. I have received and have access to such information as I consider necessary or appropriate for deciding whether to invest in the Shares that may be obtained in connection with the Performance Rights;
   
16. my investment in IperionX is a speculative investment that has limited liquidity and is subject to the risk of complete loss, and I am able to hold the Shares that may be obtained in connection with the Performance Rights for an indefinite period and to suffer a complete loss in my investment in such Shares; and
   
17. this Application shall inure to the benefit of and be binding upon my heirs, executors, administrators, successors, and assigns.

 

    46

 

 

G. EXECUTION

 

THIS APPLICATION IS HEREBY EXECUTED BY ____________________________:

 

   
Signature  
   
   
Date  

 

H. If a Related Party is nominated, please also complete the required details below and have the Related Party execute:

 

(NOTE: YOU MAY NOMINATE A RELATED PARTY TO ACCEPT YOUR PERFORMANCE RIGHTS ONLY IF YOU ARE NOT A U.S. RESIDENT)

 

Please check only one (1) of the following boxes:

 

(if related party is a trust for which you are the trustee in your personal capacity):

 

EXECUTED BY ___________________________________________________________________________ as trustee for the _______________________________________________________Trust:

 

   
Signature of trustee  

 

(if related party is a company you control which is the trustee of a trust):

 

EXECUTED BY _______________________________________________________ ACN _______________ as trustee for the _________________________________________________________Trust in accordance with s127 of the Corporations Act 2001:

 

     
Signature of director   Signature of director/company secretary
     
     
Name of director (print)   Name of director/company secretary (print)

 

(if related party is a company you control, not in the capacity of trustee):

 

EXECUTED BY ______________________________________________________ ACN _______________ in accordance with s127 of the Corporations Act 2001:

 

     
Signature of director   Signature of director/company secretary
     
     
Name of director (print)   Name of director/company secretary (print)

 

    47

 



Exhibit 4.5












Deed of Indemnity, Insurance and Access










[insert name]




IperionX Limited
Company


















Table of Contents
Clause
Page No

1.
Definitions and Interpretation
1
1.1
Definitions
1
1.2
General
4
1.3
Headings
5
1.4
Business Day
5
     
2.
Indemnity
5
2.1
Liabilities and Costs
5
2.2
Other Indemnities
5
2.3
Limitation on Indemnity
5
2.4
Continuation of Indemnity
5
2.5
Payment under the Indemnity
6
2.6
Liability not Affected
6
2.7
Void or Voidable Transactions
6
     
3.
Insurance
7
3.1
Company to Insure Officer
7
3.2
Subrogation or Action against the Company
7
3.3
Insurance Run-Off Period
7
3.4
Maintenance and Production of Policy
7
3.5
Copy of Policy
8
3.6
Full disclosure and Compliance with Policies
8
3.7
Not Prejudice Insurance
8
     
4.
Officer's Ownership of Company Records
8
     
5.
Officer’s Right to have Access to Company Records
8
5.1
Company’s Obligation to Retain
8
5.2
Officer’s Right to have Access
9
5.3
Officer’s Right to Copy
9
     
6.
Privileged Advice
9
6.1
Company Undertaking
9
6.2
Conflict of Interest
9
6.3
Privilege
9
6.4
Joint Privilege
9
6.5
Relevant Companies
10
     
7.
Notification and Settlement of Liabilities
10
7.1
Officer to Notify Company
10
7.2
Company to Notify Officer
10
7.3
Company obligations
10
     
8.
Company Merger
11
     
9.
Shareholder Approval a Condition Precedent
11
     
10.
Costs and Duties
11
10.1
Costs
11
10.2
Duties
11

i


Table of Contents
Clause
Page No

11.
Notices
11
11.1
Notices
11
11.2
Address for Service
12
     
12.
General
12
12.1
Governing Law
12
12.2
Jurisdiction
12
12.3
Severability
12
12.4
Amendments
12
12.5
Waiver
13
12.6
Further Acts
13
12.7
Approvals
13
12.8
Assignment
13
12.9
Entire Agreement
13
12.10
Counterparts
13

ii



This Deed is made this         day of                              2021

Parties
[insert name] of [insert address] (Officer)
   
 
and
   
 
IperionX Limited of Level 9, 28 The Esplanade, Perth, Western Australia 6000 (Company)

Recitals

A.
The Officer is a director of the Company.

B.
The Company’s constitution provides that every director and company secretary of the Company is indemnified out of the assets of the Company to the full extent permitted by law, and that the Company may enter into contracts or agreements to reflect matters relating to the indemnity, insurance and access of such directors or company secretary.

C.
The Corporations Act provides that the Company must provide directors with access to certain documents.

D.
The Company has agreed to indemnify the Officer in respect of certain liabilities incurred by the Officer while acting as a director of the Company.

E.
The Company has agreed to insure the Officer against certain risks the Officer is exposed to as an officer of the Company.

F.
The Company has agreed to grant a right of access to certain Company Records to the Officer.

This Deed provides

1.
Definitions and Interpretation

1.1
Definitions

In this Deed the following terms shall bear the following meanings:

Access Period means in relation to the Company or a Relevant Company the period commencing on the Effective Date and expiring on the date 7 years after the Retirement Date.

ASX means the Australian Securities Exchange Limited ACN 008 624 691 or, where the context requires, the securities exchange operated by ASX.

Board means, in relation to the Company, the board of directors of the Company and in relation to each Relevant Company, the board of directors of the Relevant Company.

Business Day means a day on which banks are open for general banking business in Perth, Western Australia.

1



Company Records means, in relation to the Company, all records (in any form) which the Company:


(a)
is required to keep by law; or


(b)
circulates to the Officer or other Officers of the Company for the purposes of meetings of:


(i)
the Board;


(ii)
a subcommittee of the Board; or


(iii)
the Company,

and includes, without limitation:


(c)
monthly or periodical board papers;


(d)
submissions, agendas, minutes;


(e)
letters, memoranda and correspondence between the Company and third parties, such as regulatory authorities and legal and other advisers to the Company;


(f)
Board sub papers;


(g)
copies of other documents prepared for the Board, made available to any Officer of the Company or referred to in any of the above documents; and


(h)
legal advices or opinions obtained by the Company.

and in relation to each Relevant Company, means all records (in any form) which the Relevant Company:


(i)
is required to keep by law; or


(j)
circulates to the Officer or other Officers of the Relevant Company for the purposes of meetings of:


(i)
the Board;


(ii)
a subcommittee of the Board; or


(iii)
the Relevant Company,

and includes, without limitation:


(k)
monthly or periodical board papers;


(l)
submissions, agendas, minutes;


(m)
letters, memoranda and correspondence between the Relevant Company and third parties, such as regulatory authorities and legal and other advisers to the Relevant Company;


(n)
Board sub papers;


(o)
copies of other documents prepared for the Board, made available to any Officer of the Relevant Company or referred to in any of the above documents; and


(p)
legal advices or opinions obtained by the Relevant Company.

2



Corporations Act means the Corporations Act 2001 (Cth).

Costs means any damages, fines, penalties, costs, charges, fees and expenses, including, without limitation, legal fees, costs and disbursements assessed on a solicitor/own client basis without the necessity of taxation.

Deed means the deed between the parties constituted by this document and includes the recitals and amendments made from time to time.

Documents includes software (including source code and object code versions), manuals, diagrams, graphs, charts, projections, specifications, estimates, records, concepts, documents, accounts, plans, formulae, designs, methods, techniques, processes, supplier lists, price lists, customer lists, market research information, correspondence, letters and papers of every description, including all copies of and extracts from any of the same.

Effective Date means the date and time at which the Officer is or was appointed as an Officer of the Company.

Indemnity means the indemnity granted by the Company in favour of the Officer in clause 2.1.

Insolvency Provision means any law relating to insolvency, sequestration, liquidation or bankruptcy (including any law relating to the avoidance of conveyances in fraud of creditors or of preferences, and any law under which a liquidator or trustee in bankruptcy may set aside or avoid transactions), and any provision of any agreement, arrangement or scheme, formal or informal, relating to the administration of any of the assets of any person.

Insurance Policy means any insurance policy to be procured under clause 3.

Insurance Run-Off Period means that period commencing on the Retirement Date and expiring on the earlier of:


(a)
the date 7 years after the Retirement Date; or


(b)
where run-off insurance cannot be procured at reasonable Policy premiums for the full period in paragraph (a), the latest date to which run-off insurance can be procured.

Legal Expenses means any liability for costs, charges or expenses incurred:


(a)
in defending any proceedings relating to the Officer’s position with the Company or a Relevant Company, whether civil or criminal, in which judgment is given in the Officer’s favour or in which the Officer is acquitted or which are withdrawn before judgment;


(b)
in connection with any administrative proceedings relating to the Officer’s position with the Company or a Relevant Company, except proceedings which give rise to civil or criminal proceedings against the Officer in which judgment is not given in the Officer’s favour or in which the Officer is not acquitted or which arise out of conduct involving a lack of good faith; or


(c)
in connection with any proceedings relating to the Officer’s position with the Company or a Relevant Company, whether civil or criminal, in which relief is granted to the Officer under the Corporations Act by the court.

3



Policies means the Insurance Policy and any further insurance policy or policies effected in relation to the Insurance Run-Off Period under clause 3.1 and 3.3 and "Policy" means any of these.

Relevant Company means any Subsidiary of the Company of which the Officer is at any time after the date of this Deed appointed as a director.

Relevant Papers has the meaning given in clause 5.2.

Retention Period means a period:


(a)
commencing on the later of:


(i)
the date being 7 years before the date of this Deed; or


(ii)
the date of the incorporation of the Company; and


(b)
expiring on the date 7 years after the Retirement Date.

Retirement Date means the earlier of the date on which:


(a)
the Officer;


(i)
is removed; or


(ii)
resigns (except where the Officer retires from office and seeks re-election pursuant to the Company's constitution, and is duly re-elected),

as a director of the Company, or


(b)
the Officer’s office is vacated or the Officer is disqualified from holding such office by operation of law, as a matter of contract or for any other reason whatsoever.

Subsidiary has the meaning given in section 9 of the Corporations Act and refers to any corporation of that kind whenever it becomes a subsidiary.

Term means the period commencing on the Effective Date and expiring on the Retirement Date.

1.2
General

In this Deed, unless the context otherwise requires:


(a)
a reference to any legislation or legislative provision includes any statutory modification or re-enactment of, or legislative provision substituted for, and any subordinate legislation under, that legislation or legislative provision;


(b)
the singular includes the plural and vice versa;


(c)
a reference to an individual or person includes a corporation, firm, partnership, joint venture, association, authority, trust, state or government and vice versa;


(d)
a reference to any gender includes all genders;


(e)
a reference to a recital or clause is to a recital or clause of this Deed;

4




(f)
a recital forms part of this Deed;


(g)
a reference to any agreement or document is to that agreement or document (and, where applicable, any of its provisions) as amended, notated, supplemented or replaced from time to time;


(h)
a reference to any party to this Deed or any other document or arrangement includes that party’s executors, administrators, substitutes and successors;


(i)
a reference to "dollar” or “$” is to Australian dollars; and


(j)
where an expression is defined, another part of speech or grammatical form of that expression has a corresponding meaning.

1.3
Headings

In this Deed, headings are for convenience of reference only and do not affect interpretation.

1.4
Business Day

If the day on which any act, matter or thing is to be done under or pursuant to this Deed is not a Business Day, that act, matter or thing may be done on the next Business Day.


2.
Indemnity

2.1
Liabilities and Costs

Subject to clause 2.3, with effect from the Effective Date and to the maximum extent permitted by law, the Company agrees to indemnify and keep indemnified the Officer against:


(a)
all liabilities incurred by the Officer as a director of the Company or a Relevant Company; and


(b)
without limiting subparagraph (a), all Legal Expenses incurred by the Officer as a director of the Company or a Relevant Company.

2.2
Other Indemnities

The Officer must repay to the Company any amount paid to the Officer under this Deed to the extent that the Officer receives money or is reimbursed under the insurance policy maintained by the Company under clause 3 of this Deed or any other contract of insurance, or otherwise from any third party, in respect of any matters the subject of a payment or advance from the Company under this Deed. The Officer must repay any such amount within 30 days after receipt of the relevant payment.

2.3
Limitation on Indemnity

In relation to the indemnity given by the Company under clause 2.1, the Indemnity does not apply to the extent that the Indemnity is prohibited by the Corporations Act.

2.4
Continuation of Indemnity

The Company acknowledges that the Indemnity continues in full force and effect without limit in point of time in relation to any act, omission, matter or event occurring while the Officer is a director of the Company and even if the Officer has ceased to be a director of the Company before any claim is made under the Indemnity.

5



2.5
Payment under the Indemnity

It is not necessary for the Officer to incur expense or make payment before enforcing the Indemnity. The liability for the Company under the Indemnity arises simultaneously with the liability of the Officer and upon demand by the Officer, the Company must pay the Officer any sum due and payable by it pursuant to the Indemnity.

2.6
Liability not Affected

The liability of the Company under this Deed will not be affected by any act, omission, matter or thing that would otherwise operate in law or in equity to reduce or release either from such liability including, without limitation:


(a)
the Officer granting time, waiver or other indulgence or concession to, or making any composition or compromise with the Company;


(b)
the full, partial or conditional release or discharge by the Officer or by operation of law, at any time, of the Company from this Deed or any other document; or


(c)
the Officer agreeing with the Company not to sue, issue process, sign or execute judgment, commence proceedings for bankruptcy or liquidation, participate in any administration, scheme or deed of arrangement or reconstruction, prove in any bankruptcy or liquidation or do any other act, matter or thing in respect of the liability of the Company.

2.7
Void or Voidable Transactions

If:


(a)
the Officer has at any time released or discharged the Company from its obligations under this Deed in reliance on a payment, receipt or other transaction to or in favour of the Officer; or


(b)
any payment or other transaction to or in favour of the Officer has the effect of releasing or discharging the Company from its obligations under this Deed; and


(c)
that payment, receipt or other transaction is subsequently claimed by any person to be void, voidable or capable of being set aside for any reason, including under an Insolvency Provision or under the general law; and


(d)
that claim is upheld, conceded or compromised, then:


(i)
restitution of rights: the Officer will immediately become entitled against the Company to all such rights as the Officer had immediately before that release or discharge;


(ii)
restore Officer’s position: the Company must immediately do all things and execute all documents as the Officer may reasonably require to restore to the Officer all those rights; and


(iii)
indemnity: the Company must indemnify and keep indemnified the Officer against costs, losses and expenses suffered or incurred by the Officer in or in connection with any negotiations or proceedings relating to the claim or as a result of the upholding, concession or compromise of the claim.

6



3.
Insurance

3.1
Company to Insure Officer


(a)
Subject to clause 3.4 and to the extent permitted by law, the Company must during the Term and the Insurance Run-Off Period pay the premium for (or ensure the payment of premiums for) an insurance policy which insures the Officer against all liabilities incurred by the Officer acting directly or indirectly as a director of the Company or a Relevant Company.


(b)
The Insurance Policy to be effected under clause 3.1(a) must:


(i)
be effected with a reputable and solvent insurer (other than the Company); and


(ii)
insure the Officer for Costs incurred by the Officer in defending proceedings, whether civil or criminal and whatever their outcome, except to the extent that the Company may be unable to obtain insurance to defend criminal proceedings where the Officer is not acquitted.

3.2
Subrogation or Action against the Company

Unless the Company agrees otherwise, the Insurance Policy will contain a provision waiving all rights of subrogation or action against the Company.

3.3
Insurance Run-Off Period

During the Insurance Run-Off Period the Company must ensure that the Officer is at all times covered under the Insurance Policy, or a further insurance policy on terms not materially less favourable to the Officer than the terms of the Insurance Policy operating at the Retirement Date.

3.4
Maintenance and Production of Policy

The Company will:


(a)
to the extent permitted by law, maintain the Policies;


(b)
to the extent permitted by law, duly and punctually pay or cause to be paid all premiums and other money payable by it under the Policies, and if the Company cannot lawfully pay any part of the premium under the Policies it must give the Officer notice of that fact and give the Officer a reasonable opportunity to contribute to that part of the premium to the extent to which that part is attributable to the Officer (if such contribution is necessary for the Policies to be effective);


(c)
perform, observe and fulfil those terms of the Policies to be performed, observed or fulfilled by it;


(d)
produce to the Officer copies of the Policies and certificates of currency or the receipts for the payment of each premium and all other money payable in respect of each Policy (or other evidence of payment satisfactory to the Officer) on or before the due date for renewal; and


(e)
ensure that no Policy is capable of being avoided as against the Officer as a result of a breach of the duty of disclosure by any party or person other than the Officer.

7



3.5
Copy of Policy

The Company must, at the request of the Officer and as soon as practicable after that request, deliver to the Officer copies of all documents relating to each Policy, including a certified copy of each proposal form under which the application for insurance was made, the relevant Policy, all renewal certificates, certificates of currency and endorsement slips.

3.6
Full disclosure and Compliance with Policies

To the extent required by the relevant Policy, the Officer will disclose to the Company and the Company will disclose to the proposed insurer all facts material to the insurer’s risk before entering into a Policy.

3.7
Not Prejudice Insurance

Neither the Company nor the Officer will cause or permit anything to be done which may:


(a)
render any part of a Policy void, voidable or otherwise unenforceable; or


(b)
hinder or prevent the recovery of any money in respect of a Policy,

and the Company will use its reasonable endeavours not to vary any terms so as to render them materially less favourable to the Officer or cancel the Policy without the prior written consent of the Officer, unless generally accepted industry practice amongst reputable brokers dictates otherwise.


4.
Officer's Ownership of Company Records

The Officer owns the copies of the Company Records provided by the Company or a Relevant Company to the Officer during the Term.


5.
Officer’s Right to have Access to Company Records

5.1
Company’s Obligation to Retain

The Company must, and must procure each Relevant Company to:


(a)
keep a complete set of all Company Records to which the Officer is entitled to access under clause 5.2, in order and in suitable, secure custody for the Retention Period; and


(b)
nominate a person or persons from time to time to take custody of the Company Records and regulate access to them.

8



5.2
Officer’s Right to have Access

Throughout the Access Period, the Officer is entitled, during office hours (or at such other times which the parties agree), to have access to and inspect the Company Records or records which have been either prepared, or provided to the Officer, during the Retention Period and are in any way relevant to:


(a)
the Officer’s holding of office as a director in respect of the Company or a Relevant Company; or


(b)
any claim which the Officer reasonably anticipates may be made against the Officer in relation to matters arising in the course of the Officer acting in connection with the affairs of the Company or a Relevant Company or otherwise concerning or relating to the Officer’s holding of office as a director in respect of the Company or a Relevant Company

(such Company Records to be referred to as the “Relevant Papers”), and the Company must procure that each Relevant Company provides access to the Officer as set out in this clause 5.2.

5.3
Officer’s Right to Copy

The Officer is entitled during the Access Period to make and receive a copy of any of the Relevant Papers at the cost of the Company.


6.
Privileged Advice

6.1
Company Undertaking

Subject to clause 6.2, the Company will instruct all legal advisers retained by the Company that all legal advice provided to the Company from the date of this Deed which may in any way be relevant to the Officer is also to be provided for the benefit of the Officer as a director of the Company and in the Officer’s personal capacity.

6.2
Conflict of Interest

The Company will not be required to instruct any legal advisers in the manner provided by clause 6.1 in relation to any allegations made by the Company against the Officer or in relation to any other matter where the interests of the Company and the Officer are, or are potentially, in conflict.

6.3
Privilege

The Officer’s right to have access to Company Records to which sole legal professional privilege, public interest privilege or other privilege (“Privilege”) is held by the Company is subject to the absolute discretion of the Company.

6.4
Joint Privilege

Where the Company and the Officer both have the benefit of Privilege in respect of a document forming part of the Relevant Papers, neither party will waive such privilege without the consent of the other (such consent not to be unreasonably withheld).

9



6.5
Relevant Companies

The Company will procure that each Relevant Company complies with this clause 6 as if references to ‘the Company’ were references to ‘the Relevant Company’.


7.
Notification and Settlement of Liabilities

7.1
Officer to Notify Company

The Officer must:


(a)
notify the Company if proceedings are anticipated, threatened or commenced against the Officer which may give rise to a liability of the Company, immediately after becoming aware of the same; and


(b)
must not settle or compromise any claim referred to in clause 7.1(a) or make any admission or payment in relation to such a claim without the prior written consent of the Company, and will provide the Company, with a copy of any originating proceedings or other materials served on, supplied to, or otherwise within the possession of the Officer in connection with such proceedings unless the Officer receives legal advice that to do so may cause substantial or material prejudice to the interests of the Officer.

7.2
Company to Notify Officer

The Company will immediately notify the Officer if:


(a)
proceedings are anticipated, threatened or commenced against the Company or a Relevant Company; and


(b)
such proceedings or the facts giving rise to them may:


(i)
result in a claim against the Officer; or


(ii)
require the Officer to consider his legal position,

and will provide the Officer with a copy of any originating proceedings or other materials served on, supplied to, or otherwise within the possession of, the Company or the Relevant Company in connection with such proceedings unless the Company or the Relevant Company receives legal advice that to do so may cause substantial or material prejudice to the interests of the Company or the Relevant Company (as the case may be).

7.3
Company obligations

In the course of conducting any litigation or proceedings, the Company must:


(a)
use its best endeavours to ensure that the Officer's reputation is not injured; and


(b)
not settle any claim without the Officer's prior written approval unless it reasonably believes that money is available to pay the settlement amount and all costs and disbursements.

10



8.
Company Merger

Where the Company merges with another entity by way of scheme of arrangement or in any other way where the Company ceases to exist then the Company will use its reasonable endeavours that the merged entity succeeds to and assumes the Company’s obligations under this Deed.


9.
Shareholder Approval a Condition Precedent

Where the Company is required by the Corporations Act, or is otherwise required by law, in the reasonable opinion of the Officer or the Company, to seek the approval of its shareholders for the provision and payment of the premium for an insurance policy insuring the Officer during the Insurance Run-Off Period under this Deed, the provisions of this Deed which would contravene the Corporations Act or other law but for such approval, will not become operative until such approval has been obtained. In such circumstances, the Company will use reasonable endeavours to obtain such approval of shareholders.


10.
Costs and Duties

10.1
Costs

Each party will bear its own costs in relation to the negotiation, preparation and execution of this Deed.

10.2
Duties

The Company will pay and be responsible for any stamp duty payable on this Deed.


11.
Notices

11.1
Notices

Any notice or other communication which must be given, served or made under or in connection with this Deed:


(a)
must be in writing in order to be valid;


(b)
is sufficient if executed by the party giving, serving or making the notice or on its behalf by any attorney, director, secretary, other duly authorised officer or solicitor of such party;


(c)
will be deemed to have been duly served, given or made in relation to a person if it is delivered or posted by prepaid post to the address, or sent by facsimile to the number of that person set out in clause 11.2 of this Deed (or at such other address or number as is notified in writing by that person to the other parties from time to time); and

11




(d)
will be deemed to be served, given or made:


(i)
(in the case of prepaid post) on the second business day after the date of posting;


(ii)
(in the case of facsimile) on receipt of a transmission report confirming successful transmission;


(iii)
(in the case of email), at the time shown in the delivery confirmation report generated by the sender’s email system which indicates that the email was sent to the recipient’s email address; and


(iv)
(in the case of delivery by hand) on delivery.

11.2
Address for Service

The parties’ respective addresses and facsimile numbers for service of notices or other communications under this Deed are:

 
(a)
The Company:
IperionX Limited
   
Address:
Level 9
     
28 The Esplanade
     
Perth WA 6000
   
Email:
gswan@apollogroup.com.au
   
Attention:
Mr. Gregory Swan
       
 
(b)
Officer:
[insert name]
   
Address:
[insert address]
     
[insert address]
   
Email:
[insert email]


12.
General

12.1
Governing Law

This Deed is governed by and is to be construed according to the laws of Western Australia.

12.2
Jurisdiction


(a)
Acceptance of jurisdiction: Each of the parties irrevocably submits to and accepts generally and unconditionally, the non-exclusive jurisdiction of the courts and appellate courts of Western Australia with respect to any legal action or proceedings which may be brought at any time relating in any way to this Deed.


(b)
No objection to inconvenient forum: Each of the parties irrevocably waives any objection it may now or in the fixture have to the venue of any action or proceedings, and any claim it may now or in the future have that the action or proceeding has been brought in an inconvenient forum.

12.3
Severability

Any provision of this Deed which is illegal, void or unenforceable is only ineffective to the extent of that illegality, voidness or unenforceability, without invalidating the remaining provisions.

12



12.4
Amendments

This Deed may not be modified, amended or otherwise varied except by a document in writing signed by or on behalf of each of the parties.

12.5
Waiver

No waiver or indulgence by any party to this Deed is binding on the parties unless it is in writing. No waiver of one breach of any term or condition of this Deed will operate as a waiver of another breach of the same or any other term or condition of this Deed.

12.6
Further Acts

The parties will promptly do and perform all further acts and execute and deliver all further documents required by law or reasonably requested by any other party to carry out and effect the intent and purpose of this Deed.

12.7
Approvals

Subject to any law to the contrary, where the doing or execution of any act, matter or thing is dependent on the consent or approval of a party, that consent or approval may be given or withheld in the absolute discretion of that party, unless this Deed expressly provides otherwise.

12.8
Assignment

None of the parties may assign any of its rights and obligations under this Deed without the prior written consent of the other parties.

12.9
Entire Agreement

This Deed shall constitute the sole understanding of the Parties with respect to the subject matter and replaces all other agreements with respect thereto.

12.10
Counterparts

This Deed may be executed in any number of counterparts all of which taken together constitute one and the same document.

13



Executed as a Deed.


Signed by [insert name] in the presence of:
)
)
)
 
 
Signature
 

   
Signature of Witness
   
 

   
Name of Witness in full
   

Executed by IperionX Limited in
accordance with section 127 of the
Corporations Act:
)
)
)
)
 
 
 

   
Signature of Director
 
Signature of Secretary/other Director
 

   
Name of Director in full
 
Name of Secretary/other Director in full


14

Exhibit 8.1

List of Subsidiaries


Name
Jurisdiction of Organization
Ownership Percentage
Hyperion Metals (Australia) Pty Ltd
Australia
100%
TN Exploration LLC
USA
100%
Calatos Pty Ltd LLC
USA
100%
Hyperion Materials & Technologies LLC
USA
100%


 

 

Exhibit 15.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the use in this Registration Statement on Form 20-F of IPERIONX LIMITED of our report dated 17 February 2022 relating to the consolidated financial statements of IperionX Limited (formerly Hyperion Metals Limited and Tao Commodities Limited), which appears in this Registration Statement.

 

We also hereby consent to the use in this Registration Statement on Form 20-F of IPERIONX LIMITED of our report dated 17 February 2022, except for Note 1(x) which is dated 29 March 2022, relating to the consolidated financial statements of IperionX Limited (formerly Hyperion Metals Limited and Tao Commodities Limited), which appears in this Registration Statement.

 

We also consent to the references to us under the headings “Statement by Experts” in such Registration Statement.

 

/s/ PricewaterhouseCoopers LLP

Perth, Australia

March 29, 2022